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Section 1: Introduction
During the past three decades, catheter and surgical ablation
of atrial ﬁbrillation (AF) have evolved from investigational
procedures to their current role as effective treatment options
for patients with AF. Surgical ablation of AF, using either
standard, minimally invasive, or hybrid techniques, is avail-
able in most major hospitals throughout the world. Catheter
ablation of AF is even more widely available, and is now
the most commonly performed catheter ablation procedure.
In 2007, an initial Consensus Statement on Catheter and
Surgical AF Ablation was developed as a joint effort of the
Heart Rhythm Society (HRS), the European Heart RhythmAs-
sociation (EHRA), and the European Cardiac Arrhythmia So-
ciety (ECAS).1 The 2007 document was also developed in
collaboration with the Society of Thoracic Surgeons (STS)
and the American College of Cardiology (ACC). This
Consensus Statement on Catheter and Surgical AF Ablation
was rewritten in 2012 to reﬂect the many advances in AF abla-
tion that had occurred in the interim.2 The rate of advancement
in the tools, techniques, and outcomes of AF ablation continue
to increase as enormous research efforts are focused on the
mechanisms, outcomes, and treatment of AF. For this reason,
theHRS initiated an effort to rewrite and update this Consensus
Statement. Reﬂecting both theworldwide importance ofAF, as
well as the worldwide performance of AF ablation, this docu-
ment is the result of a joint partnership between the HRS,EHRA, ECAS, the Asia Paciﬁc Heart Rhythm Society
(APHRS), and the Latin American Society of Cardiac Stimula-
tion and Electrophysiology (Sociedad Latinoamericana de Es-
timulación Cardíaca y Electroﬁsiología [SOLAECE]). The
purpose of this 2017 Consensus Statement is to provide a
state-of-the-art review of the ﬁeld of catheter and surgical abla-
tion of AF and to report the ﬁndings of a writing group,
convened by these ﬁve international societies. The writing
group is charged with deﬁning the indications, techniques,
and outcomes of AF ablation procedures. Included within
this document are recommendations pertinent to the design
of clinical trials in the ﬁeld of AF ablation and the reporting
of outcomes, including deﬁnitions relevant to this topic.
The writing group is composed of 60 experts representing
11 organizations: HRS, EHRA, ECAS, APHRS, SOLAECE,
STS, ACC, American Heart Association (AHA), Canadian
Heart Rhythm Society (CHRS), Japanese Heart Rhythm Soci-
ety (JHRS), and Brazilian Society of CardiacArrhythmias (So-
ciedade Brasileira deArritmias Cardíacas [SOBRAC]). All the
members of the writing group, as well as peer reviewers of the
document, have provided disclosure statements for all relation-
ships that might be perceived as real or potential conﬂicts of
interest. All author and peer reviewer disclosure information
is provided in Appendix A and Appendix B.
In writing a consensus document, it is recognized that
consensus does not mean that there was complete agreement
among all the writing group members. Surveys of the entire
writing group were used to identify areas of consensus con-
cerning performance of AF ablation procedures and to
develop recommendations concerning the indications for
catheter and surgical AF ablation. These recommendations
were systematically balloted by the 60 writing group mem-
bers and were approved by a minimum of 80% of these mem-
bers. The recommendations were also subject to a 1-month
public comment period. Each partnering and collaborating
organization then ofﬁcially reviewed, commented on, edited,
and endorsed the ﬁnal document and recommendations.
The grading system for indication of class of evidence
level was adapted based on that used by the ACC and the
AHA.3,4 It is important to state, however, that this document
is not a guideline. The indications for catheter and surgical
ablation of AF, as well as recommendations for procedure
performance, are presented with a Class and Level of
Evidence (LOE) to be consistent with what the reader is
familiar with seeing in guideline statements. A Class I
recommendation means that the beneﬁts of the AF ablation
procedure markedly exceed the risks, and that AF ablation
should be performed; a Class IIa recommendation means that
the beneﬁts of an AF ablation procedure exceed the risks,
and that it is reasonable to perform AF ablation; a Class IIb
recommendation means that the beneﬁt of AF ablation is
greater or equal to the risks, and that AF ablation may be
considered; and a Class III recommendation means that AF
ablation is of no proven beneﬁt and is not recommended.
The writing group reviewed and ranked evidence support-
ing current recommendations with the weight of evidence
ranked as Level A if the data were derived from high-quality
Table 1 Atrial ﬁbrillation deﬁnitions
AF episode An AF episode is deﬁned as AF that is
documented by ECG monitoring or
intracardiac electrogram monitoring
and has a duration of at least 30
seconds, or if less than 30 seconds, is
present throughout the ECG
monitoring tracing. The presence of
subsequent episodes of AF requires
that sinus rhythm be documented by
ECG monitoring between AF episodes
Chronic AF Chronic AF has variable deﬁnitions and
should not be used to describe
populations of AF patients
undergoing AF ablation.
Early persistent AF Early persistent AF is deﬁned as AF that
is sustained beyond 7 days but is
less than 3 months in duration.
Lone AF Lone AF is a historical descriptor that is
potentially confusing and should
not be used to describe populations
of patients with AF undergoing AF
ablation.
Long-standing
persistent AF
Long-standing persistent AF is deﬁned
as continuous AF of greater than 12
months’ duration.
Paroxysmal AF Paroxysmal AF is deﬁned as AF that
terminates spontaneously or with
intervention within 7 days of onset
Permanent AF Permanent AF is deﬁned as the presence
of AF that is accepted by the patient
and physician, and for which no
further attempts to restore or
maintain sinus rhythm will be
undertaken. The term permanent AF
e282 Heart Rhythm, Vol 14, No 10, October 2017evidence from more than one randomized clinical trial, meta-
analyses of high-quality randomized clinical trials, or one or
more randomized clinical trials corroborated by high-quality
registry studies. The writing group ranked available evidence
as Level B-R when there was moderate-quality evidence
from one or more randomized clinical trials, or meta-
analyses of moderate-quality randomized clinical trials. Level
B-NRwas used to denote moderate-quality evidence from one
or more well-designed, well-executed nonrandomized studies,
observational studies, or registry studies. This designation was
also used to denote moderate-quality evidence from meta-
analyses of such studies. Evidence was ranked as Level C-
LD when the primary source of the recommendation was ran-
domized or nonrandomized observational or registry studies
with limitations of design or execution, meta-analyses of
such studies, or physiological or mechanistic studies of human
subjects. Level C-EO was deﬁned as expert opinion based on
the clinical experience of the writing group.
Despite a large number of authors, the participation of several
societies and professional organizations, and the attempts of the
group to reﬂect the current knowledge in the ﬁeld adequately,
this document is not intended as a guideline. Rather, the group
would like to refer to the current guidelines on AF management
for the purpose of guiding overall AF management strategies.5,6
This consensus document is speciﬁcally focused on catheter and
surgical ablation of AF, and summarizes the opinion of the
writing group members based on an extensive literature review
as well as their own experience. It is directed to all health care
professionals who are involved in the care of patients with AF,
particularly those who are caring for patients who are
undergoing, or are being considered for, catheter or surgical
ablation procedures for AF, and those involved in research in
the ﬁeld of AF ablation. This statement is not intended to
recommend or promote catheter or surgical ablation of AF.
Rather, the ultimate judgment regarding care of a particular
patient must be made by the health care provider and the
patient in light of all the circumstances presented by that patient.
The main objective of this document is to improve patient
care by providing a foundation of knowledge for those
involved with catheter ablation of AF. A second major objec-
tive is to provide recommendations for designing clinical tri-
als and reporting outcomes of clinical trials of AF ablation. It
is recognized that this ﬁeld continues to evolve rapidly. As
this document was being prepared, further clinical trials of
catheter and surgical ablation of AF were under way.represents a therapeutic attitude on
the part of the patient and physician
rather than an inherent
pathophysiological attribute of AF.
The term permanent AF should not be
used within the context of a rhythm
control strategy with antiarrhythmic
drug therapy or AF ablation.
Persistent AF Persistent AF is deﬁned as continuous
AF that is sustained beyond 7 days.
Silent AF Silent AF is deﬁned as asymptomatic AF
diagnosed with an opportune ECG o
rhythm strip.
AF 5 atrial ﬁbrillation; ECG 5 electrocardiogram.Section 2: Deﬁnitions, Mechanisms, and
Rationale for AF Ablation
Deﬁnition
AF is a common supraventricular arrhythmia that is charac-
terized by rapid and irregular activation in the atria without
discrete P waves on the surface electrocardiogram (ECG).
AF can be diagnosed with a surface ECG, an intracardiac
atrial electrogram, or both. An arrhythmia that has the ECG
characteristics of AF and lasts sufﬁciently long for a 12-
lead ECG to be recorded, or is otherwise documented tolast for at least 30 seconds, should be considered to be an
AF episode. The 30-second duration was selected based on
previous published consensus statements and is used as the
minimal duration to deﬁne recurrence of AF after catheter
ablation.1,7 This duration of AF has not been linked to a
speciﬁc outcome of AF. In addition to the duration
requirements listed above, the diagnosis of AF requires an
ECG or rhythm strip demonstrating: (1) “absolutely”
irregular R-R intervals (in the absence of complete
atrioventricular [AV] block); (2) no distinct P waves on the
surface ECG; and (3) an atrial cycle length (when visible)
that is usually less than 200 ms.2,7
Although there are several classiﬁcation systems for AF, for
this consensus document, we have adopted in large part the clas-
siﬁcation system that was presented in the 2014 AHA/ACC/.
.
r
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Fibrillation.5 We recommend that this classiﬁcation system be
used for future studies of catheter and surgical ablation of AF.
Paroxysmal AF (PAF) is deﬁned as AF that terminates sponta-
neously or with intervention within 7 days of onset (Table 1);
persistent AF is deﬁned as continuous AF that is sustained
beyond 7 days; and long-standing persistent AF is deﬁned as
continuous AF of greater than 12 months’ duration. Early
persistent AF is a new term we have deﬁned as continuous
AF of more than 7 days’ duration but less than 3 months’ dura-
tion. Within the context of AF ablation and clinical trials of AF
ablation, early persistent AF deﬁnes a population of patients in
whom better outcomes of AF ablation are anticipated as
compared with persistent AF of more than 3 months’ duration.
The term permanent AF is deﬁned as AF in which the presence
of the AF is accepted by the patient and physician, and no
further attempts will be made to either restore or maintain sinus
rhythm. It is important, therefore, to recognize that the term per-
manent AF represents a therapeutic attitude on the part of a pa-
tient and their physician rather than on any inherent
pathophysiological attribute of the AF. Such decisions can
change as symptoms, the efﬁcacy of therapeutic interventions,
and patient and physician preferences evolve. If a rhythm con-
trol strategy is recommended after reevaluation, the AF should
be redesignated as paroxysmal, persistent, or long-standing
persistent AF. Within the context of any rhythm control strat-
egy, including catheter and surgical AF ablation, the term per-
manent AF is not meaningful and should not be used.
Silent AF is deﬁned as asymptomatic AF diagnosed by an
opportune ECG or rhythm strip. Paroxysmal, persistent, and
long-standing persistent AF can be silent. We recognize that a
particular patient might have AF episodes that fall into one or
more of these categories; therefore, we recommended that pa-
tients be categorized by their most frequent pattern of AF during
the 6 months prior to performance of an ablation procedure.
Lone AF is a descriptor that has been applied to younger patients
without clinical or echocardiographic evidence of cardiac dis-
ease. Because the deﬁnitions are variable, the term lone AF is
potentially confusing, and should not be used to describe popu-
lations of patients with AF nor to guide therapeutic decisions.5
The term chronic AF also has variable deﬁnitions and should
not be used to describe populations of patients with AF.
The writing group recognizes that these deﬁnitions of AF
are very broad, and that additional details should be provided
when describing a population of patients undergoing AF
ablation. With the increased use of implantable loop recorders
(ILRs), pacemakers, and implantable cardioverter-
deﬁbrillators for rhythm diagnosis, we urge the investigators
to specify the duration of time patients have spent in contin-
uous AF prior to an ablation procedure, including the
24-hour AF burden, when data are available. The investigators
should also specify whether patients undergoing AF ablation
have previously failed pharmacological therapy, electrical car-
dioversion, catheter and/or surgical ablation. Shown in Table 1
are a series of deﬁnitions of AF types that can be used for
future trials of AF ablation and in the literature to help stan-
dardize reporting of patient populations and outcomes.Demographic Proﬁle of Patients with AF and Risk
Factors for Development of AF
AF is an exceedingly common age-related arrhythmia. Among
people of European descent, the lifetime risk of developing AF
after age 40 is 26% for men and 23% for women.8 There are
multiple risk factors for development of AF.5,7 Some of these
risk factors are modiﬁable, including hypertension, obesity,
endurance exercise, obstructive sleep apnea (OSA), thyroid
disease, and alcohol consumption, whereas many others are
not.5,7,9,10,11 Nonmodiﬁable risk factors include age, sex,
family history, race, tall stature, and other types of heart and
valvular disease.5,7 Among the many risk factors for
development of AF, age is perhaps the most powerful.8,9 The
relative risks (RRs) of AF development associated with a
number of risk factors are provided in a recent systematic
review.12 It is rare to develop AF prior to age 50; and by age
80, approximately 10% of individuals are diagnosed with AF.
The precise pathophysiological basis of this link between AF
and age is not completely understood; however, age-related
ﬁbrosis likely plays a key role.9 AF risk factors have also
been shown to be of value in predicting progression of parox-
ysmal to persistent AF.13 It is notable that many of the risk fac-
tors that have been associated with development of AF also
contribute to AF progression, recurrences of AF following abla-
tion, and complications associated with AF (e.g., stroke).Natural History of AF
The concept of “AF begets AF” remains a cornerstone in the
understanding of the natural history of AF progression.14
Increasing AF burden is associated with progressive atrial re-
modeling and the development of atrial ﬁbrosis, which can
contribute to the long-term persistence of AF.15 A wealth of
experimental data exist regarding structural and functional
atrial changes that contribute to the development, maintenance,
and progression of AF. In contrast, considerably less data exist
regarding the natural history of AF.16,17 This is in large part
related to the difﬁculty in accurately assessing the underlying
burden of AF in individuals and large populations. Thus,
estimates of the prevalence of clinical AF subtypes and their
progression have evolved with the changes in population
characteristics, associated comorbidities, and development of
modern arrhythmia monitoring technology. For example, the
rate of progression appears to be very low in individuals
with an initial diagnosis of AF who are younger than 60
years of age and who have no concomitant heart disease.
Among 97 individuals followed over three decades, 21% had
an isolated AF event without further recurrence, 58% had
recurrent AF, and 22% developed persistent AF.18 Other lon-
gitudinal studies have demonstrated a much higher rate of
AF progression. One recent study examined the rate of pro-
gression to persistent AF among 1219 paroxysmal patients
with AF.13 Progression to persistent AF was observed in
15% of the patients over 12 months of follow-up. Predictors
of progression included age, hypertension, prior transient
ischemic attack (TIA) or stroke, and chronic obstructive pul-
monary disease. Similar results were reported in another recent
e284 Heart Rhythm, Vol 14, No 10, October 2017study that examined AF progression while waiting for an AF
ablation procedure.19 Among 564 patients with PAF, 11% pro-
gressed to persistent AF during a 10-month follow-up period.
In this study, heart failure (HF) and a left atrial (LA) diameter
.45 mm were predictive of progression. These ﬁndings raise
the possibility that the clinical progression of AF could be
driven by the development of associated comorbidities as
opposed to the arrhythmia itself. Moreover, recent studies us-
ing pacemaker-documented AF burden have demonstrated a
more complex natural history of the arrhythmia, with persistent
AF reverting to paroxysmal forms, without intervention.20
This highlights our incomplete understanding of the natural
history of clinical AF and the need for larger studies focusing
on the accurate assessment of AF progression and regression.Genetic Contribution to AF
It is now well recognized that AF is heritable.21,22,23
Individuals having a ﬁrst-degree relativewith AF have approx-
imately a 40% increased risk for development of AF after ac-
counting for established clinical AF risk factors.23 In the last
decade, great progress has beenmade in identifying the genetic
determinants of AF. Although studies of families with AF
have led to the identiﬁcation of mutations in a series of ion
channels and molecules, these mutations are typically
family-speciﬁc, rare, and do not explain a signiﬁcant portion
of the heritability of AF.24 Therefore, population-based or
genome-wide studies have been used to identify many AF
risk loci.25,26,27,28,29,30 The genes at these loci encode
transcription factors and ion channels, and many are without
a clear relation to AF at the present time.
There is interest in trying to use genetics to predict the onset
of AF, to stratify the risk of AF outcomes such as stroke and
HF, and to identify the response to treatments including anti-
arrhythmic medications or catheter ablation procedures. Inter-
estingly, a genetic risk score consisting of the top 12 loci for
AF can be used to identify as much as a 5-fold gradient in
the risk of AF or those at greatest risk for a stroke.31,32
However, similar to other common diseases, the genetic risk
for AF provides minimal additional predictive value after
considering basic clinical risk factors such as age and sex.33,
34 Future studies will be directed at using a comprehensive
panel of genetic variants to identify those at greatest risk for
AF, and also to predict stroke risk and outcomes to AF
therapy, including AF ablation.35 Whether genetic testing
will ultimately prove to be an important clinical marker of
AF risk will become clear over time. An alternative and/or
complementary strategy, which might be easier for clinicians
to employ, will be the use of a clinical risk score.Genetic Determinants of Ablation Outcome
Because many genetic determinants of AF have been identi-
ﬁed, a logical question would be to ask whether genetics can
help predict the outcome of an ablation procedure.35 At the
present time, however, whether genetics will help predict
outcomes remains an unanswered question. Although there
have been a number of studies exploring the relation betweena genetic variant or single nucleotide polymorphism (SNP)
and AF ablation outcome, these studies have been challenged
by small sample sizes, testing of a limited number of SNPs,
and variable endpoints.
One recent study pooled ablation data from three different
sites consisting of 991 individuals of European ancestry.36
They tested representative SNPs at the top three loci
(PITX2, ZFHX3, and KCNN3) identiﬁed for AF in
genome-wide association studies and related these SNPs to
ablation outcome. The primary ﬁnding was that an SNP,
rs2200733, at the chromosome 4q25 or the PITX2 locus
for AF was associated with a 1.4-fold increased risk of late
AF recurrence. In contrast, another recent study found
differing results in a large Korean population of 1068 individ-
uals undergoing catheter ablation for AF.37 This second
study tested a similar set of SNPs, representing the PITX2,
ZFHX3, and KCNN3 loci, yet they did not observe any
long-term difference in AF recurrence after an ablation.
It is possible that the different outcomes noted in these two
studies are due to a racial difference in the genetic inﬂuence
on ablation outcome, although future studies will be neces-
sary to resolve this issue. Larger, prospective, multiethnic
studies that test a comprehensive number of SNPs will be
necessary before genetic data can be considered clinically
useful when considering AF ablation procedures.Signiﬁcance of AF
AF is an important arrhythmia for many reasons. First, it is
common: current estimates reveal that more than 33million in-
dividuals worldwide have AF.38 In the United States alone, it
is estimated that between 3 and 5 million people have AF, and
that by 2050 this number will exceed 8 million.39 Second, AF
increases risk of stroke by an average of 5-fold.40 AF-related
strokes are more severe than those not related to AF.41 Third,
AF increases mortality, and has been linked to an increased
risk of sudden death.42,43 Consistent with these prior studies,
a recent Framingham study reported that those with
recurrent or sustained AF had a higher multivariable-
adjusted mortality compared with those with an isolated AF
episode.44 Fourth, AF increases the risk of HF.45 Fifth, recent
studies have linked AF with the development of dementia.46
Finally, AF causes a wide variety of symptoms, including fa-
tigue and reduced exercise tolerance, and signiﬁcantly impairs
quality of life (QOL).47 It is notable that asymptomatic status is
associated with similar (or worse) prognosis compared with
symptomatic status.48 AF is also important when considered
in terms of use of health care resources and cost. In the United
States, AF accounts for more than 450,000 hospitalizations
yearly and has contributed to more than 99,000 deaths.49,50
AF has been reported to increase annual health care costs by
$8700 per patient, resulting in a $26 billion annual increase
in U.S. health care costs. Although studies have not been
performed to address the question of whether AF control
with catheter ablation impacts the morbidity and mortality
associated with AF, it is notable that emerging data have
revealed that persistent forms of AF are associated with a
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with PAF.51
The morbidity and mortality associated with AF provide a
rationale to maintain sinus rhythm. Given the anticipated
enormous public health impact of AF, proven interventions
to reduce the risk of stroke, HF, cognitive impairment, and
mortality are direly needed. Large, prospective, multicenter,
randomized clinical trials will help address whether sinus
rhythm achieved with ablation techniques lowers morbidity
and mortality compared with rate control alone or treatment
with antiarrhythmic therapy. These studies will also best
deﬁne the patient population that will derive the most beneﬁt.
Until the results of these types of clinical trials are available,
it must be recognized that the only proven beneﬁt of AF abla-
tion remains the reduction of symptoms and an improvement
in QOL.Relationship Between Presence and Type of AF and
Symptoms
During the past 15 years, multiple studies have investigated
the impact of rate vs rhythm control on stroke risk and mortal-
ity.52,53,54,55 These studies have demonstrated no difference in
these endpoints. When interpreting the results of these studies,
it is important to keep in mind the population of patients who
were enrolled, the approach used for rhythm control, and the
duration of follow-up. These studies enrolled predominantly
elderly, minimally symptomatic patients with AF in whom
either a rate or rhythm control strategy would be acceptable;
the mean duration of follow-up was less than 4 years. The pri-
mary indication for catheter ablation is to reduce patient symp-
toms and improve QOL. Therefore, prior to undergoing
catheter ablation, it is important to conﬁrm that the patient’s
symptoms (palpitations, fatigue, or effort intolerance) result
from AF and to assess their severity. In some patients with
PAF, arrhythmia-monitoring tools (e.g., transtelephonic moni-
toring, Holter) are useful to establish the correlation between
symptoms and rhythm. In patients with persistent AF who
initially appear to be asymptomatic, a reassessment of symp-
toms after restoration of sinus rhythmwith cardioversion often
reveals that the patient does in fact feel better when in sinus
rhythm. Because of this observation, many experienced clini-
cians routinely recommend cardioversion with a reassessment
of symptoms in apparently asymptomatic patients with persis-
tent AF. If the patient is ultimately demonstrated to be symp-
tomatic, a rhythm control strategy becomes an attractive
therapeutic approach. Conversely, if there is no change in
symptoms postrestoration of sinus rhythm, a rate control strat-
egy could be preferable.
Several AF ablation studies evaluated the relationship be-
tween patient characteristics and the presence of AF symp-
toms.56,57,58 It is well recognized that patients’ perception of
AF varies widely. One of the ﬁrst studies to examine AF
symptoms prior to and following ablation found that among
114 patients who underwent 7-day Holters prior to and
following ablation, 38% of the patients had only symptomatic
AF episodes, 57%had both symptomatic and asymptomatic ep-isodes, and 5% of the patients had only asymptomatic episodes.
Following the ablation, the percentage of patients with only
asymptomatic episodes of AF increased to 37%.56 Asymptom-
atic AF is more frequent in men than in women.48,59,60 In two
prospective registries and in one recent retrospective study,
older age was associated with asymptomatic AF.48,60,61
Inconsistent results have been reported for the association
between asymptomatic AF and cardiac and noncardiac
comorbidities.48,59,60 Although any type of AF can be
asymptomatic, asymptomatic AF is more common in patients
with continuous persistent AF.48 In approximately half of the
patients with highly symptomatic AF referred for catheter abla-
tion, asymptomatic episodes are also present.45,50,57,62
Arrhythmia episodes are more likely to be asymptomatic
following, as compared with prior to, AF ablation. Therefore,
assessment of freedom from AF postablation cannot be based
on freedom from symptoms alone.63
Anatomic and Electrophysiological Features of the
Atria, Coronary Sinus, and Pulmonary Veins
In recent decades, the development of catheter ablation of AF
and other atrial arrhythmias has made it necessary to have a
sound understanding of cardiac anatomy (Figure 1). Figure 1
shows the cardiac anatomy relevant for AF ablation when
viewed from the anterior (Figure 1A), right lateral
(Figure 1B), left lateral (Figure 1C), and posterior projections
(Figure 1D, 1E).64 Viewed from the front, the right atrium
(RA) is right and anterior, while the LA is situated to the left
and mainly posteriorly, with the right pulmonary veins
(PVs) adjacent to the intercaval area of the RA.65,66
Consequently, the plane of the atrial septum lies at an angle
to the sagittal plane of the body. The front of the LA and the
medial wall of the RA lie just behind the aortic root,
separated only by the transverse pericardial sinus. The
posterior wall of the LA is just in front of the tracheal
bifurcation and the esophagus, with the ﬁbrous pericardium
separating the heart from these structures.
PV anatomy is highly variable between patients (Figure 2).
Four distinct PV ostia are present in approximately 60% of pa-
tients, whereas variant anatomy is observed in 40% of patients
undergoing ablation.67 In approximately 80% of cases, the
anterior part of the ostium of the left PVs is common, separated
from the appendage by a ridge.68,69 The most frequent type of
variant anatomy is a left common PV, and the second most
frequent variant anatomy is a right middle PV. Anomalous
PVs can also be observed arising from the roof of the
atrium. The oriﬁces of the left PVs are located more superior
than those of the right PVs. The right superior (RS) PV and
the left superior (LS) PV project forward and upward,
whereas the right inferior (RI) PV and the left inferior (LI)
PV project backward and downward. The RSPV lies just
behind the superior vena cava (SVC) or RA, and the left
PVs are positioned between the left atrial appendage (LAA)
and the descending aorta.
Nathan and Eliakim ﬁrst drew attention to the presence of
sleeves of cardiac tissue that extend onto the PVs
(Figure 1E).70 Myocardial muscle ﬁbers extend from the
Figure 1 Anatomical drawings of the heart relevant to AF ablation. This series of drawings shows the heart and associated relevant structures from four
different perspectives relevant to AF ablation. This drawing includes the phrenic nerves and the esophagus. A: The heart viewed from the anterior perspective.
B:The heart viewed from the right lateral perspective.C: The heart viewed from the left lateral perspective.D: The heart viewed from the posterior perspective.E:
The left atrium viewed from the posterior perspective. Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
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sleeve is highest at the proximal ends (1–1.5 mm), and then
gradually decreases distally.16,64,71 The orientation of the
major atrial muscular bundles (e.g., Bachmann’s bundle or
Crista terminalis) has been recognized from anatomical
dissections, with mostly circular bundles around the ostia
of the PVs, AV valves, and LAA.72 Studies have described
how premature ﬁring from the PVs can initiate AF by inter-
acting with tissue mechanisms, using diffusion tensor imag-
ing (at present, in vitro).73,74 These ﬁndings have been
reproduced by cardiac magnetic resonance imaging (MRI),
highlighting the very variable individual pattern of ﬁber
orientation.75 Future in vivo implementation (in addition to
identiﬁcation of ﬁbrosis), combined with simultaneous map-
ping techniques, could allow individual tailoring of interrup-
tion of potential reentrant “pathways.”76,77The greater coronary venous system drains approxi-
mately 85% of the venous ﬂow into the RA, with the
most proximal part being called the coronary sinus (CS).
The great cardiac vein ascends into the left AV groove,
where it passes close to the circumﬂex artery and under
the cover of the LAA. The juncture between the great car-
diac vein and the CS is marked by the entrance of the vein
of Marshall (which is typically obliterated in adults and is
referred to as the ligament of Marshall), which descends
along the epicardium between the LAA and the LSPV
and can contain sympathetic nerves and ganglia.78 Espe-
cially around the CS itself, muscular bundles are present
that interconnect to the LA, thereby serving as additional in-
teratrial electrical “conductors.”79,80
PV focal ﬁring can trigger AF or act as a rapid driver
to maintain the arrhythmia. During embryological
Figure 2 This ﬁgure includes six CT or MR images of the left atrium and pulmonary veins viewed from the posterior perspective. Common and uncommon
variations in PV anatomy are shown. A: Standard PV anatomy with 4 distinct PV ostia. B: Variant PV anatomy with a right common and a left common PV. C:
Variant PV anatomy with a left common PVwith a short trunk and an anomolous PV arising from the right posterior left atrial wall.D and E:Variant PV anatomy
with a common left PV with a long trunk. F: Variant PV anatomy with a massive left common PV.
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the conduction system is deﬁned by the looping process
of the heart tube.81,82 Cell markers common to precursors
of specialized conduction tissue derived from the heart
tube have been found within myocardial sleeves.83 The
presence of P cells, transitional cells, and Purkinje cells
has been demonstrated in human PVs.84,85 PV-sleeve cardi-
omyocytes have discrete ion channel and action potential
properties that predispose them to arrhythmogenesis.84,85
They have small background IK1, which could favor
spontaneous automaticity,84 as could their reduced coupling
to atrial tissue, a property common to pacemaking struc-
tures.86 Other studies show susceptibility to Ca21-depen-
dent arrhythmia mechanisms,87 possibly due to cells of
melanocyte origin.88 Some, but not all, studies have re-
ported that isolated cardiomyocytes from rabbit and canine
PVs show abnormal automaticity and triggered activity
during manipulations that enhance Ca21 loading.87,88,89
These properties might explain the electrical activity
within the PVs that is commonly observed after electrical
disconnection of the PVs from the atrium.90
Other studies have provided evidence to suggest that the
PVs and the posterior LA are also preferred sites for reentrant
arrhythmias.90,91 One important factor could be the shorter
action potential duration (APD) of the PVs vs the atrium84
due to larger delayed-rectiﬁer K1 currents and smaller inward
Ca21 currents in the PV.89,92,93 In addition, PVs demonstrate
conduction abnormalities that promote reentry due to abrupt
changes in ﬁber orientation as well as Na1 channel
inactivation by reduced resting potentials due to small IK1.
84
Yet another study examined the impact of increasing atrialpressure on PV activation, ﬁnding that as LA pressure was
increased above 10 cm H2O, the PV–LA junction became
the source of dominant rotors.94 These observations help
explain the clinical link between AF and increased atrial pres-
sure. Several clinical studies have reported shorter refractory
periods (RPs) inside PVs compared to the LA, decremental
conduction inside PVs, and easy induction of PV reentry
with premature stimulation from the PVs. Accordingly, rapid
reentrant activity with entrainment phenomena have
been described inside PVs after successful PV isolation
(PVI).95,96 Electrophysiological evaluation of the PVs using
multielectrode basket catheters has revealed effective
refractory period (ERP) heterogeneity and anisotropic
conduction properties within the PV and at the PV–LA
junction, which can provide a substrate for reentry.97 The
response of PV activity to adenosine administration in pa-
tients with PAF is more consistent with a reentrant than a
focal-ectopic type of mechanism.98,99 In addition, dominant
frequency analysis points to an evolution of mechanisms in
patients with AF, with PV sources becoming less
predominant as AF becomes more persistent and atrial
remodeling progresses.95Autonomic Nervous System and How It Relates to
AF and AF Ablation
The cardiac autonomic nervous system (ANS) can be divided
into the extrinsic and intrinsic ANS.100 The extrinsic cardiac
ANS consists of sympathetic and parasympathetic compo-
nents,101,102 and includes neurons in the brain and spinal
cord and nerves directed to the heart. The intrinsic ANS
e288 Heart Rhythm, Vol 14, No 10, October 2017primarily includes thousands of autonomic neurons and
nerves located in ganglionated plexi (GP), which are
transitioned to the epicardial fat pads outside the heart and
along the great vessels in the thorax.100,103,104 There are 7
major GP, including 4 located in the LA around the
PVs.103,105 The ligament of Marshall, which also contains
GP, plays a coordination role between the extrinsic and
intrinsic ANS.106 The GP predominantly contain parasympa-
thetic neurons, but also sympathetic neurons. In humans,
numerous autonomic nerves are located at the PV–LA junc-
tion. The nerve densities are much more pronounced within 5
mm of the PV–LA junction and are higher in the epicardial
surface than in the endocardium.107,108 These data reveal
that the areas of LA endocardial surface most suitable for
ANS modiﬁcation are located in the immediate vicinity of
the PV–LA junction. Due to close relationship of the
sympathetic and parasympathetic ANS components, it is
difﬁcult to perform selective radiofrequency (RF) ablation
of a particular part of the ANS,109 and ablation of these sites
can destroy both adrenergic and cholinergic nerves.
In an animal model of PAF, injection of parasympathomi-
metics into the fat pad adjacent to the PV-atrial junctions re-
sulted in spontaneous or easily induced sustained AF,
suggesting that a hyperactive ANS can play an important
role in patients with focal AF arising from the PV.110,111
Stimulation of GP by pacing at the base of the PV can also
provide a substrate of AF initiation from PV ﬁring.112,113
Studies have shown that the intrinsic ANS has a potential
impact on acute atrial electrical remodeling induced by
rapid atrial pacing.113 Other studies have shown that synergic
actions of both the sympathetic and parasympathetic neuro-
transmitters promote rapid PV ﬁring in an experimental sys-
tem.114 Another study demonstrated that stimulation of the
right anterior GP converts isolated premature depolarization
from the RSPV into AF-inducing premature depolariza-
tions,115 indicating a link between GP activity and AF induc-
ibility. The authors proposed a model of a highly integrated
atrial neural network in which a GP hyperactive state could
release a gradient of locally excessive concentrations of neu-
rotransmitters that initiate AF, whereas activation of the
axons can “retrogradely” excite the GP at a distance to cause
the release of neurotransmitters to induce AF. Several studies
have identiﬁed a link between the intrinsic cardiac nervous
system and complex fractionated atrial electrograms
(CFAEs) and AF triggers.113,116
The effectiveness of catheter ablation of GP in patients
with AF remains controversial. One of the major challenges
has been the lack of a sensitive and speciﬁc means to localize
the GP in patients.117,118,119,120 Whereas several small studies
have reported improved outcomes using an anatomically
based approach to localize autonomic ganglia, these ﬁndings
have not been replicated by other investigators.121,122 A recent
prospective randomized surgical AF ablation study reported
no improvement of outcomes by ablation of autonomic
ganglia.123
The most commonly used approach to localize the major
atrial GP is to apply high-frequency stimulation (HFS) to thepresumed GP areas to elicit AV block. This method has low
speciﬁcity and sensitivity because endocardial GP can be
embedded in epicardial fat pads.106,124 Some investigators
have suggested that HFS mainly reveals the afferent link of
the ANS, suggesting that sites eliciting vagal responses do
not coincide with sites where GP clusters and efferent
autonomic nerves are located.125 Another issue is
reinnervation of the ANS during follow-up.108,114 Whether
reinnervation causes recurrent AF postablation remains
uncertain. One study has reported that reinnervation of the
ANS in patients after RF ablation is not directly related to
AF recurrence.126
In summary, there is considerable evidence that the ANS
contributes to the initiation and maintenance of AF. Whether
ablation of the ANS impacts the outcomes of AF ablation re-
mains uncertain. In the future, novel approaches for ANS
modulation could increase the efﬁcacy of AF ablation treat-
ment.127,128,129Cardiac Fibrosis: Etiology and How It Relates to AF
Atrial ﬁbrosis is a common ﬁnding in patients with AF. The
question of whether atrial ﬁbrosis stems from AF itself, from
AF-related risk factors, or from a speciﬁc ﬁbrotic atrial cardio-
myopathy (FACM) is under debate.130,131,132,133,134 Recently,
a subgroup of patients with recent onset persistent AF have
been described with a diffuse abnormal substrate and with
poor outcome after ablation.135 There is great variability in
the amount of ﬁbrosis in patients with AF, in which some pa-
tients with PAF have massive ﬁbrosis and some patients with
persistent AF show mild ﬁbrosis.134,136 Some morphological
studies have shown that ﬁbrosis in humans is related to the
underlying disease rather than being caused by AF.73,137,138
The speciﬁc role of age and AF risk factors in atrial ﬁbrosis
was questioned by an autopsy study, in which only small
amounts of ﬁbrofatty tissue were described in atrial
specimens from patients with a high mean CHA2DS2-VASc
score of 4.3 but no AF.139 In addition, a low correlation be-
tween risk factors and the ﬁbrotic substrate as estimated
from electroanatomic voltage mapping in patients with non-
PAF has been described.140 Similarly, cardiovascular risk fac-
tors were found to be equally distributed in various classes of
LA ﬁbrosis as described by MRI studies, and structural atrial
remodeling was the same in patients with and without cardio-
vascular risk factors.130 On the other hand, there is extensive
evidence that many AF risk factors do substantially increase
atrial ﬁbrosis content, and that AF itself might have a proﬁ-
brotic effect.141,142,143 One study reported that elevated
serum markers of collagen synthesis were associated with
postsurgical AF, compared with those who stayed in sinus
rhythm.144
It is possible that the ﬁbrotic atrial substrate could be a
result of a speciﬁc FACM.131,133,140 FACM has been
described as a speciﬁc disease with various expressions,
from mild, to moderate, to severe atrial ﬁbrosis, and with
a potentially progressive disease process. Consequently,
AF—and other arrhythmias such as reentrant atrial
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understood as a manifestation of the preexisting
FACM.131,133,145,146Atrial Electrical and Structural Remodeling
The pathophysiology of AF is complex, involving interac-
tion among multiple factors, including triggers, which are
responsible for AF initiation; substrate, which is necessary
for AF maintenance; and perpetuators, which underlie the
progression of the arrhythmia from paroxysmal to the
persistent forms.146,147 The recently published EHRA/
HRS/APHRS/SOLAECE expert consensus document on
atrial cardiomyopathies provides a detailed review of the
important topic of atrial cardiomyopathies and their
interrelationship with AF.148 It is generally believed that
some degree of structural remodeling must predate electri-
cal remodeling. The trigger mechanisms can include focal
enhanced automaticity or triggered activity. Initiation of
AF can be favored by both parasympathetic and sympa-
thetic activation, which also appear to play a role in main-
taining AF.149 However, the central mechanisms governing
AF initiation and perpetuation are poorly understood,
which explains in part why treatment of patients with all
forms of AF, and particularly long-standing persistent
AF, remains suboptimal. Although AF usually starts with
paroxysmal episodes, it can evolve to a persistent form
in a signiﬁcant number of patients.150 A few clinical
factors have been associated with transition from parox-
ysmal to persistent AF.20,151,152 The transition likely
reﬂects progressive structural and electrophysiological
remodeling in both atria, making the sources of the
arrhythmia more stable by fundamental mechanisms that
have been incompletely explored.153,154,155,156AF-Related Extracellular Matrix Remodeling
Persistent AF itself leads to electrical remodeling and ﬁbrosis
of the atria.157,158 Experimental and clinical data point to a
complex pathophysiology involving diverse factors,
including oxidative stress, calcium overload, atrial
dilatation, microRNAs, inﬂammation, and myoﬁbroblast
activation.141,159,160,161,162 In a recent study of
transcriptional changes associated with AF, susceptibility to
the arrhythmia was associated with decreased expression of
targets of several transcription factors related to
inﬂammation, oxidation, and cellular stress responses.163
However, it is unknown to what extent and at which time
points such alterations inﬂuence the remodeling process that
perpetuates AF. Moreover, rapid atrial rates activate ﬁbro-
blasts to increase collagen-gene activity, and AF in isolation
might promote cardiac ﬁbrosis.131,133,134
Cardiac ﬁbrosis is part of the maladaptive cardiac remod-
eling in response to cardiac injury164,165 and has been
implicated in initiation and maintenance of AF.166 The
mechanisms that are responsible for ﬁbrosis and its
consequences comprise many phenomena occurring at
various scales, including molecular, organelle, cellular, andtissue scales.167 At the molecular scale are dynamics changes
in the genome, the transcriptome, and the signaling pathways
underlying the generation of proﬁbrotic molecules168;
cellular changes involve interactions among the various car-
diac cells, including myocytes, ﬁbroblasts or myoﬁbroblasts,
and inﬂammatory cells such as macrophages and neutro-
phils169; and tissue changes relate to the dynamics of scar,
angiogenesis, electrical conduction, and contractility.153
Fibrosis can certainly act as an electrically insulating
obstacle. Proﬁbrotic stimuli promote differentiation of ﬁbro-
blasts into activated myoﬁbroblasts, which electronically
couple to myocytes in vitro20,150,151,152; whether this occurs
to a signiﬁcant extent in AF atria in vivo remains uncertain.
Fibrosis affects electrical propagation through slow,
discontinuous conduction with “zigzag” propagation,170,171
reduced regional coupling,172 abrupt changes in ﬁbrotic
bundle size,173 interruption of bundle continuity, and
micro-anatomical reentry.174
Another potentially important factor in AF-related atrial re-
modeling is fatty inﬁltration, which is known to increase in a
number ofmyocardial pathophysiological conditions and is re-
garded as arrhythmogenic.175,176,177 Obesity is a known AF
risk factor, and the increasing incidence of AF could be
related to increasing rates of obesity.177,178 Obesity
frequently coexists with other AF risk factors that improve
in response to weight loss, emphasizing the importance of
weight loss in AF risk factor management.179 Epicardial fatty
inﬁltration occurs with obesity180 and has been associated with
AF.177 Biofactors released from fat might promote ﬁbrosis and
myocardial remodeling.Atrial Amyloidosis
Over the past decade, a number of studies have called attention
to a link between atrial amyloidosis and AF.74,181,182
Amyloidosis is characterized by the presence of extracellular
proteinaceous deposits showing characteristic structural and
tinctorial properties. The various types of amyloidosis are
distinguished based on the ﬁbril protein deposited and the
clinical presentation. Amyloidosis can affect the heart as part
of a systemic process, as in immunoglobulin-derived light-
chain amyloidosis. Amyloid can also be deposited in the heart
as a manifestation of aging (senile amyloidosis), with amyloid
observed in cardiac vessels, in the ventricular interstitium, and
in the atria. The heart can also be affected by an organ-limited
variant called isolated atrial amyloidosis. The incidence of iso-
lated atrial amyloidosis exceeds 90% in the ninth decade.
Studies have shown that isolated atrial amyloidosis affects
atrial conduction and increases the risk of AF. Notably, there
is an inverse correlation between isolated atrial amyloidosis
and atrial ﬁbrosis.Role of Intracellular Ca21 Dysregulation
Spontaneous Ca21 release promoting triggered activity is
likely to be an important mechanism of AF initiation.183 Dur-
ing AF, the exceedingly high frequency of atrial excitation is
expected to lead to RyR2 refractoriness184 and
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vent triggered activity in the presence of persistent AF.
RyR2 leakiness is therefore unlikely to contribute to persis-
tent AF.185 However, such considerations do not apply in
PAF, in which ectopic activity likely related to Ca21-depen-
dent ectopy could play an important role. There is evidence
that Ca21 released from the leaky RyR2 receptors in the
sarcoplasmic reticulum (SR) is exchanged by the Na1-
Ca21 exchanger (NCX), which produces an arrhythmogenic
depolarizing current that induces atrial ectopic activity.186,187
In a mouse model characterized by progressive AF, SR Ca21
leak is enhanced in association with Ca21/calmodulin-
dependent protein kinase II (CaMKII)-dependent
hyperphosphorylation of the ryanodine receptor.188 Genetic
inhibition of the Ca21 leak reduced structural remodeling
and prevented the development of persistent AF.188 Howev-
er, in isolated remodeled rabbit and human atrial myocytes,
Ca21 signaling was silenced through a variety of mecha-
nisms.185 The authors suggested that Ca21 silencing might
be a protective mechanism against the Ca21 overload that oc-
curs during chronic AF, and challenged the notion that aber-
rant Ca21 release contributes to the pathophysiology of
persistent AF. However, during AF, the exceedingly high fre-
quency of atrial excitation is expected to lead to RyR2 refrac-
toriness and downregulation of Ca21-handling proteins,
acting to prevent triggered activity. Therefore, whether
RyR2 leakiness contributes to persistent AF is now being
disputed.158,184,185 A popular concept that had been
promoted by some investigators over the last several years
was that both initiation and maintenance of AF could be
related to increased activity of protein kinase A (PKA) and/
or Ca21/CaMKII, with subsequent uncontrolled diastolic
Ca21 release from the SR.186 The idea is that Ca21 released
from the “leaky” RyR2 receptors in the SR would overacti-
vate the NCX to extrude Ca21 and produce an arrhythmo-
genic depolarizing current, thereby explaining both the
contractile dysfunction and the high recurrence rate of the
arrhythmia.186,187 In a recent study in mice with a mutation
causing progressive AF, SR Ca21 leak was reported to be
enhanced in association with Ca21/CaMKII–dependent
hyperphosphorylation of the ryanodine receptor.188 Genetic
inhibition of Ca21/CaMKII-mediated RyR2-S2814 sup-
pressed the Ca21 leak, reduced structural remodeling, and
prevented the development of persistent AF.188 However,
recent studies in large animals and in humans have chal-
lenged the idea that Ca21 dysfunction underlies AF mainte-
nance and perpetuation. In isolated rabbit atrial myocytes,
remodeling in response to sustained tachycardia for up to 5
days was shown to silence Ca21 signaling through a failure
of subcellular propagated Ca21 release.185 The authors sug-
gested that Ca21 silencing might be a protective mechanism
against the massive Ca21 overload that occurs during chronic
AF. In another study in human atrial myocytes, although
CaMKII appeared to facilitate catecholamine-evoked ar-
rhythmias in the atrial myocardium of patients with sinus
rhythm, the same agonists failed to elicit arrhythmias in the
atrial myocardium of patients with chronic AF, likely relatedto atrial remodeling, which included decreases in CaMKII-
mediated processes.189
The above results in patients are consistent with data
derived from western blot analyses in sheep, designed to
test whether remodeling was related to altered intracellular
calcium dysfunction.158 Although the Na1-Ca21 exchange
was increased in the LAA of animals with persistent AF,
both total RyR2 and phosphorylated RyR2 proteins were
decreased, and the ratio of phosphorylated RyR2 to total
RyR2 phosphorylation was unaffected. Thus, the transition
from paroxysmal to persistent AF in the sheep model of atrial
tachypacing did not appear to depend on Ca21 leak or de-
layed afterdepolarizations (DADs).Ion Channels and Electrical Remodeling
Electrical remodeling, manifested as shortening of
atrial refractoriness, develops within the ﬁrst few days of
AF.13,153,154,190 A number of ion channel modiﬁcations
underlying such electrical changes have been described in
animal models and humans.17,190,191,192 A recent study158
used a clinically relevant ovine model of intermittent RA
tachypacing and demonstrated that, after the ﬁrst AF
episode, the dominant excitation frequency (DF) increased
gradually during a 2-week period in both LA and RA until
it stabilized at a time that coincided with the onset of
persistent AF. The DF changes were associated with down-
regulation of ICaL and INa and upregulation of IK1, along
with corresponding mRNA or protein changes, as
described in extensive previous studies of atrial remodel-
ing.17 Interstitial ﬁbrosis developed at 6–12 months and
coincided with persistent AF. This study highlighted pro-
gressive forms of atrial remodeling in the increasing ten-
dency of AF to persist over time. Consistent with these
ﬁndings, another study recently demonstrated that AF
persistence was associated with numerous transcriptional
changes in ion channel expression.163 Such changes
included upregulation of KCNJ2 and KCNJ4 (encoding
Kir2.1 and Kir2.3 subunits, respectively, which contribute
to IK1) and downregulation of CACNA1C (encoding the
ICaL a-subunit) and CACNAB2 (an ICaL b-subunit).
163,193
Therefore, the progressive DF increase during PAF is
also consistent with the fact that AF frequency is usually
higher in patients with persistent than with PAF,98 a differ-
ence that is now clearly due to sustained AF-related electri-
cal remodeling. Sustained AF shortens APD and the ERP,
decreasing the wavelength and facilitating the acceleration
and stabilization of sustained reentry. The primary determi-
nants of APD shortening are the decrease in ICaL and in-
crease in IK1.
158Mechanisms of AF: Multiple Wavelet Hypothesis,
Reentry, Spiral Waves, Rotational Activity, and
Focal Triggers from the Pulmonary Veins and Other
Sites
For many years, three concepts competed to explain the
mechanism of AF: multiple reentrant wavelets (Figure 3A),
Figure 3 Schematic drawing showing various hypotheses and proposals concerning the mechanisms of atrial ﬁbrillation. A:Multiple wavelets hypothesis. B:
Rapidly discharging automatic foci. C: Single reentrant circuit with ﬁbrillatory conduction. D: Functional reentry resulting from rotors or spiral waves. E: AF
maintenance resulting from dissociation between epicardial and endocardial layers, with mutual interaction producing multiplying activity that maintains the
arrhythmia.
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reentrant circuit with ﬁbrillatory conduction (Figure 3C).194,
195,196 Considerable progress has been made in deﬁning the
mechanisms underlying initiation, perpetuation, and
progression of AF (Figures 3, 4).16,17 A key breakthrough
was the recognition that in some patients, AF is triggered
and/or maintained by rapidly ﬁring foci and can be “cured”
by local catheter ablation.197 This crucial observation
focused attention on the PV cardiomyocyte sleeves. Subse-
quent work conﬁrmed the key role of the PVs in AF, partic-
ularly paroxysmal forms, and showed that the PVs have
features that make them favored zones to harbor both focal
automatic and microreentrant activity.157
The multiple wavelet concept was initially proposed by
Garrey (Figure 3A), was later reﬁned by Moe, and for at least
50 years became the dominant mechanistic framework for
AF. Engelmann had earlier suggested that AF was main-
tained by rapidly discharging atrial ectopic foci,198,199,200 a
notion that was subsequently rejected only to periodically
resurface.201 Finally, Thomas Lewis suggested that a single
rapidly rotating primary reentrant circuit (a “mother wave”)
was the most likely mechanism underlying AF.202 For AF
due to a single ectopic focus or a rapidly rotating single cir-
cuit, ﬁbrillatory conduction is required to account for theirregular activation typical of AF.203 All three of these clas-
sical mechanisms were proposed in the early 20th century
and continue to underlie much of the contemporary thinking
about AF mechanisms.195
As mentioned above, the observations of early investiga-
tors who recognized the importance of the PVs in AF were
critical. Their initial observations pointed to a critical role
for very rapidly discharging PV foci in maintaining AF. Sub-
sequent experimental studies indicated that the PVs could
indeed represent sites of very rapid automatic activity, which
is enhanced by the rapid activation caused by AF.204 Subse-
quent detailed studies of PV cardiomyocyte ion-current func-
tion84 and structure91 indicated that the PVs also have
properties favoring local microreentry, which likely
contribute to their participation in AF. Recent studies have
implicated abnormal Ca21 handling and DAD related to
spontaneous ectopic activity of patients with paroxysmal or
long-standing persistent AF.186,205 However, more recent
studies strongly suggest that during long-term sustained AF,
one should not expect an increase in the spontaneous release
of Ca21 from the SR, nor that DADs or triggered activity is
involved in AF maintenance or in the progression to stable
forms of the arrhythmia.158,206,207 Subsequent to recognition
of the importance of the PVs, a variety of sites other than the
Figure 4 Structure and mechanisms of atrial ﬁbrillation. A: Schematic drawing of the left and right atria as viewed from the posterior perspective. The exten-
sion of muscular ﬁbers onto the PVs can be appreciated. Shown in yellow are the ﬁve major left atrial autonomic ganglionic plexi (GP) and axons (superior left GP,
inferior left GP, anterior right GP, inferior right GP, and ligament of Marshall). Shown in blue is the coronary sinus, which is enveloped by muscular ﬁbers that
have connections to the atria. Also shown in blue is the vein and ligament ofMarshall, which travels from the coronary sinus to the region between the left superior
PV and the left atrial appendage. B: The large and small reentrant wavelets that play a role in initiating and sustaining AF. C: The common locations of PV (red)
and also the common sites of origin of non-PV triggers (shown in green).D:Composite of the anatomic and arrhythmic mechanisms of AF. Adapted with permis-
sion from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
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sources,208 but the critical importance of the PVs has withstood
the test of time.
Allessie et al induced and mapped electrically induced
tachycardia in isolated rabbit atria and documented the circular
movement reentry in that model.209 Using a limited number of
electrodes, the authors detected an activation sequence that
suggested centripetal direction of wavelet propagation. The
authors proposed that these centripetal wavelets activated tis-
sue at the center of the circuit, resulting in double responses
(double potentials) of subnormal amplitude. Because the cen-
tripetal wavelets were unable to propagate beyond the center,
they prevented the impulse from shortcutting the circuit, result-
ing in the maintenance of reentry. This mechanism of reentry
was named leading circle reentry byAllessie et al.209 Building
on ideas put forward initially by Mines and later quantiﬁed by
Wiener and Rosenblueth, Allessie et al suggested that func-
tional reentry naturally establishes itself in the shortest circuit
that can maintain reentry, deﬁned by the distance a cardiac im-pulse travels during the RP.210,211,212 This distance determines
the length of the shortest reentrant cardiac excitation wave
(wavelength, WL) and is equal to the product of conduction
velocity (CV) and RP (e.g., WL 5 CV ! RP). If AF is
maintained by multiple simultaneous reentrant waves, the
likelihood of spontaneous termination is greatest when the
atria are only large enough to maintain one reentrant wave;
if the wavelength is shortened so that multiple waves can be
maintained simultaneously, the chances of spontaneous
termination will be greatly reduced and AF is likely to be
sustained. Evidence to support this notion was obtained in a
dog model by varying autonomic tone and administering
antiarrhythmic drugs (AADs).211 However, some clinical ob-
servations were incompatible with the leading circle mecha-
nism, notably the effectiveness of Na1 channel blockers in
AF. According to the leading circle notion, Na1 channel
blockers should decrease the wavelength by reducing CV
and thereby promote, rather than terminate, AF. Furthermore,
for many years, multiple numerical studies and high-density
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idea of the leading circle or the presence of centripetal wavelets
in the maintenance of reentrant excitation.
Computer simulations and experiments in multiple
mammalian species suggest that functional reentry is better
explained by rotors or spiral waves (Figure 3D). This idea
was ﬁrst conceptualized by Russian scientists in the 1960s,
and later popularized by Arthur Winfree to explain the
reentry in all excitable media.213,214,215 The rotor is the
organizing center of the reentrant excitation215; it spins at
exceedingly high frequencies, radiating spiral wavefronts
with outwardly decreasing curvature, forming an Archime-
dean spiral, and resulting in wave fragmentation in its
periphery.216,217 Because CV decreases as the wavefront
curvature becomes steeper toward the center tip, it
follows that at that site (sometimes called the phase
singularity [PS]) the curvature reaches a critical value, the
velocity becomes zero, and the PS follows a circular
trajectory.215,218 At each point the direction of propagation
is perpendicular to the wavefront and the velocity increases
toward the periphery. The PS is a unique point where the
wavefront and the wavetail converge and velocity is zero,
preventing the impulse from extending toward the
center of the rotation. Instead, the PS becomes the rotor,
circling around a small center of unexcited but excitable
tissue.218 The concept of rotor can also be applicable to
anatomical reentry in the atria; a pectinate muscle or the
oriﬁce of a PV can stabilize a reentrant rotor.156,219 Unlike
leading-circle reentry, spiral-wave reentry is not determined
by the wavelength, but rather by the source-sink relationship
between the activation wavefront and the tissue that must be
excited in front of it to maintain activity. The rotor concept
has been applied to AF, and subsequent studies have
conﬁrmed its ability to account for the AF-suppressing ac-
tions of Na1 channel blockers.119
Recent advances in electrophysiological recording and
analysis have led to important advances in appreciating AF-
maintaining mechanisms in patients. Interestingly, they have
also led to new controversies. The application of advanced
computing technology to the deﬁnition of detailed intracardiac
electrical activity based on highly sophisticated body surface
mapping (BSM), a technique called electrocardiographic im-
aging (ECGI), has led to the noninvasive analysis of underly-
ing mechanisms in patients with AF.220,221 Both focal and
reentrant rotor sources were visualized and tended to
become more numerous as AF was maintained for longer
periods.221 Detailed analysis of patients undergoing AF abla-
tion indicates that rotors are localized to speciﬁc atrial regions
and tend to be short-lasting, with rotor cores tending to occur at
the interface between ﬁbrotic tissue and more normal atria.222
Investigators have also applied intra-atrial basket catheters and
complex mathematical analysis to deﬁne AF mechanisms and
target them in the electrophysiology laboratory with a tech-
nique called focal impulse and rotor modulation (FIRM).77
FIRM procedures have identiﬁed rotational activity in patients
with AF. A number of studies have shown the superiority of
FIRM-based ablation over conventional ablation strategies.223However, the success of targeted rotational activity ablation, as
well as the meaning of rotors detected by FIRM technology,
have been disputed in recent clinical studies. A prospective
randomized clinical trial is now underway. It is notable that
conventional mapping techniques using isochronal mapping
have not been able to identify continuous rotational activa-
tion.224,225 It is also notable that detailed human atrial
mapping studies have not observed discrete rotors, but rather
suggest that AF is maintained by dissociation between
epicardial and endocardial layers, with mutual interaction
producing multiplying activity that maintains the arrhythmia
(Figure 3E).226,227,228,229 Investigators have recorded more
than 500 epicardial electrograms from both atria during
cardiac surgery in patients with persistent AF and were
unable to identify reentrant activity.229 They interpreted their
results as suggesting predominance of focal activity and break-
throughs. Potential unifying ﬁndings were recently presented
by investigators, who performed high-resolution endocardial
and epicardial optical mapping in explanted diseased human
hearts.227 They noted that AF was driven by stable transmural
reentrant sources anchored to anatomical complexities and
ﬁbrotic regions. One limitation of their studies was a need
for an action potential abbreviating drug (pinacidil) to observe
AF, limiting the applicability of their ﬁndings to spontaneous
AF.
In summary, although the presently available data leave a
number of questions open, they do indicate that both ectopic
activity and reentry play important roles in AF. The speciﬁc
mechanisms and determinants remain to be elucidated, along
with their implications for therapy.Mechanisms of Atrial Tachycardia and Atrial Flutter
Atrial arrhythmias can be broadly classiﬁed as focal, small
circuit, or macroreentry (Figure 5A–5F). Focal ATs can
originate from anywhere within the atria or venous struc-
tures but do have a classical anatomic distribution
(Figures 4, 5C). In the absence of a prior LA catheter or
surgical ablation procedure, approximately two-thirds of
focal tachycardias have an RA origin and one-third occur
from the LA. In the RA, the most common anatomic loca-
tions are the crista terminalis, tricuspid annulus, CS ostium,
and perinodal regions. In the LA, the pulmonary venous
ostia and mitral annulus are most common. Focal tachycar-
dias also can arise from the LA and RA appendages, but
these sites of origin are rare.
Macroreentry is a broad term that encompasses what have
been considered to be typical and atypical atrial ﬂutters
(AFLs). The hallmark of macroreentry is that two sites 2
cm apart demonstrate entrainment with a postpacing inter-
val–tachycardia cycle length of 20 ms (i.e., within the cir-
cuit). The most common forms of atrial macroreentry are
variants of classical common and reverse common cavotri-
cuspid isthmus-dependent ﬂutter (Figure 5A, 5B). These
include both counterclockwise (common) and clockwise
(reverse common) variants, with the circuit originally
described as a broad active wavefront rotating around the
Figure 5 Schematic drawing showing mechanisms of atrial ﬂutter and atrial tachycardia. A: Isthmus-dependent reverse common (clockwise) atrial ﬂutter. B:
Isthmus-dependent common (counter clockwise) atrial ﬂutter. C: Focal atrial tachycardia with circumferential spread of activation of the atria (can arise from
multiple sites within the left and right atrium).D:Microreentrant atrial tachycardia with circumferential spread of activation of the atria.E: Perimitral atrial ﬂutter.
F: Roof-dependent atrial ﬂutter.
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variants exist, such as lower loop reentry and forms in which
the active wavefront crosses immediately anterior or poste-
rior to the inferior vena cava. Rarely, intraisthmus reentry
can occur. Classical AFL almost invariably coexists with
AF. Studies of AFL onset and termination have demonstrated
that both invariably require transitional AF, indicating that
ﬂutter is largely a downstream arrhythmia. Attempts to
modify the natural history of AF by ablation of AFL have
thus far largely been unsuccessful. Nevertheless, cavotricus-
pid isthmus ablation is a simple procedure with high efﬁcacy
and low risk that can provide good arrhythmia palliation in
the appropriately selected patient. However, long-term
follow-up studies following ﬂutter ablation have demon-
strated increasing prevalence of AF during long-term
follow-up.230
Atypical forms of macroreentry can occur in both the LA
and RA and are most common in the setting of prior atrial sur-
gery or prior ablation for AF. They can also occur spontane-
ously. In the RA, these can occur in the free wall, where a
surgical or spontaneous scar creates the central obstacle; or
in the form of upper loop reentry in which the SVC is the cen-
tral obstacle, often with some anchoring scar. Circuits have
also been described around segments of the crista terminalis,
which acts as a central barrier and creates regions of slowconduction. Reentrant circuits on the right septum, even in
the context of surgical scars or prosthetic material, are un-
common. In the LA, macroreentry is most common in the
context of prior ablation. The type of circuit varies according
to the nature of prior ablation and to the underlying structural
heart disease. Patients with more advanced atrial remodeling,
such as those with persistent AF, will be more likely to have
regions of slow conduction. Linear ablation particularly in-
duces macroreentry due to the propensity for gaps in lines
to develop. At the gap site, conduction can also be slowed
due to the presence of damaged tissue. Common reentrant
circuits are perimitral- or mitral isthmus-dependent or, alter-
nately, roof-dependent circuits (Figure 5E, 5F), which occur
around either the left- or right-sided PVs. Ablation of these
circuits can be accomplished by creation of a linear ablation
lesion in the form of a mitral or an anterior line for perimitral
ﬂutter or a roof line for roof-dependent ﬂutters. Microreen-
trant AFL can be ablated with a focal lesion (Figure 5D).
When ﬂutter occurs through a gap in a preexisting line, focal
ablation at that gap can often be sufﬁcient to create complete
conduction block. With the diminished use of linear ablation
for persistent AF treatment, the prevalence of these circuits is
expected to diminish. Whenever linear ablation is required
for ablation of a macroreentrant circuit it is important to
check for bidirectional conduction block. Macroreentrant
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These can either occur spontaneously, particularly in the
setting of structural heart disease and atrial enlargement, or
be due to prior ablation. Simultaneous dual-loop reentry
can also be observed in this situation. Left septal ﬂutter has
been described, but is an uncommon arrhythmia. When pa-
tients present with macroreentrant arrhythmias following
AF ablation, it is important to also identify and ablate the
trigger causing onset. Common sources of triggers include
the PVs, reﬂecting PV reconnection, or non-PV triggers.
Small circuit reentry has been described more recently,
and most classically occurs in the context of a prior catheter
or surgical ablation procedure due to islands of scar that form
a central obstacle and regions of slow conduction
(Figure 5D). The deﬁnition of a small circuit as being less
than 2 cm in diameter creates a rather arbitrary distinction
from macroreentry, but it does have clinical relevance. In
the majority of small circuits, a single focal isthmus of
slow conduction can be found in which focal ablation elimi-
nates the circuit.Potential Beneﬁts and Rationale for Eliminating AF
with Ablation
As described earlier in this document, AF is associated
with many adverse outcomes, including stroke, dementia,
HF, impaired QOL, increased medical costs, and mortal-
ity. Understanding the effect of catheter ablation of AF
on these outcomes is important in the overall assessment
of the role of ablation in the long-term management of pa-
tients with AF. There have been a number of studies that
have examined long-term outcomes with AF ablation. To
date, however, none have prospectively randomized pa-
tients to ablation vs medical management and followed
them longitudinally for more than 1 to 2 years. There
are some long-term prospective registries of patients who
have undergone AF ablation, with patients matched to
those treated medically. Despite rigorous propensity
matching, there could still be unrecognized differences
in the populations treated with ablation compared with
those receiving medical management. Thus, most of the
evidence we have, while suggestive of beneﬁt from abla-
tion, cannot be taken as deﬁnitive with respect to major
health outcomes. This lack is the rationale behind the
Catheter Ablation vs Anti-arrhythmic Drug Therapy for
Atrial Fibrillation Trial (CABANA) (ClinicalTrials.gov
identiﬁer NCT00911508), which is a prospective, random-
ized trial of ablation vs medical management of AF. The
trial has completed enrollment, but it will be some time
before the results are known.
It is widely recognized that AF ablation is effective in con-
trolling AF and its associated symptoms. Multiple studies
have demonstrated that AF ablation improves QOL in a pa-
tient with symptomatic AF, including those with HF.231,232
Many patients with AF have HF with reduced ejection
fraction (EF). Multiple studies have examined the effect of
ablation on EF.63,76,233,234,235,236 In a meta-analysis of ninestudies of AF ablation in patients with HF, mean EF
improved 11% (95% conﬁdence interval [CI] 6.9–15.3, P
,.001).237 The effect of ablation on the future risk of stroke
is of great interest, partly because of the morbidity and mor-
tality associated with stroke, but also because of the need to
inform decisions regarding continuing anticoagulation in pa-
tients with apparently successful ablations. A number of
studies, but not all, have reported a low stroke rate in patients
who have undergone AF ablation when followed long
term.238,239,240,241,242 Although the results of these studies
taken as a whole report a lower than expected stroke rate,
these results can be considered preliminary data because
many of these trials enrolled patients with a CHA2DS2-
VASc score of ,2, in whom stroke rates will be
anticipated to be low. This reﬂects the fact that very few
patients with a high stroke risk proﬁle were followed long
term after suspension of anticoagulation. Notably, it has
recently been shown that patients with PAF have a lower
stroke rate than those with persistent AF.51 These observa-
tions, while preliminary, are supportive of the emerging
belief that AF ablation could in fact reduce stroke risk. The
ultimate proof that elimination of AF by ablation lowers
stroke risk will require a large, prospective, randomized clin-
ical trial such as CABANA. Limited studies have evaluated
the effect of ablation on the risk of dementia. Prior studies
have reported that Alzheimer’s dementia occurred in 0.2%
of AF ablation patients compared with 0.9% of patients
with AF who did not have ablation and 0.5% of patients
without AF (P ,.0001). Other types of dementia were also
reduced signiﬁcantly in patients who had undergone abla-
tion.239 Although these ﬁndings are of interest, they must
be considered preliminary because this was not a prospective
randomized trial. The impact of AF ablation on mortality is
also uncertain. Although a number of preliminary studies
have reported encouraging results, not all studies have re-
ported a reduction in mortality. These results must also be
considered preliminary due to their study design.232,239,241
In summary, there is strong evidence that AF ablation im-
proves QOL, and reasonable evidence that AF ablation im-
proves ventricular function in those patients with AF who
have HF. The impact of AF control with ablation on other
endpoints, including stroke risk, dementia, and mortality,
will require further study.Electrophysiological Basis of AF Ablation
It is generally accepted that development of AF requires
both a trigger and a susceptible substrate. Figures 3 and 4
summarize the many mechanisms of AF. Over time, AF
progresses from a trigger-driven to a more substrate-
mediated arrhythmia due to structural remodeling of the at-
ria.153,243 Ablative therapy is therefore aimed at either
eliminating the trigger initiating AF or modifying the
arrhythmogenic substrate. The most commonly employed
ablation strategy consists of electrical isolation of the PVs
by creation of circumferential lesions around the right and
the left PV.197,244,245 A schematic overview of common
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shown in Figure 6. The effects of these lesions have been
attributed to isolation of AF triggering PV foci, elimination
of non-PV triggering foci, and/or as the result of modiﬁca-
tion of the arrhythmogenic substrate.246 The latter might
include interruption of crucial pathways of conduction be-
tween pulmonary-atrial junctions, which play a role in sus-
tenance of AF, reduction of the amount of mass available for
the number of simultaneously circulating wavelets (atrial
debulking), or partial vagal denervation by interruption of
vagal stimulation from the autonomic ganglia.109,247,248,249
Adjuvant substrate modiﬁcation is targeted at patient-
speciﬁc AF sources in the RA and LA.250 AF recurrences af-
ter an initially successful AF ablation procedure are typicallyFigure 6 Schematic of common lesion sets employed in AF ablation. A: The c
around the right and the left PVs. The primary endpoint of this ablation strategy is
sites of linear ablation lesions. These include a “roof line” connecting the lesions enc
valve and the lesion encircling the left PVs at the end of the left inferior PV, and
circumferential lesion to the mitral annulus anteriorly. A linear lesion created at the c
who have experienced cavotricuspid isthmus-dependent atrial ﬂutter clinically or h
linear ablation lesions between the superior and inferior PVs resulting in a ﬁgure
isolation of the posterior left atrial wall. An encircling lesion of the superior vena ca
tion is performed if focal ﬁring from the SVC can be demonstrated. A subset of ope
targeting rotational activity or CFAEs are targeted. Modiﬁed with permission fromassociated with PVI reconnection. A more recent strategy for
AF ablation involves mapping and ablation of rotational ac-
tivity.222,223The Mechanisms of AF Recurrence After Catheter
Ablation or Surgical AF Ablation
Although its efﬁcacy has been established, both catheter
and surgical ablation of AF are associated with a substantial
risk of AF recurrence.251,252 It is important to recognize
that late recurrences are often asymptomatic.56 Recur-
rences of AF after ablation are generally classiﬁed into
three types according to the phase after ablation in which
they appear: (1) early recurrence (within 3 months); (2)ircumferential ablation lesions that are created in a circumferential fashion
the electrical isolation of the PV musculature. B: Some of the most common
ircling the left and/or right PVs, a “mitral isthmus” line connecting the mitral
an anterior linear lesion connecting either the “roof line” or the left or right
avotricuspid isthmus is also shown. This lesion is generally placed in patients
ave it induced during EP testing. C: Similar to 6B, but also shows additional
of eight lesion sets as well as a posterior inferior line allowing for electrical
va (SVC) directed at electrical isolation of the SVC is also shown. SVC isola-
rators empirically isolates the SVC.D: Representative sites for ablation when
Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
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late recurrence (more than 1 year). The characteristics
and optimal managements differ according to the type of
recurrence.
Early recurrence, which is deﬁned as recurrence within
the ﬁrst 3 months after the procedure, is observed in 50%
or more of patients.253,254,255 Although its precise
mechanisms have not been fully elucidated, the possible
causes include (1) a transient stimulatory effect of the
tissue inﬂammatory response to the application of RF256;
(2) a transient imbalance of the ANS257; and (3) a delayed
effect of the application of RF, likely due to the maturation
of the ablation lesion soon after the procedure.258 A “blank-
ing period” of 3 months after the procedure, during which
reintervention should be avoided, is recommended because
up to half of the patients with early recurrence remain AF-
free during long-term follow-up.254,255,259 It has recently
been shown that patients who experience multiple early
recurrences, especially more than a month postablation,
are more likely to have an unsuccessful response to AF
ablation at 1-year follow-up. It is for this reason that
some electrophysiologists recommend early reablation in
this subset of patients.260
Late recurrence, during the ﬁrst 9 months after the
blanking period, occurs in 25%–40% of cases261,262;
however, the incidence differs depending on the patient
population (ratio of paroxysmal to persistent form) and
the manner in which recurrence is screened for and
detected. Studies have shown that the mechanism for
late-term recurrence is predominantly linked to the recov-
ery of electrical conduction between the PVs and the LA,
irrespective of the type of AF.261,263 Accordingly,
ongoing efforts are focused on identifying techniques to
achieve permanent PVI during an initial AF ablation
procedure.264,265
The incidence of very late recurrence (after more than
12 months postablation) has been shown to be higher
than previously expected. Multiple studies of long-term
follow-up data (more than 5 years) have demonstrated
that the longer the follow-up postablation, the higher the
recurrence rate.266,267,268 The predominant mechanism of
very late recurrence includes PV reconnection, the
development of non-PV triggers, and development
and maturation of substrate.267,269,270 The predictors of
the very late recurrence of AF appear to be the
nonparoxysmal form of AF at baseline, organic heart
disease (valvular heart disease and cardiomyopathy),
advanced age, and obesity.268,271
One study investigated the relationship between time to
recurrence of AF following AF ablation, response to ther-
apy, and outcome.272 This study found that time to recur-
rence is a major determinant of outcome. Patients with
later recurrences were more likely to have sporadic epi-
sodes and respond better to AADs and repeat ablation.
This observation suggests pathophysiological differences
based on time to recurrence, and have implications for clin-
ical management.Section 3: Modiﬁable Risk Factors for AF and
Impact on Ablation
AF Risk Factors and Their Interaction with AF
Management and Ablation
Management of patients with AF has traditionally consisted
of three main components: (1) anticoagulation for stroke pre-
vention; (2) rate control; and (3) rhythm control. With the
emergence of large amounts of data, which have both deﬁned
and called attention to the interaction between modiﬁable risk
factors and the development of AF and outcomes of AF man-
agement, we believe it is time to include risk factor modiﬁca-
tion as the fourth pillar of AF management.7,10,273,274,275 In
this section of the document, we will review the link
between modiﬁable risk factors and both the development
of AF and their impacts on the outcomes of AF ablation.Obesity
Data from population studies have demonstrated a signiﬁcant
dose relationship between increasing risk of developing AF
and increasing severity of obesity.8 This relationship holds
true even after multivariate adjustment for other known risk
factors, with 3%–7% increased AF risk per unit increment
of body mass index (BMI).8,276,277,278 Obesity is an
important contributor to the burden of AF, explaining one-
ﬁfth of all AF cases.279
Obesity results in signiﬁcant atrial remodeling, which pre-
disposes an individual to the development of AF. Progressive
weight gain has been associated with increasing atrial size,
interstitial ﬁbrosis, pericardial fat, heterogeneous and slowed
conduction, and inﬁltration of the atrial myocardium by the
adjacent pericardial fat.180,280,281 As a consequence of these
changes, AF is more frequently induced and sustained.
There is increasing recognition that obesity can inﬂuence
the risk of AF recurrence after catheter ablation proced-
ures.268,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298
A recent meta-analysis identiﬁed 16 studies involving 5864
individuals reporting on the link between obesity and recur-
rence of AF after catheter ablation, identifying that there was
a 3.1% greater risk of recurrent AF postablation for every one
unit increase in BMI (RR 1.03; 95% CI 1.00–1.07).299
Much less information is available on the effect of weight
management on reducing the risk of developing AF and on
the impact of weight management on AF burden and the out-
comes of ablation in those with AF. In light of the above dis-
cussion, it was somewhat surprising that the 5067-patient
Action for Health in Diabetes (Look AHEAD) randomized
trial of an intensive lifestyle intervention failed to reduce
the risk of developing AF in individuals with type 2 dia-
betes.300 In a recent, randomized, controlled clinical study,
patients with highly symptomatic AF were randomized to
either physician-directed weight and cardiometabolic risk
factor management or standard of care. Weight and risk fac-
tor management were associated with a reduction in AF
symptom burden and reduced number and duration of AFs
on ambulatory monitoring. Indeed, a dose-dependent
improvement in arrhythmia-free survival has been observed
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the Long-Term Effect of Goal Directed Weight Management
on an Atrial Fibrillation Cohort (LEGACY) study, with the
best outcomes being observed in those having a linear loss
of weight10% and without weight ﬂuctuation. The Aggres-
sive Risk Factor Reduction Study for Atrial Fibrillation and
Implications for the Outcome of Ablation (ARREST-AF)
cohort study evaluated the impact of weight and risk factor
management in the context of patients undergoing AF abla-
tion. In this observational study, adjunctive weight and risk
factor management resulted in improvement in AF symptoms
and a 5-fold greater likelihood of maintaining sinus rhythm
after ablation; at a 42-month follow-up, 87% in the interven-
tion group, compared with 18% in the control group, were in
sinus rhythm (P ,.001).301
Although there are randomized data demonstrating the
impact of weight and cardiometabolic risk factor management,
data after catheter ablation remain observational and require
conﬁrmation. A survey of the writing group shows that 96%
recommend weight loss as part of a comprehensive risk factor
management strategy for patients with AF, including those
who are being evaluated for an AF ablation procedure.
Eighty-eight percent of the writing group consider a patient’s
BMI when discussing the risks, beneﬁts, and outcomes of AF
ablation with a patient being evaluated for an AF ablation pro-
cedure. One limitation to enacting aweight loss program is that
only 34% of the writing group members currently have ready
access to a weight loss clinic at their center.Sleep Apnea
Types, Assessment, and Treatment of Apnea
Sleep-disordered breathing includes OSA, central sleep ap-
nea (CSA), periodic breathing (including Cheyne-Stokes
breathing), and sleep-related hypoventilation. OSA affects
approximately 24% of men and 9% of women between 30
and 60 years of age. Several studies revealed that the preva-
lence of OSA is substantially higher among patients with AF
(ranging from 32% to 39%), indicating that OSA could be
contributing to the initiation and progression of AF.
OSA is caused by repeated upper airway collapse leading
to oxygen desaturation and disrupted sleep. Pathogenesis
varies; predisposing factors include small upper airway
lumen, unstable respiratory control, low arousal threshold,
and dysfunctional upper airway dilator muscles. Risk factors
include obesity, male sex, age, menopause, ﬂuid retention,
adenotonsillar hypertrophy, and smoking. Continuous posi-
tive airway pressure (CPAP) is the treatment of choice for
OSA, with adherence of 60%–70%. The positive pressure
keeps the pharyngeal area from collapsing, and thus helps
alleviate the airway obstruction.
Bi-level positive airway pressure or adaptive servoventila-
tion can be used for patients who are intolerant of CPAP.
Other treatments include mandibular advancement devices,
upper airway surgery, and lifestyle modiﬁcation (weight
loss, avoidance of alcohol and sedatives).AF Mechanisms in Sleep Apnea
A variety of mechanisms have been implicated in the patho-
genesis of OSA-associated AF.302 Exposure of rats over 35
days to episodic hypoxia of the type caused by OSA causes
a sustained increase in blood pressure (BP) due to activation
of sympathetic nerves and the renin-angiotensin-aldosterone
system.303 Although intrinsic endothelial sensitivity appears
unaltered in OSA, the vasoconstrictor response to angio-
tensin is enhanced.304
A variety of lines of evidence point to an important role of
the ANS. Prolonged apneic episodes in dogs (2 min) enhance
ganglionated plexus neural activity and increase AF induc-
ibility.305 Strong negative intrathoracic pressure applied to
pigs during 2-minute apneic episodes reduces the atrial
ERP and enhances AF inducibility, effects reversed by atro-
pine or vagotomy.306 Renal denervation suppresses postap-
neic BP increases, AF inducibility and neurohumoral
activation in pigs.307,308
That altered autonomic nerve activity is not the entire
explanation for the inﬂuence of sleep apnea in AF occurrence
was shown in a study of sleep apnea in a rat model of
obesity.309 Obstructive apnea promoted AF induction in
obese rats much more than in lean rats, with only partial pro-
tection (,50%) by autonomic blockade. On the other hand,
obstructive episodes caused LA dilation that was enhanced
in obese rats by obesity-associated left-ventricular diastolic
dysfunction. Prevention of LA dilation fully prevented
apnea-associated AF. In this model, neither obstructive apnea
nor obesity was enough to cause signiﬁcant AF vulnerability;
the interaction appeared necessary to cause the degree of LA
dilation needed to allow for AF induction.
Subsequent studies evaluated the effects of repeated
obstructive apnea, as occurs in patients with OSA, on cardiac
structure, function, and electrophysiology.310 In a rat model
of repeated OSA for 4 weeks, atrial conduction slowed
considerably in association with connexin downregulation
and atrial ﬁbrosis. Left ventricular dilation, hypertrophy,
and diastolic dysfunction also occurred. In addition to the
remodeling-induced AF substrate caused by repeated apneic
episodes, AF inducibility was further enhanced by superim-
posed episodes of acute obstructive apnea in over 80% of
the rats.310 The role of atrial remodeling by repeated OSA
is supported by electroanatomical studies in the clinical elec-
trophysiology lab, with OSA associated with prolonged atrial
conduction times, slower conduction, reduced electrogram
amplitudes, and widespread complex atrial electrograms.311
Finally, experiments in sheep demonstrated that hyper-
capnia per se causes profound atrial conduction slowing
and increased AF inducibility, which persists following the
return of CO2 levels to normal.
312 This effect was indepen-
dent of oxygen levels. Taken together, the results suggest
that acute OSA episodes enhance AF vulnerability via a com-
bination of LA dilation and autonomic and electrophysiolog-
ical changes; however, these abnormalities alone are not
enough to signiﬁcantly enhance AF risk in normal hearts.
Repeated nocturnal OSA activates neurohormonal systems
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structural and electrophysiological remodeling. These render
the atria susceptible to AF, particularly during an acute OSA
episode.Sleep Apnea Treatment and AF Ablation Outcomes
Several studies have observed associations between AF
and OSA. Epidemiological data suggest AF prevalence
and progression are linked with OSA severity,313,314
whereas observational data have linked OSA with a
more severely remodeled atrial substrate.311 Treatment of
OSA with CPAP, however, appears to favorably impact
AF management, regardless of the rhythm control strategy
adopted.315,316
Several studies have examined the impact of CPAP inter-
vention on arrhythmia-free survival following catheter abla-
tion of AF.283,289,290,291,316,317,318,319 Although OSA has
been associated with poorer outcomes, CPAP appears to
attenuate the deleterious impact of OSA. Pooled analysis
suggests that although OSA increases the risk of AF
recurrence following ablation (RR 1.31; 95% CI 1.16–1.48;
P ,.001), CPAP therapy improves ablation success to rates
comparable with non-OSA populations (RR 1.25; 95% CI
0.77–2.03; P 5 .37).320 Nonuse of CPAP increases the risk
of recurrent AF after ablation by 57% (RR 1.57; 95% CI
1.36–1.81; P ,.001).320 One study demonstrated an
increased prevalence of non-PV triggers in patients with
OSA.290
The observational nature of the literature that evaluates
CPAP use in OSA, however, limits its generalizability and
precision. In most studies, formal sleep studies were not
used to systematically screen all patients for sleep apnea.
Clinical history or diagnostic questionnaires (e.g., Berlin
questionnaire) formed the basis of OSA diagnosis in some,
whereas the diagnosis was rarely excluded by sleep study
in non-OSA groups.283,289,290,291,316 Similarly, treatment
efﬁcacy was assessed by self-reported CPAP use.289,290,291,316
These study deﬁciencies lead to a poorly deﬁned treatment
effect of CPAP on AF recurrence after ablation.
A survey of the writing group shows that 80% of the
writing group members screen for signs and symptoms of
sleep apnea when evaluating patients for an AF ablation pro-
cedure. This survey also revealed that 94% refer patients be-
ing evaluated for an AF ablation procedure, in whom signs
and symptoms of sleep apnea are detected, to a sleep center
for evaluation and management of sleep apnea. Eighty-six
percent of the writing group members currently have ready
access to a sleep program at their center.Hypertension
Hypertension is a well-established, independent risk factor
for AF,9,279,321,322 and this risk increases in patients with
uncontrolled systolic BP,323 particularly in those with EF
less than 40%.324 Even BPs that are near the upper limit
of normal (systolic 130–139 mm Hg, diastolic 85–89 mmHg) predict risk for AF in healthy middle-aged men325
and women.326 Hypertensive animal models have shown
that elevated systolic and diastolic BP promote the develop-
ment of the atrial substrate for AF by increasing LA
pressure, promoting interstitial ﬁbrosis and inﬂammatory
inﬁltrates.327
Following AF ablation, hypertension has been shown to
be an independent predictor of recurrence.268,328,329,330
Conversely, patients with pharmacologically controlled hy-
pertension could have similar risk of AF recurrence postabla-
tion as those without hypertension.279 Pooled analysis of two
small studies demonstrated that renal artery denervation re-
sulted in both sustained lowering of BP and reduction in
AF recurrence postablation.127,331 However, the
antiarrhythmic effect of renal denervation is not well
established, and whether it is mediated by remodeling of
the hypertension-associated atrial substrate or decrease in
neurohormonal activation remains uncertain.129 Whereas up-
stream therapy with angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers might be effective
for primary prevention of AF in patients with systolic LV
dysfunction or left ventricular hypertrophy,332 their effect
on secondary prevention postablation of AF is uncertain.
Numerous, mostly retrospective, studies have shown that
modulation of the renin-angiotensin-aldosterone system
does not improve ablation outcome.289,290,291,333,334
In summary, studies have shown that hypertension pre-
dicts AF recurrence after AF ablation; however, it is not
well established whether aggressive BP reduction with
antihypertensive therapy, modulation of the autonomic sys-
tem, or inhibition of the renin-angiotensin-aldosterone sys-
tem is required for reducing AF reoccurrence in patients
with hypertension undergoing AF ablation. Despite this,
aggressive treatment of hypertension is warranted in all
patients with AF due to the well-established link between
hypertension and stroke risk.Diabetes
Diabetes promotes atrial remodeling characterized by diffuse
interstitial ﬁbrosis and conduction slowing,335 and has been
shown to be an independent risk factor for development of
AF.9,336,337 At least 10 studies have evaluated whether
diabetes or impaired glucose metabolism predicts AF
recurrence following ablation, with varying results. A
systematic review and meta-analysis reported that the risk
of AF postablation was not elevated in patients with dia-
betes.338
Overall, studies have not consistently demonstrated differ-
ences in AF ablation outcomes in patients with diabetes, and
whether aggressive glucose control is effective for secondary
AF prevention following ablation is uncertain.Alcohol
Alcohol consumption at varying degrees could increase the
likelihood of incident AF and might also elevate the risk of
e300 Heart Rhythm, Vol 14, No 10, October 2017thromboembolic events and postablation recurrence in pa-
tients with AF.339,340,341,342 Fibrotic changes in the
myocardium caused by alcohol toxicity potentially
facilitate development of LA scar and origin of non-PV trig-
gers.301,343 A recent observational study demonstrated a
lower AF ablation success rate in moderate and heavy
drinkers.342 Furthermore, binge drinking has been reported
to be associated with increase in the risk of postablation AF
recurrence. Finally, the ARREST-AF study demonstrated
signiﬁcant reduction in symptom severity, burden, and recur-
rence rate in patients with risk factor management that
included lowering alcohol intake to 30 g per week.344
Thus, limiting alcohol intake is a potential target to increase
the success rate in AF ablation, but deﬁnitive evidence is
required before stronger conclusions can be made.Exercise
Recent studies have observed a U-shaped risk relationship of
physical activity to AF. At one end of the spectrum, a large
observational study of 64,561 people showed that those at
the lowest levels of physical ﬁtness had a 5-fold increased
risk of AF.345 Increasing the physical activity of sedentary
patients could help reduce the risk or burden of AF. For
example, one randomized study demonstrated that just 12
weeks of moderate-intensity physical activity decreased the
AF burden by 41%.346 Of the physically inactive with AF,
the obese might beneﬁt the most from moderate levels of
physical activity.345 In contrast, a meta-analysis of 655
endurance athletes also demonstrated a 5-fold increased
risk of AF.347 Of these studies, increased AF risk was gener-
ally only observed with the highest levels of physical activity
over a prolonged period of time.348,349 One explanation for
the exercise paradox is that both long-term endurance
training and a sedentary lifestyle increase chronic systemic
inﬂammation.
The risk of AF from sustained high levels of physical ac-
tivity is likely modulated by age, given studies of young ath-
letes have failed to show an increased risk.350,351 Indeed, AF
is the primary arrhythmia observed in middle-aged ath-
letes.352 AF in athletes tends to be paroxysmal, vagally medi-
ated, and highly symptomatic.353 Risk is augmented in
athletes who are better conditioned, participate more often,
and have faster performance times.354
The mechanism of increased AF risk at either end of the
physical activity spectrum likely includes autonomic, struc-
tural, inﬂammatory, and ﬁbrotic changes to the heart. For
example, increased vagal tone, which is often observed in
the endurance athlete, has been shown to result in a short atrial
RP, and thus initiates AF.355 Most studies have shown struc-
tural changes in endurance athletes, which have resulted in
the term athlete’s heart. These changes include dilatation of
all four heart chambers, increase in left ventricular mass, and
mild right ventricular hypertrophy.356 Initially, these adaptive
changes were felt to be benign; however, emerging evidence
suggests otherwise, with endurance athletes experiencinghigher-than-expected rates of coronary artery calcium scores,
myocardial ﬁbrosis, AF, and sinus node dysfunction.357
Long-term endurance training, as well as a sedentary
lifestyle,358 increase chronic systemic inﬂammation,359
which in turn could also facilitate AF.360 Studies show
that moderate physical activity might reduce inﬂammatory
markers.361,362,363
Extreme levels of exercise are a known cause of cardiac
ﬁbrosis, particularly in hinge point locations of the heart,
such as the right ventricle; however, the signiﬁcance of
MRI-detected ﬁbrosis remains controversial.349 Athletes
who experience higher levels of ﬁbrosis also have higher
levels of coronary calcium.364 In turn, ﬁbrosis is a well-
established risk factor of AF.365 In one study, the ﬁbrotic
changes caused by vigorous exercise were reversed after an
8-week period of physical activity cessation.366 One study
showed an increase in collagen and other ﬁbrosis biomarkers
in athletes.367 Murine models have found that losartan re-
duces all ﬁbrosis biomarkers and the histologic ﬁndings of
ﬁbrosis induced by long-term intensive exercise.368
Although increasing physical activity might reduce AF in
sedentary patients, decreasing physical activity levels in elite
endurance athletes could also reduce AF.350 Professional ath-
letes represent a unique treatment dilemma because medical
therapy for AF might not only reduce athletic performance
but it could also be prohibited in some sports.369
Furthermore, many athletes have marked resting brady-
cardia, limiting use of AAD therapy. Because most high-
level endurance athletes are unwilling to give up or reduce
their level of their sports participation, AF ablation might
be the only viable treatment option for these patients.
Although there are limited data on the efﬁcacy of AF ablation
in athletes, two small studies involving a total of 276 patients
suggested equal beneﬁt of ablation compared with AAD ther-
apy for the endurance athlete.370,371 However, caution should
be exercised when interpreting these data because a third
small study reported that, although ablation can result in a
durable arrhythmia-free beneﬁt, athletes typically require
multiple procedures—an average of 2.3—to achieve a
long-term beneﬁt.372
Although moderate levels of physical activity have not
been independently shown to improve AF ablation outcomes
in the sedentary patient, one observational study of 308 pa-
tients showed that increased physical ﬁtness was associated
with a dose-dependent reduction in AF burden. Moreover,
the AF beneﬁt of physical ﬁtness provided a 12% incremental
gain over weight loss, resulting in an improved AF risk factor
proﬁle, inﬂammatory state, and cardiac remodeling.373 These
observed beneﬁcial changes of moderate physical activity
would predict a better AF ablation outcome in the sedentary
patient. Given that interventions aimed at increasing physical
activity could be more successful than those targeting weight
loss,374 increasing physical activity could be an attractive op-
tion to prevent or treat AF. To date, however, deﬁnitive evi-
dence of the impact of physical activity on ablation outcomes
is lacking.
Table 2 Indications for catheter (A and B) and surgical (C, D, and E) ablation of atrial ﬁbrillation
Recommendation Class LOE References
Indications for catheter ablation of atrial ﬁbrillation
A. Indications for catheter ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Catheter ablation is recommended. I A 261,262,462,489,503,655,
673,684,709,1027–1029
Persistent: Catheter ablation is reasonable. IIa B-NR 245,262,515,527,733,
1015,1025–1030
Long-standing persistent: Catheter ablation
may be considered.
IIb C-LD 245,262,515,527,733,
1015,1025–1030
Symptomatic AF
prior to initiation
of antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Catheter ablation is reasonable. IIa B-R 370,372,377–383
Persistent: Catheter ablation is reasonable. IIa C-EO
Long-standing persistent: Catheter ablation
may be considered.
IIb C-EO
B. Indications for catheter atrial ﬁbrillation ablation in populations of patients not well represented in clinical trials
Congestive heart
failure
It is reasonable to use similar indications for
AF ablation in selected patients with heart
failure as in patients without heart failure.
IIa B-R 233–237,384,386–395,1042
Older patients
(.75 years of age)
It is reasonable to use similar indications for
AF ablation in selected older patients with
AF as in younger patients.
IIa B-NR 396–398,401–404
Hypertrophic
cardiomyopathy
It is reasonable to use similar indications for
AF ablation in selected patients with HCM
as in patients without HCM.
IIa B-NR 385,1043,1044
Young patients
(,45 years of age)
It is reasonable to use similar indications for
AF ablation in young patients with AF
(,45 years of age) as in older patients.
IIa B-NR 405,1045
Tachy-brady
syndrome
It is reasonable to offer AF ablation as an
alternative to pacemaker implantation in
patients with tachy-brady syndrome.
IIa B-NR 381–383
Athletes with AF It is reasonable to offer high-level athletes
AF as ﬁrst-line therapy due to the
negative effects of medications on athletic
performance.
IIa C-LD 370–372
Asymptomatic AF** Paroxysmal: Catheter ablation may be
considered in select patients.**
IIb C-EO 416,418
Persistent: Catheter ablation may be
considered in select patients.
IIb C-EO 417
(Continued )
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e301
Table 2 (Continued )
Recommendation Class LOE References
Indications for surgical ablation of atrial ﬁbrillation
C. Indications for concomitant open (such as mitral valve) surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1290,1326–1338
Persistent: Surgical ablation is recommended. I B-NR 1290,1326–1338
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1290,1326–1338
Symptomatic AF
prior to initiation
of antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1290,1326–1338
Persistent: Surgical ablation is recommended. I B-NR 1290,1326–1338
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1290,1326–1338
D. Indications for concomitant closed (such as CABG and AVR) surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 1339–1344
Persistent: Surgical ablation is recommended. I B-NR 1339–1344
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 1339–1344
Symptomatic AF
prior to initiation
of antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Surgical ablation is reasonable. IIa B-NR 1339–1344
Persistent: Surgical ablation is reasonable. IIa B-NR 1339–1344
Long-standing persistent: Surgical ablation is
reasonable.
IIa B-NR 1339–1344
E. Indications for stand-alone and hybrid surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Stand-alone surgical ablation can be
considered for patients who have failed one or
more attempts at catheter ablation and also for
those who are intolerant or refractory to antiarrhythmic
drug therapy and prefer a surgical approach, after
review of the relative safety and efﬁcacy of catheter
ablation versus a stand-alone surgical approach.
IIb B-NR 123,601,1306,1339–1341,
1349,1351–1361
Persistent: Stand-alone surgical ablation is reasonable
for patients who have failed one or more attempts
at catheter ablation and also for those patients who
prefer a surgical approach after review of the relative
safety and efﬁcacy of catheter ablation versus a
stand-alone surgical approach.
IIa B-NR 123,601,1306,1339–1341,
1349,1351–1361
Long-standing persistent: Stand-alone surgical ablation
is reasonable for patients who have failed one or more
attempts at catheter ablation and also for those patients
who prefer a surgical approach after review of the relative
safety and efﬁcacy of catheter ablation versus a
stand-alone surgical approach.
IIa B-NR 123,601,1306,1339–1341,
1349,1351–1361
It might be reasonable to apply the indications for
stand-alone surgical ablation described above to
patients being considered for hybrid surgical
AF ablation.
IIb C-EO 1361–1366
AF 5 atrial ﬁbrillation; LOE 5 Level of Evidence; HCM 5 hypertrophic cardiomyopathy.
**A decision to perform AF ablation in an asymptomatic patient requires additional discussion with the patient because the potential beneﬁts of the procedure
for the patient without symptoms are uncertain.
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Figure 7 Indications for catheter ablation of symptomatic atrial ﬁbrillation.
Shown in this ﬁgure are the indications for catheter ablation of symptomatic
paroxysmal, persistent, and long-standing persistent AF. The Class for each
indication based on whether ablation is performed after failure of antiar-
rhythmic drug therapy or as ﬁrst-line therapy is shown. Please refer to
Table 2B and the text for the indications for catheter ablation of asymptom-
atic AF.
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Figure 8 Indications for surgical ablation of atrial ﬁbrillation. Shown in this ﬁgur
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Recommendations and General Considerations
Shown in Table 2, and summarized in Figures 7 and 8 of
this document, are the Consensus Indications for Catheter
and Surgical Ablation of AF. As outlined in the introduc-
tion section of this document, these indications are stratiﬁed
as Class I, Class IIa, Class IIb, and Class III indications.
The evidence supporting these indications is provided, as
well as a selection of the key references supporting these
levels of evidence. In making these recommendations, the
writing group considered the body of published literature
that has deﬁned the safety and efﬁcacy of catheter and sur-
gical ablation of AF. Also considered in these recommenda-
tions is the personal lifetime experience in the ﬁeld of each
of the writing group members. Both the number of clinical
trials and the quality of these trials were considered. In
considering the class of indications recommended by this
writing group, it is important to keep several points in
mind. First, these classes of indications only deﬁne theSymptomatic 
AF
Paroxysmal 
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e are the indications for surgical ablation of paroxysmal, persistent, and long-
erformed after failure of antiarrhythmic drug therapy or as ﬁrst-line therapy is
lation procedure is performed concomitantly with an open surgical procedure
tery bypass graft surgery), or as a stand-alone surgical AF ablation procedure
Table 3 Atrial ﬁbrillation ablation: strategies, techniques, and endpoints
Recommendation Class LOE References
PV isolation by catheter ablation Electrical isolation of the PVs is
recommended during all AF
ablation procedures.
I A 245,261,262,456,462,489,503,515,527,
655,673,684,709,733,1015,1025,1026,
1027,1030
Achievement of electrical
isolation requires, at a
minimum, assessment and
demonstration of entrance
block into the PV.
I B-R 245,261,262,456,462,489,503,515,527,
655,673,684,709,733,1015,1025,1026,
1027,1030
Monitoring for PV reconnection
for 20 minutes following initial
PV isolation is reasonable.
IIa B-R 263,265,448,450,451,452,457–461,462
Administration of adenosine 20
minutes following initial PV
isolation using RF energy with
reablation if PV reconnection
might be considered.
IIb B-R 265,448,449–451,454,456,461,463–468
Use of a pace-capture (pacing
along the ablation line)
ablation strategy may be
considered.
IIb B-R 264,472–475
Demonstration of exit block may
be considered.
IIb B-NR 445,477–481
Ablation strategies to be
considered for use in
conjunction with PV isolation
If a patient has a history of
typical atrial ﬂutter or typical
atrial ﬂutter is induced at the
time of AF ablation, delivery of
a cavotricuspid isthmus linear
lesion is recommended.
I B-R 230,504,511,1397
If linear ablation lesions are
applied, operators should use
mapping and pacing
maneuvers to assess for line
completeness.
I C-LD 245,504,506–508,510–513,1397
If a reproducible focal trigger that
initiates AF is identiﬁed
outside the PV ostia at the time
of an AF ablation procedure,
ablation of the focal trigger
should be considered.
IIa C-LD 96,197,208,257,530,531,533–535,537–539
When performing AF ablation with
a force-sensing RF ablation
catheter, a minimal targeted
contact force of 5 to 10 grams
is reasonable.
IIa C-LD 453,468,668,670–686
Posterior wall isolation might be
considered for initial or repeat
ablation of persistent or long-
standing persistent AF.
IIb C-LD 522–529
Administration of high-dose
isoproterenol to screen for and
then ablate non-PV triggers
may be considered during
initial or repeat AF ablation
procedures in patients with
paroxysmal, persistent, or
long-standing persistent AF.
IIb C-LD 96,197,208,257,530,531,533–535,537–539
DF-based ablation strategy is of
unknown usefulness for AF
ablation.
IIb C-LD 587–594
The usefulness of creating linear
ablation lesions in the right or
left atrium as an initial or
repeat ablation strategy for
IIb B-NR 245,507–521
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Recommendation Class LOE References
persistent or long-standing
persistent AF is not well
established.
The usefulness of linear ablation
lesions in the absence of
macroreentrant atrial ﬂutter is
not well established.
IIb C-LD 245,507–521
The usefulness of mapping and
ablation of areas of abnormal
myocardial tissue identiﬁed
with voltage mapping or MRI as
an initial or repeat ablation
strategy for persistent or long-
standing persistent AF is not
well established.
IIb B-R 140,522,553–561
The usefulness of ablation of
complex fractionated atrial
electrograms as an initial or
repeat ablation strategy for
persistent and long-standing
persistent AF is not well
established.
IIb B-R 245,514–517,540,545–552
The usefulness of ablation of
rotational activity as an initial
or repeat ablation strategy for
persistent and long-standing
persistent AF is not well
established.
IIb B-NR 76,221–226,562–575
The usefulness of ablation of
autonomic ganglia as an initial
or repeat ablation strategy for
paroxysmal, persistent, and
long-standing persistent AF is
not well established.
IIb B-NR 103,105,114,116,122–124,245,355,
576–586
Nonablation strategies to
improve outcomes
Weight loss can be useful for
patients with AF, including
those who are being evaluated
to undergo an AF ablation
procedure, as part of a
comprehensive risk factor
management strategy.
IIa B-R 8,180,268,276–301
It is reasonable to consider a
patient’s BMI when discussing
the risks, beneﬁts, and
outcomes of AF ablation with a
patient being evaluated for an
AF ablation procedure.
IIa B-R 8,180,268,276–301
It is reasonable to screen for signs
and symptoms of sleep apnea
when evaluating a patient for
an AF ablation procedure and
to recommend a sleep
evaluation if sleep apnea is
suspected.
IIa B-R 283,289–291,302–320
Treatment of sleep apnea can be
useful for patients with AF,
including those who are being
evaluated to undergo an AF
ablation procedure.
IIa B-R 283,289–291,302–320
The usefulness of discontinuation
of antiarrhythmic drug therapy
prior to AF ablation in an effort
IIb C-LD 617–621
(Continued )
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Recommendation Class LOE References
to improve long-term
outcomes is unclear.
The usefulness of initiation or
continuation of antiarrhythmic
drug therapy during the
postablation healing phase in
an effort to improve long-term
outcomes is unclear.
IIb C-LD 617–621
Strategies to reduce the risks of
AF ablation
Careful identiﬁcation of the PV
ostia is mandatory to avoid
ablation within the PVs.
I B-NR 434,505,778,927,928,1143–1160
It is recommended that RF power
be reduced when creating
lesions along the posterior wall
near the esophagus.
I C-LD 341,417,637,806,866,900,906–911,920,
1162–1178,1398
It is reasonable to use an
esophageal temperature probe
during AF ablation procedures
to monitor esophageal
temperature and help guide
energy delivery.
IIa C-EO 341,417,910,1398
AF5 atrial ﬁbrillation; LOE5 Level of Evidence; PV5 pulmonary vein; RF5 radiofrequency; MRI5 magnetic resonance imaging; BMI5 body mass index.
e306 Heart Rhythm, Vol 14, No 10, October 2017indications for catheter and surgical ablation of AF when
performed by an electrophysiologist or a surgeon who
has received appropriate training and/or who has a certain
level of experience and is performing the procedure in an
experienced center (Section 11). Catheter and surgical
ablation of AF are highly complex procedures, and a care-
ful assessment of the beneﬁt and risk must be considered
for each patient. Second, these indications stratify patients
based only on the type of AF and whether the procedure is
being performed prior to or following a trial of one or
more Class I or III antiarrhythmic medications. This docu-
ment for the ﬁrst time includes indications for catheter
ablation of select asymptomatic patients. As detailed in
Section 9, there are many other additional clinical and
imaging-based variables that can be used to further deﬁne
the efﬁcacy and risk of ablation in a given patient. Some
of the variables that can be used to deﬁne patients in
whom a lower success rate or a higher complication rate
can be expected include the presence of concomitant heart
disease, obesity, sleep apnea, LA size, patient age and
frailty, as well as the duration of time the patient has
been in continuous AF. Each of these variables needs to
be considered when discussing the risks and beneﬁts of
AF ablation with a particular patient. In the presence of
substantial risk or anticipated difﬁculty of ablation, it could
be more appropriate to use additional AAD options, even
if the patient on face value might present with a Class I
or IIa indication for ablation. Third, it is important to
consider patient preference and values. Some patients are
reluctant to consider a major procedure or surgery and
have a strong preference for a pharmacological approach.
In these patients, trials of antiarrhythmic agents including
amiodarone might be preferred to catheter ablation. Onthe other hand, some patients prefer a nonpharmacological
approach. Fourth, it is important to recognize that some
patients early in the course of their AF journey might
have only infrequent episodes for many years and/or could
have AF that is responsive to well-tolerated AAD therapy.
And ﬁnally, it is important to bear in mind that a decision
to perform catheter or surgical AF ablation should only be
made after a patient carefully considers the risks, beneﬁts,
and alternatives to the procedure.
As demonstrated in a large number of published studies,
the primary clinical beneﬁt from catheter ablation of AF is
an improvement in QOL resulting from elimination of
arrhythmia-related symptoms, such as palpitations, fatigue,
or effort intolerance (see Section 9). Thus, the primary selec-
tion criterion for catheter ablation should be the presence of
symptomatic AF. The indications for catheter and surgical
ablation of symptomatic AF shown in Table 2, and summa-
rized in Figures 7 and 8, are for the most part consistent
with the indications for AF ablation recommended in the
recently published 2016 ESC Guidelines for the
Management of AF, as well as in the 2014 ACC/AHA/
HRS Guidelines for AF management.5,6 These
recommendations for AF ablation present the indications
for AF ablation as second-line therapy, after failure of a Class
I or III antiarrhythmic agent and also the indications for AF
ablation as ﬁrst-line therapy. As shown in Table 2, catheter
ablation is recommended for patients with symptomatic
PAF who have failed AAD therapy (Class I, LOE A). For pa-
tients with symptomatic persistent AF who have failed AAD
therapy, catheter ablation has a Class IIa, LOE B-NR indica-
tion, and for patients with symptomatic long-standing persis-
tent AF who have failed drug therapy, catheter ablation has a
Class IIb, LOE C-LD indication.
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to address for the ﬁrst time the important issue of catheter
ablation of AF in select asymptomatic patients. We have
also addressed the important issues of AF ablation as ﬁrst-
line therapy, the role of AF ablation in patients with HF,
and the role of AF ablation in subgroups of patients not
well represented in clinical trials. Each of these important
considerations is addressed in detail below.Catheter Ablation of AF as First-Line Therapy
The role of catheter ablation as ﬁrst-line therapy, prior to a trial
of a Class I or III antiarrhythmic agent, is an appropriate indi-
cation for catheter ablation of AF in patients with symptomatic
paroxysmal or persistent AF. These recommendations are
consistent with the indications for AF ablation recommended
in the recently published 2016 ESC guidelines for the
management of AF as well as in the 2014 ACC/AHA/HRS
Guidelines for AF management.5,6,375,376 For patients
with paroxysmal symptomatic AF who have not failed drug
therapy, catheter ablation has a Class IIa, LOE B-R
indication; for patients with persistent symptomatic AF who
have not failed drug therapy, catheter ablation has a Class
IIa, LOE C-EO indication; and for patients with long-
standing persistent AF who have not failed drug therapy, cath-
eter ablation has a Class IIb, LOE C-EO indication.
There have been three prospective randomized clinical
trials that have examined the relative efﬁcacy and safety of
ﬁrst-line AF ablation vs pharmacological therapy.377,378,379
The outcomes of these three trials have recently been
summarized in a meta-analysis.380 A total of 491 young,
generally healthy patients with predominantly PAF were ran-
domized to AF ablation vs pharmacological therapy. Cath-
eter ablation of AF was associated with a signiﬁcantly
higher freedom from AF recurrence, as compared with
drug therapy. The difference in the rate of symptomatic AF
recurrences was not signiﬁcant. There was one procedure-
related death due to a stroke in the ablation arm. The main
major complication was cardiac tamponade which occurred
in 1.7% of patients in the ablation arm. Taken as a whole,
these ﬁndings provide evidence to support the role of AF
ablation as ﬁrst-line therapy.
It is important to recognize that there are certain situations
in which ﬁrst-line AF ablation is a preferred treatment option.
For example, ﬁrst-line AF ablation is often recommended in
patients with PAF who have symptomatic pauses (tachy-
brady syndrome). For these patients, initiation of pharmaco-
logical therapy would be inappropriate in the absence of a
permanent pacemaker. Over the past 15 years, a body of liter-
ature has been published demonstrating that catheter ablation
is effective, without concomitant need of a permanent pace-
maker in the great majority of patients with tachy-brady
syndrome.381,382,383 Based on this body of literature and
the cumulative experience of the writing group, we believe
that it is appropriate to consider AF ablation as ﬁrst-line ther-
apy in this clinical situation. Another speciﬁc population ofpatients in whom ﬁrst-line AF ablation is often recommended
as an initial approach are high-level competitive athletes with
paroxysmal or persistent AF. These individuals often are
strongly against taking a medication, which could potentially
reduce their peak heart rate and/or impair cardiac function;
they often have a marked resting bradycardia. Several studies
have reported favorable outcomes of AF ablation in this sub-
group of patients.371,372,373Catheter Ablation of AF in Patients with Heart
Failure and Reduced Cardiac Function
AF and HF are closely related conditions. HF can predispose
an individual to the occurrence of AF through various mech-
anisms, such as the increase of the left ventricular ﬁlling pres-
sure or LA dilatation and ﬁbrosis, each of which can lead to
atrial structural and electrical remodeling. Conversely, AF
with the loss of atrial contraction and potential uncontrolled
heart rate secondary to arrhythmia can predispose an individ-
ual to the development of HF, thus leading to impaired
contractility and reduced cardiac output. AF can increase
mortality in patients with left ventricular dysfunction; there-
fore, the treatment of AF in this subset of patients is of pivotal
importance.
Much controversy still exists regarding how to maintain
sinus rhythm in patients with HF; undoubtedly, however,
maintenance of sinus rhythm is beneﬁcial in restoring
atrial-ventricular coordination, thus favoring an improved
left ventricular performance and a better QOL.
The published literature describing the safety and efﬁcacy of
AF ablation in patients withHF and/or a reduced EF is consider-
able. When viewed cumulatively, these published results
describe the outcomes ofAF ablation inmore than 1000 patients
with HF.233,234,235,236,237,384,385,386,387,388,389,390,391,392,393,394
Included within this large body of literature are four
prospective, randomized clinical trials, the results of which
were recently summarized in a meta-analysis.235,236,237,390,392
A total of 224 patients were randomized, among whom 83%
had persistent AF. AF ablation resulted in an increase in left
ventricular ejection fraction (LVEF) by a mean of 8.5%
compared with rate control alone. AF ablation also was
superior to rate control in improving QOL. Peak oxygen
consumption and 6-minute walk test distance increased in abla-
tion compared with rate control patients. Major adverse events
were not different in the two treatment arms. Themeta-analysis
of these four studies concluded that catheter ablation is
superior to rate control in improving LVEF, QOL, and func-
tional capacity. This conclusion is consistent with other data
that reveal that adequate rate control alone is insufﬁcient to pre-
vent AF-mediated cardiomyopathy in a subset of AF
patients.395 Prior to accepting a rate control strategy, patients
with HF and persistent AF or drug-refractory AF should be
advised to consider AF ablation.
Based on this growing body of data, the writing group be-
lieves that catheter ablation of AF is a safe, effective, and
clinically acceptable therapeutic option in patients with AF
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cardiomyopathy that is strongly suspected to be due to AF,
with a rapid ventricular response, as well as to other popula-
tions of patients with AF. The writing group recommends
that it is reasonable to use similar indications for AF ablation
in selected patients with HF as for patients without HF (Class
IIa, LOE B-R).Catheter Ablation in Older People
AF is in large part a disease of the older person. During the
past decade, there have been a number of studies that have
speciﬁcally focused on reporting the outcomes of AF ablation
in older individuals.396,397,398,399,400,401,402,403,404 The age
cutoff for deﬁning elderly varied between age 70 years,
age 75 years,397,402,404 and age 80 years.398,399,400,401
The number of older people in these studies was small,
with ﬁve of the seven studies enrolling fewer than 100
patients and the largest reporting outcomes on 261 older
people. Taken as a whole, the results of these studies
provide evidence that catheter ablation of AF has an
acceptable safety and efﬁcacy proﬁle in selected older
individual over the age of 75 or 80 years. However, as
shown in analysis of the relationship between age and
5-year outcomes of AF ablation,403 age signiﬁcantly impacts
long-term outcomes of AF ablation. This study reported that
for every 10-year increase in age there was a higher
multivariate-adjusted risk of AF recurrence, death, and major
cardiac events.
The writing group recommends that it is reasonable to use
similar indications for AF ablation in selected older people
with AF as in younger patients (Class IIa, LOE B-NR). It
is important to note that the complications of the procedure
are somewhat increased in older individuals, the need for
concomitant antiarrhythmic therapy postablation is greater,
and the efﬁcacy is somewhat reduced.396,405 It is also
important to recognize that amiodarone, although not a
good long-term pharmacological option in younger individ-
uals, is an appropriate treatment strategy in older people.Catheter Ablation in Other Populations of Patients
Not Well Represented in Clinical Trials
Shown in Table 2 are indications for AF ablation in several
additional subgroups of patients not well represented in clin-
ical trials. These subgroups include patients with hypertro-
phic dilated cardiomyopathy, young patients (,45 years of
age), high-level athletes, and patients with tachy-brady syn-
drome. The references supporting the recommendations of
the writing group are shown.Catheter Ablation to Reduce Stroke Risk
Patients with AF might seek catheter ablation to avoid long-
term oral anticoagulation (OAC) therapy. Multiple studies re-
ported a low thromboembolic risk in patients who discontin-
ued OAC after successful AF ablation.238,406,407,408,409,410,411
However, an important limitation of these studies is the
fact that only a small subset of patients had a CHA2DS2-VASc score 2, and almost no patients were at extreme
increased stroke risk due to a prior stroke or TIA and/or
age 75 years. Recent data from the German Ablation
Registry412 showed a high thromboembolic risk after abla-
tion in high-stroke-risk patients. Furthermore, it is well
recognized that both symptomatic and asymptomatic AF
can recur after AF ablation procedures,56,58,413 and late
recurrence of AF is observed in 50% or more patients by
5 years. Absence of symptomatic AF after ablation does
not necessarily indicate an absence of asymptomatic AF
or a low risk of stroke.414 The writing group also recom-
mends that systemic anticoagulation with warfarin or a
novel oral anticoagulant (NOAC) is recommended for at
least 2 months post-catheter ablation of AF (Class I, LOE
C-EO). The writing group recommends that decisions
regarding continuation of systemic anticoagulation more
than 2 months postablation should be based on the patient’s
stroke risk proﬁle and not on the perceived success or failure
of the ablation procedure (Class I, LOE C-EO, Table 4). An-
ticoagulation is recommended for patients with a
CHA2DS2-VASc score of 2 in men or 3 in women. For pa-
tients with one stroke risk factor (e.g., CHA2DS2-VASc 1 in
men or 2 in women), the role of OAC is borderline, and can
“be considered.” Anticoagulation is generally not recom-
mended 2 or more months post-AF ablation in patients
with a low stroke risk proﬁle (e.g., CHA2DS2-VASc 0 in
men or 1 in women) unless cardioversion is anticipated or
has recently been performed.415
The writing group also recommends that adherence to AF
anticoagulation guidelines is recommended for patients who
have undergone an AF ablation procedure, regardless of the
apparent success or failure of the procedure (Class I, LOE
C-EO, Table 4). Patients in whom discontinuation of antico-
agulation is being considered based on patient values and
preferences should consider undergoing continuous or
frequent ECG monitoring to screen for AF recurrence (Class
IIb, LOE C-EO, Table 4).414 A patient’s desire to eliminate
the need for long-term anticoagulation by itself should not
be considered an appropriate selection criterion for AF abla-
tion. In arriving at this recommendation, the writing group
recognizes that patients who have undergone catheter abla-
tion of AF represent a new and previously unstudied popula-
tion in trials of OAC therapy. Clinical trials are therefore
needed to deﬁne the stroke risk of this patient population
and to determine whether the risk factors identiﬁed in the
CHA2DS2-VASc or other scoring systems apply to these pa-
tients. Please refer to Section 7 for a more detailed discussion
of this topic and the writing group recommendations for long-
term anticoagulation.Catheter Ablation in Patients with Asymptomatic
AF
The writing group believes that AF ablation may be consid-
ered in select asymptomatic patients with paroxysmal or
persistent AF when performed by an experienced operator
and following a detailed discussion of the risks and beneﬁts
Table 4 Anticoagulation strategies: pre-, during, and postcatheter ablation of AF
Recommendation Class LOE References
Preablation For patients undergoing AF catheter ablation who have been
therapeutically anticoagulated with warfarin or
dabigatran, performance of the ablation procedure
without interruption of warfarin or dabigatran is
recommended.
I A 400,532,829,830,833,834,837,841
For patients undergoing AF catheter ablation who have been
therapeutically anticoagulated with rivaroxaban,
performance of the ablation procedure without
interruption of rivaroxaban is recommended.
I B-R 842
For patients undergoing AF catheter ablation who have been
therapeutically anticoagulated with a NOAC other than
dabigatran or rivaroxaban, performance of the ablation
procedure without withholding a NOAC dose is reasonable.
IIa B-NR 1395
Anticoagulation guidelines that pertain to cardioversion of
AF should be adhered to in patients who present for an AF
catheter ablation procedure.
I B-NR 5,6
For patients anticoagulated with a NOAC prior to AF catheter
ablation, it is reasonable to hold one to two doses of the
NOAC prior to AF ablation with reinitiation postablation.
IIa B-NR 835–840
Performance of a TEE in patients who are in AF on
presentation for AF catheter ablation and who have been
receiving anticoagulation therapeutically for 3 weeks or
longer is reasonable.
IIa C-EO 5,6
Performance of a TEE in patients who present for ablation in
sinus rhythm and who have not been anticoagulated prior
to catheter ablation is reasonable.
IIa C-EO 5,6
Use of intracardiac echocardiography to screen for atrial
thrombi in patients who cannot undergo TEE may be
considered.
IIb C-EO 768,820–824
During ablation Heparin should be administered prior to or immediately
following transseptal puncture during AF catheter ablation
procedures and adjusted to achieve and maintain an ACT of
at least 300 seconds.
I B-NR 768,802–804,820,830,840,846–849
Administration of protamine following AF catheter ablation
to reverse heparin is reasonable.
IIa B-NR 851
Postablation In patients who are not therapeutically anticoagulated prior
to catheter ablation of AF and in whom warfarin will be
used for anticoagulation postablation, low molecular
weight heparin or intravenous heparin should be used as a
bridge for initiation of systemic anticoagulation with
warfarin following AF ablation.*
I C-EO
Systemic anticoagulation with warfarin* or a NOAC is
recommended for at least 2 months postcatheter ablation
of AF.
I C-EO 1,2
Adherence to AF anticoagulation guidelines is recommended
for patients who have undergone an AF ablation
procedure, regardless of the apparent success or failure of
the procedure.
I C-EO 5,6
Decisions regarding continuation of systemic anticoagulation
more than 2 months post ablation should be based on the
patient’s stroke risk proﬁle and not on the perceived success
or failure of the ablation procedure.
I C-EO 5,6
In patients who have not been anticoagulated prior to
catheter ablation of AF or in whom anticoagulation with a
NOAC or warfarin has been interrupted prior to ablation,
administration of a NOAC 3 to 5 hours after achievement of
hemostasis is reasonable postablation.
IIa C-EO 835–840
Patients in whom discontinuation of anticoagulation is being
considered based on patient values and preferences should
consider undergoing continuous or frequent ECG
monitoring to screen for AF recurrence.
IIb C-EO
AF5 atrial ﬁbrillation; LOE5 Level of Evidence; NOAC5 novel oral anticoagulant; TEE5 transesophageal electrocardiogram; ACT5 activated clotting time.
*Time in therapeutic range (TTR) should be . 65% – 70% on warfarin.
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recognized that a decision to perform AF ablation in an
asymptomatic patient requires additional discussion with
the patient, given the potential beneﬁts of the procedure for
the patient without symptoms are uncertain. AF ablation is
not recommended for patients with asymptomatic long-
standing persistent AF. The justiﬁcation for making this
recommendation is as follows. First, it is well established
that the duration of time a patient is in continuous AF directly
impacts the outcomes of AF ablation or other rhythm control
strategies. Whereas AF ablation in patients with symptomatic
PAF is associated with high efﬁcacy, the efﬁcacy of AF abla-
tion in patients who have been in continuous AF for 2 or more
years is dramatically reduced. Second, it is well established
that AF is associated with an increased risk of stroke, HF, de-
mentia, and mortality. It is also notable that asymptomatic
status is associated with similar (or worse) prognosis
compared with symptomatic status.48 Furthermore, the risk
of stroke has been shown to be lower in patients with parox-
ysmal rather than continuous AF. Although large-scale, pro-
spective, randomized clinical trials have not been performed
to evaluate the impact of AF ablation on stroke risk, demen-
tia, HF, and mortality, it is plausible that maintenance of si-
nus rhythm will ultimately be shown to reduce these risks.
While awaiting the results of these trials, it is important to
recognize that if a physician makes a decision to leave a pa-
tient with apparent asymptomatic continuous AF in AF rather
than to pursue restoration of sinus rhythm, it will be
extremely difﬁcult or impossible to restore and maintain si-
nus rhythm later in this patient’s life.
There have been three small studies that have described
the safety and efﬁcacy of AF ablation in patients with
asymptomatic AF.416,417,418 The ﬁrst compared the
outcomes of 54 patients with asymptomatic subclinical
AF with 486 patients with drug-refractory symptomatic
AF.416 No difference in safety or efﬁcacy of the procedure
was observed at the 24-month follow-up. The second study
reported the outcomes of 61 patients with asymptomatic
long-standing persistent AF.417 At 50 6 5 months’
follow-up, 57% remained AF recurrence-free after removal
from drugs. QOL improved, with the physical component
summary and the mental component summary demon-
strating substantial improvement. Improvement was also
noted on metabolic stress testing. A third study compared
the outcomes of 61 patients with asymptomatic persistent
AF with 132 otherwise matched symptomatic patients
with AF.418 In this study, the outcomes of ablation were su-
perior in the symptomatic patients compared with the
asymptomatic patients (71% vs 27% freedom from AF).
Also of note was the fact that 16 patients (37%) in the
asymptomatic group developed symptomatic AT. Perhaps
not surprisingly, the asymptomatic patients showed less
improvement in QOL than the symptomatic patients. The
study concludes that the outcomes of AF ablation are worse
in asymptomatic patients, predominantly due to the risk of
developing a symptomatic AT postablation of asymptom-
atic AF. There are no prospective randomized clinical trialsthat determine the beneﬁt and risk ratio of ablation in pa-
tients with asymptomatic AF.
While considering the issues of rhythm control and AF
ablation in apparently asymptomatic AF patients, the writing
group of this document feels it is important to note that many
patients with apparently asymptomatic AF are in fact symp-
tomatic once an assessment of how the patient feels in sinus
rhythm has been carried out. It has become common practice,
when faced with a relatively young person with apparently
asymptomatic persistent AF, to cardiovert the patient, with
or without concomitant use of antiarrhythmic medications,
and then reassess the patients’ symptom status while in sinus
rhythm. In our experience, many patients subjected to this
“trial of sinus rhythm” recognize that they feel better in sinus
rhythm. This ﬁnding is important because a rhythm control
strategy and/or catheter ablation then becomes a more accept-
able therapeutic strategy.
At the end of the day, the writing group believes that in
selected patients, after a careful discussion of the risks, ben-
eﬁts, and alternatives, that AF ablation may be considered in
patients with asymptomatic paroxysmal or persistent AF
(Class IIb, LOE C-EO) (Table 2). Patients in whom this man-
agement strategy should be entertained include patients
whose clinical proﬁle would be associated with a high efﬁ-
cacy and safety of AF ablation.Indications for Surgical Ablation of AF
Indications for surgical ablation of AF are also shown in
Table 2 and are summarized in Figure 8. Safety and efﬁcacy
of AF ablation have been well supported for a surgical
approach, either performed in conjunction with another car-
diac surgical procedure or when carried out as a stand-
alone procedure. The rationale and detailed indications for
surgical ablation of AF are discussed in more detail in
Section 12.Section 5: Strategies, Techniques, and
Endpoints
Historical Considerations
Cox and colleagues are credited with developing and demon-
strating the efﬁcacy of surgical ablation of AF.419,420
Subsequent surgeons evaluated the efﬁcacy of surgical
approaches that limit the lesion set to PVI.421,422 The ﬁnal
iteration of the procedure developed by Cox, which is
referred to as the MAZE-3 procedure, was based on a model
of AF in which maintenance of the arrhythmia was shown to
require a critical number of circulating wavelets for reentry.
The success of the Maze-3 procedure in the early 1990s led
some cardiac electrophysiologists to attempt to reproduce
the procedure with RF catheter ablation. Swartz and col-
leagues reported replication of the MAZE-1 lesion set in a
small series of patients using specially designed sheaths
and standard RF ablation catheters.423 The efﬁcacy was
modest, the complication rate was high, and the procedure
and ﬂuoroscopy times were long. As a result, this approach
was quickly abandoned. This report demonstrated a proof
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based ablative treatment of AF. Subsequently, a large number
of investigators attempted to replicate the surgical MAZE
procedure through the use of either three-dimensional (3D)
mapping systems or the use of multipolar ablation catheters.
These clinical trials had limited success.424,425,426,427,428,429
Based on these observations and the rapid advances in
ablation of AF targeting focal triggers that initiate AF in
the PVs, electrophysiologists lost interest in linear non-PV-
based approaches to catheter ablation of AF that attempted
to replicate various aspects of the surgical MAZE procedure.
The identiﬁcation by Haissaguerre and colleagues of trig-
gers that initiate AF within the PVs led to prevention of AF
recurrence by catheter ablation at the site of the origin of
the trigger.197,430,431,432,433 Direct catheter ablation of the
triggers was limited by the infrequency with which AF
initiation could be reproducibly triggered. To overcome
these limitations, an ablation approach was introduced433
that was designed to electrically isolate the PVs. This
segmental PVI technique involved the sequential identiﬁca-
tion and ablation of the PV ostium close to the earliest sites
of activation of the PV musculature. An ablation strategy
of encircling the PVs guided by 3D electroanatomical map-
ping (EAM) was subsequently developed by Pappone
et al.244,432
The recognition of PV stenosis as a complication of RF
delivery within a PV, as well as the recognition that sites of
AF initiation and/or maintenance were frequently located
within the PV antrum, resulted in a shift in ablation strategies
to target the atrial tissue located in the antrum rather than in
the PV itself.434,435 Ablation at these sites was either
performed segmentally, guided by a circular mapping
catheter433,436 positioned close to the PV ostium, the so-
called segmental PV ablation, or by wider continuous
circumferential ablation lesions created to surround the right
or left PVs,244,432 the so-called wide-area circumferential
ablation (WACA). The circumferential ablation or isolation
line was either guided by 3D EAM,244,437,438 by
ﬂuoroscopy,439 or by intracardiac echocardiography
(ICE).435,440 Studies comparing these two procedures
reported contradictory data.441,442 A subsequent
randomized study compared isolation of each individual
PV vs isolation of large areas around both ipsilateral PVs.
This study reported that isolation of a large circumferential
area around both ipsilateral PVs with veriﬁcation of
conduction block is a more effective treatment of AF than
segmental isolation of each PV.443 The endpoint for this pro-
cedure was either amplitude reduction within the ablated
area,244,437 elimination (or dissociation) of the PV
potentials recorded from either one or two circular mapping
catheters, or a basket catheter within the ipsilateral
PVs435,438,439,441,442,444 and/or exit block from the PV.445
PVI is now widely accepted as the cornerstone of AF abla-
tion procedures (Table 3).2 Electrical isolation of the PVs is
recommended during all AF ablation procedures (Class I,
LOE A). Elimination (or dissociation) of the PV potentials
recorded from a multipolar electrode catheter is the primaryendpoint for AF ablation procedures for 95% of the writing
group members. A single-catheter approach to AF ablation,
without employing a circular multipolar electrode catheter
as an ablation endpoint, is used by 5% of the writing group
members, whereas 95% employ both an ablation catheter
and a mapping catheter in the LA when performing AF abla-
tion using either RF energy or cryoballoon (CB) ablation
(CBA). Due to the high recurrence rate observed in patients
with persistent and long-standing persistent AF with PVI
alone, efforts continued to identify additive strategies to
improve the outcomes of AF ablation. These strategies
have included linear RF lesions in the LA and RA, ablation
of autonomic ganglia, ablation by CFAE, ablation of non-
PV foci, isolation of the LAA, ablation of scar identiﬁed by
voltage mapping or MRI, and most recently, ablation of rota-
tional activity. Whether any or all of these strategies will
emerge as standard proven components to AF ablation pro-
cedures will be determined over time. The results of the
recent randomized Substrate and Trigger Ablation for Reduc-
tion of AF Trial Part II (STAR AF II) trial failed to demon-
strate any reduction in AF recurrence by adding either
linear or CFAE ablation to PVI in patients with persistent
AF.245 This study represented a sobering landmark in the
ﬁeld of AF ablation, which has served to remind those in
the ﬁeld that rigorous clinical trials are needed to deﬁne the
safety and efﬁcacy of a particular ablation strategy before it
is adopted widely as part of routine clinical care. Other ad-
vancements in the ﬁeld include the introduction of the
CBA system, as well as the introduction of force-sensing
ablation catheters. In the following sections of this document
we will go through the data supporting each of these ap-
proaches and technologies in detail. We will also provide
input as to the importance of these approaches as assessed
by this large international writing group.Ablation Approaches Targeting the PVs and
Techniques to Obtain Permanent PVI Using RF
Energy
Permanent electrical isolation of the PVs is well established as
the cornerstone of AF ablation. Despite the importance of this
ablation endpoint, permanent electrical isolation of the PVs can
rarely be achieved.263,446,447,448,449,450,451,452,453,454,455,456
Among patients returning to the electrophysiology laboratory
for a repeat ablation procedure after failing an initial ablation
procedure, most studies report that recurrence of PV
conduction is observed in one or more PVs in more than
80% of patients.263,446,447,452,454
Studies have also been performed to deﬁne the rate of PV
reconduction among patients who are AF-free after an initial
PVI procedure. Although several of these series reported
rates of PV reconduction less than 20%,263,447 most studies
have reported far higher reconduction rates, varying from
62% to 90%.449,454,456 The time course of electrical
reconduction appears to be rapid, with studies reporting
acute reconduction rates of 33% at 30 minutes448,450,451
and 50% at 60 minutes.457 In this section of the document,
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attempt to improve the rate of permanent PVI. We will also
provide input concerning which approaches are most widely
used by the writing group members of this document.
Optimal Initial Lesion Creation and Waiting Phase
It is widely recognized that the likelihood of obtaining per-
manent PVI is related to the quality of ablation energy deliv-
ery and lesion formation. There are many factors that play a
role in determination of lesion size. With RF energy it is well
recognized that important variables that impact lesion size
and transmurality include catheter stability, contact force
(CF), power output, temperature, and duration of RF output.
Please refer to Section 6 of this document for a more detailed
discussion of these topics. Each of these variables is of
importance. The writing group recommends that when per-
forming AF ablation with a force-sensing RF catheter, that
a minimum targeted CF of 5 to 10 grams is reasonable (Class
IIa, LOE C-LD) (Table 3).
The writing group also recommends that it is reasonable
to use an esophageal temperature probe during RF ablation
procedures to monitor esophageal temperature and help
guide energy delivery (Class IIa, LOE C-EO) (Table 3).
In contrast to these two topics on which consensus was
achieved, there is much less consensus regarding power
output and the duration of energy delivery because a wide
variety of approaches are used by members of the writing
group.
One of the approaches that has been proposed as a tech-
nique to increase the rate of permanent PVI is to incorporate
a 20- to 30-minute waiting period following initial isolation
of each PV. The prevalence of time-induced PV reconnection
is most frequent at 30 minutes, with a signiﬁcant proportion
of patients having further reconnection at 60 minutes and very
few between 60 and 90 minutes.265,448,450,451,457,459,460,461
In a retrospective study including patients undergoing a
repeat ablation procedure for recurrent AF, receiver
operating characteristic analysis revealed a strong
negative correlation between the observation time after
complete PVI during the initial procedure and chronic
PV reconnection.452 The optimal cutoff value was 35 mi-
nutes, although the diagnostic accuracy was not high
(sensitivity 66.9%, speciﬁcity 60.6%). A small, prospec-
tive randomized trial comparing the outcomes of AF abla-
tion in which no waiting period, a 30-minute, and a 60-
minute waiting period was incorporated into the ablation
procedure revealed a clear beneﬁt of incorporating a 30-
minute or longer waiting phase (60.7%, 84.3%, and
86.7%, respectively).457 It is notable that reevaluation of
the need for a waiting phase has not been reassessed since
the widespread availability of contact force-sensing (CFS)
ablation catheters. The need for a waiting phase has been
less completely assessed with CB AF ablation. The Sus-
tained Treatment of Paroxysmal Atrial Fibrillation
(STOP-AF) Trial did require a 30-minute waiting period
before termination of the observation period. It is unclear
whether this contributed to the 69.9% success rate in elim-ination of AF, although those outcomes are similar to
equivalent studies during that time frame.462
The above data would suggest that a 20- to 30-minute
waiting phase is reasonable to incorporate into an AF ablation
procedure. A limitation of a longer observation period is the
impact on the total procedure duration and work ﬂow in the
electrophysiology laboratory. A survey of the writing group
members shows that 80% incorporate at least a 20-minute
waiting period following initial isolation of the PVs when
performing AF ablation with RF energy. Based on this infor-
mation, the published literature, and the experience of this
writing group, the writing group recommends that moni-
toring for PV reconnection for 20 minutes following initial
PVI “is reasonable” (Class IIa, LOE B-R) during AF ablation
using RF energy (Table 3).
Adenosine Testing
Intravenous adenosine (or adenosine triphosphate [ATP]) can
transiently restore cellular excitability and differentiate per-
manent conduction block from dormant conduction (e.g.,
viable but latently nonconducting tissue) across circumferen-
tial PV ablation (CPVA) lines.463,464,465,466,467 The ability of
adenosine to unmask dormant PV reconnection is impacted
by the adenosine dose as well as by the waiting time since
initial documentation of PVI.466,467 The results of one
recent study suggest that the demonstration of a
physiological effect of adenosine (e.g., sinus tachycardia,
hypotension) is inadequate, and that sufﬁcient adenosine
needs to be administered to demonstrate transient AV
block.467 There have been more than a dozen studies that
have investigated the role of adenosine as an adjunct to
achieving permanent PVI and improving the outcomes of
AF ablation; these are summarized in a recent review
article.466 Among these studies are two large, prospective,
randomized clinical trials.
The ﬁrst study was a prospective, randomized clinical trial
involving 534 patients with PAF. All the patients were
administered adenosine 20 minutes following initial PVI.
The initial dose was 12 mg, which was titrated until at least
one blocked P wave or a 3-second pause was observed.265
The presence of dormant PV conduction was associated
with an increased risk of arrhythmia recurrence. Patients
with dormant PV conduction were randomly assigned to
additional adenosine-guided or to no further ablation. Elimi-
nation of dormant PV conduction by additional targeted abla-
tion signiﬁcantly reduced recurrent atrial tachyarrhythmias
(ATAs) by 56% during follow-up (P ,.0001).265 The most
recent study enrolled 2113 patients with paroxysmal, persis-
tent, and long-standing persistent AF.461 In this study, 0.4 mg
per kg of adenosine was administered after a variable waiting
time (median time 43 minutes). Early reconduction after the
waiting time alone was observed in 42% of the patients in
both groups. Subsequent administration of adenosine demon-
strated further reconduction in an additional 27% of the pa-
tients. Further ablation was then performed to eliminate
dormant conduction. At the end of 1 year of follow-up, no
difference in outcome was observed, with a success rate of
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observed 27.6% prevalence of dormant conduction in the
latter trial, a risk reduction of 72.4% in those patients with
dormant conduction would have been required to detect a sig-
niﬁcant overall difference.466 It is also notable that the use of
force-sensing ablation catheters is associated with a signiﬁ-
cant reduction in the prevalence of dormant conduction,
therefore limiting the impact of an adenosine-guided ablation
strategy on clinical outcome.468
Although the above data would suggest that administra-
tion of adenosine 20 minutes after initial PVI at a dose titrated
to achieve AV block or a 3-second pause could improve out-
comes of AF ablation, the impact of such a strategy is limited.
Furthermore, the addition of an adenosine testing strategy
prolongs procedure time and increases costs. A survey of
the writing group members shows that 61% routinely incor-
porate use of adenosine into their ablation procedure when
using RF energy and 25% incorporate this approach into their
ablation strategy when using CB. Based on this information,
the published literature, and the experience of this writing
group, the writing group recommends that administration
of adenosine 20 minutes after initial PVI phase “may be
considered” (Class IIb, LOE B-R) during AF ablation
(Table 3).Isoproterenol Infusion
Some studies reported the use of adenosine during isoproter-
enol infusion to unmask dormant PV conduction.460,469,470 A
prospective clinical and experimental evaluation of various
pharmacological strategies found that adenosine was
superior to an isoproterenol infusion, with no signiﬁcant
additional value of combining the two.471 Therefore,
although isoproterenol infusion can be used to identify
non-PV triggers in paroxysmal and persistent AF, there is
only a limited role of isoproterenol infusion alone to reveal
dormant PV conduction after PVI. A survey of writing group
members shows that less than one-third administer isoproter-
enol to search for PV reconnection.Loss of Pace Capture on the Ablation Line
The use of a pace capture-guided ablation strategy as an addi-
tional endpoint in PVI procedures has been proposed as
another method to improve the durability of PVI.264,472,473,474,475
Using this approach, after completion of PVI, high-output
pacing (10 mA) from the ablation catheter’s distal bipole is
performed during sinus rhythm while slowly moving the
catheter along the entire circumference of the ipsilateral
PVI lines.264,472 Where local LA capture is identiﬁed,
additional ablation is performed until loss of capture, with
the goal of closure of the residual gaps. In a recent
randomized study involving 102 patients at two centers,
this technique signiﬁcantly improved arrhythmia-free sur-
vival compared with conventional PVI.474 Another study
compared an ablation strategy of loss of pace capture vs aden-
osine administration to identify dormant conduction. The
outcomes were no different in the two groups.473 Anotherstudy revealed that a strategy of pace-capture-guided PVI
was found to be associated with a signiﬁcant reduction in
dormant PV conduction revealed by adenosine.475 It is also
notable that reevaluation of value of pace capture has not
been reassessed since the widespread availability of CFS
ablation catheters.
Although the above data would suggest that using pace
capture might improve outcomes of AF ablation, the data
are somewhat limited and have been published from a very
small number of centers. Like other strategies to improve out-
comes of AF ablation, this strategy also prolongs procedure
time. A survey of the writing group members shows that
24% routinely incorporate the strategy of pace capture
when using RF energy. This strategy is not applicable for
the CB approach. Based on this information, the published
literature, and the experience of this writing group, the
writing group recommends that pace-capture-guided ablation
strategy may be considered following PVI with RF energy
(Class IIb, LOE B-R) (Table 3).Exit Block
Although the demonstration of entrance conduction block is
the standard endpoint of PVI procedures, permanent PV exit
conduction block (or the “stable absence of PV-LA conduc-
tion”) is the ultimate goal for prevention of PV-induced AF.
Exit block can be demonstrated either by spontaneous dis-
charges recorded circumferentially around the PV or by
continuing arrhythmia within the PV, which are dissociated
from sinus rhythm or by pacing from within the PV.476 In
the case of PV pacing, it is imperative to demonstrate local
PV capture without conduction to the LA to prove exit block.
It is also important to avoid inadvertent capture of adjacent
far-ﬁeld structures, which would result in misinterpretation
of apparent exit conduction.477,478 The presence of entrance
block appears to be effective in predicting bidirectional
block across CPVA lines.141,142,143 Mechanistically, the
most likely explanation is source–sink mismatch, which is
deﬁned as delay or block of conduction observed when the
size of a given excited region supplying depolarizing
current (the current source) is insufﬁcient for the amount of
depolarizing current necessary to excite the regions ahead
(the current sink).479 Although an initial report has observed
unidirectional entrance block in more than 40% of PVs,445
the incidence was much lower in more recent studies
(1.5%–16%).477,479,480,481 Interestingly, in one of these
studies, the presence of PV discharges conducted to the LA
(exit conduction) was followed by recovery of entrance
conduction during a 30-minute waiting period.480 None of
the reported studies compared success rates of PVI using
only veriﬁcation of PV entrance block vs bidirectional PV
conduction block.
The above data would suggest that demonstration of exit
block is feasible, and is a reasonable endpoint for AF ablation
when combined with the presence of exit block. A survey of
the writing group members shows that 60% routinely pace in
the PV and employ exit block as an endpoint during AF
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and employ exit block as an endpoint during CBA. Based on
this information, the published literature, and group experi-
ence, the writing group recommends that demonstration of
exit block may be considered following PVI with RF or
CB energy (Class IIb, LOE B-NR) (Table 3).
Techniques for Obtaining Permanent PVI with
Balloon Technologies
PVI is the cornerstone of all ablation strategies in AF. How-
ever, it is still challenging, and there exists a considerable
learning curve to develop the skills needed to safely and
effectively perform RF AF under 3D electroanatomical guid-
ance. Therefore, novel catheter designs with alternative en-
ergy sources have been developed. These catheter
technologies are balloon-based ablation systems using
various energy modalities, such as cryoenergy (Arctic Front,
Medtronic, Inc., Minneapolis, MN, USA), laser (Heartlight,
CardioFocus, Marlborough, MA, USA), and radiofrequency
catheter (RFC) (Hot Balloon Catheter, Hayama Arrhythmia
Institute, Kanagawa, Japan). These technologies will be dis-
cussed in detail in the technologies section of this document.
The present section will focus on some of the strategies that
have been developed to facilitate the endpoint of achieving
permanent PVI.Obtaining Permanent PVI with the Cryoballoon
The ﬁrst-generation CB was introduced approximately 10
years ago and consisted of a noncompliant balloon with
two different diameters (23 mm and 28 mm), using N2O as
the refrigerant. A stiff wire or a spiral mapping catheter
(Achieve, Medtronic, Inc.) is inserted via a central lumen
of the catheter shaft. Applying the ﬁrst-generation CB and
freeze cycle durations of 300 seconds, successful PVI was
routinely followed by a bonus freeze cycle of the same dura-
tion. The 1-year success rate was approximately 70%–
73%.462,482 More than 80% of the patients with AF
recurrence after ﬁrst-generation CB-based PVI demonstrated
recurrence of conduction at the time of a repeat ablation pro-
cedure.483 The second-generation CB (Arctic Front Advance,
Medtronic, Inc.) was introduced in 2012 and incorporates a
modiﬁed refrigerant injection system characterized by 8 in-
jection jets in a more distal balloon position. Thus, a more ho-
mogeneous cooling of the complete distal balloon
hemisphere, including the distal tip, was achieved. Multiple
studies have demonstrated clinical success rates of 65% or
greater.484,485,486,487,488,489,490,491,492,493 The recently
published FIRE AND ICE trial was the ﬁrst to compare the
acute and long-term efﬁcacy as well as the safety proﬁle of
the second-generation CB with conventional RFC ablation
in a prospective, randomized, multicenter fashion.489 The
study demonstrated the noninferiority of CBA compared
with RF-based ablation with respect to efﬁcacy and safety
of patients with drug-refractory PAF.494 However, secondary
endpoints, such as the rate of rehospitalization and reabla-
tions, or the necessity of electrical cardioversion duringfollow-up were in favor of CB.490 Among patients who fail
AF ablation with the CB2 system, recurrent PV conduction
is observed in 27% to 65% of patients.487,491 The role of
adenosine in revealing dormant conduction has also been
evaluated. One study reported that administration of 12 mg
or more of adenosine (titrated to AV block) 30 minutes
postablation resulted in an 11% incidence of recurrent PV
conduction.495 A second study reported similar ﬁndings,
with a 12% incidence of recurrent conduction after a waiting
phase plus adenosine administration. This small study of 90
patients reported a higher success rate (84% vs 79%) when a
strategy of reablation based on adenosine-induced dormant
conduction was targeted.495
A survey of the writing group shows that only 51% of the
writing group members employ a 20-minute or longer wait-
ing phase when using CBA. This survey also revealed that
46% of operators routinely pace in the PV and employ exit
block as a secondary endpoint during AF ablation using
CB energy.Endoscopic Laser Balloon PVI
The endoscopic laser balloon is a recently introduced balloon-
based ablation system incorporating a titratable laser source
and a 2F endoscope. This ablation system received U.S.
Food and Drug Administration (FDA) approval in the United
States for ablation of PAF in 2016. It consists of a compliant
balloon (9–35 mm) that can be adapted according to the indi-
vidual PV diameter. The laser arc covers 30 of a complete
circle and allows energy titration in ﬁve steps, from 5.5 W
to a maximum of 12 W. The rate of acute PVI when applying
this system is 98%–100%.496,497,498,499 A study in which 52
patients underwent chronic reassessment of PV conduction
revealed that 14% of PVs demonstrated reconnection,
translating to 38% of patients with reconduction of one or
more veins.497 The application of higher energy levels (8.5
W or 10 W) was associated with a signiﬁcant increase in
the rate of acute PVI after a purely visually guided ablation
circle.500,501,502 At the same time, the application of higher
energy settings did not compromise the safety proﬁle. One-
year clinical follow-up data from two prospective, multicenter
studies in patients with PAF demonstrated a single-procedure
clinical success rate of 63% and 60% with no anti-arrhythmic
medication.498,499 A prospective comparison with RF
ablation revealed equivalent 1-year outcomes, with a success
rate of 61%.503 There have been no studies that have exam-
ined how often vein reconnection is observed within the ﬁrst
60 minutes post-PVI. There are also no data on the role of
adenosine.
Adjunctive Ablation Strategies to Be Performed in
Addition to PVI During AF Ablation
Cavotricuspid Isthmus Ablation
Catheter ablation of typical AFL involving the cavotricuspid
isthmus is a safe, effective, and well-established ablation pro-
cedure. For patients undergoing AF ablation, creation of a
cavotricuspid isthmus line can be performed safely, easily,
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vey of the writing group members shows that ablation of the
cavotricuspid isthmus is performed by 94% of the writing
group members in patients undergoing AF ablation who
have previously been documented by ECG to have experi-
enced isthmus-dependent AFL, as well as those with induc-
ible cavotricuspid isthmus-dependent AFL at the time of
the ablation procedure. This is based on decades of experi-
ence demonstrating the safety and efﬁcacy of catheter abla-
tion of AFL as well as data from clinical trials comparing
ablation with AAD therapy.230,504,511,1397 The writing
group recommends that if a patient has a history of typical
AFL or typical AFL is induced at the time of AF ablation,
delivery of a cavotricuspid isthmus linear lesion is
recommended (Class I, LOE B-R, Table 3).Linear Lesions Not Involving the Cavotricuspid Isthmus
Circumferential isolation of PVs has become the standard
therapy for PAF. However, due to the high recurrence rate
observed in patients with persistent and long-standing persis-
tent AF with PVI alone, continued efforts are underway to
identify additive strategies to improve outcome. One of these
strategies is to create additional linear lesions in the LA
similar to those that are a part of that advocated with the
Cox-Maze III lesion set (Figure 6).505,506 The most
common sites for linear ablation are the LA “roof”
connecting the superior aspects of the left and right upper
PVI lesions, the region of tissue between the mitral valve
and the LIPV (the mitral isthmus), and anteriorly between
the roof line near the left or right circumferential lesion and
the mitral annulus. A prior randomized, prospective trial of
catheter ablation of PAF comparing segmental PVI vs
CPVA plus LA linear ablation (CPVA-LALA) at the LA
roof and myocardial infarction showed that signiﬁcantly
more patients had LA ﬂutter in the CPVA-LALA group.507
A survey of the writing group shows that only 2% perform
linear ablation during an initial AF ablation in patients with
PAF. For redo ablation procedures in PAF, only 10% of
the writing group members routinely employ linear ablation.
Based on this information, the published literature, and the
experience of this writing group, we recommend that creation
of linear lesions not be performed during initial or redo AF
ablation for PAF unless a macroreentrant AT is induced.
The role of additional lines in cases of persistent AF remains
controversial.508 The recently completed STAR-AF study of
ablation strategies for persistent AF showed no improvement
in ablation efﬁcacy for linear lesions plus PVI vs PVI
alone.245 The Catheter Ablation of Persistent Atrial Fibrilla-
tion (CHASE-AF) study also revealed that the addition of
linear lesions and defragmentation of PVI did not improve
outcomes for ablation of persistent AF compared with PVI
alone.509 For patients with persistent or long-standing persis-
tent AF, 25% of the writing group members perform linear
ablation at the time of an initial ablation procedure,
increasing to 45%when redo procedures are performed in pa-
tients with persistent and long-standing persistent AF. Thewriting group recognizes that the usefulness of linear ablation
lesions in the absence of macroreentrant AFL is not well es-
tablished (Class IIb, LOE C-LD). For patients with PAF,
linear ablation should not be performed. The usefulness of
creation of linear ablation lesions in the RA or LA as an initial
or repeat ablation strategy for persistent or long-standing
persistent AF is not well established (Class IIb, LOE B-
NR) (Table 3). It has been widely demonstrated that incom-
plete block across the ablation lines can be responsible for AT
recurrence.510,511,512,513 Therefore, if linear ablation lesions
are applied, operators should use mapping and pacing
maneuvers to assess for line completeness (Class I, LOE C-
LD) (Table 3). Well-designed, prospective, randomized clin-
ical trials must be the ultimate test of linear ablation tech-
niques.
In patients with long-standing persistent AF, the step-
wise approach has been proposed.514,515 The strategy
starts by pulmonary isolation, followed by ablation of
CFAE, looking for reversion to sinus rhythm or AT. If
this endpoint is not achieved, additional linear lesions are
deployed.514,516,517 Whether the endpoint of AF
termination is associated with improved long-term results
remains controversial.518 Despite encouraging acute out-
comes, with termination of AF in 80% of patients, the
follow-up data were less impressive with a 1-year single
procedure efﬁcacy of 35% and a 5-year efﬁcacy of 17%.
Arrhythmia-free survival rates after the last procedure
(mean 2.1 6 1.0 procedures) were 89.7% 6 2.5%,
79.8% 6 3.4%, and 62.9% 6 4.5%, at 1, 2, and 5 years,
respectively.515 More recent data also suggest that linear
ablation does not improve outcomes compared with PVI
alone.245,515,519,520,521 The recently completed CHASE-
AF study also reported no improvement in efﬁcacy for
ablation of persistent AF with PVI plus linear lesions and
defragmentation compared with PVI alone.509 The clinical
signiﬁcance of these data, which appear to be contrary to
our understanding of the mechanisms of AF, predicting
that AF is less likely to be sustained in electrophysiologi-
cally smaller, segmented atria, is of clinical importance.
Potential explanations for this discrepancy might be that
the linear lesions are incomplete, are in the wrong place,
or that our understanding of the AF mechanism is incor-
rect.Posterior Wall Isolation
Some patients with PAF can be undertreated with PVI alone,
and PVI might not be enough to control persistent and long-
standing persistent AF. Further modiﬁcation of the atrial sub-
strate might be required. One of the strategies that has been
proposed is electrical isolation of the posterior wall. This
can be performed by creating a linear ablation of the LA
roof joining the superior PVs and the LA ﬂoor joining the
inferior PVs or by point-by-point ablation of the entire poste-
rior wall (Figure 6). Entrance block of the box lesion is
conﬁrmed by lack of potentials in the box. Exit block of
the box lesion is conﬁrmed by pacing in the box and
e316 Heart Rhythm, Vol 14, No 10, October 2017demonstrating exit block during sinus rhythm. Gaps along
the ablation lines, if present, are mapped and ablated.522,523,
524 With lack of LA capture outside the box, the lines are
considered complete. The endpoint of box isolation is
deﬁned as bidirectional conduction block, i.e., both lack of
potentials in the box and lack of LA capture.
Although some studies have been published that report
improved outcomes,525,526 with posterior wall isolation,
other clinical trials report no improvement on
outcomes.527 The recently published BELIEF trial reported
at 28% efﬁcacy of an extensive ablation strategy, including
ablation of the posterior wall, in patients with long-standing
persistent AF.528,529 A survey of the writing group shows
that 15% of the writing group members perform posterior
wall isolation in patients with PAF during an initial AF
ablation procedure, and 18% isolate the posterior wall
during a repeat ablation procedure in a patient with PAF.
The role of posterior wall isolation in cases of persistent
AF also remains controversial.508 For patients with persis-
tent or long-standing persistent AF, 22% of the writing
group members perform posterior wall isolation at the
time of an initial AF ablation procedure and 38% of the
writing group members perform posterior wall isolation
for repeat AF ablation procedures in patients with persistent
and long-standing persistent AF. Based on this information
and a review of the literature, the writing group recommends
that posterior wall isolation might be considered during an
initial or repeat AF ablation for paroxysmal, persistent, or
long-standing persistent AF (Class IIb, LOE C-LD,
Table 3).
Nonpulmonary Vein Triggers
Non-PV “triggers” can be identiﬁed in 10%–33% of
unselected patients referred for catheter ablation of
AF.96,197,208,257,530,531,532,533,534 The prevalence of non-PV
triggers in different studies varies with the speciﬁc deﬁnition
adopted, which ranges from repetitive atrial premature depo-
larizations without deﬁnitive AF initiation532,533 to
reproducible sustained AF triggering.534 Supraventricular
tachycardias, such as AV nodal reentry or accessory
pathway-mediated AV reciprocating tachycardia, can also
be identiﬁed in up to 4% of unselected patients referred for
AF ablation and can serve as a triggering mechanism for
AF.458 Non-PV triggers can be provoked in patients with
both paroxysmal and more persistent forms of AF.531,534 In
selected patients with reproducible non-PV triggers and
without provocable PV AF triggers with high-dose isoproter-
enol, elimination of only the non-PV triggers has resulted in
elimination of AF.96,458,535
The most common sites of origin for non-PV atrial triggers
include the posterior wall of the LA, the SVC, the crista termi-
nalis, the fossa ovalis, the CS, the eustachian ridge, the liga-
ment of Marshall, and adjacent to the AV valve annuli
(Figure 4).96,208,458,530,531,536 More recently, frequent and
repetitive atrial premature depolarizations have been
identiﬁed in the LAA in patients with more persistent AF,
which have been targeted by LAA isolation techniques.532,533Isoproterenol is the most commonly used agent to provoke
non-PV triggers. Withholding of antiarrhythmic agents for
ﬁve half-lives and withholding beta-blockers for at least 24
hours is important when a strategy of searching for non-PV
triggers is employed. A typical protocol for initiating non-
PV triggers includes:
1. Baseline infusion of a vasoconstrictor (e.g., phenyleph-
rine) to maintain mean arterial pressure (MAP) .70
mm Hg and increase the bolus vasoconstrictor throughout
infusion to maintain adequate perfusion. This is particu-
larly important under general anesthesia. Careful titration
of a vasoconstrictor allows for higher doses of isoproter-
enol infusion.
2. Graded infusion of isoproterenol using up to 20–30 mg per
minute for at least 10 minutes is recommended. Most
members of the non-PV trigger writing group felt that
lower-dose isoproterenol infusion was frequently ineffec-
tive.
3. If no effect with isoproterenol infusion, burst pacing into
AF and then cardioversion during low-dose isoproterenol
infusion (2–6 mg per minute) may be considered.
4. Use of adenosine bolus or burst atrial pacing during
lower-dose isoproterenol infusion to attempt to identify
repetitive triggers after the drive train is an adjunctive
technique employed by a subset of the non-PV trigger
writing group. Localization of non-PV AF triggers can
be challenging, particularly when only the ﬁrst triggering
beat is being targeted, and typically involves recognition
of speciﬁc intra-atrial activation patterns on multipolar
catheters placed in the RA and CS, together with informa-
tion from the surface ECG to help regionalize an area of
interest.458,534,535 Moving the circular mapping or
ablation catheters around the LA and reinitiating AF can
be useful to localize AF triggers, taking care to
minimize ectopy with catheter manipulation. Placement
of a multipolar catheter inside the SVC is important for
identifying SVC triggers. The majority of the writing
committee members perform SVC isolation if an SVC
trigger is identiﬁed. To isolate the SVC, a circular
mapping catheter is placed inside the SVC to identify
SVC potentials. Ablation is performed proximally at the
SVC/RA junction. While isolating the SVC, high-
voltage pacing (at least 20 mA) is used before each RF
application to check for phrenic nerve (PN) stimulation.
Ablation is avoided in areas of PN capture, even if incom-
plete isolation is the result. SVC isolation should ideally
be performed in sinus rhythm after isoproterenol infusion
has worn off to avoid sinus node injury. RF application is
ceased if sinus node acceleration or pauses are observed.
The endpoint of SVC isolation is entry and exit block into
the SVC, as is typically seen with PVI. Dissociated ﬁring
of the SVC can also be observed. In contrast to wide-area
PVI and because of phrenic capture or risk of sinus node
injury, a segmental approach targeting the earliest break-
through on the circular mapping catheter is most
commonly employed.
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RF power is typically decreased to 30 W. An esophageal
temperature probe is frequently used. The writing group
also recommends that it is reasonable to use an esophageal
temperature probe during RF ablation procedures to monitor
esophageal temperature and to help guide energy delivery
(Class IIa, LOE C-EO, Table 3). Some committee members
isolate the entire posterior wall if numerous or multifocal pos-
terior wall triggers are identiﬁed. This can be accomplished
using a “box” lesion set, including a roof line (RSPV to
LSPV) and ﬂoor line (RIPV to LIPV) after PVI. If triggers
are observed to be originating from the CS or the LAA,
some writing committee members perform isolation of these
structures, while most prefer focal ablation. LAA triggers can
be identiﬁed by observing far ﬁeld LAA activity on a circular
mapping catheter placed in the LSPV; placing the ablation
catheter into the LAA should be avoided to minimize risk
of perforation or catheter-induced ectopy. Isolation of the
LAA should be performed only after prior discussion with
the patient and consideration of the long-term need for throm-
boembolic prophylaxis, with consideration given to LAA
closure by one of the available methods. For other non-PV
triggers, such as AT, AV nodal reentry tachycardia or AV
reentrant tachycardia, focal ablation is performed. Inability
to provoke the trigger with repeat isoproterenol infusion is
considered as the endpoint. Observational studies have
shown improved arrhythmia-free survival when non-PV trig-
gers are targeted for ablation and effectively eliminated at the
time of PVI.537,538
In some redo ablation cases, if non-PV triggers cannot be
provoked, empiric ablation of non-PV trigger sites may be at-
tempted. The empiric targeting of frequently deﬁned non-PV
trigger sites can have more value in persistent forms of AF
when triggers are not observed with provocative maneu-
vers.539 The most common empiric non-PV trigger ablation
is SVC isolation. Other common sites for empiric non-PV
trigger ablation include the mitral annulus, limbus of the
crista terminalis, mid to inferior crista terminalis, and eusta-
chian ridge.539 Some investigators also advocate empiric
LAA and CS isolation.
Despite the suggested improved outcome with elimina-
tion of non-PV triggers, the minority of operators according
to a recent European survey routinely perform non-PV
trigger initiation and ablation.540 Ablation of non-PV trig-
gers might be more important for patients with persistent
forms of AF and for those patients who undergo repeat
ablation procedures in whom all PVs are found to be
isolated.
Additional investigation is needed on the optimum
method for initiating and mapping infrequent non-PV trig-
gers. Furthermore, the value of routine non-PV trigger iden-
tiﬁcation and ablation with the initial ablation procedure and
at the time of repeat procedure following recurrence warrants
further study.
A survey of the writing group members shows that when
ablating PAF with the CB system, 18% also search for
non-PV triggers. Among those who use RF energy for AFablation in patients with PAF, 41% routinely employ a strat-
egy including administration of high-dose isoproterenol to
screen for and then ablate non-PV triggers. When performing
a repeat procedure in a patient with PAF, 57% of the writing
group members search for non-PV triggers. When ablating
persistent and long-standing persistent AF with RF energy,
the percentage of the writing group members who use a
non-PV trigger protocol are 35%, and 46% for ﬁrst-time
and redo AF ablation procedures, respectively. Based on
this information and a review of the literature, the writing
groups recommends that administration of high-dose isopro-
terenol to screen for and then ablate non-PV triggers may be
considered during initial or repeat AF ablation procedures in
patients with paroxysmal, persistent, or long-standing persis-
tent AF (Class IIb, LOE C-LD).LAA Focal Ablation, Isolation, and Ligation or
Resection
A relatively new non-PV-based strategy for ablation of AF
involves targeting non-PV triggers and reentrant tachycardias
that arise from the LAA.541 Over the past 5 years, new infor-
mation has been published showing promising outcomes us-
ing a variety of non-PV-based ablation strategies that target
the LAA. These strategies include focal ablation of non-PV
triggers arising in the appendage,541 electrical isolation of
the LAA,541,542,543,544 and most recently, ligation of the
LAA, although this approach is an off-label use of LA tissue
ligation.532,533,535,536 LAA isolation has been described
using a technique similar to that of PVI: with the circular
mapping catheter positioned at the level of the LAA
ostium, addressing the earliest LAA activation site
(preferably during sinus rhythm). Care should be taken not
to ablate inside the LAA (risk of perforation and PN
injury). After LAA isolation, patients should be kept on
long-term OAC or considered for LAA occlusion. This re-
ﬂects the results of a recent study that has reported an
increased stroke risk following LAA electrical isolation.544
The recently published BELIEF trial randomized 173 pa-
tients to start AF ablation or to start standard AF ablation
with empirical electrical isolation of the LAA. After an
average of 1.3 procedures, the cumulative success at 24
months’ follow-up was 76% in the combined group vs
56% with standard AF ablation.528,529 One approach to
address this potential issue is to combine LAA electrical
isolation with placement of a Watchman Device.542,543
Recent animal and human studies have also reported the
feasibility of this combined strategy.542,543 Currently, a
prospective randomized clinical trial is being performed to
determine if LAA ligation with the LARIAT device will
improve the efﬁcacy of PVI in patients with persistent AF.
The outcome of this trial will be required to provide a clear
indication for this approach. A survey of the writing group
members shows LAA focal ablation, isolation, or ligation
as an initial ablation strategy in patients with PAF is used
by 2% of the writing group members, and 4% use the
above for repeat AF ablation procedures in patients with
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AF, LAA focal ablation, isolation, or ligation was used by 9%
of the writing group members as an initial ablation strategy in
patients with PAF, and was used by 11% of the writing group
members for repeat AF ablation procedures in patients with
persistent and long-standing persistent AF. There is need for
additional well-performed, prospective, multicenter random-
ized trials in order to determine the safety and efﬁcacy of
this approach.Complex Fractionated Atrial Electrogram Ablation
More than a decade ago, CFAEs were reported to potentially
represent AF substrate sites and became target sites for
AF.516,545 CFAEs are electrograms with highly fractionated
potentials or with a very short cycle length (,120 ms).
CFAEs are typically low-voltage multiple potential signals be-
tween 0.06 and 0.25 mV. The primary endpoints using this
approach during RF catheter ablation strategies for AF are
either complete elimination of the areas identiﬁed with
CFAEs, conversion of AF to sinus rhythm (either directly or
ﬁrst to an AT), and/or noninducibility of AF. In patients
with persistent AF, the endpoint of ablation with this approach
is AF termination. Although use of the AF termination
endpoint has been reported to be associated with improved
short-term outcomes, the long-term results have been disap-
pointing.245,515,517,546 When the areas identiﬁed with CFAEs
are completely eliminated, but the arrhythmias continue as
organized AFL or AT, the ATAs are mapped and ablated. In
patients with long-standing persistent AF, a step-wise
approach to ablation has been reported to successfully convert
AF to either sinus rhythm or AT in greater than 80% of pa-
tients.514,547 Despite these encouraging acute outcomes, the
follow-up data were disappointing, with a 1-year single pro-
cedure efﬁcacy of 35% and a 5-year efﬁcacy of 17%.515
One of the limitations of ablation targeting with CFAEs has
been the extensive amount of ablation needed. As a result,
some strategies for differentiating “active” from “passive” sites
have been described. These include pharmacological interven-
tions, the use ofmonophasic action potentials, limiting ablation
to areas of continuous electrical activity, and activation map-
ping of AF.540,548,549,550,551 Unfortunately, improved
outcomes with CFAE ablation in patients with persistent AF
have not been uniformly reported, and the scientiﬁc basis for
CFAE ablation is not universally accepted. Moreover, results
from the STAR AF II trial have shown that the addition of
further ablation (lines or CFAEs) to PVI increased ablation
time but did not reduce the recurrence of AF in 589 patients
with persistent AF.245 At 18months, the percentage of patients
whowere free fromAF recurrence after one procedure without
antiarrhythmic medication did not signiﬁcantly differ among
groups. Similar ﬁndings were reported in the CHASE-AF trial,
which reported that the addition of defragmentation and linear
ablation to PVI did not improve ablation outcomes for persis-
tent AF compared with PVI alone.509 This suggests that CFAE
has clearly lost momentum, perhaps in favor of less extensive
approaches for AF ablation.552None of the writing group members routinely employ
CFAE-based ablation as part of an initial ablation strategy
in patients with PAF, and only 4% of the writing group mem-
bers employ CFAE ablation during repeat procedures. Ten
percent of the writing group members routinely employ
CFAE-based ablation as part of an initial ablation strategy
in patients with persistent and long-standing persistent AF,
and 26% incorporate CFAE-based ablation for redo proced-
ures in this subset of patients. Based on this information and a
review of the literature, the writing group recognizes that the
usefulness of CFAE-based ablation as an initial or repeat
ablation strategy for persistent and long-standing persistent
AF is not well established (Class IIb, LOE B-R). Focal abla-
tion of sites targeted by CFAE without anchoring the lesion
to a nonconducting neighboring area might simply lead to
formation of a substrate prone to produce future AFLs.
CFAE ablation is not recommended for ablation of PAF.Ablation of Fibrosis Identiﬁed by Voltage Mapping
and/or MRI Mapping
Another new ablation strategy that has been developed to
improve the outcomes of ablation involves targeting detected
areas of ﬁbrosis, based either on voltage mapping or on MRI.
The regional and individual extent of the ﬁbrotic LA sub-
strate in patients with AF can be visualized during ablation
intervention in sinus rhythm by applying electroanatomical
voltage mapping (EAVM). This technique led to the use of
a patient-tailored ablation strategy called box isolation of
ﬁbrotic areas (BIFA), with circumferential isolation of the
severely affected ﬁbrotic areas (e.g., ,0.5 mV), and with
complete isolation conﬁrmed by a circular mapping cath-
eter.140,553 Early pilot data using this approach combined
with PVI was encouraging.
This approach involves ﬁrst isolating the PVs. A voltage
map is then recorded during sinus rhythm, and the low
voltage areas are identiﬁed and subsequently isolated accord-
ing to the individual localization and extent. Efforts are made
to connect these BIFA ablation lines to the initial PVI lines to
prevent the production of small channels, such as is possible
with CFAE or GP ablation. Using this approach, approxi-
mately one-third of the patients with persistent AF were iden-
tiﬁed as not having substantial LA ﬁbrosis and, accordingly,
only PVI was performed. This limited approach led to
freedom from AF at 12 months with a single procedure in
69% of the patients and with only 1.2 procedures per patient
in 85%.140 These results were comparable to patients with
substantial ﬁbrosis and subsequent BIFA ablation. In addi-
tion, in a small portion of patients with massive ﬁbrosis
(the strawberry), failure of the initial ablation was likely,
and further ablation procedures were discouraged.140 Other
investigators have also described a tailored substrate modiﬁ-
cation based on low-voltage areas.554 They used several stra-
tegies, including linear lines encircling of low-voltage areas,
with demonstration of a signiﬁcant reduction in local electro-
grams, defractionation, and/or loss of capture. Even earlier,
isolation of the posterior wall at the level of the PVs without
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e319prior EAVM was introduced522; however, this strategy did
not address the individual localization of the ﬁbrotic disease
at that time. Several other groups have recently reported on
voltage-guided substrate modiﬁcation in patients with persis-
tent AF.555,556,557 The durability of RFC-induced isolating
lesions is clearly still an issue. The same holds true for
BIFA lines for substrate modiﬁcation guided by EAVM.
Recent technology improvements of point-by-point catheter
approaches (e.g., CF measurement) could further pave the
way for improving these approaches. However, the realiza-
tion of the proposed strategies for BIFA substrate modiﬁca-
tion requires of the operator extensive manual skills and
experience.
The methods to describe the ﬁbrotic substrate with EAVM
are also under intensive investigation, and several limitations
yet remain. The voltage maps using point-by-point mapping
not only take time, but the measured voltage also depends on
the rhythm (sinus rhythm vs extrasystole or AF), the contact
of the electrode to the tissue, the thickness of the atrial
myocardium, the size of the mapping electrodes, interelec-
trode distance, and other variables. Investigators described
preexistent LA scarring in patients undergoing PVI as an in-
dependent predictor of procedural failure.558 Low voltage for
abnormal areas in their study was also deﬁned as an ampli-
tude 0.5 mV, and scar 0.05 mV, indistinguishable from
noise. Other investigators recently described contact EAM-
derived voltage criteria for characterizing LA scar in patients
undergoing ablation for AF.559 In their study, a voltage range
of 0.2 to 0.45 mV was found to delineate scar. Others used
0.2 to 0.5 mV as diseased and .0.5 mV as healthy.554
This differs from the experience of another investigator, in
whose studies 0.5 to 1.5 mV presented an intermediate
zone that did not denote substantial ﬁbrosis but that also
did not provide clear evidence for a normal atrial myocar-
dium.140,553 The fragmented electrogram appearance of
voltages in the range of 0.5 and 1.5 mV frequently argue in
favor of mild ﬁbrosis. Certainly, there is no “yes or no”
with respect to atrial ﬁbrosis, but various grades can be
observed. In summary, atrial scar is proposed for sites with
no discrete electrograms (apart from potential far-ﬁeld elec-
trograms) and no local capture during pacing, dense ﬁbrosis
for sites with voltages0.5 mV, an intermediate zone ofmild
ﬁbrosis for sites with voltages .0.5 to 1.5 mV, and normal
for sites with voltages.1.5 mV. However, with some excep-
tions, mild ﬁbrosis is even assumed at sites with voltages be-
tween 1.5 and 2.5 mV. Furthermore, criteria need to be
developed when other diagnostic catheters are used for
EAVM, e.g., the circular mapping catheter or the Pentaray
catheter. Overall, these initial single-center observational
studies on ablation or isolation of ﬁbrotic areas need to be
conﬁrmed and extended in multicenter randomized studies.
Recently, the utility of delayed enhancement (DE) MRI
has been introduced for detecting, quantifying, and local-
izing atrial ﬁbrosis, including the deﬁnition of four cate-
gories of structural changes (Utah stages I–IV).130,560,561
The tissue characterization of the LA wall on DE MRI
correlated with EAVM and with histology from surgicalbiopsy specimens.560,561 The association of atrial tissue
ﬁbrosis and AF catheter ablation outcomes, with more
extensive ﬁbrosis associated with lower efﬁcacy, was
conﬁrmed in the multicenter Delayed Enhancement MRI
and Atrial Fibrillation Catheter Ablation (DECAAF)
study.365 On the other hand, these MRI ﬁndings at this
point in time require extensive MRI experience, including
speciﬁcation of image contrast and continuity, required to
set boundaries for the various degrees of ﬁbrosis. The repro-
ducibility of this approach is still under investigation. A ma-
jor limitation of this approach is that the degree of scar
identiﬁed depends strongly on the above thresholds used
to deﬁne scar. At the present time, no uniform standard
has been developed. This limitation hinders the reader-to-
reader and day-to-day reproducibility of MRI-determined
measurements of atrial scar. Once established, however,
the DE MRI quantiﬁcation and localization of atrial ﬁbrosis
might be used effectively to guide individually tailored sub-
strate elimination comparable to EAVM-guided substrate
modiﬁcation. Finally, tissue visualization before and also
during and directly after RF catheter ablation is the target
for introducing real-time MRI into the clinical electrophys-
iological laboratory. Currently, the DECAAF-2 trial has
been launched to test the hypothesis that ablation of scar de-
tected on MRI improves ablation outcomes for persistent
AF compared with PVI alone.
A survey of the writing group members shows that for pa-
tients undergoing an initial AF ablation for PAF, 7% of the
writing group members employ an ablation strategy based
in part on MRI or voltage mapping-detected scar, and 9%
of the writing group members employ this strategy for repeat
AF ablation procedures in patients with PAF. For an initial
ablation procedure in patients with persistent and long-
standing persistent AF, 15% of the writing group members
employ an ablation strategy based in part on MRI or voltage
mapping-detected scar. The proportion increases to 22% for
repeat ablation in patients with persistent or long-standing
persistent AF. Based on this information and a review of
the literature, the writing group recognizes that the usefulness
of mapping and ablation of areas of abnormal myocardial tis-
sue identiﬁed with voltage mapping or MRI as an initial or
repeat ablation strategy for persistent and long-standing
persistent AF is not well established (Class IIb, LOE B-R,
Table 3).Mapping and Ablation of Rotational Activity
Several approaches have been developed to identify areas of
rotational activity in the atria. The ﬁrst identiﬁcation and tar-
geted ablation of rotational activity with ﬁbrillatory activities
was reported in 2005, using the noncontact mapping tech-
nique by Lin et al.562 The next system that was developed
for clinical use employed two 64-pole basket catheters to
obtain simultaneous unipolar endocardial electrograms
from 128 locations in both atria of patients undergoing AF
ablation.563 A computational mapping system (Rhythm-
View, Topera, Inc.) was used to process the electrograms
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After considerable processing and interpolation, evidence
was found for rotational activity in patients with paroxysmal,
persistent, and long-standing persistent AF.564 MAPs estab-
lished the minimum repolarization interval and provided
physiologically feasible sequential activation paths. Movies
of activation patterns and isochronal maps from individual
cycles showed circulating activity around a center of rotation
that was identiﬁed as rotational activity.564 Focal (centrifu-
gal) activations were also identiﬁed. Both were considered
drivers only if they sustained for 50 rotations or focal dis-
charges.563 This approach has recently been validated by
linking FIRM simultaneously with optically mapped rota-
tional activity in the same human hearts.76 Although early re-
ports documented ﬁndings showing that this approach to
mapping and ablating rotational activity improved outcomes
of AF ablation,223,226,563,565,566,567 more recent studies have
failed to conﬁrm these early ﬁndings.568 Issues associated
with the FIRM-guided protocol that have contributed to un-
certainty regarding its clinical value include difﬁculties
with basket catheter placement and appropriate electrode
contact, and the inability to identify atrial electrogram charac-
teristics expected from rotational activity that differ quantita-
tively from surrounding tissue. At the time this document is
being written, the approach of FIRM-guided ablation has
not been universally adopted. Considerable debate continues
concerning the efﬁcacy of this ablation strategy. Further
research is clearly needed.223,564,566,569 At the present time,
several prospective, randomized clinical trials are underway
to evaluate the long-term safety and efﬁcacy of this approach.
Several other approaches have recently been developed
to identify rotational activity as a potential target for abla-
tion. One of these systems involves the use of high-
density multipolar recordings with nonlinear analysis of
the similarity index and phase mapping of rotational activ-
ity. This approach has resulted in improved ablation
outcome for patients with persistent AF.224,225 Another
system that has been developed to noninvasively map
rotational activity is the ECGI mapping system.221,570,571,572
This system utilizes a multielectrode vest that records 224
body surface ECGs; electrical potentials, electrograms, and
isochrones are then reconstructed on the heart’s surface
using geometrical information from computed tomography
(CT). A mathematical algorithm combines the body
surface potentials recorded by the electrodes and the
geometric information provided by CT and solves the
electrocardiographic inverse problem in order to
noninvasively obtain estimated epicardial electrograms.221,
570 An advantage of this approach is that it is noninvasive,
and thus can be used to provide detailed follow-up informa-
tion on AF recurrence. Disadvantages of the system are that it
is limited to providing virtual electrograms of the atrial
epicardium; activity on the interatrial septum, the PV-LAA
ridge, etc., is not recorded. Another limitation has to do
with workﬂow and the fact that CT imaging is required to
obtain the torso geometry. An additional limitation of this
system is that it requires the assumption that the torso has uni-form electrical properties when, clearly, thoracic tissue
conducts electricity nonuniformly. A clinical trial used
ECGI combined with phase mapping to identify the drivers
of persistent AF in 103 patients undergoing AF ablation.
They observed continuously changing wavefronts and a
wide variety of rotational activity behaviors.222 Reentrant
drivers were unsustained and meandered substantially,
but recurred repetitively within the same region. Computa-
tion of aggregated driver-density maps over a cumulative
registering period allowed identiﬁcation of a median of
four driver domains per patient and helped to guide the
ablation procedure. Of note, the longer the duration of sus-
tained AF, the larger the number of driver regions. Abla-
tion of driver domains alone terminated AF in 75% of
patients with persistent AF and in 15% of patients with
long-standing persistent AF. The onset or extinction of
drivers during ablation was not assessed; thus, there is
room for improving the ablation results if real-time data
are used.222 At the 12-month follow-up, 83% of the pa-
tients with PAF and 75% of the patients with persistent
or long-lasting AF were free from AF.222 At the present
time, this system is not widely available, and few members
of the writing group have clinical experience with this
system.
Other investigators have also reported the ability of body
surface potential mapping to detect rotational activity and sta-
ble propagation patterns during AF.573 Phase maps computed
from the TQ intervals in 64 surface potentials showed com-
plex patterns in which rotational activity could be identiﬁed,
but they were unstable and lasted for a very short time.
Noninvasive BSM methodology has recently started to gain
momentum for the analysis of activation patterns during
AF.574,575 These investigators used a custom-made 67-
electrode vest that covered the whole torso of the patient;
intracardiac signals at several locations were simultaneously
recorded.574 They selected either segments without ventricu-
lar activity after adenosine infusion, or applied complex sub-
traction of QRST if such intervals were not found. After
computing and performing comparisons between intracar-
diac and surface DF maps, the investigators demonstrated
that high-frequency sources could be reﬂected on a small
area of the body surface close to the atrium harboring the
highest DF.574 More recently, investigators have used phase
mapping to ﬁlter the unipolar signals with a narrow 2-Hz
band-pass around the highest DF (HDF ﬁltering) to signiﬁ-
cantly improve the detection of stable rotational activity.575
Prior to HDF band-pass ﬁltering, phase maps displayed un-
stable reentries, likely as a result of superposition of the disor-
ganized electrical activity coming from the rest of the atrial
tissue. HDF ﬁltering accentuated the organized activity of
scroll waves, after which rotational activity was the main
pattern of activation during AF (median of 2.8 rotations, pre-
sent 73% of the time). Also, computer simulations showed
that epicardial propagation is spatially smoothened when
projected on the torso. For example, nearby epicardial rota-
tional activity with opposing chirality might not be detected
on the torso. This fact and the possibility of temporal
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could explain the lack of detected rotational activity during
the remaining 27% of the time.575
Improved understanding of underlying mechanisms im-
proves therapy. High-frequency reentrant sources are an
important mechanism of AF maintenance in humans, even
if other mechanisms might also be involved in AF initiation
and maintenance.17 Experimental data and ablation out-
comes are making it increasingly clear that multielectrode
approaches that provide simultaneous acquisition of tens
or hundreds of recording sites from the ﬁbrillating atria pro-
vide substantial improvement for the identiﬁcation and
eventual termination of AF sources. Although there is still
substantial room for improvement, mapping technology is
evolving at an accelerating pace, which gives hope that
novel breakthroughs will enable panoramic assessment of
the underlying mechanisms that underlie electrical turbu-
lence in AF. Simultaneous high-resolution panoramic
assessment of wave propagation from the body surface
and the endocardium could help in tracking drifting or
more stationary rotational activity trajectories over wide
areas of the atria with better accuracy, and hopefully should
advance ablation therapy. An important issue with these
mapping forms is that they are critically dependent on elec-
trogram acquisition, electrogram integration, and a variety
of signal manipulations with mathematical techniques,
including inverse solution, Hilbert, and phase transforma-
tions that produce an additional level of complexity in at-
tempting to simplify mapping. Registration of the maps to
anatomic structures, or CT or MRI and subsequent naviga-
tion, likewise add complexity to the process and underscore
the need for additional translational and clinical studies to
validate and clarify their utility.
A survey of the writing group shows that none of the
members routinely employ ablation of rotational activity dur-
ing initial or repeat ablation procedures in patients with PAF;
7% do so during initial ablation of persistent and long-
standing persistent AF, and 9% do so during repeat ablation
of persistent and long-standing persistent AF. Based on this
information and a review of the literature, the writing group
recognizes that the usefulness of ablation of rotational activ-
ity as an initial or repeat ablation strategy for persistent and
long-standing persistent AF is not well established (Class
IIb, LOE B-NR, Table 3).Localization and Ablation of Left Atrial
Ganglionated Plexi
Recent experimental and clinical studies have shown that
the intrinsic cardiac ANS, which is formed by interconnected
clusters of autonomic ganglia, known as GP, plays
an important role in the initiation and maintenance
of AF.103,105,114,116,124,355,576,577,578,579,580,581,582 Because
the GP are consistently located within areas of highly
fractionated atrial potentials (FAPs), also referred to as
CFAEs,103,105,114,116,124,355,576,577,578,579,580,581,582,583,584 it
is useful to begin with a fractionation map of the LA andPVs during AF. The LA FAPs are usually located in four
areas: (1) LAA ridge FAP area (between LAA and left
PVs); (2) superior left FAP area; (3) inferoposterior FAP
area; and (4) anterior right FAP area (Figure 4). GP can be
localized using HFS to identify sites exhibiting transient
AV block during AF. In one approach,124,582 endocardial
HFS (cycle length 50 ms, 12–15 V, 10 ms pulse width) is
delivered through the distal pair of the electrodes on a
mapping or ablation catheter to sites within FAPs in the
LA. Sites exhibiting a positive HFS response (transient AV
block, increase in mean R-R interval .50% during AF)
identify the 5 major GP (Marshall tract GP, superior left
GP, anterior right GP, inferior left GP, and inferior right
GP) (Figure 4). HFS of a GP generally increases the degree
of fractionation in the adjacent PV and frequently in distant
PVs.
For endocardial catheter ablation of the GP, RF energy is
applied to each site exhibiting a positive HFS response (usu-
ally 25–35 W for 30–60 seconds, but the RF power and/or
time is reduced when close to the esophagus).105,124,582
HFS is repeated after each RF application. If the positive
HFS response is still present, RF energy is reapplied until
the response is eliminated (generally only one or two RF
applications are required). Ablation of each of the ﬁve GP
areas usually requires 2–12 (median 6) RF applications.124,582
A positive HFS response might not identify the entire GP
area. HFS-induced transient AV block is driven by activation
of the inferior right ganglionated plexi (IRGP). Therefore,
activating the Marshall tract GP, superior left GP, inferior
left GP, or anterior right GP byHFS is followed by activation
of other GP, including the inferior right GP, which inner-
vates the AV node. The positive response to HFS (transient
AV block) might not occur, due to ablation of one of the in-
termediate GP along the line to the IRGP. To minimize the
loss of a positive HFS response, ablation of the GP should
be performed in the following order: Marshall Tract GP,
superior left GP, anterior right GP, inferior left GP, and
ﬁnally inferior right GP. Other signs of GP activation
(such as the onset of PV ﬁring other than the PV adjacent
to the stimulated GP) are occasionally observed during
HFS, which does not produce an AV block response, sug-
gesting lower sensitivity of HFS in identifying GP. Some
reports targetedGPwithout HFS, delivering RF applications
to the presumed anatomical locations of theGP.245,576,583,584
The GP (identiﬁed by HFS) are consistently located
within an area of FAPs, which is much larger than the GP
area, suggesting that although GP ablation consistently pro-
duces CFAE (or FAP) ablation, CFAE ablation is not equiv-
alent to GP ablation. In patients with either paroxysmal or
persistent AF, GP ablation (before PVI) signiﬁcantly reduced
the inducibility of sustained AF. If AF remains inducible after
GP ablation, GP ablation often eliminates the majority of
CFAEs, despite ablating a much smaller area than the overall
CFAE area.124,582
One clinical study randomized a total of 242 patients with
PAF to conventional PVI, PVI plus GP ablation, and GP
ablation alone.122 Freedom from ATAs (followed for at least
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conventional PVI and GP ablation alone groups (56% and
48%, respectively), and in a signiﬁcantly greater number of
patients in the PVI plus GP ablation group (74%; P 5
.004). In another randomized study including 264 patients
with persistent or long-standing persistent AF, GP ablation
as an adjunct to PVI resulted in higher rates of sinus rhythm
maintenance at 3 years (49%) compared with PVI plus LA
linear lesions (34%).585,586 In addition, LA tachycardias
were less common with PVI plus GP ablation than with
PVI plus linear lesions. GP ablation alone was also tested
in patients with drug-refractory long-standing persistent
AF, resulting in a lower success rate (38% sinus rhythm
maintenance at 2 years).583,584 A recent, prospective,
randomized, surgical AF ablation study reported no
improvement of outcomes by ablation of the autonomic
ganglia.123 Again, anchoring the focal ablation of a GP to
other nonconducting tissue produced by PVI or anatomic
structures remains critical to prevent subsequent ATs.
A survey of the writing group showed that 7% of the
writing group members routinely employ ablation of auto-
nomic ganglia during initial or repeat ablation procedures
in patients with PAF, and 7% do so during initial or repeat
ablation of persistent and long-standing persistent AF.
Based on this information and a review of the literature,
the writing group recognizes that usefulness of ablation
of autonomic ganglia as an initial or repeat ablation strat-
egy for paroxysmal, persistent, and long-standing persis-
tent AF is not well established (Class IIb, LOE B-NR,
Table 3).Dominant Frequency Mapping
An emergent property of the complex spatiotemporal dy-
namics is that during AF, the local cycle length (atrial ﬁbril-
lation cycle length [AFCL]) varies depending on electrode
location, with the shortest AFCLs usually localized in the
LA.587,588 The combined use of phase mapping589 and DF
mapping demonstrated that the highest DF corresponded
with the location of rotational activity that was driving the
arrhythmia.590,591 A subsequent study in patients with
paroxysmal or persistent AF showed that ablation of PVs
harboring high DF sites resulted in an increase in the
AFCL (5 ms) within the CS in 89% of cases.98 Arrhythmia
termination occurred during ablation in 15 of 17 patients
(88%) with PAF, but in none with permanent AF. In 87%
of patients with PAF, ablation at a high DF site terminated
the arrhythmia. Subsequent studies supported the notion
that the high DF (DFmax) sites play a role in the maintenance
of AF in a signiﬁcant number of patients.592,593
Based on these mechanistic studies, a small trial of 50 pa-
tients with paroxysmal and persistent AF was performed,
combining PVI with ablation of DFmax sites. At a mean of
9.36 5.4 months, freedom fromAF after one or more ablation
procedures was achieved in 88% and 56% of paroxysmal and
persistent AF patients, respectively.593 A more recent prospec-
tive randomized clinical trial of 232 patients with paroxysmaland persistent AF reported no improvement in ablation out-
comeswith a DF-based approach comparedwith PVI alone.594
None of the writing group members incorporate DF mapping
as a routine AF ablation strategy in initial or repeat ablation
of PAF. One writing group member (2%) incorporates a DF-
based approach during initial and repeat ablation of persistent
and long-standing persistent AF. Based on this information
and a review of the literature, the writing group recognizes
that a DF-based ablation strategy is of unknown usefulness
for AF ablation (Class IIb, LOE C-LD, Table 3).Renal Denervation
Arterial hypertension (AH) is the most frequent comorbidity
in patients with AF, and this condition is also an important
risk factor for the triggering and maintenance of AF. The po-
tential antiarrhythmic role of renal denervation was demon-
strated in animal studies suggesting a beneﬁcial effect on
AF inducibility, maintenance, and progression.307,595,596,597
The positive impact of renal denervation on AF recurrence
was demonstrated in a ﬁrst-in human study, including 27 pa-
tients with paroxysmal or persistent AF and refractory hyper-
tension. At 12-month follow up, the group of patients who
underwent PVI plus renal denervation had a signiﬁcantly
higher success rate in terms of freedom from AF compared
with PVI alone (69% vs 29%, respectively). Also, the reduc-
tion in BP was much more signiﬁcant in the PVI-plus-renal-
denervation group.331 Recently, data were reported from a
combined analysis of two randomized studies with a large
and diverse group of 80 patients with AF and hypertension.
For the entire cohort, renal artery denervation signiﬁcantly
reduced the rate of AF recurrences; however, this result
was more pronounced in patients with persistent AF and re-
fractory hypertension.331 A case report using renal denerva-
tion instead of PVI in a patient with drug-refractory
persistent AF was recently published, with no AF recurrence
at 6-month follow-up. Moreover, the renal denervation re-
sulted in a reduction of LA size.598 The mechanism by which
renal denervation, when combined with PVI, can impact out-
comes of AF ablation has not been well deﬁned. One poten-
tial mechanism is through improved control of hypertension.
An alternate mechanism is through a decrease of central sym-
pathetic activity by renal denervation.599 The current body of
evidence supporting a role of renal denervation in improving
outcomes of AF ablation is extremely limited. This is an area
in need of further investigation. At the present time, we do
not advise renal denervation as a technique to improve out-
comes of AF ablation outside of a clinical trial. This senti-
ment reﬂects not only the limited body of literature
supporting this approach, but also the recent large prospec-
tive randomized SIMPLICITY HTN-3 trial that showed
that renal artery denervation was safe, but was not effective
in lowering hypertension.600Epicardial Ablation of AF
More data concerning thoracoscopic epicardial ablation and
combined epicardial-endocardial ablation procedures have
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ment. In addition to a potentially more durable lesion set,
other advantages of an epicardial approach include access
to epicardial structures such as the ligament of Marshall
and GP, management of the LAA, and avoidance of
damaging collateral structures, such as the PN and esoph-
agus.
To date, three randomized prospective trials have compared
a video-assisted thoracoscopic surgical (VATS) approach to
percutaneous endocardial catheter ablation for the treatment
of patients with paroxysmal and non-PAF, most of whom
had failed an initial catheter ablation.585,586,601,602 A meta-
analysis of these and other observational studies demonstrated
a signiﬁcant improvement of arrhythmia-free survival for the
VATS procedure (78.4 vs 53%; RR 1.54; 95% CI 1.50–
2.14; I2 5 0%; P ,.0001), with a clearer beneﬁt for patients
with persistent AF.603 Complications were three times more
frequent in the VATS group, mostly due to pneumothorax
and pleural effusion. VATS procedures can also provide a
reasonable outcome for patients with large atria and long-
standing persistent AF.604,605
Many observational studies have reported promising re-
sults for so-called hybrid ablation procedures, which combine
elements of VATS and catheter ablation procedures; however,
no randomized controlled trials (RCTs) have been performed
to demonstrate effectiveness and safety relative to either
procedure alone.606,607,608,609,610,611,612,613,614,615,616 Before
these approaches are applied more widely, a streamlining
of the workﬂow of the dual procedure approach will be
required.Nonablative Strategies to Improve Outcomes of AF
Ablation
AAD Therapy
There is evidence that reverse remodeling occurs after cardio-
version of AF. The evidence in support of this conclusion is
based on changes in atrial APD, ERP, CV, and P wave dura-
tion when measured 1–4 weeks after achieving sinus
rhythm.617,618,619,620 The changes in P wave duration occur
more slowly and do not predict long-term maintenance of si-
nus rhythm.619 An important question is whether AAD ther-
apy can be used to prevent or initiate reverse remodeling even
prior to ablation, thereby improving the success rate for abla-
tion procedures. AAD therapy would be beneﬁcial if it
prevented electrical and structural remodeling by reducing
the burden of AF, but it might also affect the therapeutic
endpoints of conduction into or out of the PVs and the
automaticity of PV or non-PV triggers of AF. The effect of
drugs on mapping putative rotational activity or repetitive
wavelets in humans with AF is unknown.
Four trials have evaluated the effect of preprocedural
amiodarone or dofetilide therapy on outcomes of ablation.
One study reported that the recurrence rate of AF following
ablation was lower when treatment with dofetilide prior to
ablation reduced the burden of AF, and was associated
with a decrease in P wave duration.617,618 Another single-center nonrandomized study found that amiodarone pro-
longed the cycle length of AF and reduced the time spent
on CFAE ablation, but it did not have any effect on long-
term outcomes.619 A second single-center study treated pa-
tients with Class I or III drugs for long-standing persistent
AF and compared the outcomes of ablation in those who
were successfully converted to sinus rhythm months prior
to ablation as opposed to those who were not. They observed
decreases in LA dimensions (LADs) in the group that
achieved preprocedural sinus rhythm. Long-term freedom
from recurrent atrial arrhythmias was higher in the group
that achieved sinus rhythm prior to ablation.620 The multi-
center randomized Effect of Amiodarone on the Procedure
Outcome in Long-standing persistent AF Undergoing PV
Antral Isolation (SPECULATE) trial studied the effect of
preprocedural interventions in patients with long-standing
persistent AF. Termination of AF was more common in
the patients treated with amiodarone, and fewer non-PV trig-
gers were identiﬁed. At 6 months, both groups had similar
recurrence rates; however, at 12 months, arrhythmia-free sur-
vival was higher in the patients who were not treated with
amiodarone. A signiﬁcant limitation of the SPECULATE
trial is that many patients who were assigned treatment
with amiodarone remained in AF; thus, there was no oppor-
tunity for remodeling to occur.621
From a practical standpoint, patients often require AAD
therapy prior to ablation to reduce the burden of symptomatic
AF. Whether this delays the progression of remodeling or re-
verses it is not well established, although there is evidence
from these studies that conversion to sinus rhythm affects
the atrial electrophysiological properties. Studies that showed
improved outcomes in patients who regained sinus rhythm
might be interpreted to show that remodeling occurs and is
beneﬁcial, but the alternative interpretation could be that pa-
tients who regain sinus rhythm have less advanced disease
and are better candidates for ablation. The data also suggest
that amiodarone affects the cycle length of AF, has increased
conversion rates to sinus during ablation, and might mask
triggers of AF, which could adversely affect the success of
the procedure.
Based on this information, the published literature, and the
experience of this writing group, the writing group recog-
nizes that the usefulness of discontinuation of AAD therapy
prior to AF ablation in an effort to improve long-term out-
comes is unclear (Class IIb, LOE C-LD, Table 3). The
writing group also recognizes that the usefulness of initiation
or discontinuation of AAD therapy during the postablation
healing phase in an effort to improve long-term outcomes
is unclear (Class IIb, LOE C-LD, Table 3).Risk Factor Modiﬁcation
In Section 3 of this document, we have summarized the
emerging data supporting risk factor modiﬁcation as an
approach to improve outcomes of AF ablation. Based on
this information, the published literature, and the experience
of this writing group, for patients with AF, including those
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ure, it is felt that that weight loss can be useful as part of a
comprehensive risk factor management strategy (Class IIa,
LOE B-R, Table 3). The writing group also recommends
that it is reasonable to screen for signs and symptoms of sleep
apnea when evaluating a patient for an AF ablation proced-
ure, and recommends a sleep evaluation if sleep apnea is sus-
pected (Class IIa, LOE B-R). And ﬁnally, the writing group
recommends that the treatment of sleep apnea can be useful
for patients with AF, including those who are being evaluated
to undergo an AF ablation procedure (Class IIa, LOE B-R,
Table 3).Mechanisms of Nonisthmus-Dependent Atrial
Flutter and Approaches to Mapping and Ablation
The occurrence of AFL after AF ablation is common enough
that all operators performing AF ablation should be skilled in
mapping and ablating both typical and atypical AFL. The
incidence of AFL after AF ablation depends on the type of
ablation performed during the initial procedure, varying
from 2.6% in centers performing PVI alone to 31% in centers
performing linear ablation.622,623,624,625 AFL is less common
after PVI with CB compared with RF-based PVI.489 The
mechanism of AFL is reentry. Reentrant arrhythmias include
focal reentry occurring through gaps in the prior PVI line (PV
tachycardia) or macroreentry around anatomic obstacles
created during ablation (mitral annular ﬂutter, LA
roof-dependent ﬂutter, or septal ﬂutters around areas of
scar).447,506,626,627 Typical cavotricuspid isthmus-dependent
ﬂutter can also occur (Figure 5).
Determining the location of the reentry circuit starts with
examination of the 12-lead ECG. A clear isoelectric line in
all 12 leads suggests a focal AT involving a small reentrant
circuit (e.g., microreentry), whereas continuous activation
suggests a macroreentrant ﬂutter involving a larger cir-
cuit.628 Typical cavotricuspid isthmus-dependent ﬂutter
frequently has an atypical appearance on the 12-lead ECG
after prior LA ablation, and this should not be excluded
based on an atypical ECG appearance alone.629 Although
extensive LA ablation can limit interpretation of the 12-
lead ECG, certain rules apply. Tachycardias arising near
the PV ostia will typically have an inferior axis and positive
F waves across the precordial leads. An “m”-shaped F-wave
in lead V1 suggests a left PV exit. Right PV tachycardias are
characterized by the ECG amplitude in lead II greater than
that in lead III and a positive F wave in lead I. Mitral annular
ﬂutter has a similar appearance to left PV tachycardias,
although an initial negative component in the precordial
leads or amplitude in lead V2 less than that in V1 and V3
might be suggestive.630 These rules, however, could be
less applicable in patients with extensive scarring, including
that from prior ablations.
Initial localization of an atypical ﬂutter can frequently be
facilitated by simply observing the activation sequence on a
CS catheter. Proximal to distal activation suggests cavotri-cuspid isthmus-dependent ﬂutter, right PV tachycardia, or
counterclockwise mitral annular ﬂutter, whereas distal to
proximal activation suggests a left PV tachycardia or clock-
wise mitral ﬂutter. An “on time” or fused CS pattern could
be suggestive of a roof-dependent ﬂutter.631 When acquiring
an electroanatomical activation map, each acquired point
should be carefully annotated by the operator, taking care
to tag and not include widely split potentials that might
indicate a line of block. Multipoint mapping can
decrease the time needed for acquiring a map, but
automated electrogram annotation might lead to errors and
confusing maps. A novel very automated high-density
automated mapping system has recently become avail-
able.627,632 Early results using this system to determine
activation sequences and perform ablation based solely on
activation rather than entrainment mapping have been
encouraging.627 However, the true clinical value of this
type of system is unknown and will require a prospective ran-
domized comparison with conventional electroanatomical
and entrainment mapping. When performing ablation of
AFL with a conventional 3D mapping system, scar should
be labeled as such to identify anatomic obstacles. Focal mi-
croreentrant tachycardias can also occur and are typically
indicated by centrifugal conduction away from a focal
area of onset and by long fractionated potentials with dura-
tion .50% of the tachycardia cycle-length.628 The main
strength of activation mapping is that it is unlikely that
the tachycardia will terminate. The disadvantage is that
these activation maps can be extremely difﬁcult to interpret
and might not translate to identifying successful ablation
sites. When performing ablation of atypical AFL with a
conventional 3D mapping system, especially when a stable
reentrant circuit is present that allows entrainment, most
operators ﬁnd that entrainment mapping from multiple
sites is a better and more accurate approach to localize
the reentrant circuit and target ablation lesions. It is for
this reason that entrainment mapping is the gold standard
for mapping reentrant tachycardias and is the preferred
mapping strategy employed by most writing group mem-
bers at the present time. For atypical ﬂutter, because fusion
of the F wave can be difﬁcult to interpret, the primary goal
is to identify regions with a postpacing interval within 20
ms of the tachycardia cycle length. Care should be taken to
pace at or near threshold, given high-output pacing can
capture adjacent tissue that leads to an erroneous postpac-
ing interval. High-output pacing can also lead to electrode
polarization that obscures the return electrogram. Once the
reentry circuit is delineated, an ablation strategy can be de-
signed to connect anatomic obstacles and interrupt the
tachycardia. Despite this current preference, new high-
density automated mapping systems have been developed,
as noted above, which allow development of successful
ablation strategies based on high-density activation map-
ping alone, without the risk of entrainment pacing resulting
in termination of the ﬂutter under study or its degeneration
into a different ﬂutter or ﬁbrillation. Prospective
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determine the true clinical value of these new automated
high-density mapping systems.627,632
For PV tachycardias, 2 gaps in the PVI line are typically
present and reisolation of the PVs sufﬁces to eliminate the
tachycardia.447 For macroreentrant tachycardias, ablation
that connects anatomic obstacles is required. The classic
post-PVI macroreentrant tachycardia is mitral annular ﬂutter;
ablation between the mitral annulus and left lower PV (mitral
isthmus) is typically performed (Figure 5), although an ante-
rior line between the mitral annulus and the LSPV, the RSPV,
or the roof line can also be performed. For mitral isthmus
ablation, epicardial ablation within the CS is required approx-
imately 80% of the time. The endpoint of linear ablation
should be proof of bidirectional block using pacing maneu-
vers rather than simply tachycardia termination. Interruption
of the clinical tachycardia should be performed ﬁrst, because
burst pacing might induce multiple tachycardias of unclear
signiﬁcance. After termination of the clinical tachycardia, re-
isolation of any reconnected PVs should always be per-
formed.Anesthesia During AF Ablation
The type of anesthesia used for AF ablation depends in part
on the availability of anesthesia support for ablation proced-
ures. Given the need to minimize patient movement to
improve catheter andmapping system stability, deep sedation
or general anesthesia is generally preferred. One prospective
randomized clinical trial randomized patients with general
anesthesia or conscious sedation. This study reported that
use of general anesthesia increased the single procedure suc-
cess rate, lowered the prevalence of PV reconnection among
those who needed a redo procedure, and shortened ﬂuoros-
copy time and procedure time.633 Another nonrandomized
clinical trial reported improved efﬁcacy of AF ablation
with use of jet ventilation.634 A survey of the writing group
members performing AF ablations found that 73% use gen-
eral anesthesia, 13% use deep sedation with an anesthesiolo-
gist, and 14% use moderate conscious sedation with an
electrophysiology nurse. Jet ventilation was used by only
8%. The major reason cited for not using general anesthesia
was lack of anesthesiologist availability. Some proponents of
not employing general anesthesia believe that the risk of an
atrial esophageal ﬁstula (AEF) could be higher in patients
in whom general anesthesia is employed.635,636,637,638,639Recurrent AF with or without PV Reconnection
Some degree of PV reconnection is observed in more than
80% of patients who are returned to the electrophysiology
laboratory for a clinically indicated electrophysiology pro-
cedure. PV reconnection is also observed in patients doing
well post-PVI. The Gap-AF trial reported PV reconnection
at 3 months in 70% of patients randomized to complete
PVI and in 89% of patients in whom a PV “gap” was left
intentionally. AF recurred during the ﬁrst 3 months postabla-
tion in 62% of the patients with complete PVI vs 79% of thepatients in whom a gap was left intentionally.456When recon-
nection of the PVs is observed, it is recommended that the
PVs be reisolated. This can be accomplished by a limited
approach, which involves only targeting those PVs that
demonstrate reconnection, and only targeting the segment
of the PV circumference in which the PV reconnection is de-
tected. Among the writing group members, 73% employ this
strategy. An alternate approach is to be more liberal with
ablation, with creation of a new circumferential lesion set
around each of the PVs, which demonstrates reconnection.
This approach is employed by 20% of the writing group
members. An even more liberal approach is to repeat the
entire WACA lesion set that was delivered the ﬁrst time;
this approach is employed by the remaining 7% of the
writing group members. In the small proportion of patients
in whom no PV reconnection is observed, there is
agreement that a number of non-PV-based strategies should
be considered, including searching for non-PV triggers, de-
livery of one or more linear lesions, isolation of the CS, isola-
tion of the LAA, ablation of autonomic ganglia, CFAE
ablation, and rotational activity ablation. A recent report sug-
gested that the best outcomes following ablation of non-PV
triggers are achieved in patients with a well-deﬁned provoca-
ble target.640 Each of these strategies has been described in
detail in the rest of this document.Endpoints for Ablation of Paroxysmal, Persistent,
and Long-Standing Persistent AF
PVI is the cornerstone of AF ablation. Among the writing
group members, 95% employ this endpoint during all AF
ablation procedures. PVI is demonstrated by entrance block
alone by 35%, and both entrance and exit block by 65%.
Beyond PVI, other endpoints, particularly during ablation
for persistent AF, are unclear. It has been suggested that
regardless of other non-PV targets ablated, the endpoint for
ablation of persistent AF should be the termination of AF
either to a regular ATA, or to a sinus rhythm. Although termi-
nation of AF has been shown by some to be predictive of
longer-term outcome, other studies have not conﬁrmed this
ﬁnding.399,400,401,515,621,641,642 It is unclear whether acute,
intraprocedural termination is a true indication of procedural
success, or simply might indicate patients with less persistent
AF who are destined to do better regardless of the approach
used. A substudy of the STAR AF II trial has suggested this
latter point.643 Slowing of AF cycle length as measured from
the CS or the LA or RA appendage has also been used as a sur-
rogate for acute procedural success. However, AF cycle length
prolongation canbedifﬁcult tomeasure reliably inAF, andpro-
longation is often used as a harbinger of acute termination.
Again, longer baseline AF cycle length can be an indication
of AF that is more likely to terminate or respond to ablation
rather than indicating a procedural endpoint in and of itself.643
Thus,AF termination of cycle length prolongationmight not be
useful as a sole procedural endpoint.
Other non-PV targets have been suggested for ablation,
particularly for persistent AF. CFAEs have been put forward
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studies and meta-analyses have not concluded that there is
any beneﬁt.644 Ablation of non-PV focal triggers identiﬁed
via isoproterenol challenge, ablation of atrial scarred re-
gions, or ablation of localized rotational activations (so-
called rotational activity) have also been reported to have
beneﬁt over PVI alone.140,534,538,645 It appears that
regardless of which target is chosen, complete local
elimination of the target should be the goal, so as not to
leave behind partially ablated tissue that could serve as a
site for future AT recurrence. The best method of ablating
a localized rotational activation is as yet unclear. Early
descriptions suggested ablating the center of activation
with several lesions and then remapping to conﬁrm that
the rotation is terminated.563 Others have suggested that cen-
tral ablation should be combined with creation of a short line
to an anatomical or ablated boundary that crosses and inter-
rupts the rotational pathway. The choice at this point is un-
clear. Similarly, for scar-based ablation, the best methods of
deﬁning scar are not yet conﬁrmed (late gadolinium
enhancement vs voltage mapping), and even for voltage
mapping, the appropriate voltage cutoffs have not yet been
validated. Furthermore, it is unclear whether such scar re-
gions should be surrounded by lesions to isolate them
from the rest of the atrium; whether ablation within the
scar to eliminate all residual electrograms (so-called
homogenization) should be employed; or whether these re-
gions should also be tied to anatomical boundaries by short
linear ablations. It follows from earlier comments that these
scar ablations should be anchored to other nonconducting
anatomical structures. There will need to be much further
research into the best ablative endpoint for these ancillary
targets. Empiric linear ablation likely does not add muchFigure 9 Schematic drawing showing catheter ablation of atrial ﬁbrillation using
lesion set created using RF energy. Ablation lesions are delivered in a ﬁgure of eight
isthmus lesion created for ablation of typical atrial ﬂutter in a patient with a prior hist
at the time of ablation. A multielectrode circular mapping catheter is positioned in
system. Ablation lesions have been created surrounding the right PVs, and the cr
the lumen multielectrode circular mapping catheter is positioned in the left superioto ablation of persistent AF.646,647 However, if linear
ablation along the roof or mitral annulus is added to target
roof or mitral-dependent ﬂutters, then bidirectional block
is a prerequisite endpoint. Block across a line must be as-
sessed in sinus rhythm and with differential pacing maneu-
vers, and these are described in detail in the following
section.Section 6: Technology and Tools
In this section, we provide an update on many of the technol-
ogies and tools that are employed for AF ablation procedures.
It is important to recognize that this is not a comprehensive
listing and that new technologies, tools, and approaches are
being developed. It is also important to recognize that RF en-
ergy is the dominant energy source available for ablation of
typical and atypical AFL. Although cryoablation is a
commonly employed tool for AF ablation, it is not well suited
for ablation of typical or atypical AFL. Other energy sources
and tools are available in some parts of the world and/or are in
various stages of development and/or clinical investigation.
Shown in Figure 9 are schematic drawings of AF ablation us-
ing point-by-point RF energy (Figure 9A) and AF ablation
using the CB system (Figure 9B).Radiofrequency Energy
Biophysics and Irrigation
The presumed basis of successful AF ablation is production
of myocardial lesions that block the propagation of
rapidly ﬁring PV triggers or modiﬁcation of the arrhythmo-
genic substrate responsible for reentry. Successful ablation
depends on achieving lesions that are reliably transmu-
ral.648,649 The conventional approach employed by cardiaceither RF energy or cryoballoon AF ablation. A: Shows a typical wide area
pattern around the left and right PV veins. Also shown is a linear cavotricuspid
ory of typical atrial ﬂutter or inducible isthmus-dependent typical atrial ﬂutter
the left inferior PV. B: Shows an ablation procedure using the cryoballoon
yoballoon ablation catheter is positioned in the left superior PV. A through
r PV. Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
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energy delivery by way of a transvenous electrode catheter.
RF energy achieves myocardial ablation by causing
resistive heating of the tissue with subsequent heat
conduction to deeper tissue layers. Most RF energy is
delivered in a unipolar fashion between the tip of the
ablation catheter and a large surface-area dispersive electrode
applied to the patient’s thorax or thigh. The position of the
dispersive electrode does not greatly affect lesion size or ge-
ometry. If a high-power system is used, two dispersive elec-
trodes should be employed to avoid skin burns. With bipolar
RF delivery, there is no dispersive electrode, and both elec-
trodes are active. One commercial system delivers RF energy
simultaneously through multiple electrodes in a unipolar,
blended, or bipolar fashion, using either continuous unipolar
delivery with an offset of the phase of the RF wave between
electrodes (phased RF delivery), or ﬁeld sequential unipolar
and bipolar delivery between contiguous electrodes in a pre-
speciﬁed ratio.650 Although bipolar ablation can be effective
in heating tissue between contiguous electrodes, the lesions
are not as deep as those using unipolar ablation.
Factors that will determine the size and depth of RF en-
ergy ablative lesions are power, impedance, temperature,
duration, and CF.651,652,653 High-power delivery and good
electrode–tissue contact promote the formation of larger le-
sions and improve procedure efﬁcacy. However, if the tem-
perature of the electrode–tissue interface exceeds 100C,
then blood will boil and the blood proteins will form char
and coagulum. As coagulum adheres to the electrode, less
surface area is available for electrical conduction and the cur-
rent density rises, resulting in more tissue and blood heating
in a positive feedback spiral leading to a rapid rise in electri-
cal impedance. Higher power delivery can be achieved with
saline-irrigated tip catheters that cool the endocardial surface
and prevent char and impedance rise. Increased convective
cooling can also be achieved passively by using electrode
material with high thermal conductivity, such as gold.653
The higher power delivery achieved with tip irrigation results
in greater depth of resistive heating, with signiﬁcant increase
in lesion size. If intramural temperatures exceed 100C,
steam expansion can suddenly vent through the endocardium
or epicardium (pop lesion) and potentially cause a perfora-
tion.654 Because of more reliable creation of transmural le-
sions, and reduced risk of formation of endocardial
thrombus and char, AF ablation with RF catheters is most
commonly performed with tip irrigation. Optimal catheter–
tissue contact is achieved by a combination of steerable cath-
eter selection, guide sheath manipulation, operator skill, and
monitoring catheter–tissue CF.655 Signiﬁcant complications
can occur during AF ablation if high RF power is adminis-
tered in an uncontrolled fashion. The increased risk of AF
ablation compared with ablation of other arrhythmias can
be attributable to the great surface area of tissue ablated,
the large cumulative energy delivery, the risk of systemic
thromboembolism, and the close location of structures sus-
ceptible to collateral injury, such as the PN, PVs, and esoph-
agus. Thrombus and char can be minimized by limitingpower and/or target temperature by monitoring the produc-
tion of steam microbubbles at the catheter tip with ICE,
and by cooling the electrode–tissue interface with saline-
irrigated tips.656,657,658,659 Intramural steam pops can be
reduced by limiting both power and the electrode–tissue
contact pressure. Duration of energy delivery affects the
tissue temperature proﬁle. The half-time of lesion growth is
approximately 5–15 seconds, depending on the power
used; thus, maximum lesion size is usually achieved within
1 minute. A long ablation duration will allow the heat gener-
ated in the region of resistive heating to conduct to deeper tis-
sue layers, with maximum lesion size being achieved when
the system has reached steady state. A short duration will
yield maximal heating close to the source, with a steep
drop in temperature in deeper layers, and might be preferred
when ablating thinner regions such as the posterior LA when
heating of contiguous structures (esophagus) needs to be
avoided.
Immediately postablation, lesions show typical coagulation
necrosis, hemorrhage, and edema. Subacute lesions examined
2–7 days later show inﬁltration of inﬂammatory cells, and
early chronic lesions show replacement of myocardium with
granulation tissue at 4 weeks.660 Myocardium exposed to tem-
peratures of 50C or higher for more than several seconds will
show irreversible coagulation necrosis and evolve into
nonconducting myocardial scar.652 The mechanism of acute
injury to myocardium is attributed to thermal injury to the
sarcolemmal membrane with resultant depolarization and
intracellular calcium overload.661,662 In the border zone
region of lesion formation, myocytes can become inactive or
dormant, but then subsequently reestablish a normal resting
membrane potential and normal electrical conduction. These
dormant zones can be reactivated by the hyperpolarizing
effects of adenosine.465 Conversely, the inﬂammatory
response to the acute injury and damage to the microvascula-
ture can lead to lesion progression.
Various techniques have been proposed to minimize collat-
eral injury. Temperature sensors at the electrode catheter tip
can provide gross feedback of surface temperature, but
because of passive convective cooling from circulating blood
ﬂow or active cooling in a cooled tip catheter, temperatures
measured at the catheter tip signiﬁcantly underestimate peak
tissue temperatures. Limiting power and shortening duration
of energy delivery will limit collateral injury, but at the
expense of reliably creating transmural lesions. ICE has been
used to monitor lesion formation. If the tissue shows evidence
of increased echogenicity, or if small gas bubbles are observed,
then power should be reduced or terminated.663,664Contact Force-Sensing Catheters and Systems
Contact Force
During RF catheter ablation, electrode–tissue CF is one of the
primary determinants of lesion size.636,665,666,667 No
effective lesion is formed without adequate CF, and
excessive CF is associated with excessive deep tissue
heating and an increased risk of deep steam pop (and
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pulmonary, and PN injury.
Ablation catheters using two different technologies have
been developed recently to measure real-time catheter–tissue
CF during mapping and RF ablation. One catheter uses three
optical ﬁbers to measure the microdeformation of a deform-
able body in the catheter tip (TactiCath, St. Jude Medical,
Inc.), which correlates with tip force.668,669,670 The second
catheter uses a small spring between the ablation tip
electrode and the catheter shaft, with a tiny magnetic
transmitter in the tip and magnetic sensors proximal to the
tip to measure microdeﬂection of the spring (ThermoCool
SmartTouch, Biosense Webster, Inc.), corresponding to tip
force.671,672,673 Both systems have high resolution (,1
gram) in bench testing and accurately display the direction
of force. These two catheters, equipped with saline-
irrigated tip electrodes, underwent extensive preclinical
studies and were introduced for clinical use, beginning in
2010. The surrogate measures of contact used previously,
including the ﬂuoroscopic appearance of catheter motion,
intracardiac electrogram amplitude, and impedance, have
been found to be very poor predictors of CF.668,670,671,672,674
Preclinical experimental studies have shown that (1) at
constant RF power and application time, RF lesion size
signiﬁcantly increases with increasing CF; (2) the incidence
of steam pop and thrombus also increase with increasing
CF; and (3) modulating RF power based on CF (e.g., high
RF power at low CF and lower RF power at high CF) results
in a similar and predictable RF lesion size.668,670,672
AF ablation studies using CFS catheters have provided
important insight into the spatial distribution of CF during
PVI. When the operator was blinded to CF measurements
during catheter manipulation and ablation, sites of high CF
were identiﬁed to be the RS aspect of the anterior LA wall,
the posterior antrum of the RSPV, the inferior posterior LA
wall, the posterior antrum of the LSPV, and the LA
roof.671 Sites of low CF have been identiﬁed to be anterior
to the left PVs and right carina.675,676,677 These low CF
sites have correlated with sites of PV reconnection.677 CFS
catheters provide operator feedback to allow for more homo-
geneous force delivery and reduce impedance rise, cardiac
perforation, steam pops, and thrombus formation while at
the same time improving effective lesion formation.453,668,
671,676,678,679,680
Several clinical studies have compared circumferential
antral PVI using the ThermoCool SmartTouch CFS catheter
with ablation using a non-CFS catheter. The SmartTouch
catheter has been shown to reduce gaps, prevalence of
adenosine-induced dormant conduction, ﬂuoroscopy time,
and AF recurrence.468,673,679,681,682,683 One of the largest
studies was a retrospective, case-control study of 600 patients
followed for mean duration of 11.46 4.7 months. The use of
the SmartTouch CFS catheter predicted freedom from ATA
in patients with PAF (hazard ratio [HR] 2.24; 95% CI
1.29–3.90; P 5 .004), but not in those with non-PAF (HR
0.73; 95% CI 0.41–1.30; P 5 .289). These ﬁndings could
be due to differences in the AF substrate in which recurrencein patients with PAF is attributed to gaps in lesion sets rather
than advanced AF substrate, and CFS improves lesion forma-
tion. There was no difference in complication rate between
the CFS and non-CFS catheters. Another evaluation of the
SmartTouch catheter was the ThermoCool SmartTouch
Catheter for the Treatment of Symptomatic Paroxysmal
Atrial Fibrillation (SMART-AF) trial, which was a multi-
center, prospective, randomized clinical trial performed for
FDA approval of this catheter.673 The outcomes were
compared with the earlier clinical trial for ThermoCool
approval,684 in which 170 patients were enrolled. The 12-
month freedom from AF/AT/AFL was 72.5% at 1-year
follow-up, compared with 66% efﬁcacy for the ThermoCool
noncontact-force catheter.684 The average CF per procedure
was 18 grams. Four patients experienced cardiac tamponade.
A post hoc analysis revealed that when the CF employed was
between the investigator-selected working ranges .80% of
the time, outcomes were 4.25 times more likely to be success-
ful.673 The most recent study to evaluate the efﬁcacy of CF
catheters randomized 117 patients with PAF to AF ablation
with the Smart-Touch Catheter. Patients were randomized
to having the CF information available or not available to
the operator. The availability of CF information resulted in
a lower incidence of acute reconnection (22% vs 32%); how-
ever, there was no difference in long-term efﬁcacy, ﬂuoros-
copy times, or complications.685
The efﬁcacy of the TactiCath CFS catheter for AF ablation
has been evaluated in a number of clinical trials, one of which
resulted in FDA approval of this device. The TOCCATA
study enrolled 35 patients with PAF and demonstrated that
CF predicted freedom from AF postablation.676 All the pa-
tients in whom the average ablation CF was less than 10
grams (n 5 5) had recurrent AF by 1-year follow-up;
whereas, 80% of the patients (n 5 8 of 10) were free from
AF at 1 year when the average CF was greater than 20 grams.
The EFFICAS I study enrolled 46 patients with PAF and
correlated CF with incidence of gaps in PVI lines 3 months
after the initial PVI procedure.453 The number of ablation le-
sions, minimum CF, and minimum force time integral ,400
grams were highly predictive of gap presence and PV recon-
nection 3 months postablation.
A small study enrolling 6 patients used late gadolinium-
enhanced (LGE) cardiac MRI to assess scar formation 3
months postablation following PVI. Increasing force-time
integral (FTI) correlated with increased LGE signal inten-
sity.680 This was particularly so when the FTI was .1200
grams. Segments with FTI ,1200 grams showed less scar
formation 3 months postablation. In addition to being able
to provide feedback to improve durability of AF ablation le-
sions sets, the TactiCath catheter has been shown to decrease
ﬂuoroscopy time and reduce the number of RF applications
for PVI compared with a non-CFS catheter.686 The most
recent and most important clinical trial of the TactiCath cath-
eter was the TOCCASTAR clinical trial performed for FDA
approval of this device.655 In this prospective, randomized
clinical trial, 300 patients with PAF were randomized to abla-
tion with the TactiCath catheter or to the non-CFS
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observed, with success rates of 67.8% and 69.4% in the CF
and control arms, respectively. When the CF arm was strati-
ﬁed into optimal CF and nonoptimal CF groups, effective-
ness was achieved in 75.9% vs 58.1%, respectively. There
was no difference in the rate of complications in the two
groups. Cardiac tamponade occurred in one patient in each
group.
Despite the absence of prospective clinical trials that have
proven that CF monitoring improves not only the efﬁcacy but
the safety of AF ablation, operators worldwide have quickly
adopted these new advanced ablation tools. Many of these
operators who employ CFS during AF ablation believe that
CF monitoring provides important biomechanical feedback
to improve effective lesion formation, durability of PVI,
and clinical outcomes. Future systems combining CF, RF po-
wer, and application time (such as the Force-Power-Time In-
dex) could provide real-time assessment of lesion formation
to increase the efﬁcacy and safety of RF ablation. It should be
remembered that CF is only one of the surrogate markers of
ablative energy delivery. Power, impedance, temperature,
and other factors remain in place and interact with the CF
measurements. Several systems now employ a monitoring
system that uses an integral of two or more of these factors.
It is also possible that when higher CFs are realized, the po-
wer of RF delivery might need to be reduced. Achieving an
adequate CF does not eliminate the user’s responsibility to
maintain awareness of other factors, such as power or other
matrix components of ablation.
A survey of the writing group shows that among those
who perform AF ablation with RF energy, 70% routinely
use CFS. Two-thirds of the writing group members allow
at least 20 seconds at a given ablation site to elapse before
moving the ablation catheter to a new site. The target minimal
CF used by the writing group members is.5 grams by 28%,
.10 grams by 62%, .15 grams by 8%, and .20 grams by
3%. A CF upper limit of 30 grams is employed by 48%
of the writing group members, less than 40 grams by 36%,
and ,50 grams by 15%. As noted in Section 5 and
Table 3, the writing group recommends that when perform-
ing AF ablation with a force-sensing RF catheter, that a start-
ing point minimum targeted CF of 5 to 10 grams is reasonable
(Class IIa, LOE C-LD, Table 3).
Cryoablation
In recent years, CBA has become the most efﬁcient alterna-
tive to RF catheter ablation (RFCA) for the treatment of
AF (Figure 9B).
The CB single shot ablation approach to AF has been de-
signed to shorten and simplify the ablation procedure for
achieving an effective PVI. Preclinical and clinical studies
have shown that CB is effective in achieving PVI, offering
a valid alternative to RF’s point-by-point approach to
PAF treatment.494,687,688 The multicenter, prospective
randomized controlled Sustained Treatment of Paroxysmal
Atrial Fibrillation (STOP-AF) trial has reported that PVIwith the ﬁrst-generation CB achieved 69.9% freedom
from AF at 12 months compared with 7.3% with
AADs.462 More recently, the second-generation CB has
become available to overcome some of the limitations of
the ﬁrst CB generation.689 These improvements include
expansion of the cooling zone from the equatorial surface
of the balloon to the entire distal half, leading to a more uni-
form circumferential ablation.473,484,690,691,692 Composite
circumferential lesion size could be a second factor in this
process.
In a prospective, multicenter registry, there was no differ-
ence between conventional RFCA and CB in terms of acute
success rate and overall complications; however, ﬂuoroscopy
times were longer in CBA procedures.693 Many studies
(mostly nonrandomized) showed that CBA yields similar or
higher success rates in comparison to RF in patients present-
ing with drug-resistant PAF, and that the procedure is some-
what less time-consuming and might be associated with a
safer proﬁle.482,694,695,696 More recently, the multicenter
randomized clinical trial FIRE AND ICE, comparing
conventional PVI with RFCA (force-sensing catheters were
used in approximately 25% of the procedures) to CBA (CB-
2 in approximately 75% of the procedures) in drug-
refractory PAF has shown that CBA is noninferior to RFCA
with respect to efﬁcacy and overall safety.489,697 More
speciﬁcally, the primary efﬁcacy endpoint (any atrial
arrhythmia recurrence, use of AADs, or repeat ablation at 1
year) was not different between the CBA and RFCA
groups; neither was the primary safety endpoint. PN injury
at the time of discharge was the most frequent adverse
event reported in the CBA group (2.7%), but lower than
what was observed in the STOP-AF trial (13.5%). Permanent
PN injury occurred in 0.3% of patients. A recent analysis of
the secondary endpoints of FIRE AND ICE has shown that
CBA had signiﬁcantly fewer repeat ablations, direct current
cardioversions, all-cause rehospitalizations, and cardiovascu-
lar rehospitalization during the follow-up compared with
RFCA, with a similar improvement in QOL.490
A recent trial reported their pivotal ﬁndings on CBA as
ﬁrst-line therapy in a selected population suffering from
PAF; the authors suggest that it might be appropriate to
consider CBA therapy for PVI as ﬁrst-line therapy in patients
with PAF in the absence of signiﬁcant structural heart
disease.698 Yet, the decision whether to perform a catheter-
based intervention in a symptomatic patient still takes into ac-
count the stage of atrial disease, the presence and severity of
any underlying cardiovascular disease, potential treatment al-
ternatives, and—in particular—patient preference and oper-
ator experience.7 Cryoballoon AF ablation requires a
shorter learning curve than point-by-point RFCA. The results
of the currently ongoing Catheter Cryoablation vs Antiar-
rhythmic Drug as First-Line Therapy of Paroxysmal
AF (Cryo-FIRST) trial (NCT01803438), expected in 2017,
will help answer the question of whether to propose CBA
as a ﬁrst-line therapy in highly symptomatic patients with
PAF.
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A laser balloon ablation system transmits light energy
through a balloon ﬁlled with deuterium oxide (D2O, or
“heavy water”) to perform PVI.498,508,699,700,701 The unique
part of this system is that the lumen of the catheter contains
a ﬁber optic endoscope that allows PVI under direct
visualization. The balloon is compliant, allowing a variable
inﬂation diameter from 25–32 mm, depending on PV size,
and is delivered via a 16 Fr outer-diameter steerable sheath.
Once the balloon is inﬂated, the diode laser emits energy in
a 30-degree arc of overlapping lesions that can be rotated
around the circumference of the PV and tracked visually us-
ing special software. The power of the laser ablation energy
can be titrated from 5.5 to 12W, lasting for 20–30 seconds for
each ablation lesion. Lower power is used when blood is pre-
sent in the ﬁeld of view or when the laser is overlying the pos-
terior LA wall, and higher power is favored over remaining
PV segments in order to achieve persistent PVI.502 The endo-
scope has a 115-degree ﬁeld of view (partially blocked by the
lesion generator), and the balloon catheter is then rotated to
complete the isolation. Each PV is typically individually iso-
lated, as opposed to the individual or pairwise isolation used
during point-by-point RF ablation. A multicenter, prospec-
tive pivotal trial of the laser balloon for treating PAF found
that freedom from AF after a single laser balloon ablation
was noninferior, and nearly identical, to the success rate us-
ing irrigated RF ablation (61.1% laser vs 61.7% RF; P 5
.003 for noninferiority), with a similar safety proﬁle.503 PN
injury was more common using the laser balloon (3.5% vs
0.6%; P 5.05), but PV stenosis was less common (0.0% vs
2.9%; P 5.03). In a single-center randomized study, AF
recurrence after ablation was similar using the laser balloon
compared with the ﬁrst-generation CB (27% vs 37%; P 5
.18).501,502 The laser balloon has been used commercially
in Europe and has received FDA approval for use in the
United States to treat patients with drug refractory recurrent
symptomatic PAF.
A novel automated low-intensity collimated ultrasound
ablation system is in development.702 This system uses low-
intensity collimated ultrasound (LICU) to automatically create
a 3D anatomical map of the LA. A graphical interface allows
the operator to deﬁne a desired lesion set on the 3D map, then
delivers computer-controlled LICU along the desired ablation
path to create a contiguous lesion. The lesions are created
without contacting the atrial wall and are calibrated with
respect to detected tissue thickness. Ultrasonic power is varied
along the ablation path to achieve transmurality while reducing
the risk of damage to extracardiac structures. Animal studies
show that PVs are electrically isolated with a single planned
set of lesions. Initial phase clinical trials are being performed
at this time, and the results are pending.Other Balloon Technologies
Balloon-based ultrasound and RF ablation systems have also
been developed for AF ablation.703,704,705 The ﬁrst of these
balloon ablation systems to be approved for clinical use inEurope was the focused ultrasound ablation system.703,704,
705 Although this balloon-based ablation system was demon-
strated to be effective, it was removed from the market
because of a high incidence of AEFs, some of which resulted
in patient death.
The hot balloon ablation catheter employs a compliant
balloon ﬁlled with saline that is inﬂated to occlude the
PV.706 A central electrode delivers RF energy to the saline
in the balloon, and a unique mixing system creates turbulent
ﬂow, promoting uniform distribution of the heated saline
throughout the balloon. The balloon surface directly heats
the PV wall circumferentially. Tissue heating occurs
through direct conductive heating.707 This technology has
been used to successfully treat patients with PAF, with a re-
ported 65% long-term single-procedure success rate
without AADs. The main reported complication with this
technology was PN palsy (3.4%) and PV stenosis
(1.7%).708 A recent prospective multicenter clinical trial
compared the outcomes of hot balloon ablation vs AAD
therapy for PAF. Freedom from atrial arrhythmias was
achieved at 12-month follow-up in 59% of patients under-
going ablation vs 4.7% with AAD therapy. Serious adverse
events occurred in 10% of hot balloon patients. The inci-
dence of PV stenosis was 5.2%, and the incidence of PN
injury was 3.7%. The clinical availability of this ablation
technology is limited at the present time.709Multielectrode Circumferential Ablation Catheters
Currently, two multielectrode circumferential catheter sys-
tems are in clinical use: The PV ablation catheter (PVAC)
and the nMarq system. From a historical standpoint, the
ﬁrst catheter using a circumferential multielectrode
approach for sensing and simultaneous ablation with the
same electrodes was the Mesh ablator.710 However, due
to technical limitations of the system and poor clinical
outcome, this system is no longer available. The nMARQ
catheter is a combined decapolar irrigated ablation and
mapping RF system.711,712,713,714 The catheter has a
circular design and consists of 10 platinum-coated 3 mm
electrodes with a 4 mm interelectrode spacing. Irrigation
is performed via 10 holes in each electrode. RF ablation
can be performed via all 10 electrodes simultaneously,
up to a maximum of 25 W in unipolar and 15 W in bipolar
mode. In an initial evaluation phase in smaller patient co-
horts, a high acute success rate of PV disconnection was
reported.715,716,717 A multicenter prospective registry
reported data on approximately 180 consecutive patients
with paroxysmal (140 patients) and persistent (40
patients) AF who underwent nMARQ AF ablation. Aside
from a high acute success rate, acute complications and
rate of AF relapse (e.g., 27% in the PAF group) were
comparable to other ablation techniques after a mean
follow-up of 13.9 months.718 Esophageal injury has been
reported in several studies using the nMARQ AF ablation
catheter.719,720 Comparing the intracardiac signals from
the nMARQ to a standard “lasso”-like mapping resulted
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postablation (which were still detectable in the lasso) and
overestimation by sensing fragmented electrograms that
could not be veriﬁed with a lasso mapping.721 This appears
to be an area with a need for further investigation, because
underestimation of remaining PV potentials can lead to a
pseudo-high acute success rate but higher AF relapses dur-
ing long-term follow-up. The nMARQ is not currently
available for clinical use in the United States. A prospec-
tive clinical trial is underway to demonstrate the safety
and efﬁcacy of this ablation system, needed for FDA
approval.722
The PVAC in its ﬁrst version used 10 platinum-iridium
electrodes in a circular fashion to deliver duty-cycled bipo-
lar or unipolar phased RF energy via selected or even all
electrodes (temperature-controlled and power-limited:
60C/10 W/60 second delivery time). Following initial,
mostly single-center, experiences that demonstrated excel-
lent clinical efﬁcacy, several studies reported a high inci-
dence of asymptomatic cerebral emboli (ACE) lesions
after PVI with the PVAC compared with irrigated focal
RF and CBA.650,723,724,725,726,727 These reports triggered
an evaluation of the underlying mechanisms; the
Endovascular Revascularization and Supervised Exercise
Therapy in Patients with Peripheral Artery Disease and
Intermittent Claudication trial subsequently demonstrated
that through modiﬁcations in the catheter design,
including the elimination of overlying pole 1 and 10
ablation, and protocol for use, it was possible to reduce
the incidence of ACE lesions to 1.7%.722,727,728,729,730
These ﬁndings were conﬁrmed in the PRECISION
GOLD trial.731,732 This ablation system was not
approved for clinical use by the FDA due in part to
this initial safety signal and the occurrence of 4
strokes (2.9% of patients randomized to ablation)
following ablation in the pivotal Tailored Treatment
of Permanent Atrial Fibrillation study.733,734 An
additional single-arm study to again elucidate the
safety of PVAC technology, the Evaluation of Multi-
electrode Phased RF Technology in Persistent AF
(NCT01693120), was subsequently launched but has
recently been closed due to lack of enrollment. In summary,
there is considerable reason and data to believe that PVAC
technology in its redesigned format has achieved at least a
similar safety proﬁle as CB or irrigated tip catheter abla-
tion. The relative efﬁcacy of this ablation system compared
with the CB system or point-by-point RF ablation will
require an adequately powered prospective, randomized
clinical trial.734 Several prospective and randomized data
collections are starting, but results will not soon be avail-
able, including the Efﬁciency Study Evaluating the Use
of the PVACCatheter Technology for Performing Ablation
in Patients with AF (CAPCOST) (NCT01562912) and
PVAC GOLD Versus Irrigated RF Single Tip Catheter
with Contact FORCE Ablation of the PVs for Treatment
of Drug Refractory Symptomatic Paroxysmal and Persis-
tent AF (GOLD FORCE) (NCT02463851).Electroanatomical Mapping Systems
AF is a disease frequently progressing from paroxysmal to
persistent AF. The mechanisms underlying the process of
arrhythmia perpetuation are complex. Major contributions
to the understanding of the initiating and perpetuating factors
derive from mapping studies in both patients and in animal
models of AF. Mapping and ablation of AF require accurate
navigation in the LA within the context of the underlying mi-
crostructures and physiology of the electrogram formation.
This can be obtained using standard ﬂuoroscopy or, more
commonly, with EAM systems that combine anatomical
and electrical information by catheter sequential point-by-
point or simultaneous multielectrode mapping, allowing an
accurate anatomical reconstruction of the 3D shell of the tar-
geted cardiac chamber. There are several different EAM sys-
tems that are widely used in clinical practice. The current
generation of the CARTO mapping system (CARTO 3; Bio-
sense Webster, Diamond Bar, CA, USA) relies both on a
magnet-based system for accurate localization of dedicated
mapping or ablation catheters and an electrical impedance-
based system that allows for visualization of electrodes and
shaft of various types of electrophysiological catheters. The
second EAM system is the electrical mapping system EnSite
NavX (current version, Velocity; St. Jude Medical, Minneap-
olis, MN, USA), which uses both voltage and impedance for
localization of proprietary and nonproprietary diagnostic and
ablation catheters. This system has now been modiﬁed to also
provide magnetic-based navigation, which is anticipated to
increase the precision of this system. Another 3D mapping
system that has been developed is the 3D MediGuide sys-
tem.735 This sensor-based electromagnetic navigation system
allows real-time catheter tracking in the environment of pre-
recorded X-ray loops. This system has been shown to easily
integrate into the workﬂow of a standard AF ablation and al-
lows for high-quality catheter tracking. Studies have shown
that this system is useful in reducing ﬂuoroscopy exposure
for patients and staff. A third EAM system that is available
for clinical use is the magnetic electrical Rhythmia mapping
system (Boston Scientiﬁc, Marlborough, MA, USA), which
is an EAM system that allows for automated high-density
mapping using a dedicated steerable 64-electrode mini basket
catheter.627,632,736 This system has only become available in
the past several years, and as a result, the experience with this
system is limited. A recent report describes the value of this
system for activation mapping and ablation of complex left
AFLs.627
To further improve the anatomical accuracy of the maps,
integration of 3D images obtained by CT or MRI and of im-
ages acquired with intracardiac ultrasound during the proced-
ure has become available.737,738 Another approach involves
use of 3D rotational angiography images that can be
merged with live two-dimensional ﬂuoroscopy.739 This
approach is rarely used at the present time. It is important
to recognize that CT and MRI are not real-time images,
and that the accuracy of the use of multiple imaging modal-
ities is dependent on the accuracy of the image fusion. This
requires the matching of ﬁducial points from both image
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face space. In addition, the utility of multimodal ap-
proaches to ablation depends on the quality of
electrogram acquisition and the registration of that phys-
iology onto the 3D images. Again, as more electrodes are
simultaneously used in mapping, synthesizing informa-
tion from that number of electrograms might require the
use of electrogram single processes made simpler by
mathematical manipulations, such as fast Fourier trans-
form, inverse solution, Hilbert, and phase transforma-
tions. The positive and negative beneﬁts of these
manipulations require increased understanding on the
part of the user and do not excuse a clear understanding
of the ﬁrst principles of cardiac electrophysiology.
The use of these 3D mapping systems has been demon-
strated to reduce ﬂuoroscopy duration.740,741,742 However,
several studies performed to deﬁne the clinical beneﬁt of
EAM systems have generated mixed results: whereas
some studies have reported that use of these mapping
systems with or without image integration improves
the safety and efﬁcacy of AF ablation, other studies
have reported contradictory ﬁndings.743,744,745,746,747
Obviously, the use of 3D mapping systems will increase
the cost of the procedure.
A survey of the writing group members showed that 93%
routinely employ 3D EAM when performing AF ablation
with RF energy.Robotic and Magnetic Catheter Navigation
The concept of remote catheter navigation is appealing for
the operator because these systems can reduce radiation
exposure and the risk to the physician of developing orthope-
dic problems related to prolonged use of protective lead
aprons during protracted cases. They also can facilitate anal-
ysis of intracardiac electrograms and 3D images because the
catheter navigation and analysis can be performed from the
workstation where the operator is seated. The four technolo-
gies developed to meet these objectives include the magnetic
navigation system designed by Stereotaxis Inc; a second
magnetic system referred to as the Catheter Guidance, Con-
trol, and Imaging (CGCI) system, for which there is limited
experience; a third robotic-controlled catheter system manu-
factured by Hansen Medical; and the remote catheter system
developed by Catheter Robotics.748,749,750,751 These
technologies have been used to ablate AF, and there is
evidence that they are safe, effective, and result in a
signiﬁcant reduction in ﬂuoroscopy time and radiation
exposure; however, the studies are relatively small, not
randomized, and the populations of patients are not
uniform.646,647,748,749,750,751,752,753,754,755,756,757,758,759 Use
of these technologies is a matter of operator preference.
The potential advantages of the systems are offset by
additional costs for the navigation systems, disposables,
and maintenance contracts. A survey of the writing group
members shows that 10% routinely employ a robotic or
magnetic system when performing AF ablation procedures.Ultrasound
In the electrophysiology lab, ultrasound is a valuable tool,
used both for guiding vascular access and during the proced-
ure. With a linear probe, central venous access to the femoral,
internal jugular, and subclavian veins can be obtained safely,
reducing complications, the number of attempts, and the time
required to gain access.760,761 The impact of real-time ultra-
sound guidance is even greater in obese patients, in proced-
ures with less experienced operators, and in patients
undergoing anticoagulation therapy.
ICE, which allows for real-time imaging of cardiac anat-
omy, is used in many electrophysiology laboratories
throughout the world to facilitate AF ablation proced-
ures.762,763,764,765,766,767 Advocates of the use of ICE ﬁnd it
to be of value because it can (1) help identify anatomical
structures relevant to ablation, including the PVs and
esophagus; (2) facilitate transseptal access and allow selective
puncture in various regions of the fossa; (3) guide accurate
placement of the multielectrode circular ablation catheter and/
or balloon-based ablation system; (4) allow titration of the
delivered energy; (5) provide feedback about catheter contact;
(6) allow for recognition of thrombus formation on sheaths and
catheters; and (7) allow early recognition of cardiac perforation
and/or development of a pericardial effusion.767,768 Some
centers also use ICE to screen for the presence of LAA
thrombus, because it has been shown to be comparable to
transesophageal echocardiogram (TEE) when performed by
experienced operators. A survey of the writing group
members shows that 53% of the members routinely employ
ICE imaging during AF ablation. Our survey revealed that
ICE was being used routinely by 87% of the writing group
members in the United States and Canada compared with
13% of the writing group members from other countries.
Among those who employ ICE imaging, 37% use ICE to
screen for LA thrombi prior to performing the transseptal stick.PV Venography
PV venography is commonly performed at the time of AF
ablation procedures.769,770 The purpose of PV venography is
to help guide catheter manipulation, determine the size and
location of the PV ostia, and assess PV stenosis, particularly
among patients undergoing repeat ablation procedures.
Among the writing group members, 25% routinely use PV
venography during their AF ablation procedures. There are
three techniques that have been described for PV
venography. The ﬁrst technique involves selective delivery
of contrast media into each of the PV ostia. This can be
accomplished by positioning the transseptal sheath in the
region of the right and left PV trunks and injecting contrast,
or by selectively engaging each of the four PV ostia using a
deﬂectable catheter or a multipurpose angiography
catheter.769 A limitation of the selective PV venography
approach is that noncatheterized PVs can be missed if a preac-
quired CT or MRI scan is not available to ensure that all the
PVs are identiﬁed. The second technique is performed by in-
jection of contrast medium into the left and right pulmonary
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then be assessed during the venous phase of pulmonary arteri-
ography. The third technique involves the injection of contrast
media in the body of the LA or at the roof of the right or left
superior PV ostium immediately after delivery of a bolus of
adenosine to induce AV block. The contrast media will ﬁll
the LA body, the PV antrum, and the proximal part of the
PV during the phase of ventricular asystole.CT and/or MRI Scans and Rotational Angiography to
Deﬁne the Anatomy of the Atrium, PVs, and Antrum
The complex anatomy of the LA plays a major role in the
pathophysiology of AF.771 A detailed understanding of this
anatomy is essential for a safe and effective AF ablation pro-
cedure.772 There is a signiﬁcant inter- and intrapatient vari-
ability in the number, size, and bifurcation of the PVs67,773,
774,775,776,777,778 (Figure 2). Common variations include su-
pernumerary right PVs (18%–29%) and common trunk
(.30%), mainly located on the left side and right middle or
right top PV.69,776 Knowledge of the presence of additional
veins prevents placing ablation lesions over their ostia,
which could result in PV occlusion, whereas knowledge of
the bifurcation pattern is essential during CB PVI, in which
wiring of various branches might be needed to ensure
optimal occlusion.779 LA imaging facilitates ablation by
providing detailed anatomical description of the PVs,
antrum, and the remainder of the LA, enabling selection of
the most suitable ablation technique prior to the proced-
ure.772,780 During the procedure, integration of LA images
obtained by CT or MRI reduces procedural time because it
enables a more accurate reconstruction of the anatomy.41
However, this requires accurate registration. Prior to RF abla-
tion, imaging of LA anatomy with either MRI or CT imaging
is performed routinely by 59% of the writing group members.
Prior to CB, AF ablation imaging of the LA anatomy with
either MRI or CT imaging is performed routinely by 56%
of the writing group members.
Another method of intraprocedural 3D imaging of the LA
is rotational angiography. After contrast medium injection in
the right heart chambers, the ﬂuoroscopy c-arm is rapidly
rotated around the patient, and images are acquired
throughout the rotation to generate 3D volumetric anatomical
rendering of the LA. These images can then be integrated into
an EAM system or superimposed on the ﬂuoroscopic projec-
tions of the heart.781,782 A survey of the writing group
members shows that rotational angiography is routinely
performed prior to AF ablation by 0% of the writing group
members.
After the procedure, LA imaging is valuable in detection
of postprocedural complications such as PV stenosis or
AEF.783MRI of Atrial Fibrosis and Ablation Lesions and
MRI-Guided AF Ablation
AF is associated with various degrees of structural remodeling
of the atrial myocardium.134,136,139,161,784 In the ventricularmyocardium, MRI is an established modality to visualize
myocardial inﬂammation and ﬁbrous tissue by using
LGE.134,560,561,785,786 However, high-resolution imaging of
atrial ﬁbrosis remains technically challenging, with limited
reproducibility of accuracy of MRI measures of ﬁbrosis by
different centers.787 In a recent study, MRI data of 17% of pa-
tients were excluded due to poor quality.365 MRI may be per-
formed before catheter ablation of AF to identify atrial ﬁbrosis,
or after ablation to visualize RF lesions.134,784,788,789 Several
studies have demonstrated that the extent of atrial ﬁbrosis
evaluated by LGE prior to ablation can predict the outcomes
of catheter ablation of AF.789 Other studies have reported con-
tradictory results.790 In the multicenter prospective DECAAF
trial, the extent of atrial ﬁbrosis found on preablation MRI was
categorized as stage 1 (,10%), stage 2 (10%–20%), stage 3
(20%–30%), and stage 4 (.30%). AF recurrence 325 days af-
ter ablation was independently associated with the extent of
atrial ﬁbrosis (15% for stage 1, 33% for stage 2, 46% for stage
3, and 51% for stage 4).365 These preliminary results suggest
that the extent of ﬁbrosis can be useful to predict arrhythmia
recurrences and to guide the decision to perform catheter abla-
tion in selected patients with AF. Studies evaluating whether
LGE can visualize scar lesions induced by catheter ablation
with RF cryoablation or laser ablation in atrial tissue, or
identify PV reconnection sites have reported conﬂicting
results.784,791 Overall, despite the promise of MRI
techniques to improve the outcomes of AF ablation, further
investigation is needed before advocating the systematic use
to assist catheter ablation of AF. The DECAAF-2 study has
just been launched for this purpose. This randomized, prospec-
tive, multicenter clinical trial is designed to test the hypothesis
that PVI plus consolidation of ﬁbrotic areas with RF ablation is
superior to PVI alone.791 A survey of the writing group mem-
bers shows that MRI for detection of scar is routinely per-
formed prior to AF ablation by 8% of the writing group
members.
During the past decade, a number of centers have devel-
oped the technology to allow real-time MR-guided electro-
physiology intervention. Advantages of this approach
include the absence of ionizing radiation and the ability to
monitor lesion development in real time. Although these sys-
tems are still under development and are not available with
routine clinical use at this time, this is an area of considerable
interest that could emerge as an important ablation moni-
toring and guidance strategy in the future.792,793,794,795Section 7: Technical Aspects of Ablation to
Maximize Safety and Anticoagulation
Prevention of Thromboembolism During and
Following AF Ablation
Patients with AF are at increased risk of thromboembolism
during, immediately following, and for several days to
months after their ablation.796,797,798,799 ACE lesions have
also been observed after AF ablation.800 The prothrombotic
state associated with AF ablation results in a higher, but tran-
sient, thromboembolism risk in patients with AF who were
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anticoagulation of patients before, during, and after ablation
for AF is critical to avoid the occurrence of a thromboembo-
lism event. Consensus recommendations for anticoagula-
tion prior to, during, and following ablation are
summarized in Table 4. The ablation procedure leaves pa-
tients with substantial areas of damaged LA endothelium
that can become a nidus for thrombus formation. Transsep-
tal sheath placement and insertion of electrode catheters can
precipitate thrombus formation on the catheter or on or
within the sheath during the procedure.768,801,802,803,804
The atrial tissue can be stunned for weeks or months
postprocedure, leading to impairment of normal
contraction.805 Anticoagulation, in turn, contributes to
some of the most common complications of the procedure,
including hemopericardium, pericardial tamponade, and
vascular complications.806,807,808 Therefore, attention
must be paid to achieving the optimal safe level of
anticoagulation throughout the process.Screening for LAA Thrombi Prior to Ablation
Transesophageal Echocardiography
Thromboembolic stroke after AF ablation is a devastating
consequence of an invasive procedure. One of the mecha-
nisms could be dislodgement of a pre-existing clot that could
be identiﬁed by a screening TEE. The risk of a thromboem-
bolic event at the time of an AF ablation procedure varies, de-
pending on a number of factors, including (1) the type of AF;
(2) the presence, absence, and duration of AF as the present-
ing rhythm on the day of ablation; and (3) the patient’s stroke
risk proﬁle, including LA size and CHA2DS2-VASc score.
With careful, multiplanar inspection of the LAA and the
number of LAA lobes, the TEE can also provide additional
information to help guide the procedure, such as identiﬁca-
tion of a pre-existing pericardial effusion, globally impaired
cardiac function, presence of an atrial septal defect (ASD)
or persistent foramen ovale, or ﬁbrosis of the interatrial
septum after previous ablation.809,810,811 In addition, LA
anatomical features, such as a thickened ridge toward the
left PVs, PV stenosis or occlusion, or cor triatriatum, can
be identiﬁed.
Because many centers perform their procedures on unin-
terrupted OAC, one could argue that TEE is unnecessary;
however, studies evaluating the incidence of LA thrombus
on TEE among patients undergoing AF ablation who have
been therapeutically anticoagulated have consistently
demonstrated that 1.6% to 2.1% of patients will have a
thrombus or “sludge” in the LAA.796,812,813 The probability
of identifying a thrombus was related to the CHA2DS2-
VASc score in some but not in every case. Other risk
factors for thrombus were LA size and a history of
persistent AF. Among patients with a CHA2DS2-VASc
score of zero, a thrombus was identiﬁed in ,0.3% of
patients compared with .5% of patients with a CHA2DS2-
VASc score of 2. The practice of routine vs selective
TEE surveillance for LAA or intracavitary thrombus priorto PVI varies widely, given evidence to guide this decision
is limited in terms of important clinical outcomes.796,809,810,
811,812,813,814
A survey of the writing group members shows that 51%
perform a TEE in all patients presenting for AF ablation
regardless of presenting rhythm and anticoagulation status.
This survey also revealed that 71% of the writing group mem-
bers perform a TEE in patients presenting AF who have been
therapeutically anticoagulated for 3 or more weeks prior to
ablation. Among patients who present for AF ablation in sinus
rhythm who have not been previously anticoagulated, 78% of
the writing group members routinely perform a TEE. Among
patients presenting for AF ablation who are chronically antico-
agulated with warfarin, 87% of the writing group members
perform AF ablation on uninterrupted warfarin. Among pa-
tients undergoing AF ablation who are chronically maintained
on a NOAC, 38% of the writing group members perform AF
ablation on a patient receiving uninterrupted NOAC without
withholding a dose. For patients not anticoagulated prior to
ablation or in whom NOAC therapy is interrupted prior to
ablation, 16% of the writing group members reinitiate the
NOAC at 2 hours, 12% at 3 hours, 37% at 4 hours, and 35%
at 4 or more hours after initially achieving hemostasis. It is
important to recognize that this is a rapidly evolving area in
AF ablation. The results of the above survey were obtained
prior to publication of the results of the Randomized Evalua-
tion of Dabigatran Etexilate Compared to Warfarin in Pulmo-
nary Vein Ablation: Assessment of an Uninterrupted
Periprocedural Anticoagulation Strategy (RE-CIRCUIT) trial,
which demonstrated that performance of AF ablation on pa-
tients receiving uninterrupted dabigatran results in a lower
rate of major bleeds compared with the uninterrupted warfarin
strategy.815,841 Shown in Table 4 are the writing group recom-
mendations concerning anticoagulation strategies prior to
ablation. As with the anticoagulation guidelines for cardiover-
sion of AF, if a thrombus is identiﬁed in the LAA prior to cath-
eter ablation of AF, the AF ablation procedure should not be
performed.
Computer Tomographic Angiography
Data are emerging to suggest that CT imaging can be valu-
able in detecting thrombi prior to an AF ablation procedure.
Several studies have investigated whether CT imaging can be
used to screen for LA thrombi, with the hope of obviating the
need for a screening TEE in at-risk patients. Compared with
TEE as a gold standard, several studies and one meta-analysis
have reported a high diagnostic accuracy of CT to detect
LAA thrombi.780,816,817 Other studies have reported lower
diagnostic accuracy and high inter-reader variability in de-
tecting LA thrombi with CT imaging.818,819 In a meta-
analysis of studies using delayed imaging protocols, the diag-
nostic accuracy for detection of LAA thrombi was reported to
be 99%.817 These ﬁndings suggest that cardiac CT (with an
acceptable radiation dose) could be of value in detecting
LA thrombi. It is important to note that in many centers the
CT is obtained days to weeks prior to ablation, rendering
this imaging modality of no value because of this time delay.
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currently insufﬁcient to recommend widespread use of CT
imaging as an alternative to TEE for preablation screening
for LA thrombi. This sentiment reﬂects in large part a great
variability in CT detector imaging equipment and protocols.
Further large-scale studies will be required before CT imag-
ing can be considered an alternative for TEE screening prior
to AF ablation. A survey of the writing group members
shows 49% of the members employ CT imaging on a routine
basis prior to AF ablation. Among those who obtain CT im-
aging, 32% use the CT image to identify LAA thrombi.Intracardiac Echocardiography
Data are also emerging to suggest that ICE can be valuable in
detecting LAA thrombi prior to an AF ablation procedure.
Imaging from the pulmonary artery is preferred. Whereas
the ICE-CHIP study demonstrated that ICE imaging from
the RA had reduced sensitivity in the detection of LA thrombi
compared with standard TEE, other studies showed that ICE
imaging from the pulmonary artery can be used safely and
effectively (compared with TEE) for the evaluation of the
LAA in patients undergoing ablation.768,820,821,822,823 Of
interest, ICE has been shown to have complementary value
in rescreening the LA and the LAA for thrombus after a
recent negative or equivocal TEE.824 These ﬁndings suggest
that ICE could be of value in detecting LA thrombi. Howev-
er, the writing group members believe that the data are
currently insufﬁcient to recommend widespread use of ICE
imaging as an alternative to TEE for preablation screening
for LA thrombi. This sentiment reﬂects in large part a great
variability in the skills needed to both perform and interpret
the results of ICE imaging for thrombi detection. Further
large-scale studies will be required before ICE imaging can
be considered to be a standard and proven alternative for
TEE screening prior to AF ablation. A survey of the writing
group members shows that 53% of the members routinely
employ ICE imaging during AF ablation. Our survey re-
vealed that ICE was being used routinely by 87% of the
writing group members in the United States and Canada
compared with 13% of the writing group members from other
countries. Among those who employ ICE imaging, 37% use
ICE to screen for LA thrombi prior to performing the trans-
septal stick. Based on this information and a review of the
literature, the writing group recommends that use of ICE to
screen for atrial thrombi in patients who cannot undergo
TEE imaging may be considered (Class IIb, LOE C-EO,
Table 4).
Anticoagulation
Systemic Anticoagulation Prior to AF Ablation
Many patients who are undergoing AF ablation have an
elevated risk of stroke as assessed using the CHA2DS2-
VASc score and are therefore systemically anticoagulated
with warfarin or with a direct thrombin or factor Xa inhibi-
tor.825,826,827,828 Most operators initiate therapeutic
anticoagulation for at least 3 weeks prior to ablation inpatients with a CHA2DS2-VASc risk score of 2 or greater,
especially if they are likely to present for the procedure in
AF. Because of the slow offset and onset of warfarin, these
patients were historically transitioned or “bridged” with
heparin or low molecular weight heparin before and after
the ablation procedure. An increased recognition of
bleeding complications associated with this practice,
especially at the site of vascular access, has led to the use
of uninterrupted warfarin, which has been shown to have a
better safety proﬁle, provided the international normalized
ratio (INR) is within the target range.399,400,401,532,533,829,
830,831,832,833,834
Dabigatran and the factor Xa inhibitors (apixaban, rivar-
oxaban, edoxaban) have a more rapid onset of action, a
shorter half-life, and a more predictable dose response
compared with warfarin. Accumulating evidence and several
meta-analyses have demonstrated similar efﬁcacy and safety
of dabigatran and the factor Xa inhibitors compared with
warfarin in the setting of catheter ablation.835,836,837,838,839,
840,841,842,843 These data provide reassurance; however,
several methodological considerations warrant mention. In
most of these studies, one or two doses of the NOACs
were held prior to AF ablation. Nearly all of the included
studies were observational in design, and are therefore
subject to confounding and selection bias. The sample sizes
of the individual treatment arms were small, and study
heterogeneity precludes statistically robust comparisons. In
addition, the study populations were predominantly male,
largely characterized by normal renal function, and the
mean patient age was 61 years, a decade younger than the
stroke prevention trial populations.
The results of the RE-CIRCUIT study were recently pub-
lished, which was a head-to-head comparison of performing
AF ablation on patients receiving uninterrupted dabigatran vs
uninterrupted warfarin.841 This study randomized 704 pa-
tients across 104 sites to these two anticoagulation strategies.
The incidence of major bleeding events during and up to 8
weeks postablation among the 635 patients who underwent
AF ablation was signiﬁcantly lower with dabigatran than
with warfarin (5 patients [1.6%] vs 22 patients [6.9%]); abso-
lute risk difference [RD] 25.3%, RR reduction 77%. There
were six patients with cardiac tamponade in the warfarin
arm vs one in the dabigatran arm. No strokes or other throm-
boembolic events occurred in the dabigatran arm compared
with one TIA in the warfarin arm. No patients in the dabiga-
tran arm required the speciﬁc reversal agent idarucizumab.
There has been one other smaller head-to-head comparison
published of uninterrupted rivaroxaban vs uninterrupted
warfarin (Venture-AF, N 5 248).842 This study reported
one major bleeding event, one ischemic stroke, and one
vascular death, each of which occurred in the warfarin arm
of the study. A third trial of apixaban vs coumadin is also un-
derway (NCT02227550).
Based on these clinical trials, it is now apparent that a
strategy of performing AF ablation on patients receiving un-
interrupted anticoagulation can be performed safely and min-
imizes the risk of thromboembolic events. Speciﬁc
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tion are shown in Table 4. Although further studies are
needed to further deﬁne the efﬁcacy and safety of performing
AF ablation on uninterrupted Factor XA inhibitors or direct
thrombin inhibitors, the writing committee believes that the
data and worldwide experience are now sufﬁcient to provide
a Class I recommendation for performing AF ablation with
uninterrupted dabigatran (Class I, LOE A) or rivaroxaban
(Class I, LOE B-R), and a 2A recommendation for the other
XA inhibitors for which speciﬁc clinical studies have not
been performed at this time. Further studies are needed to
determine if a TEE can be omitted in patients with a high
stroke risk proﬁle who present for ablation in AF and are un-
dergoing ablation on uninterrupted anticoagulation. Data will
also be needed on outcomes and use of speciﬁc reversal
agents in this setting, particularly for management of serious
procedural bleeding complications.844,845
Table 4 summarizes the recommendations for anticoagu-
lation pre-, during, and post-AF ablation, both for warfarin
and for the NOACs.Intraprocedural Anticoagulation
Optimal anticoagulation using heparin with close attention to
maintaining therapeutic dosing during the procedure is
important. It is recommended that heparin be administered
prior to or immediately following transseptal puncture during
AF ablation procedures and adjusted to achieve and maintain
a target activated clotting time (ACT) of 300 seconds or
greater (Class I, LOE B-NR, Table 4). It has been observed
that thrombi can form on the transseptal sheath and/or the
electrode catheter almost immediately after crossing the
septum and that early heparinization substantially decreases
this risk.768,802,803,804,846,847,848 A recent meta-analysis of
more than 7000 patients supports this recommendation,
showing that performing ablation of AF with a target ACT
.300 seconds decreases the risk of thromboembolic compli-
cations without increasing the risk of bleeding.849 Seventy-
seven percent of the writing group members administer hep-
arin prior to the transseptal puncture. A heparin loading dose
should be administered initially, followed by a standard hep-
arin infusion. The ACT level should be checked at 10–15
minute intervals until therapeutic anticoagulation is achieved,
and then at 15–30 minute intervals for the duration of the pro-
cedure. Patients receiving a vitamin K antagonist (VKA)
require less heparin and reach the target ACT faster compared
with NOACs; thus, when using anticoagulation strategies
with the latter, more frequent ACT monitoring and higher
heparin doses should be used.840,849 This recent report from
a large-volume medication center employs an initial heparin
bolus of 50 units per kg in patients who are therapeutically
anticoagulated with warfarin, 75 units per kg in patients
who are not anticoagulated prior to ablation, and 120 units
per kg for patients who are anticoagulated on a NOAC and
have held one to two doses. A survey of the writing group
showed great variability in loading protocols for heparin
prior to an ablation procedure. The heparin dose should beadjusted to maintain an ACT of at least 300–350 seconds
throughout the procedure. One-third of the writing group
members routinely employ a target ACT of .350 sec-
onds.820,830,846 Heparinized saline should be infused
continuously through each transseptal sheath to further
reduce the risk of thrombi.802 The risk of systemic emboliza-
tion of thrombus formed on a sheath can be reduced by with-
drawing the sheath to the RA once a catheter is positioned in
the LA. Heparin infusion can be discontinued once all cath-
eters are removed from the LA, and the sheaths removed
from the groin when the ACT is less than 200–250 seconds.
Sheaths can be removed during full anticoagulation by em-
ploying a ﬁgure-of-eight suture.850 Alternatively, the heparin
effect can be reversed with protamine (Class IIa, LOE B-NR,
Table 4).851 This approach is used by 70% of the writing
group members.
In the event of persistent bleeding or cardiac tamponade,
protamine should be administered to reverse heparin. If
bleeding resolves, then reversal of the oral anticoagulant is
not recommended, because this continues to offer protection
from thromboembolic complications postprocedure. Howev-
er, if pericardial or other bleeding persists with the above
measures, fresh frozen plasma can be administered for
reversal of warfarin. Dabigatran can be reversed with idaru-
cizumab.844 Development of a reversal agent for Factor Xa
inhibitors is underway but is not yet available on a clinical ba-
sis.845 Until these agents are available, it is recommended that
prothrombin complex concentrates (PCC: Factors II, VII, IX,
and X) or recombinant activated factor VII (rFVIIa) be
administered.852 The increasing availability of speciﬁc
reversal agents for factor IIa and Xa inhibitors will certainly
encourage the adoption of continuous anticoagulation with
the newer oral anticoagulants during AF ablation.Early Postprocedural Anticoagulation
There is a prothrombotic milieu following RF ablation for AF
due to reduced contraction of the atria, endothelial damage
from ablation lesions, and a thrombogenic state. Therefore,
it is the consensus recommendation of the writing group
members that patients should be anticoagulated for at least
2 months postablation, regardless of their CHA2DS2-VASc
score or rhythm status (Class I, LOE C-EO, Table 4). In pa-
tients treated with warfarin who have a subtherapeutic INR
the day of the procedure, there are two options. First, a direct
thrombin or Factor Xa inhibitor can be administered several
hours following ablation.826,827,853,854 Second, low
molecular weight heparin (enoxaparin 0.5–1.0 mg per kg
twice daily) or intravenous heparin can be used as a bridge
to resumption of INR 2.0–3.0. For most patients, other than
those with prosthetic valves who will need to remain
indeﬁnitely on warfarin, initiation of a NOAC postablation
is a preferred strategy to use instead of heparin or low
molecular weight heparin due to the increased bleeding risk
with these agents.
It is expected that patients will have their sheaths removed
immediately after ablation, either with or without the use of
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procedure. Hemostasis can be achieved by either direct pres-
sure or the use of a ﬁgure-of-8 suture. Evidence for the safety
of uninterrupted NOAC therapy has increased with the recent
publication of Venture AF and RE-CIRCUIT.841,842 Despite
these new data, some centers have the patient withhold one
to two doses of NOACs in the days prior to their ablation
procedure. For these patients, reinitiation of the NOAC
should take place as soon as the clinician is satisﬁed that
there is no signiﬁcant pericardial effusion or vascular
bleeding following the ablation. Similarly, for the small
subset of low-risk patients who were not being treated with
anticoagulation before the procedure, a NOAC can be admin-
istered immediately following ablation. The writing group
members advise that readministration of a NOAC be given
3 to 5 hours after completion of the procedure and removal
of the vascular sheaths, provided there is no evidence of
ongoing bleeding, or a signiﬁcant pericardial effusion or car-
diac tamponade is reasonable (Class IIa, LOE C-EO,
Table 4).Anticoagulation Considerations Two or More
Months Postablation
Whether elimination of AF or reduction of AF burden by
catheter ablation results in a signiﬁcant reduction in stroke
risk is an important, and as yet unanswered, question. Until
this important question is addressed by an adequately de-
signed clinical trial, adherence to the AF anticoagulation
guidelines is recommended for patients who have undergone
AF ablation procedures, regardless of the apparent success or
failure of the procedure (Class I, LOE C-EO, Table 4). The
writing group advises that decisions regarding continuation
of systemic anticoagulation more than 2 months postablation
should be based on a patient’s stroke risk proﬁle and not on
the apparent success or failure of the ablation procedure
(Class I, LOE C-EO, Table 4). And ﬁnally, the writing group
recommends that for patients in whom discontinuation of an-
ticoagulation is being considered based on the patient’s
values and preferences, they should consider undergoing
continuous or frequent ECG monitoring to screen for AF
recurrence (Class IIb, LOE C-EO, Table 4). This recommen-
dation is based on the following: (1) recurrences of AF are
common both early and late following AF ablation; (2)
asymptomatic AF is common, and is more common
following AF ablation than prior to AF ablation; (3) AF abla-
tion destroys a portion of the atria and the impact of this on
stroke risk is uncertain; (4) there have been no large, random-
ized prospective trials that have assessed the safety of discon-
tinuing anticoagulation in this patient population; (5) studies
have shown that strokes in patients with AFmight not be tem-
poraneously related to an AF event855; and (6) the use of
direct thrombin inhibitors or Factor Xa inhibitors, such as da-
bigatran, rivaroxaban, edoxaban and apixaban, is more
convenient than warfarin.825,826,827,828
The small subset of writing group members who support
the discontinuation of systemic anticoagulation in patientswith an increased stroke risk proﬁle make the argument
that (1) continuing anticoagulation exposes patients to the
risks for hemorrhage and the unfavorable effects of anticoa-
gulation on long-term QOL; (2) several large outcome
studies have reported a lower-than-expected stroke risk in pa-
tients who undergo AF ablation compared with control pop-
ulations239; and (3) one center has reported a low stroke risk
in patients postablation who screen for AF recurrence by
pulse assessment or ECG monitoring.238,407,409,545,856,857,
858,859,860
In considering these consensus recommendations, it is
worth commenting that some patients who have multiple
stroke risk factors are highly motivated to discontinue sys-
temic anticoagulation and are willing to accept a possible
increased risk of stroke. It is for these patients that we recom-
mend that some type of continuous monitoring be performed
to screen for silent AF at regular intervals as long as they
remain untreated with systemic anticoagulation. A survey
of the writing group members shows that 77% continue anti-
coagulation indeﬁnitely in patients who have undergone AF
ablation and who have a CHA2DS2-VASc score of 2 or
greater. It is possible that the outcomes of the CABANA
and Early Treatment of Atrial Fibrillation for Stroke Preven-
tion Trial (EAST) (NCT01288352) will help clarify this
issue. In selected patients with ECG, evidence of AF control,
and diligent follow-up for AF recurrences, 23% of the writing
group members indicated that they would consider discontin-
uing anticoagulation after a conversation with the patients in
which risks and beneﬁts were discussed. This survey also
shows that only 1 writing committee member (2%) routinely
discontinues anticoagulation in all patients following AF
ablation who are AF-free.
It is important to recognize that the above discussion has
focused on patients at high risk of stroke (i.e., CHA2DS2-
VASc score2). There is far greater ﬂexibility as to how anti-
coagulation is managed in patients at a low or moderate risk of
stroke because current guidelines do not mandate systemic an-
ticoagulation. Another important consideration is that patient
preference plays a large role in this decision. It is our belief
that patients should be made aware of the available data and
consensus recommendations, and then should be encouraged
to consider the risks and beneﬁts of continuing vs discontinu-
ing systemic anticoagulation. Some patients who are at
increased risk of stroke are highly motivated to discontinue
systemic anticoagulation and are willing to accept an increased
risk of stroke. For these patients, we recommend diligent pulse
assessment at least twice daily and strong considerations that
some type of continuous monitoring be performed to screen
for silent AF at regular intervals as long as they remain free
from systemic anticoagulation. A ﬁnal comment worth
mentioning is that the mechanisms of stroke are not limited
to cardioembolism due to AF; thus, other sources of emboli
should also be considered, such as paradoxical embolism
and atheromas from the aortic arch. In the remainder of this
section, we will brieﬂy review some of the available data.
In multiple randomized trials, AF ablation was superior to
AADs in reducing AF recurrence in drug-refractory
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gies has been largely similar. One investigator recently un-
dertook a meta-analysis to evaluate whether AF ablation
reduces the long-term risk of stroke compared with AAD
therapy.857 Thirteen RCTs were analyzed, with 1097 patients
treated by catheter ablation and 855 patients receiving AAD
therapy. Overall, seven patients (0.64%) in the catheter abla-
tion group had ischemic stroke or TIAs vs two patients
(0.23%) in the drug therapy group. No difference was shown
in the rate of stroke or TIA between ablation and drug ther-
apy. To date, however, no AF ablation trial has evaluated
whether successful ablation obviates the need for long-term
OAC, but there are reports from large administrative regis-
tries and observational studies addressing this issue.
One study evaluated the long-term results of OAC cessa-
tion after successful catheter ablation of AF.857 OAC and
AADs were discontinued irrespective of AF type or baseline
CHA2DS2-VASc risk score in 327 patients with drug-
refractory AF after catheter ablation. Patients with a
CHA2DS2-VASc score of 2 (45.4%) and 3 (23.2%) ac-
counted for 68.8% of this cohort. In the patients with a
high risk of recurrence or prior thromboembolic complica-
tions, OAC was continued for up to 6 to 12 months postabla-
tion, and antiplatelet therapy was administered to all patients
who maintained sinus rhythm upon OAC interruption. After
a follow-up of 46 months, 82% remained AF-free (free from
AADs). No symptomatic ischemic cerebrovascular events
were detected during follow-up, despite interruption of
OAC in 298 (91%) patients and AADs in 293 (89%) patients.
Another study reported the patterns of anticoagulation use
and cardioembolic risk after catheter ablation for AF.862 They
found an increased use of NOACs after ablation from 0% in
2005 to 69.8% in 2014. OAC discontinuation was high, with
only 60.5% and 31.3% of patients remaining on OAC at 3
and 12 months, respectively. The rate of discontinuation
was higher in low-risk patients (82% vs 62.5% at 12 months
for CHA2DS2-VASc 0–1 vs 2, respectively; P ,.001).
Stroke occurred in 1.4% of the patients with CHA2DS2-
VASc 2 and in 0.3% of those with a CHA2DS2-VASc of
0 or 1 over the study follow-up. The risk of cardioembolism
in the ﬁrst 3 months after ablation was increased among those
with any time free from OAC (HR 8.06; 95% CI 1.53–42.3;
P ,.05). The risk of cardioembolism beyond 3 months was
increased with OAC discontinuation among high-risk pa-
tients (HR 2.48; 95% CI 1.11–5.52; P ,.05) but not low-
risk patients, suggesting that continuing OAC for at least 3
months in all patients and indeﬁnitely in high-risk patients
appears to be the safest strategy in the absence of effective
monitoring and AF detection.
An AF ablation registry reported data of patients followed
up after ablation of PAF in a high-risk group (previous
stroke; group 1) and a low-risk group (no previous stroke;
group 2) based on data from the German Ablation Registry,
to reveal real-life prescription behavior.412 Between April
2008 and April 2011, 83 patients in group 1 and 377 patients
in group 2 with a ﬁrst ablation of PAF were included in the
registry. The results showed a mean CHA2DS2-VASc scoreof 4.2 6 1.4 (group 1) vs 1.6 6 1.2 (group 2) (P ,.0001).
OAC was discontinued in 38.6% of the patients in group 1
vs 66.3% of those in group 2 (P ,.0001) during follow-up.
Thromboembolism occurred more often in group 1 than in
group 2 (4.3% vs 0.3 %, P ,.05), arguing against OAC
discontinuation in a high-risk population without ongoing
pulse assessment and ECG monitoring.
Another study in a large Danish cohort410 evaluated the
long-term risk of thromboembolism and serious bleeding
associated with OAC therapy beyond 3 months after RF abla-
tion of AF. During a median follow-up of 3.4 years, 71
(1.8%) thromboembolism cases were identiﬁed, in which
incidence rates with and without OAC were similar at 0.56
(95% CI 0.40–0.78) and 0.64 (95% CI 0.46–0.89), respec-
tively. OAC therapy was signiﬁcantly associated with serious
bleeding risk (HR 2.05; 95% CI 1.25–3.35). Of note, half the
patients received OAC for at least 1 year after catheter abla-
tion, including 56% of the CHA2DS2-VASc5 0 patients and
67% of the CHA2DS2-VASc 5 1 patients. As expected,
bleeding events were higher in the patients who remained
on anticoagulation after AF ablation (HR 2.05).
Another study assessed the feasibility for discontinuation
of OAC after ablation based on the AF burden documented
by implantable cardiac monitors.859 During a follow-up
time of 326 12 months (126 patient-years), 41 of the 65 pa-
tients (63%) had an AF burden ,1 hour per day and were
able to stay off OAC. Twenty-one patients (32%) had to re-
initiate OAC due to an AF burden.1 hour, and three patients
reinitiated OAC due to other reasons. No stroke, TIA, or
other thromboembolic event was observed during follow-
up. These are important data for those patients who decide
not to receive chronic OAC, and we suggest consideration
of an anticoagulation strategy based on AF burden measured
by monitoring.
Another single-center report described outcomes in 635
patients with one or more risk factors for stroke during a
mean follow-up of 8366 605 days after an AF procedure.545
Anticoagulation was discontinued in 434 of 517 patients who
remained in sinus rhythm, and aspirin and/or clopidogrel was
prescribed. There were three ischemic strokes and two TIAs
in the anticoagulation discontinuation group. The estimated
5-year stroke rate in this group was 3%.
An observational study from ﬁve large AF ablation cen-
ters included data from 3344 patients who underwent AF
ablation.238 Oral anticoagulant therapy was typically discon-
tinued regardless of the CHA2DS2-VASc score if patients did
not manifest one of the following: (1) any recurrence of
ATAs; (2) severe PV stenosis; or (3) severe LA mechanical
dysfunction. After discontinuation of anticoagulation, the pa-
tients were treated with aspirin. If AF recurred, anticoagula-
tion was restarted in those with a CHA2DS2-VASc score of
one or more. There were 347 patients who had a
CHA2DS2-VASc score of .2. Among these 347 patients,
no thromboembolic events occurred.
One of the most recent studies to be published reports data
from the Swedish national health registry.863 Among 1175
individuals followed for more than a year post-AF ablation,
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patients with a CHA2DS2-VASc score .2, the patients dis-
continuing warfarin had a higher rate of ischemic stroke
(1.6% per year vs 0.3% per year for those who continued
warfarin). Patients with a CHA2DS2-VASc score .2 and
who had had a prior ischemic stroke displayed an especially
high risk of stroke if warfarin was discontinued (HR 4.6). It is
important to note that in this registry, recurrence rates of AF
after ablation were quite high. Sixty percent of the entire
cohort and 8 of the 11 patients with stroke (72.7%) under-
went cardioversion of AF or a second PVI. The study
convincingly demonstrated that in patients with recurrent
AF after catheter ablation, a high CHA2DS2-VASc score,
and/or a history of stroke, OAC therapy should not be discon-
tinued. Because there were so few patients without AF recur-
rence, the question of whether “successful” AF ablation
might convey a lower risk was not adequately addressed.
As stated above, there is a lack of randomized trials eval-
uating this important clinical challenge; however, there are
some ongoing trials, such as EAST and CABANA, which
will address the prognostic impact of rhythm control therapy,
including AF ablation and the effect of rhythm control ther-
apy on stroke. Other trials are needed to deﬁne the optimal
anticoagulation during AF ablation procedures in an era in
which novel anticoagulants are increasingly used. We are
optimistic about the ongoing Optimal Anticoagulation for
Higher Risk Patients Post-Catheter Ablation for Atrial Fibril-
lation (OCEAN) trial (NCT02168829), which will effec-
tively determine whether successful long-term reduction or
elimination of AF with catheter ablation will reduce stroke
risk sufﬁciently to obviate the need for long-term OAC.
Additionally, the ongoing Prevention of Silent Cerebral
Thromboembolism by Oral Anticoagulation With Dabiga-
tran After PVI for Atrial Fibrillation (ODIn-AF) trial
(NCT02067182) will address the effect of dabigatran
compared with no OAC on the incidence of silent cerebral
embolic events in patients with a high risk for embolic events,
but who are free from symptomatic AF after successful PV
ablation.
Until the outcomes of such trials are available, our cur-
rent treatment recommendations to continue OAC after
catheter ablation of AF in patients at high risk for stroke
should continue. In patients who desire to discontinue anti-
coagulants because of ECG-documented AF elimination
who remain at risk because of high CHA2DS2-VASc score,
an individualized approach after full disclosure is war-
ranted. It is important that patients who are considering
discontinuation of anticoagulation in the setting of a stroke
risk proﬁle have a complete discussion of the potential risks
of this strategy. As noted above, the writing group recom-
mends that, for patients in whom discontinuation of antico-
agulation is being considered based on the patient’s values
and preferences, they should consider undergoing contin-
uous or frequent ECG monitoring to screen for AF recur-
rence, although recurrence of AF is only one of many
reasons for stroke events after discontinuation of anticoagu-
lation (Class IIb, LOE C-EO, Table 4). Whether this strat-egy results in a signiﬁcant reduction of stroke risk remains
uncertain at this time.
Less information is available concerning the optimal ap-
proaches to anticoagulation following surgical ablation of
AF.Many variables need to be considered, including whether
the patient underwent ligation of their LAA and the patient’s
stroke risk proﬁle. At the present time, there is little to no
evaluable evidence for or against the merits of anticoagula-
tion following surgical ablation when the LAA has been sur-
gically obliterated. In the absence of current evidence, the
decision to anticoagulate and the duration of treatment should
be made on an individual basis weighing the risks and bene-
ﬁts of anticoagulation in the postsurgical patient. It is, how-
ever, not unreasonable to anticoagulate for several months
following surgical ablation, provided there are no other
bleeding risks. For patients in whom appendage closure or
ligation was performed at the time of surgical ablation, and
in whom discontinuation of anticoagulation is being consid-
ered, TEE-based assessment of whether complete appendage
closure has been accomplished is recommended because
incomplete closure of the LAA is not uncommon.Anesthesia or Sedation During Ablation
Patients undergoing catheter ablation of AF are required to lie
motionless on the procedure table for several hours, and
repeated stimuli from ablation are sometimes painful. For
these reasons, most patients are treated with conscious seda-
tion or general anesthesia. The choice of approach is deter-
mined by the institutional preference and by assessment of
the patient’s suitability for conscious sedation.General Anesthesia
AF ablation procedures are commonly performed under gen-
eral anesthesia. Not only does use of general anesthesia
improve the safety of the procedure for patients at risk of
airway obstruction, but it also improves patient comfort
and might improve efﬁcacy by preventing patient movement
during the procedure. Given the need to minimize patient
movement to improve catheter and mapping system stability,
general anesthesia or deep sedation are generally preferred.
One prospective randomized clinical trial randomized pa-
tients with general anesthesia or conscious sedation. This
study reported that use of general anesthesia increased the
single procedure success rate, lowered the prevalence of
PV reconnection among those who needed a redo procedure,
and shortened ﬂuoroscopy time and procedure time.633 Gen-
eral anesthesia is of particular importance for patients at risk
of airway obstruction, those with a history of sleep apnea, and
those at increased risk of pulmonary edema. General anes-
thesia may also be employed electively in healthy patients
in order to improve patient tolerance of the procedure. Anes-
thesia or analgesia needs to be administered by well-trained
and experienced individuals with monitoring of heart rate,
noninvasive or arterial line BP, and oxygen saturation.
Guidelines for assessing levels of anesthesia and training re-
quirements for administration of intravenous sedation during
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Anesthesiologists, which can be found on their website. A
survey of the writing group members shows that in the United
States and Canada, 85% routinely employ general anesthesia.
Outside the United States and Canada, 45% routinely employ
general anesthesia. (Please also see discussion of anesthesia
on page e51).Conscious and Deep Sedation
Deep sedation is a step beyond conscious sedation and just
before general anesthesia. Generally, only anesthesia pro-
viders or specially trained physicians can provide deep seda-
tion because airway and hemodynamic management might
be required. The major limitation to deep sedation is the
need for the patient to lie on the procedure table with minimal
movement during the entire procedure. RF lesions can be
associated with intense pain, resulting in patient movement.
The location of sites eliciting pain with RF lesions are not
predictable, although are most often located on the posterior
wall. Monitoring esophageal temperature during deep seda-
tion is possible, but more cumbersome, due to intact airway
reﬂexes that are abolished during general anesthesia. Patient
movement with right phrenic stimulation during CB proced-
ures is also a common occurrence with deep sedation, and is
largely absent with the use of general anesthesia.Jet Ventilation
Catheter stability and catheter contact during LA ablation are
crucial for effective lesion creation. Both catheter stability
and catheter–tissue CF can be further increased by reduced
respiratory thoracic excursions. Data from one institution
suggest improved clinical outcome as a result of enhanced
lesion quality and reduction of PV reconnection when
applying high-frequency jet ventilation in general anesthesia
during PVI.634,864,865 Further data from other centers are
needed, however, before ﬁnal conclusions can be drawn. A
survey of the writing group members reveals that in the
United States and Canada, 14% routinely employ high-
frequency jet ventilation. Outside the United States and Can-
ada, 4% routinely employ high-frequency jet ventilation dur-
ing AF ablation procedures.Summary
The type of anesthesia used for AF ablation depends in part
on the availability of anesthesia support for ablation proced-
ures. Given the need to minimize patient movement to
improve catheter andmapping system stability, deep sedation
or general anesthesia is generally preferred.
Approaches to Minimize Risk of an AEF
A rare but potentially devastating complication of AF ablation
is injury to the esophagus, with the possible outcome of AEF
or esophageal perforation leading to mediastinal infection,
stroke, and/or death.866,867,1398 Another complication that is
thought to be related to thermal injury to the periesophagealvagal plexus is gastroparesis.868 More information concerning
the incidence, presentation, and management of these compli-
cations is presented under Section 10. Because of the serious
consequences of an AEF, it is important to attempt to prevent
severe esophageal and periesophageal injury. Some operators
design the ablation lesions to avoid the esophagus. The loca-
tion of the esophagus can be visualized using a variety of ap-
proaches, including multidetector CT, topographic tagging of
the esophageal position with an EAM system, barium paste,
and ICE.869,870,871,872,873,874,875,876 It is important to know
that esophagus location can change during the procedure,
and repeated imaging or visualization is needed to account
for the motion of the esophagus. However, it is difﬁcult to
accomplish complete PV ablation without some ablation in
close proximity to the esophagus. Strategies to prevent and
treat esophageal injury follow.Reduced Power Delivery on the Posterior Wall
Higher power and greater depth of tissue heating or cooling are
associated with increased risk of esophageal injury. In order to
minimize injury to the esophagus during RF applications on
the posterior wall close to the esophagus, several approaches
can be employed, including (1) reduction of RF power (e.g.,
25 W); (2) shortening RF application time (e.g., 20 sec-
onds); and/or (3) decreasing CF (e.g.,10 grams). The writing
group recommends that RF power be reduced when creating
lesions along the posterior wall near the esophagus (Class I,
LOE C-LD, Table 3). Some reports employed the use of light
conscious sedation to use pain to identify potential esophageal
injury. However, there are conﬂicting data on the speciﬁcity of
the pain response. It has been proposed that an alternative
energy source, such as the CB for PVI, could minimize esoph-
ageal injury877,878; however, AEF or periesophageal vagal
plexus injury after CBA has been reported.879,880 There are
also data that other heat-based energy sources, such as high-
intensity focused ultrasound or laser energy, can damage the
esophagus.501,502,700,701,705,881 Although each of these
approaches is variously adopted by different ablation
centers, each remains largely unproven due to the rarity of
an AEF as a complication.Esophageal Temperature Monitoring
A strategy to avoid esophageal injury employed by 65% of
the writing group members is luminal esophageal tempera-
ture monitoring, used to identify potentially dangerous heat-
ing of the esophagus.882,883,884,885 Unfortunately, because
the esophagus is broad, the lateral position of the
temperature probe or mapping electrode might not align
with the ablation electrode, and the operator could receive
a false impression of safety.1398 There is general agreement
among those operators who employ temperature probes
that an increase in esophageal temperature should trigger
interruption of RF energy delivery. Three-quarters of the
writing group members terminate ablation if they observe a
1C or 2C rise in temperature from baseline, or a recorded
temperature of 39C–40C. During CBA, two-thirds of the
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e341writing group members monitor esophageal temperature, and
terminate cooling if the esophageal temperature reaches
20C–25C. A variety of esophageal temperature probes
are available for clinical use.886 A recent study has shown
the superior thermodynamic proﬁle of multisensor esopha-
geal recording systems; however, no clinical trial has demon-
strated superiority in terms of reducing AEFs.646,647 This
type of study would be impossible to perform due to the
very low event rate of this complication. Among the
writing group members who employ esophageal
temperature monitoring, single thermocouple probes are
used by two-thirds and multithermocouple probes are em-
ployed by one-third. The potential beneﬁt of multithermo-
couple probes must be weighed against their increased
complexity and cost.886,887,888,889 The writing group
recommends that it is reasonable to use an esophageal
temperature probe during RF ablation procedures to
monitor esophageal temperature to help guide energy
delivery (Class IIa, LOE C-EO, Table 3).
Another strategy to protect the esophagus uses active
cooling.890,891,892,893 This technique has not been tested on
a large scale, and the data describing this technique are
limited. Selected operators use mechanical displacement of
the esophagus.894,895 This technique appears to be
promising, but its use has been limited to a small number
of patients and is therefore an unproven approach.Pharmacological Prophylaxis
Esophageal ulcers are found in a 5%–40% of patients
following AF ablation. It is hypothesized that AEF occurs
because there is transmural necrosis of both the atrium and
esophagus with subsequent ulcer erosion from gastroesopha-
geal reﬂux.896,897 To prevent ulcer erosion, proton pump
inhibitors (PPIs) have been employed, and are used by
65% of the writing group members after ablation. PPIs are
highly effective in gastroesophageal reﬂux disease by
reducing the acidity of the gastric juice and healing
esophagitis.898,899,900 PPIs are effective in reducing the size
of iatrogenic-induced ulcers, therefore could also be helpful
for ablation-induced ulcers.901 Other mechanisms, such as
traumatic injury of the esophageal wall, could also play a po-
tential role in ﬁstula formation, although there is no proof of
this concept. Prophylactic short-term use of PPIs after AF
ablation is assumed to be effective; however, further large
randomized studies are required to determine whether PPIs
reduce AEFs. Because of the low event rate of AEFs, such
a study will not likely be performed. At the moment, PPI ther-
apy is justiﬁed as a singular preventive treatment.Role and Indications for Endoscopic Screening for Ulceration
Following AF Ablation
Because AEF can cause septicemia and air embolism leading
to death, early detection of esophageal tissue injuries is essen-
tial. Data evaluating the role of gastrointestinal endoscopy for
detection of esophageal tissue lesions are limited. In 185 pa-
tients who underwent gastrointestinal endoscopy after LA RFablative therapy, ulcer-like or hemorrhagic esophageal ther-
mal lesions (diameter: 2–16 mm) were observed in 14.6%
of the patients.902 These lesions only occurred when the intra-
luminal esophageal temperature had reached more than
41C. The odds of an esophageal lesion increased by a factor
of 1.36 (95% CI 1.07–1.74; P 5 .012) for every 1C rise in
temperature.
Gastrointestinal endoscopy in a cohort of 425 patients 1 to
3 days after AF catheter ablation, in whom intraluminal
esophageal temperatures higher than 41C were recorded, re-
vealed esophageal tissue lesions in 11.6% of asymptomatic
patients.903 Hence, these observations suggest that asymp-
tomatic patients could beneﬁt from routine gastrointestinal
endoscopy after RF catheter ablative therapy when the intra-
luminal esophageal temperature during the procedure has
reached a certain target temperature, such as 41C. However,
there are no reports on the value of this type of follow-up
endoscopic examination after ablative therapy. Only one
study did a follow-up endoscopy at least 7 days after the ﬁrst
examination in patients with an esophageal lesion diameter
.5 mm and found regression of all 3168 lesions.903 A PPI
was used in all the patients for 4 weeks after ablation.Role and Indications for CT Imaging for Diagnosis of
Atrioesophageal Fistula
After ablation, symptoms and ﬁndings suggesting the possi-
bility of evolving AEF include chest pain, painful swallow-
ing, fever, leukocytosis, TIA, and/or stroke typically
occurring between 1 and 3 weeks postablation. If esophageal
injury is suspected, CT imaging with intravenous and water-
soluble oral contrast is recommended.904,905,906 Findings on
CT imaging on an AEF include mediastinal or pericardial
free air, evidence of free communication between the
esophagus and pericardium or atrium, and inﬂammatory
phlegmon between the esophagus and the heart.
Unfortunately, these CT ﬁndings are usually observed late
in the progression of AEF. The appearance of the CT scan
early in the course of this complication can be entirely
normal. If esophageal injury postablation is suspected, but
if the CT scan is normal, the physician must continue to
have a high index of suspicion and repeat imaging if
symptoms or ﬁndings do not resolve. Esophageal
ultrasound can also be useful in this setting to disclose
muscle and external injury, beyond a simple ulcer.
Although a barium swallow can detect a ﬁstula, its
sensitivity is low. If an AEF is suspected, endoscopy with
air insufﬂation should be avoided, given that insufﬂation of
the esophagus with air can result in a large air embolus,
producing stroke or death. An alternative strategy, which
some members of the writing group employ and which
appears to have lower risk is to use CO2 instead of air for
insufﬂation in this setting. If CO2 were introduced into the
LA, there would be little adverse consequence. The early
recognition of an AEF can be missed due to the low
awareness of this rare complication. It is important for
patients to be educated as to warning signs and to contact
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develop.Management of Atrial Esophageal Fistula
The management of AEF following catheter ablation for AF
includes preventive measures and therapeutic options. If AEF
is diagnosed, available therapeutic options are as follows:
(1) surgical repair of the ﬁstula via thoracotomy (combined
LA and esophageal repair with an intercostal muscle
ﬂap inserted in between to prevent future recanalization
of the ﬁstula tract) via thoracotomy;
(2) the less invasive esophageal stenting, followed by long-
term antibiotic therapy; and
(3) conservative management with aggressive chest tube
drainage and treatment of sepsis.341,417,907,908,909,910,911
Of the above three, conservative treatment of AEF is asso-
ciated with a high mortality rate.907,1398 Similarly, with
esophageal stenting, earlier studies have reported fatality in
the majority and survival in very few only after undergoing
emergency surgical repair.341,417,896,897,907,910,911,912,913,914,1398
Mixed results have also been shown for surgical repair of
AEF complicating RFCA, some with positive outcome and
others with fatal ending.341,417,910,911 However, the only
reported survival in patients thus far underwent surgical
ﬁstula repair, and failure of surgery has been mostly
attributed to delay in diagnosis and intervention.341,417,910,911
Thus, based on currently available clinical information, it is
apparent that early surgical intervention is critical for
survival in AEF manifesting as a complication of AF
ablation. Of note, there are few reports on successful
resolution of the ﬁstula with stenting in patients with
cardioesophageal (connecting to CS) and
esophagopericardial ﬁstula.905,915,916 In cases of perforation
(not thermal injury) before the ﬁstula has formed, closure
with stent or endoscopic clip can be considered.917,918,919Summary
Although all of the approaches described above for the pre-
vention of AEF have been variously adopted by different
ablation centers, each remains largely unproven due to the
rarity of an AEF as a complication. Among the writing
group members, 67% employ an esophageal temperature
probe (single thermocouple for two-thirds, multiple thermo-
couple for one-third), 36% use 3D image integration and
import the esophagus location into the electroanatomical
map, 91% decrease RF power when ablating on the poste-
rior wall of the atrium, 7% use barium paste, and none
(0%) mechanically displace the esophagus. Among the
writing group members, 30% limit power to 20 W on
the posterior wall, 45% limit it to 25 W, 18% to 30 W,
and 7% use powers of .30 W. The writing group recom-
mends that it is reasonable to use an esophageal temperature
probe during RF ablation procedures to monitor esophageal
temperature and to help guide energy delivery (Class IIa,
LOE C-EO, Table 3). The writing group recommends thatRF power be reduced when creating lesions along the pos-
terior wall near the esophagus (Class I, LOE C-LD,
Table 3).
Despite its rarity, the devastating consequences of AEF
demand that the operator maintain a high index of suspicion
for this diagnosis. Presenting symptoms, including fever,
dysphagia, and neurological deﬁcits, often occur in the
several weeks after the procedure.918 Therefore, early signs
of these symptoms should be reported by patients to their
treating electrophysiologist to avoid the delayed diag-
nosis.908 If AEF is suspected, standard transesophageal
endoscopy should be avoided, because esophageal perfora-
tion can be exacerbated and air embolism promoted by
required air insufﬂation. An alternative strategy, which
some members of the writing group employ and which ap-
pears to have lower risk is to use CO2 instead of air for insuf-
ﬂation in this setting. If CO2 were introduced into the LA,
there would be little adverse consequence. In patients diag-
nosed with an AEF, surgical treatment is recommended.Section 8: Follow-up Considerations
Monitoring for Complications in the First Months
After AF Ablation
AF ablation is an invasive procedure that entails risks,
most of which are present during the acute procedural
period. However, complications can also occur in the weeks
or months following ablation.920,921,922 Recognizing
common symptoms after AF ablation and distinguishing
those that require urgent evaluation and referral to an
electrophysiologist is an important part of follow-up after
AF ablation. Symptoms and complications can be divided
into those that occur immediately after ablation (0–3
days), early (1–4 weeks), and those that can occur late
(.4 weeks) after ablation.Signs and Symptoms of Complications Within 1 Month
Postablation
Shown in Table 5 is a list of signs and symptoms that can
occur within the ﬁrst several months following ablation.
These signs and symptoms are divided into those that occur
within 30 days of AF ablation and those that occur more
than 30 days postablation. Some complications, such as a
stroke or development of an AEF, might present within the
ﬁrst month or following the ﬁrst postablation month and
therefore are listed in both sections of this table. The differ-
ential diagnosis, which should be considered, as well as the
recommended evaluation, are also shown. AF ablation is
often performed under general anesthesia. Some patients
might feel fatigued for several days after prolonged general
anesthesia. Mechanical complications from endotracheal
intubation and transesophageal echocardiography, such as
hoarseness and difﬁculties swallowing, might also occur
and typically resolve with time.
Tenderness at the vascular access sites is common; hema-
tomas present after sheath removal will typically extend infe-
riorly (due to gravity) and might result in extensive
Table 5 Signs and symptoms following AF ablation
Differential Suggested evaluation
Signs and symptoms of complications within a month postablation
Back pain Musculoskeletal, retroperitoneal hematoma Physical exam, CT imaging
Chest pain Pericarditis, pericardial effusion, coronary
stenosis (ablation related), pulmonary vein
stenosis, musculoskeletal (after
cardioversion), worsening reﬂux
Physical exam, chest X-ray, ECG,
echocardiogram, stress test, cardiac
catheterization, chest CT
Cough Infectious process, bronchial irritation
(mechanical, cryoballoon), pulmonary vein
stenosis
Physical exam, chest X-ray, chest CT
Dysphagia Esophageal irritation (related to
transesophageal echocardiography),
atrioesophageal ﬁstula
Physical exam, chest CT or MRI
Early satiety, nausea Gastric denervation Physical exam, gastric emptying study
Fever Infectious process, pericarditis,
atrioesophageal ﬁstula
Physical exam, chest X-ray, chest CT,
urinalysis, laboratory blood work
Fever, dysphagia, neurological symptoms Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest
CT or MRI; avoid endoscopy with air
insufﬂation
Groin pain at site of access Pseudoaneurysm, AV ﬁstula, hematoma Ultrasound of the groin, laboratory blood
work; consider CT scan if ultrasound
negative
Headache Migraine (related to anesthesia or transseptal
access, hemorrhagic stroke), effect of
general anesthetic
Physical exam, brain imaging (MRI)
Hypotension Pericardial effusion/tamponade, bleeding,
sepsis, persistent vagal reaction
Echocardiography, laboratory blood work
Hemoptysis PV stenosis or occlusion, pneumonia Chest X-ray, chest CT or MR scan, VQ scan
Neurological symptoms Cerebral embolic event, atrial esophageal
ﬁstula
Physical exam, brain imaging, chest CT or MRI
Shortness of breath Volume overload, pneumonia, pulmonary vein
stenosis, phrenic nerve injury
Physical exam, chest X-ray, chest CT,
laboratory blood work
Signs and symptoms of complications more than a month postablation
Fever, dysphagia, neurological symptoms Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest
CT or MRI; avoid endoscopy with air
insufﬂation
Persistent cough, atypical chest pain Infectious process, pulmonary vein stenosis Physical exam, laboratory blood work, chest
X-ray, chest CT or MRI
Neurological symptoms Cerebral embolic event, atrial esophageal
ﬁstula
Physical exam, brain imaging, chest CT or MRI
Hemoptysis PV stenosis or occlusion, pneumonia CT scan, VQ scan
AF 5 atrial ﬁbrillation; ECG 5 electrocardiogram; CT 5 computed tomography; MRI 5 magnetic resonance imaging; VQ 5 ventilation-perfusion.
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tigation should be performed if an AV ﬁstula or pseudoaneur-
ysm is suspected. Worsening of back or buttock pain is also
common from prolonged supine positioning during the pro-
cedure. However, more severe back pain or ﬂank ecchymosis
should prompt an evaluation for retroperitoneal hematoma
with CT imaging. Signiﬁcant bleeding into the leg can also
result in compartment syndrome.
Shortness of breath soon after ablation might have several
causes. The patient should be examined after ablation for ev-
idence of volume overload related to irrigated ablation and
diuresed as necessary. Volume overload can be observed in
patients with normal or reduced cardiac function, perhaps
due to atrial stunning. If dyspnea persists or occurs in the
absence of volume overload, a chest X-ray should be ob-
tained to exclude an infectious process or elevation of the
respective hemi-diaphragm. PN injury most commonlyoccurs after balloon-based ablation, but can also occur after
RF ablation.503 Lack of diaphragmatic movement during
inspiration under ﬂuoroscopy (the sniff test) is diagnostic
of PN injury. Right PN injury is much more common after
AF ablation and is due to ablation near the RSPV or SVC
(Figure 1). Left PN injury less commonly occurs when
ablating near the LAA. Althoughmost cases of phrenic injury
recover with reinnervation over a 6–12 month period after
ablation, permanent diaphragmatic paralysis has been re-
ported.
Chest pain is common after ablation; the causes include
pericarditis, coronary ischemia, and musculoskeletal pain.
Symptoms of pericarditis (pleuritic chest pain) are the most
common (.75% of patients) and typically persist for up to
a week postablation. In the absence of evidence of hemody-
namic compromise, an ECG is of little value. It is important
to recognize that nearly all patients will demonstrate a small
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edema. Nonsteroidal anti-inﬂammatory agents are recom-
mended for symptom control. Colchicine can also be used
to treat pericardial symptoms. Oral steroids should be
avoided after catheter ablation unless pericardial symptoms
persist or are recurrent. Chest pain that is associated with
ECG changes or that occurs with exertion should prompt
evaluation of coronary ischemia. In particular, if ablation
has been performed inside the CS to target the epicardial
portion of the mitral isthmus, or for isolation of a CS tachy-
cardia, circumﬂex artery stenosis should be considered.923
Any unexplained hypotension during or following abla-
tion should be evaluated promptly. Transthoracic echocardi-
ography or ICE (if during ablation) should be performed
urgently to exclude pericardial effusion or cardiac tampo-
nade. A complete blood count should be performed to
exclude bleeding or infection.
Fever might occur early after ablation. We should exclude
infectious sources such as a urinary tract infection related to
bladder instrumentation or pneumonia related to intubation.
Low-grade fever might also be related to pericarditis. In addi-
tion, fever might be the ﬁrst marker of an impending AEF for-
mation. Chest imaging should be considered if fever persists,
an AEF is suspected, and no other clear infectious source is
identiﬁed.
Any neurological symptoms occurring shortly after abla-
tion should be taken seriously, with brain imaging performed
to exclude an embolic event. Migraine-like signs and symp-
toms have been reported and are most commonly benign and
are attributed to the residual ASD following transseptal punc-
ture. As noted above, an AEF might also present with neuro-
logical symptoms. It is also important to recognize that an
AEF might present as a neurological event and therefore
must be considered the differential diagnosis of neurological
symptoms that develop post AF ablation.
Symptoms of pericarditis typically persist up to aweek after
ablation (Table 5). If symptoms persist for .1 week or are
associated with lightheadedness or shortness of breath, further
evaluation is warranted. Groin pain that persists past 7 days or
is getting worse should prompt a physical exam and vascular
ultrasound to exclude femoral access complications. A persis-
tent nagging dry cough might also be observed for up to 6
weeks after ablation. This complication is more common
with CB than with RF ablation and is likely related to direct
bronchial or lung injury. This type of cough is generally treated
with antitussives and will typically subside over 4–6 weeks.
Some patients, particularly those with a history of mi-
graines, might experience migraine headaches in the ﬁrst
few weeks after ablation.924,925 These headaches might be
related to the residual ASD present after transseptal puncture
and will typically improve over several weeks. Hemoptysis
is rare but might result from pneumonia or pulmonary
infarction due to an occluded PV, typically occurring 3–6
months after ablation. Dysphagia in the ﬁrst days after
ablation is most likely related to irritation from
transesophageal echocardiography or intubation. If
dysphagia persists, then imaging (chest CT or MRI) shouldbe performed to exclude an AEF (see late complications).
The differential diagnosis of dyspnea occurring early after
ablation should include volume overload, pneumonia, or PN
injury as outlined above. A chest roentgenogram should be
obtained. If symptoms persist with a normal chest
roentgenogram, we should also consider PV stenosis (see
late symptoms, below). Vagal denervation of the esophagus
or stomach can occur after ablation due to ablation lesions
placed in the vicinity of the esophagus, particularly if
extensive ablation is performed along the LA posterior
wall.536,926 Symptoms can include nausea and early satiety.
Patients should be advised to eat small, frequent meals.
Symptoms will typically improve over 4–6 weeks. If
symptoms are profound or persist, a gastric emptying study
can be diagnostic. Pain at the site of sheath insertion can
result from an pseudoaneurysm, an AV ﬁstula, or a
hematoma. Evaluation usually starts with a vascular
ultrasound. Bloodwork and a CT scan might be appropriate.
Signs and Symptoms of Complications More Than a Month
Postablation
Late symptoms of dysphagia and/or fever, particularly in the
presence gastrointestinal bleeding or any neurological symp-
toms, should prompt an urgent evaluation for an AEF, a
rare but potentially lethal complication after AF ablation
(see Section 10).341,417,866,910 If AEF is suspected,
esophagogastroduodenoscopy should not be performed,
because increased pressure in the esophagus can lead to the
introduction of air into the LA and stroke. Imaging with
CT or MR is preferred, with the presence of air in the
mediastinum or LA considered diagnostic. Although
barium should not be introduced into the esophagus, a
small amount of water-soluble contrast can help identify
the location of the ﬁstula. The recommended treatment for
AEF at any stage is surgical exploration and resection of
the ﬁstulae, typically requiring resection of the involved
esophagus and repair of the posterior LA wall with a pericar-
dial patch. There have been reports of treatment of early
ﬁstulae with covered esophageal stents; however, surgical
treatment is generally preferred. A persistent cough .6
weeks after ablation, particularly if associated with atypical
chest pain, recurrent pneumonia or hemoptysis, should
prompt an evaluation for PV stenosis.927,928 A chest
roentgenogram might also show evidence of atelectasis or
inﬁltrate localized to one lobe of the lung, which is
typically related to focal pulmonary edema. Many patients
have received repeated courses of antibiotics for lung
infection before the correct diagnosis is reached. If PV
stenosis is suspected, a chest contrast CT angiogram or MR
angiogram should be performed to examine PV anatomy
and exclude PV stenosis or occlusion. If PV stenosis or
occlusion is detected, a ventilation or perfusion scan is
typically performed to quantify lung perfusion. Referral to
a center with expertise in PV stenting should be
recommended early in the course of PV stenosis, because
dilatation is more difﬁcult and has a higher incidence of
pulmonary hypertension, lung infarct, and hemoptysis
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plications). Hemoptysis should trigger an evaluation for PV
stenosis and usually indicates the presence of complete
branch or PV occlusion. Other late complications include a
stroke or embolic event related to recurrent AF or deep
vein thrombosis or pulmonary embolus related to femoral
vein instrumentation. These complications are uncommon
because anticoagulation is typically reinstated after ablation.ECG Monitoring Pre- and Postablation
Arrhythmia monitoring is an important component of the
initial evaluation of patients who are to undergo catheter abla-
tion procedures for AF. Prior to undergoing a catheter ablation
procedure, it is important to conﬁrm that a patient’s symptoms
result from AF and to determine whether a patient has parox-
ysmal or persistent AF. The choice of ablation technique, ex-
pectations with respect to the procedure’s outcome,
anticoagulation strategies employed, and the need for TEE
prior to the procedure might be impacted by the accurate char-
acterization of the AF type and burden. Preprocedure
arrhythmia monitoring is also useful to determine whether a
patient has evidence of regular supraventricular tachycardia
that degenerates into AF as a triggering mechanism or has a
pattern of repetitive “focal ﬁring,” characterized by the pres-
ence of frequent atrial premature beats (.1000 per 24 hours)
with frequent rapid salvos of nonsustained AT.458 Focal AF
is characterized by localized triggers arising from the
PVs.929 Either of these triggering patterns of AF initiation
identiﬁes a patient in whom a more limited ablation, targeted
at only the triggering arrhythmia focus or PV(s) might be
appropriate.406,458,930 An assessment of the adequacy of
heart rate control is particularly important in patients with
depressed left ventricular function who might show evidence
of a reversible tachycardia-induced cardiomyopathy.234
ECG monitoring also plays an important role in the
follow-up after an ablation procedure. Early recurrences of
AF are common during the ﬁrst 3 months following a catheter
ablation procedure.931,932 For this reason, arrhythmia
monitoring to assess the efﬁcacy of catheter ablation is
typically delayed for at least 3 months following catheter
ablation unless required to evaluate arrhythmia symptoms
during the early postablation period. However, recurrences
particularly after the ﬁrst month following an ablation
procedure are predictive of later recurrence of AF, and
therefore monitoring may be used to identify patients at
higher risk of needing a second ablation procedure or
ongoing AAD therapy.272,329,933,934,935
The two main reasons to perform arrhythmia monitoring
following catheter ablation are clinical care and as part of a
clinical research trial. From a purely clinical perspective,
arrhythmia monitoring is useful to determine whether a pa-
tient’s complaints of palpitations result from recurrent AF
or other ATA. Complaints of palpitations often result from
atrial or ventricular premature beats and are not an accurate
predictor of recurrent AF.57,936 Arrhythmia monitoring can
also be of value in asymptomatic patients and can inﬂuencedecision making regarding anticoagulant therapy after
ablation. Multiple studies have demonstrated that
asymptomatic AF commonly occurs in patients following
catheter ablation.56,57,63,413,442,936,937,938 Detection of these
asymptomatic episodes of AF impact the characterization
of the procedure as “successful.” Arrhythmia monitoring is
an essential component of clinical trials aimed at assessing
the outcomes of catheter ablation procedures and should be
incorporated into all clinical trials designed to assess the
efﬁcacy of AF catheter ablation tools and techniques. The
suggested monitoring strategies and minimum standards to
be used as part of clinical trials are discussed in Section 13:
Clinical Trial Design. These strategies and standards can be
useful in tracking the outcome of clinical care when assessing
an institution’s performance standards related to success and
complications of AF ablation procedures. However, it is
recognized that clinical endpoints and clinical trial secondary
endpoints for deﬁning success can include the elimination of
symptomatic AF and control of AF with previously ineffec-
tive AADs after the AF ablation procedure.Available Methods for Arrhythmia Monitoring
Use of ECG monitoring tools is essential to assess AF abla-
tion success, and the monitored results can have important
implications in terms of clinical care and research outcomes.
Arrhythmia monitoring can be performed with the use of
noncontinuous or continuous ECG monitoring tools
(Table 6). The choice of either method depends on individual
needs and the consequences of arrhythmia detection. More
intensive monitoring is associated with a greater likelihood
of detecting both symptomatic and asymptomatic AF.57,414,
937,938,939,940,941,942,943,944 The proportion of asymptomatic
compared with symptomatic events might be higher after
AF ablation; two studies reported that the proportion of AF
events that were asymptomatic was 11%–35% prior to and
53%–65% after ablation.63,945,946 Another study reported
that for patients in sinus rhythm, 53.8% of AF episodes
were asymptomatic, with an increase in asymptomatic
episodes changing from the acute to the chronic period
after ablation, demonstrating that AF success cannot be
based on the absence of symptoms alone.936
The identiﬁcation of AF and the assessment of AF
burden with intermittent monitoring have been shown to
depend on a patient’s actual AF burden and improve
with an increasing frequency or duration of intermittent
monitoring.943,947,948,949 Conversely, the more complex
and longer the method of monitoring used, the lower the
patient compliance.
Traditional AF detection tools for intermittent monitoring
after AF ablation include scheduled or symptom-initiated
standard ECGs, Holter monitors, patient-activated and auto-
matically activated full disclosure external loop recorders,
and transtelephonic recordings. More recently, implanted
loop recorders and external recordings with wireless connec-
tion via smartphone applications have been used for longer-
term monitoring to detect AF after ablation.
Table 6 Types of ambulatory cardiac monitoring devices
Type of
recorder
Typical monitoring
duration
Continuous
recording
Event
recording
Auto
trigger Unique features
Holter monitor 24–48 hours,
approximately
7–30 days
Yes Yes N/A Short term, provides quantitative data on
arrhythmia burden
Patch monitor 1–3 weeks Yes Yes N/A Intermediate term, can provide continuous
data for up to several weeks; improved
patient compliance without lead wires
External loop recorder 1 month Yes Yes Variable Good correlation between symptoms and
even brief arrhythmias
External nonloop recorder Months No Yes No May be used long term and intermittently;
will not capture very brief episodes
Smartphone monitor Indeﬁnite No Yes No Provides inexpensive long-term
intermittent monitoring; dependent on
patient compliance; requires a
smartphone
Mobile cardiac telemetry 30 days Yes Yes Yes Real time central monitoring and alarms;
relatively expensive
Implantable loop recorder Up to 3 years Yes Yes Yes Improved patient compliance for long-term
use; not able to detect 30-second
episodes of AF due to detection
algorithm; presence of AF needs to be
conﬁrmed by EGM review because
speciﬁcity of detection algorithm is
imperfect; expensive
Pacemakers or ICDs with atrial leads Indeﬁnite Yes Yes Yes Excellent AF documentation of burden and
trends; presence of AF needs to be
conﬁrmed by electrogram tracing review
because speciﬁcity of detection
algorithms is imperfect; expensive
Wearable multisensor ECG monitors Indeﬁnite Yes Yes Yes ECG 3 leads, temp, heart rate, HRV, activity
tracking, respiratory rate, galvanic skin
response
AF 5 atrial ﬁbrillation; ICD 5 implantable cardioverter deﬁbrillator; ECG 5 electrocardiogram; HRV 5 heart rate variability.
e346 Heart Rhythm, Vol 14, No 10, October 2017The intermittent, scheduled use of continuous short-term
ECG monitors after AF ablation has utilized traditional Hol-
ter monitors and more recently patch ECG monitors. Holter
monitors use single- or multi-lead external recorders con-
nected via wires to small recording devices. Typical Holter
monitors record 2 or 3 channels for 24–48 hours, but some
can record continuous 12-lead ECGs or for periods of 7–30
days. Patients can record symptoms on a diary and/or by acti-
vating an event button. Because Holter monitors are analyzed
by trained technicians and are read by experienced physi-
cians, these approaches might represent the standard moni-
toring method against which other methods should be
compared. Newer wearable patch ECG monitors record
from closely spaced electrodes, removing the need for wires
and typically generating up to 2 channel recordings. These
are water resistant, wearable for up to 30 days, and have en-
joyed superior patient acceptance over conventional wired
monitor systems. Symptoms can be recorded by an event but-
ton. Future devices are being developed with multiple sen-
sors that can record body temperature, activity, respiratory
rate, and galvanic skin responses.
Patient- or event-activated external loop recorders can be
used for longer or intermediate duration monitoring, typically
over weeks to months.254 These memory loop recorders can
be programmed to record ECGs for seconds to minutesbefore and after the detection of an arrhythmia or a patient-
triggered event and thus can detect and correlate rhythms
with even brief symptoms. External loop recorders should
be worn continuously to capture such events and typically
are connected via wires to skin electrodes.
Nonloop external event recorders can be used for intermit-
tent transtelephonic recordings that can be initiated by pa-
tients with symptoms or on a schedule. These recorders are
applied to the chest or held by hand. Older conventional
transtelephonic monitors required the recording of rhythm
strips while connected in real time over the phone, but
more recent monitors allow the storage of rhythm strips
with transmission at a later time. Event recording occurs after
an event is detected by the patient; the diagnostic yield is
dependent on the recognition of symptoms, the duration of
symptomatic episodes, or on scheduled or more frequent
use to detect asymptomatic arrhythmias.
More recently, smartphone-based ECG monitors have
been developed that can be helpful for long-term intermittent
surveillance.950,951 Recordings from electrodes embedded in
a smartphone case or a card are connected via low-energy
Bluetooth technology to smartphone applications. These
monitors are nonlooping; patients can record during symp-
toms that persist long enough to activate the application. Re-
cordings are stored and can be transmitted via wireless or
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smartphone-based single-lead system was compared to trans-
telephonic monitor ECGs with 100% sensitivity and 97%
speciﬁcity in detecting AF or ﬂutter.951 Multi-lead and recon-
structed 12-lead recording devices are being developed, but
have not been studied in the setting of AF ablation. Contin-
uous ECG monitoring technology using such applications
are also in development.
Mobile cardiac outpatient telemetry devices provide real-
time monitoring and wireless transmission to trained personnel
at a central monitoring center with activation of alarms to care-
givers for speciﬁed signiﬁcant arrhythmias. These monitors are
typically worn continuously for a period of 2–4 weeks and can
record 1–3 leads connected to a small device via conventional
wires or embedded in a patch. The advantage of these systems
is their ability to capture and identify potentially severe or sig-
niﬁcant arrhythmias in an immediate or timely fashion.
Continuous ECGmonitoring for longer periods (1–3 years)
can be facilitated with the use of implantable devices. Long-
term subcutaneous implantable loop monitors can facilitate
continuous AF monitoring based on R-R interval analysis
over a time period of up to 3 years.952,953 These types of
continuous ECG monitoring devices have been used in
several studies to evaluate the results of surgical or catheter
AF ablation.127,607,938,953,954,955,956,957,958,959,960,961 Although
implantable subcutaneous monitors hold promise for the
determination of AF burden in the long term, AF detection
algorithms are primarily based on R-R interval regularity,
and important limitations include reduced speciﬁcity due to
undersensing of beats, oversensing of myopotentials, and
irregular atrial and ventricular premature beats, as well as
limited memory resulting in electrograms not being
retrievable to verify the correct rhythm diagnosis.941,944,962
Nevertheless, implantable continuous monitors can
ameliorate patient compliance issues and provide an
assessment of long-term AF burden and late recurrences,
including asymptomatic episodes that might have implications
for continuation of anticoagulation. In one study after concom-
itant surgical ablation, ILRs compared with conventional Hol-
ter monitoring facilitated more follow-up antiarrhythmic
management, including cardioversions and catheter ablation
procedures, which were associated with a trend toward higher
sinus rhythm rates at 1 year.942
Implantable pacemakers or deﬁbrillators with atrial leads
allow the burden of AF to be assessed by tracking the number
and duration of mode-switch episodes.963,964 These devices
can also assess long-term AF burden, burden trends, and late
or asymptomatic recurrences.940,965,966 The ability to record
intracardiac atrial electrograms provides excellent sensitivity
and speciﬁcity for the diagnosis of atrial arrhythmias,
especially with durations exceeding a few minutes.937,967,968Follow-up and Monitoring Guidelines for Routine
Clinical Care
There is a consensus among the writing group members
that all patients who undergo catheter ablation of AF,regardless of whether they are enrolled in a clinical trial,
should be seen in follow-up a minimum of 3 months
following the ablation procedure. There is also consensus
that all patients who undergo catheter ablation should be
seen by some type of physician (family physician, inter-
nist, cardiologist, or electrophysiologist) on an annual ba-
sis thereafter. These ongoing interactions with the medical
profession allow the patient’s clinical status to be evalu-
ated, including an assessment of the presence or absence
of AF as well as their stroke risk proﬁle and anticoagula-
tion needs. These interactions also provide an opportunity
to focus on the treatment of associated diseases and life-
style modiﬁcations. These recommendations are slightly
modiﬁed from the previous edition of this document,
which advised that all patients who undergo catheter abla-
tion of AF, regardless of whether they are enrolled in a
clinical trial, should be seen in follow-up at a minimum
of 3 months following the ablation procedure, and then
every 6 months for at least 2 years. A 12-lead ECG was
recommended at all follow-up visits and more intense
monitoring driven mainly by the clinical impact of AF
detection with strict monitoring necessary (suspected
rate-related cardiomyopathy). This modiﬁcation of our
writing group recommendations reﬂects, in part, data
from real life clinical practice.969 This European study re-
vealed that one-third of the 12-month follow-up evalua-
tions were performed by telephonic contact, only 87.2%
of the patients had at least one ECG during the follow-
up, and the patients with continuous monitoring of 24
hours (Holter- or implanted monitoring systems) repre-
sented only 57.4% of the population.
Explanations of this gap between prior expert
consensus recommendations and routine clinical practice
might reﬂect the current disconnect between indications
for catheter ablation and clinical outcomes of the proced-
ure. Another factor can be cost. On one hand, the main
indication for catheter ablation is symptomatic AF and
decisions regarding continuation of anticoagulation ther-
apy should be based on the patient’s risk factors for
stroke and not on the presence of or type of AF. At
the same time, transtelephonic or long-term monitoring
is at times recommended after ablation to capture even
asymptomatic episodes of AF to evaluate the need to
continue anticoagulation. The majority of writing group
members do not believe that data currently exist to sup-
port this common practice of making decisions regarding
anticoagulation based on the presence or absence of AF
(see Section 7).
A signiﬁcant amount of information has accumulated
showing that cardiac risk factors such as obesity, sleep apnea,
and hypertension are associated with structural and electrical
remodeling of the atria, which forms the substrate leading to
AF development and progression (see Section 3). The recom-
mended indeﬁnite annual follow-up visits with a health care
professional allow for the evaluation and treatment of associ-
ated diseases and lifestyle modiﬁcation rather than moni-
toring of the rhythm itself.
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Deﬁnition and Incidence
Early recurrences of AF after AF ablation has been deﬁned as
any recurrence of AF .30 seconds during the ﬁrst 3 months
of follow-up. Late recurrence has been deﬁned as any recur-
rence of AF .30 seconds between 3 and 12 months after
AF.141,142,143 In using the term early recurrence of AF
(ERAF) it is recognized that the early recurrence might be
AFL or AT. Although we considered deﬁning a new term,
early recurrence of ATAs, post-AF ablation, for simplicity
we have employed the term early recurrence of AF.
Throughout the document and this section of the document,
we note that recurrences can present in the form of AF, ﬂutter,
or tachycardia.
Early recurrences of AF after RF catheter ablation have
been reported in up to 50% of patients within the ﬁrst 3
months of AF ablation.253,329,436,684,932,935,970,971,972
Because these arrhythmias do not deﬁnitively indicate
therapy failure over the long term (only half of these
patients will manifest later recurrences), this period is also
referred to as the blanking or therapy stabilization
period.935,973 It is also important to recognize that the later
AF recurrences are observed during the blanking phase, the
lower the chance of long-term success.935
Causes of Recurrences
The pathophysiological mechanisms of these early recur-
rences are attributed to various mechanisms: primarily
incomplete isolation of the PVs,973,974 acute inﬂammatory
changes owing to energy delivery,755 recovery of conduction
in a previously isolated PV,448,622,975 modiﬁcation of the
ANS, changes in the atrial substrate, and delayed effect of
RF ablation due to lesion consolidation.257,258
Early Recurrence as a Predictor of Failure
The occurrence of atrial arrhythmias early after ablation does
not necessarily indicate treatment failure later during follow-
up.974 Nevertheless, early recurrences have been shown to
predict arrhythmia recurrences late after catheter ablation of
AF in some patients.260,329,935,976,977,978
Management of early recurrences is controversial and has
been treated by AADs, corticosteroids, early cardioversion,
or repeat catheter ablation.
Antiarrhythmic Drugs
Because early AF recurrence usually peaks within the ﬁrst
few weeks following PVI, the temporary routine adminis-
tration of AADs in the immediate postablation period has
been proposed as a potential preventive strategy.1,979
Although the true efﬁcacy of this approach is unknown,
studies have suggested that transient AAD use does not
prevent late arrhythmia relapses.935,980 The 5A study
randomized 110 consecutive patients with PAF
undergoing ablation to empirical AAD therapy vs no
AAD therapy for the ﬁrst 6 weeks after RF catheterablation.980 The authors noted a signiﬁcantly lower inci-
dence of clinically signiﬁcant atrial arrhythmias (AF
.24 hours or associated with severe symptoms), cardio-
versions, and arrhythmia-related hospitalization during
the 6-week treatment period (13% vs 28% in the AAD
vs non-AAD group; P ,.05); however, there was no
difference in the 6-month freedom from recurrent
AF (72% vs 68%; P 5 .84).980 As noted earlier in this
document, the writing group also recognizes that the use-
fulness of initiation or discontinuation of AAD therapy
during the postablation healing phase in an effort to
improve long-term outcomes is unclear (Class IIb, LOE
C-LD, Table 3).Corticosteroids
Given the association between AF recurrence and RF-
induced inﬂammation, it has been postulated that empiric
pretreatment with high-dose corticosteroids could reduce
the incidence of ERAF and long-term recurrence. One
study examined this hypothesis in a population of 125 pa-
tients undergoing PV ablation for symptomatic PAF.981
Corticosteroid therapy resulted in a signiﬁcant reduction
in the early AF recurrence rate (27% vs 49% at 1 month
with corticosteroids vs placebo, respectively), which was
driven by a marked reduction in the immediate recurrence
rate (7% vs 31% within 72 hours, respectively). Interest-
ingly, despite the lack of difference in the rate of recur-
rence between 3 and 30 days (20% vs 18% in the
corticosteroid and placebo groups, respectively), the
long-term freedom from AF without any AAD was
signiﬁcantly higher in the corticosteroid group (85% vs
71% freedom from AF at 14 months, respectively).
Another study was published recently to evaluate the ef-
ﬁcacy of corticosteroids to prevent early and late recur-
rence. The authors enrolled 138 patients who were
randomly assigned to two groups (a steroid group and a
control group). The primary endpoint was ERAF during
the blanking period (3 months postablation). During the
blanking period, 51 of the 138 (37.0%) patients experienced
ERAF after AF ablation. The steroid group had a lower rate
of ERAF than the control group (15 of 64 [23.4%] vs 36 of
74 [48.6%]; P 5.003). There was no difference between the
two groups in late recurrence during a 24-month follow-up
(log-rank test, P 5 .918). In a multivariate analysis, short-
term steroid therapy was independently associated with a
lower rate of ERAF during the blanking period (adjusted
odds ratio [OR] 0.45; 95% CI 0.25–0.83; P 5 .01). The au-
thors concluded that periprocedural short-term moderate in-
tensity steroid therapy reduces early recurrence of ATA
(approximately 3 months) after catheter ablation of AF;
however, it is not effective in preventing late (3–24 months)
AF recurrence.982
Additional information regarding optimum dosing, and
safety and tolerability of corticosteroid therapy post-AF abla-
tion is needed before it can be recommended.
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Colchicine, an anti-inﬂammatory agent, has been used post-
AF ablation both to reduce pericarditis-related pain, but also
to reduce AF. Colchicine has been shown to reduce postop-
erative AF following cardiac surgery,983,984 and has also
been studied following AF ablation. The ﬁrst major study
was a prospective randomized trial in 161 patients
undergoing ablation of PAF. Patients were randomized to
receive colchicine 0.5 mg bid or placebo.985 At 3 months
of follow-up, AF recurred in 34% of the placebo patients
vs 16% of the patients treated with colchicine. Colchicine
led to a reduction in C-reactive protein and IL-6. A subse-
quent randomized study of 233 patients with PAF demon-
strated a long-term recurrence rate of 31% among the
patients treated with colchicine vs 49% among the placebo
patients.986 A survey of the writing group members shows
that 6% of the members routinely administer colchicine for
1–3 months postablation. Ninety-four percent of the writing
group members do not routinely administer colchicine.Cardioversion
Three studies examined long-term outcomes of patients who
required cardioversion for early recurrence of ATAs
following RF catheter ablation. One study examined 55 pa-
tients who underwent cardioversion 2.7 6 1.4 months after
the index procedure.987 Sinus rhythm was restored in 39 of
45 patients with persistent AF (87%) and 9 of 10 patients
(90%) with AFL (P 5 .77). After a mean follow-up of 15
6 8 months postablation, only eight patients (15%) remained
completely free of AF in the absence of AAD therapy. An
additional 11 patients (20%) achieved partial success, as
deﬁned by a 90% reduction in arrhythmia burden, whereas
the remaining 36 patients (65%) were considered to have
failed ablation. Surprisingly, no differences were noted in
acute efﬁcacy or long-term outcomes based on timing of car-
dioversion (e.g., cardioversion performed during or
following the 90-day blanking period).987 Another study re-
ported on outcomes of 384 consecutive patients undergoing
AF ablation, of whom 93 had cardioversion at a mean of
88 6 72 days after ablation (74 for AF, 19 patients for
AFL).988 A mean of 166 10 months after the index ablation
procedure and 15 6 10 months after cardioversion, 25 of 93
patients (27%) remained free from recurrent atrial arrhyth-
mias in the absence of AAD therapy. In contrast to the earlier
study, the patients in the more recent study who underwent
early cardioversion (within 30 days of arrhythmia recurrence)
were more than 20 times more likely to remain in sinus
rhythm than patients who were cardioverted after 30 days,
regardless of the timing of recurrence or whether concomitant
AAD therapy was used. In those with a delayed cardiover-
sion, only 2 of 47 patients (4%) remained in sinus rhythm
without AAD therapy. In the multivariate analysis, the time
from atrial arrhythmia recurrence to cardioversion was the
only independent predictor of maintenance of sinus rhythm
after a single ablation procedure in the absence of an AAD
(P ,.001). Interestingly, these two studies reported similaroutcomes for patients who underwent cardioversion after
30 days, suggesting that if a beneﬁt is to be gained from early
cardioversion, it must be performed within the ﬁrst month af-
ter arrhythmia recurrence. A larger study included consecu-
tive catheter ablations for AF.989 Prompt electrical
cardioversion was performed if AF or AFL was conﬁrmed
and sustained, using a standard approach with the aim of per-
forming cardioversion within 24 hours of arrhythmia onset.
Of the ablations performed, a total of 515 (29%; age: 65.6
6 11.2 years; male: 57.9%) developed AF or AFL that
required cardioversion. The majority of these arrhythmias
ﬁrst occurred in the initial 90 days (63.7%) postablation. Dur-
ing this period, 62.8% were being treated with an AAD. Only
25.1% were using an AAD at 3 months. The majority of pa-
tients postablation (75.6%) who experienced AF or AFL
within the ﬁrst 90 days after ablation were in sinus rhythm,
requiring no AAD at 1 year. Further, 48% of those patients
with the ﬁrst recurrence from 90 to 180 days were in sinus
rhythm with no AAD at 1 year. Thus, it appears that patients
undergoing their ﬁrst cardioversion early after ablation (,3
months) were more likely to remain free from arrhythmia at
1 year (75%).989 An aggressive approach with early electrical
cardioversion after LA catheter ablation appears important to
maintain sinus rhythm in order to minimize late arrhythmia
recurrences, reduce chronic AAD use, and prevent reablation
procedures. When comparing an aggressive rhythm control
strategy with amiodarone and repetitive use of cardioversion
vs amiodarone and infrequent cardioversion in surgical RF
ablated patients, systematic and repetitive use of cardiover-
sion resulted in a signiﬁcantly higher portion of patients in si-
nus rhythm during follow-up.990 Although the development
of a persistent atrial arrhythmia post-AF ablation is a sign
of poor prognosis, it is currently recommended to cardiovert
those patients preferably within 30 days of arrhythmia onset.
Pathophysiological ﬁndings supporting rapid functional and
structural remodeling during AF encourage the clinician to
cardiovert persistent arrhythmias early post-AF ablation.
However, the clinical data available supporting this approach
remain limited. The number of electrical cardioversions
needed to treat repetitive persistent AF recurrences postabla-
tion of persistent AF was investigated.991,992 In this small
trial of 40 patients, the number of electrical cardioversions
3 was the only independent predictor of an ablation
failure. Therefore, currently, reablation should be
considered in clinical practice after two cardioversions
have been performed, because of the high likelihood of
recurrent arrhythmias.Early Reablation
Performance of early reablation reduces the incidence of
further recurrences, but the overall number of procedures is
higher in the medium-term follow-up. Two studies evaluated
the use of early reablation on long-term freedom from AF in
patients with ERAF.141,142,143,989,993 In 302 consecutive
patients with RF ablation for medically refractive AF, 151
experienced an ERAF, 61 of whom underwent reablation
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remaining 90 patients had a repeat procedure at least 1
month after the index ablation. During a mean follow-up of
11 6 11 months, patients with early reablation had a lower
rate of recurrences (51% vs 91%, P ,.0001), symptomatic
improvement, and improved QOL. However, the total num-
ber of procedures required over the entire duration of follow-
up was greater in the patients who underwent early reablation
(2.56 0.7 vs 2.26 0.6, P5 .02).993 The STOP-AF trial ran-
domized 245 patients with PAF to medical therapy versus
CB-based PV ablation. Patients were followed for 12months.
Of the 163 patients randomized to cryoablation, 84 patients
experienced ERAF (51.5%). The only signiﬁcant factor asso-
ciated with ERAF was male sex (HR 2.18; 95% CI 1.03–
4.61; P5 .041). Late recurrence was observed in 41 patients
(25.1%), and was signiﬁcantly related to ERAF (55.6% late
recurrence with ERAF vs 12.7% without ERAF; P ,.001).
Among the patients with ERAF, only current tobacco use
(HR 3.84; 95% CI 1.82–8.11; P ,.001) was associated
with late recurrence. Conversely, early reablation was
associated with greater freedom from late recurrence
(3.3% late recurrence with early reablation vs 55.6%without;
HR 0.04; 95% CI 0.01–0.32; P 5 .002).141,142,143 Although
the clinical beneﬁt of early reablation was demonstrated,
the ﬁrst month following the procedure might not be the
optimal time for a repeat intervention. On the other hand,
up to 60% of the patients experiencing this event within the
ﬁrst months postablation will not have any further
arrhythmias during long-term follow-up.253,436,970,971,994
Therefore, reablation is not recommended in an ERAF that
might be a transient phenomenon.2Conclusions
Theoretically, aggressive treatment of early recurrences of
AF might prevent electrical and structural remodeling and
improve long-term outcome. Larger studies with more reli-
able follow-up methods are needed to clarify the relevance
and optimal management of early recurrences.Atrial Tachycardias After AF Ablation
ATs of new onset make up to 50% of all arrhythmias observed
following catheter-based ablation of AF.253,436,507,508,622,623,
624,625,630,870,871,995,996,997,998,999,1000,1001,1002 Most of these
tachycardias originate in the LA, although RA cavotricuspid
isthmus (CTI)-dependent ﬂutters might also occur. Patients
with a regular AT of new onset might complain of
worsening symptoms due to a faster mean ventricular rate
(frequently 2:1 ventricular response) than that during AF
preablation. Rhythm control is often difﬁcult with AADs.
The mechanisms underlying regular LA tachycardias
following AF ablation include focal microreentrant tach-
ycardias originating from reconnected PV ostia or macroreen-
trant tachycardias around anatomic obstacles or scar from
intrinsic LA disease or prior ablation(s) (Figure 5).447,508,933,
998 Occurrence of early AT within 3 months after ablationpredicts occurrence of both late AT and AF.1003,1004,1005
However, because up to 49% of ATs resolve with time,
ablation should not be undertaken for early AT occurrence
unless symptoms cannot be controlled.1003 Initial treatment
should include electrical cardioversion and AADs. Because
Vaughan Williams Class Ic antiarrhythmic agents promote
slow conduction that can facilitate macroreentrant tachycar-
dias, Class III antiarrhythmic agents (dofetilide, sotalol, or
amiodarone), together with negative dromotropic agents, are
typically preferred. For those with intolerable symptoms or
continued late AT recurrence, detailed activation and entrain-
ment mapping of the tachycardia results in effective ablation in
approximately 90% of patients.447,622,623,624,1006,1007,1008Antiarrhythmic and Other Pharmacological Therapy
Postablation
AF recurrences during the ﬁrst 3 months after ablation are
rather common. It is generally believed that the mechanisms
of AF in this setting are different from that of the patient’s
clinical arrhythmia. Acute inﬂammatory changes owing to
energy delivery1009; modiﬁcation of the ANS with consecu-
tive changes in the atrial substrate257; or delayed effect of ra-
diofrequency ablation due to lesion consolidation have been
considered.258 It is also suggested that AF might resolve
completely upon resolution of the transient factors promoting
early AF recurrences. Accordingly, suppressive antiar-
rhythmic agents are frequently prescribed for patients with
AF recurrences during the ﬁrst 1–3 months following abla-
tion.253,436,988,1010,1011 Because ATs can also occur shortly
after ablation, negative dromotropic agents (beta or calcium
channel blockers) are commonly continued for at least the
ﬁrst month after ablation. The impact of empirical AAD
therapy for 6 weeks after AF ablation on the occurrence of
AF was investigated in several randomized studies.934,979,
980 The drugs employed for this purpose vary, but most
commonly are those that have been used unsuccessfully
prior to ablation; they include ﬂecainide, propafenone,
sotalol, dofetilide, dronedarone, and amiodarone. The
short-term use of AADs after AF ablation decreased early re-
currences of atrial arrhythmias and need for hospitalization or
cardioversion, but had no effect on the prediction or preven-
tion of arrhythmia recurrence at 6 and 12 months.934,979,980
As noted earlier in this document, the writing group
recognizes that the usefulness of initiation or
discontinuation of AAD therapy during the postablation
healing phase in an effort to improve long-term outcomes
is unclear (Class IIb, LOE C-LD, Table 3).
Because an inﬂammatory process after AF ablation can be
one speciﬁc cause leading to early recurrences, the efﬁcacy of
corticosteroids for preventing early postablation atrial ar-
rhythmias was investigated in several studies.981,982 The
prevalence of immediate AF recurrences (3 days after
PVI) was signiﬁcantly lower in the corticosteroid group
compared with the placebo group (7% vs 31%). However,
few investigators routinely administer steroids during or
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e351following AF ablation. The use of PPIs or H2 blockers for 1–
4 weeks following ablation has been suggested to avoid
esophageal ulcerations observed on endoscopy following
AF ablation.896,897 However, there are no randomized data
available to demonstrate that this approach reduces the
incidence of esophageal symptoms or the development of
an AEF. Early diagnosis of AEF, with early employment of
operative intervention, is the best treatment option for AEF
(please refer to Section 10 for more information). Attention
to the control of hypertension and addressing other AF risk
factors such as sleep apnea and obesity remain an integral
part of AF management after the ablation procedure.929
The impact of angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers on the long-term outcome
of AF ablation was investigated in a prospective registry of
consecutive patients undergoing catheter ablation of parox-
ysmal or persistent AF.334 In that study, however, modulation
of the renin-angiotensin aldosterone system did not appear to
affect maintenance of sinus rhythm after catheter ablation of
AF. Thus, the hypothesis that so-called medical upstream
therapy can positively inﬂuence the reverse atrial remodeling
after catheter ablation of AF remains unproven.Later-Term Repeat Ablation Procedures
Recurrences of AF (or AT) after index AF ablation pro-
cedures lead to repeat ablation in a considerable number
of patients. Recent data show a repeat procedure rate of
15% and 50% depending on the duration of follow-up
and patient characteristics.1012 Since early recurrences of
AF and/or the development of AT are common during
the ﬁrst 2–3 months after AF ablation and might resolve
spontaneously, repeat ablation procedures should be de-
ferred for at least 3 months following the initial procedure
if possible. Nevertheless, such early recurrences are asso-
ciated with decreased long-term success of the proced-
ure.260 It is also recognized that some patients will
develop highly symptomatic early recurrence of atrial ar-
rhythmias that cannot be controlled with antiarrhythmic
therapy or slowed with rate controlling medications and
are best managed with a reablation procedure within the
ﬁrst 3 months post-AF ablation. Most studies have re-
ported that patients who fail an initial attempt at ablation
and undergo a repeat ablation procedure demonstrate
resumption of electrical conduction of the previously iso-
lated PVs rather than new arrhythmogenic foci from non-
targeted PVs or outside of the PVs.263,440,446,1013 This
outcome appears to be overwhelmingly the case for the
ﬁrst reablation procedure, whereas in further redo
procedures (e.g., second or third redo procedure) other
mechanisms also appear to play a more important
role.1014
Consequently, the ﬁrst step when performing a second AF
ablation procedure is to check each PV for reconduction of
electrical activity. If reconduction is found, the primary
goal should be reisolation of the PVs. If, however, there is
no evidence of PV reconduction, the decision on the bestablation technique is more complex. Several targets have
been proposed in this setting, such as LA substrate mapping
and tailored ablation guided by electrogram voltage, ablation
with complex fractionated electrograms, ablation of pro-
voked non-PV triggers or sites commonly associated with
non-PVs triggers such as the SVC, or targeting of focal im-
pulse and rotational activity mapping. However, deﬁnitive
evidence of the beneﬁt or superiority of any of these tech-
niques over the others is lacking.126,223,247,257,567,1015,1016
Data on current clinical practice conﬁrm the prevailing
uncertainty regarding the best reablation technique.540
High-dose isoproterenol infusions have been shown to be
helpful in the provocation of PV and non-PV triggers.440,1013
A recent randomized trial showed that adenosine
administration during the ablation procedure might
unmask dormant PV conduction and reduce the recurrence
rate of the procedure, but results were not conﬁrmed in
another trial evaluating ATP.265,1017 The value of
adenosine administration at the time of the redo procedure
to demonstrate latent PV conduction has not been
demonstrated.461Autonomic Alterations
Potential side effects of AF ablation include transient and per-
manent alterations in autonomic nerve activity. Transient
(,6 months) elevation of heart rate, inappropriate sinus
tachycardia and reduction of heart rate variability have
been observed after PVI.223,257 Others reported an
immediate decrease in autonomic function such as
deceleration capacity and acceleration capacity after PVI.
Some of these changes can last for over a year.126,1016
Although most autonomic alterations associated with PVI
are transient and are not associated with signiﬁcant
symptoms, more severe autonomic alterations can occur in
cases of periesophageal vagal nerve injury.265,461,868,1017,
1018,1019,1020 A prospective observational study showed a
high incidence (33%–48%) of transient (,6 months) new
onset alterations in esophageal motility after AF
ablation.536 Although most patients recover within several
months, gastric hypomotility can persist for over 28 months
after the procedure in rare cases.1020 A case of achalasia car-
dia has recently been reported to occur after PVI.252,1021
Another study showed a 7.9% prevalence of gastric
hypomotility after high output (25–30 W) posterior LA
ablation. Reduction of the output to 20–25 W at sites
where the ablation line transversed the esophagus
eliminated the postablation esophageal hypomotility.1020 In
additional to the watts used during ablation, it is possible
that both time and CF are factors that determine periesopha-
geal vagal nerve injury. However, the CF was not evaluated
in the latter study. In summary, most autonomic alterations
associated with AF ablation were self-terminating and
asymptomatic. However, severe symptomatic periesopha-
geal vagal nerve injury can occur after LA posterior wall
ablation.
e352 Heart Rhythm, Vol 14, No 10, October 2017Very Late Recurrence (More Than 1 Year) After AF
Ablation
Many groups have reported the incidence of very late AF re-
currences occurring up to 10 years postablation, even after an
initially successful procedure at 1 year.63,270,536,1022,1023,1024
A recent meta-analysis analyzed 19 studies including 6167
patients, describing outcomes 3 years after AF ablation
with a mean follow-up 24 months after the index proced-
ure. Single procedure and multiple procedure freedom from
atrial arrhythmias has been reported to be 53% and 80%,
respectively, with substantial heterogeneity noted for
single-procedure outcomes.
Very late recurrences have been noted after an initial
freedom from AF at 1 year postablation, with an annual
recurrence rate estimated at 7.6%, reaching attrition rates of
16%–46% and 30%–54% at 5 and 10 years, respectively.
Interestingly, despite the recurrence rates, a low incidence
of progression (0.3% per year) from paroxysmal to persistent
AF as well as stroke rates ,1% have been reported. Also
noteworthy is the fact that time to recurrence might inﬂuence
outcomes. Patients with very late recurrences are more likely
to have sporadic episodes and a better response to AADs and
repeat ablation procedures than those with earlier recur-
rences.
The most consistent predictor of late recurrence is persis-
tent AF. Other predictors include hypertension, age, LA size,
diabetes, valvular heart disease and left ventricular dysfunc-
tion, and higher thromboembolic risk scores.63 Recurrences
in patients undergoing repeat ablation procedures have
been noted to be due mostly to PV reconnection. However,
recent evidence pointing to the importance of non-PV foci
and gaps in prior ablation lines can also play a role. In partic-
ular, the LAA and LA posterior wall have been shown to
contain signiﬁcant triggers in patients with non-PAF and
isolation strategies are suggested to be of beneﬁt in
improving long-term outcomes.Section 9: Outcomes and Efﬁcacy
Overview
AF ablation is a maturing ﬁeld. Prior to the publication of the
initial consensus report in 2007, the majority of the published
literature on AF ablation consisted of uncontrolled single-
and multicenter reports.1 Further, there had been no standard-
ization in the design of clinical trials of AF ablation, and the
2007 and 2012 consensus documents were developed in part
to generate standard terminology, deﬁnitions, and recom-
mendations for end points, follow-up procedures, and
outcome reporting in an effort to make studies more rigorous
and consistent.1,2
Over the past 10–12 years, a large number of randomized
trials have been completed addressing various aspects of AF
ablation. Many have compared AF ablation with AAD
therapy in both “ﬁrst-line” (AAD-naïve patients) and “sec-
ond-line” (following the failure of 1 or more drugs)
settings.261,377,378,379,462,529,684,733,1025,1026,1027,1028,1029,1030
In some cases, these trials have supported regulatory approvalof speciﬁc ablation technologies.462,503,655,673,684,733 Some
trials have compared AF ablation with other standard
pharmacological or nonpharmacological approaches to rate
control.235,236,237,390 Many other trials have compared
various ablation techniques or alternative ablation systems
with each other. Table 7 provides a summary of the outcomes
of a selected group of clinical trials of AF ablation. This table
includes a summary of the clinical trials that have been per-
formed for FDA approval, clinical trials of AF ablation as
ﬁrst-line therapy, as well as randomized clinical trials of
AF ablation for PAF, persistent AF, mixed trials, and ran-
domized trials of AF ablation in patients with HF.
In this section, we will focus our review of this large and
growing body of literature on trials comparing AF ablation
with alternative treatment approaches—primarily AADs—
for AF, to provide support for recommendations on the role
of AF ablation in various patient groups. Outcomes for spe-
ciﬁc ablation systems (CBA, rotational activity ablation,
and laser balloon ablation) will also be reviewed. Studies
comparing ablation techniques or lesion sets with each other
are primarily discussed in Section 5: Strategies, Techniques,
and Endpoints.
Previous versions of the consensus report included a sec-
tion on nonrandomized studies of AF ablation. Due to the
very large number of studies reported, the lack of standardi-
zation among them, and their generally early time frame in
the evolution of AF ablation, we will not review that litera-
ture in the current document, and instead we refer readers
to the prior consensus documents and to a large meta-
analysis on the topic.262 Useful insights into AF ablation out-
comes outside the setting of RCTs have also been obtained
from worldwide surveys on AF ablation, and these will
also be reviewed.
In addition to a broad overview of AF ablation trials
among commonly treated patient groups, this section will
also review outcomes of AF ablation in populations not
well represented in clinical trials and with speciﬁc ablation
systems. Additionally, end points beyond maintenance of si-
nus rhythm of considerable interest to the ﬁeld (e.g., QOL,
stroke, cost-effectiveness) will be examined.Published Literature Review: Clinical Trials
Performed for FDA Approval
When AF ablation began, procedures were performed using
standard 4 mm and later 8 mm tipped, nonirrigated RF
catheters that had been developed and approved for the
treatment of other arrhythmias. The ﬁrst two classes of de-
vices to seek and achieve FDA approval for ablation of AF
were irrigated RF catheters and CBA catheters (Table 7). In
consultation with the FDA, the manufacturers of these de-
vices were required to conduct randomized trials comparing
AF ablation to AADs and chose to evaluate patients with
PAF who had previously failed treatment with one or
more drugs.
Although the two initial device approval studies had nar-
row entry criteria and enrolled primarily young and healthy
Table 7 Selected clinical trials of catheter ablation of atrial ﬁbrillation and/or for FDA approval
Trial Year Type N AF type Ablation strategy
Initial
time frame
Effectiveness
endpoint
Ablation
success
Drug/
Control
success
P value for
success
Ablation
complications
Drug/Control
complications Comments
Clinical Trials Performed for FDA
Approval
JAMA 2010; 303: 333-340
(ThermoCool AF)684
2010 Randomized to RF
ablation or AAD,
multicenter
167 Paroxysmal PVI, optional CFAEs
and lines
12 months Freedom from
symptomatic
paroxysmal atrial
ﬁbrillation, acute
procedural failure, or
changes in speciﬁed
drug regimen
66% 16% ,0.001 4.9% 8.8% FDA approval
received
JACC 2013; 61: 1713-1723
(STOP AF)462
2013 Randomized to
cryoballoon ablation
or AAD, multicenter
245 Paroxysmal PVI 12 months Freedom from any
detectable AF, use of
nonstudy AAD, or
nonprotocol
intervention for AF
70% 7% ,0.001 3.1% NA FDA approval
received
Heart Rhythm 2014; 11:
202-209 (TTOP)733
2014 Randomized to phased RF
ablation or AAD/
cardioversion,
multicenter
210 Persistent PVI 1 CFAEs 6 months Acute procedural success,
90% reduction in AF
burden, off AAD
56% 26% ,0.001 12.3% NA Not FDA
approved
JACC 2014; 64: 647-656
(SMART-AF)673
2014 Nonrandomzied
multicenter study of
contact force-sensing
RF catheter,
comparing to
performance goals
172 Paroxysmal PVI, optional CFAEs
and lines
12 months Freedom from
symptomatic AF,
ﬂutter, tachycardia,
acute procedural
failure, or changes in
AAD
72.5% N/A ,0.0001 7.5% NA FDA approval
received
Circulation 2015; 132: 907-
915 (TOCCASTAR)655
2015 Randomized to contact
force sensing RF
catheter or approved
RF catheter,
multicenter
300 Paroxysaml PVI, optional triggers,
CAFEs and lines in
both arms
12 months Acute procedural success
1 Freedom from
Symptomatic AF/
Flutter/Tachycardia
off AAD
67.8% 69.4% 0.0073 for
noninferiority
7.2% 9.1% FDA approval
received
JACC 2015; 66: 1350-1360
(HeartLight)503
2015 Randomized to
laserballoon or
approved RF catheter,
multicenter
353 Paroxysmal PVI 6 CTI ablation vs
PVI, optional
CFAEs, and Lines
12 months Freedom from
Symptomatic AF/
Flutter/Tachycardia,
acute procedural
failure, AAD, or non-
prototocol
intervention
61.1% 61.7% 0.003 for
noninferiority
5.3% 6.4% FDA approval
received
First-Line Therapy Trials
JAMA 2005; 293:
2634-2640 (RAAFT)377
2005 Randomized to drug,
multicenter
70 Paroxysmal
(N567),
persistent
(N5 3)
PVI 12 months Freedom from
detectable AF
84% 37% ,0.01 9% 11%
NEJM 2012; 367:1587-1595
(MANTRA-PAF)378
2012 Randomized to drug,
multicenter
294 Paroxysmal AF PVI, roof line, optional
mitral and tricuspid
line
24 months Cumulative
AF burden
13% AF burden 19% AF
burden
NS 17% 15%
JAMA 2014; 311: 692-700
(RAAFT-2)379
2014 Randomized to drug
multicenter
127 Paroxysmal AF PVI plus optional non-
PVI targets
24 months Freedom from
detectable AF,
ﬂutter, tachycardia
45% 28% 0.02 9% 4.9%
Other Paroxysmal AF Ablation
Trials
JACC 2006; 48: 2340-2347
(APAF)1027
2006 Randomized to drug
single center
198 Paroxysmal AF PVI, mitral line and
tricuspid line
12 months Freedom from detectable
AF, ﬂutter,
tachycardia
86% 22% ,0.001 1% 23%
Circulation 2008; 118: 2498-
2505 (A4)261
2008 Randomized to drug 112 Paroxysmal PVI (optional LA lines,
CTI, focal)
12 months Freedom from AF 89% 23% ,0.0001 5.7% 1.7%
NEJM 2016; 374: 2235-2245
(FIRE AND ICE)489
2016 Randomized RF vs Cryo,
multicenter
762 Paroxysmal AF PVI 12 months Freedom from
detectable AF, ﬂutter,
tachycardia
64.1% (RF) 65.4% (cryo) NS 12.8% 10.2%
(Continued )
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Trial Year Type N AF type Ablation strategy
Initial
time frame
Effectiveness
endpoint
Ablation
success
Drug/
Control
success
P value for
success
Ablation
complications
Drug/Control
complications Comments
JACC 2016; 68: 2747-2757709 2016 Randomized to hot
balloon or drug,
multicenter
100 Paroxysmal AF PVI 12 months Freedom from AF 59% 5% ,0.001 10.4% 4.7%
Other Persistent AF Ablation
Trials
NEJM 2006; 354:
934-9411026
2006 Randomized to RF
ablation or to CV and
short term amio
146 Persistent PVI, roof, mitral line 12 months No AF or ﬂutter month 12 74% 58% 0.05 1.3% 1.4%
EHJ 2014; 35: 501-507
(SARA)1030
2014 Randomized to drug (2:1
ablation to drug),
multicenter
146 Persistent PVI (optional LA lines,
CFAEs)
12 months Freedom from AF/ﬂutter
lasting .24h
70% 44% 0.002 6.1% 4.20%
NEJM 2015; 372:
1812-1822245
2015 Randomized ablation
strategies,
multicenter
589 Persistent PVI alone versus PVI &
CFAEs or PVI & lines
18 months Freedom from aﬁb with or
without drugs
59% (PVI alone) 49% & 46% NS 6% 4.3% & 7.6%
Other Mixed Paroxysmal and
Persistent AF Ablation Trials
J Med Assoc Thai 2003; 86
(Suppl 1): S8-S161025
2003 Randomized to RF
ablation or
amiodarone
30 Paroxysmal
(70%),
Persistent
(30%)
PVI, mitral line, CTI,
SVC to IVC
12 months Freedom from AF 79% 40% 0.018 6.70% 47%
EHJ 2006; 27: 216-2211028 2006 Randomized to RF
ablation or drug,
multicenter
137 Paroxysmal
(67%),
Persistent
(33%)
PVI, mitral line, CTI 12 months Freedom from AF, ﬂutter,
tachycardia
66% 9% ,0.001 4.40% 2.90%
JCVEP 2009, 20: 22-281029 2009 Randomized to RF
ablation or drug,
multicenter
70 Paroxysmal
(41%),
Persistent
(59%) & type 2
DM
PVI, CTI, optional
mitral line and roof
line
12 months Freedom from AF and
atypical atrial ﬂutter
80% 43% 0.001 2.90% 17%
Randomized Trials of AF Ablation
in Patients with Heart Failure
NEJM 2008; 359: 1778-1785
(PABA-HF)235
2008 Randomized to RF
ablation of AVJ abl
and BiV pacing
81 Persistent (50%),
Paroxysmal
(50%), EF 27%
abl, 29% AVJ
PVI, optional linear
abl and CFAEs
6 months Composite EF, 6 min walk,
MLWHF score;
freedom from AF
(secondary, mult
proc, 1/- AA drugs)
88% AF free, EF
35% abl, 28%
AVJ (P,.001),
. QOL and 6
min walk
increase
with abl
,0.001 14.60% 17.50%
Heart 2011; 97: 740-747236 2011 Randomized to RF
ablation or
pharmacological rate
control
41 Persistent , EF
20% abl, 16%
rate control
PVI, roof line, CFAEs 6 months Change in LVEF, sinus
rhythm at 6 months
(secondary)
50% in NSR, LVEF
increase 4.5%
0% in NSR,
LVEF
increase
2.8%
0.6 (for EF
increase)
15% Not reported
JACC 2013; 61:
1894-1903390
2013 Randomized to RF
ablation or
pharmacological rate
control
52 Persistent AF
(100%), EF
22% abl, 25%
rate control
PVI, optional linear abl
and CFAEs
12 months Change in peak O2
consumption (also
reported single
procedure off drug
ablation success)
Peak O2
consumption
increase
greater with
abl, 72% abl
success
0.018 15% Not reported
Circ A and E 2014; 7:
31-38237
2014 Randomized to RF
ablation or
pharmacological rate
control
50 Persistent AF
(100%), EF
32% abl, 34%
rate control
PVI, optional linear abl
and CFAEs
6 months Change in LVEF at 6
months, multiple
procedure freedom
from AF also reported
LVEF 40% with abl,
31% rate
control, 81%
AF free with abl
0.015 7.70%
AF 5 atrial ﬁbrillation; RF 5 radiofrequency; AVJ 5 atrioventricular junction; abl 5 ablation; BiV 5 biventricular; EF 5 ejection fraction; PVI 5 pulmonary vein isolation; CFAEs 5 complex fractionated atrial
electrograms; MLWHF 5 Minnesota Living with Heart Failure; LVEF 5 left ventricular ejection fraction; QOL 5 quality of life; NSR 5 normal sinus rhythm.
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contributed substantially to the previous literature comparing
ablation to AAD therapy.462,684 In both cases, protocol-
deﬁned success with ablation (66% and 70%, respectively)
was much higher than with drugs (16% and 7%), and accept-
able rates of serious adverse events occurred.
Given the overwhelmingly superior efﬁcacy of AF abla-
tion in this patient population, ablation has become the stan-
dard of care in many centers. Accordingly, subsequent FDA-
regulated device approval studies of novel ablation technolo-
gies have not required randomization against AADs, because
doing so would be not be feasible. Instead, several new tech-
nologies have been either compared with a previously
approved device with the same indications for use in a ran-
domized, controlled noninferiority study or, in the case of a
second generation RF ablation catheter, compared with pre-
deﬁned performance goals in a single-arm study. Examples
of this pathway include recent trials of force-sensing655,673
and the laser balloon ablation system.503,673 Each of these
trials met its prespeciﬁed end points, generally conﬁrming
the safety and efﬁcacy of AF ablation in patients with PAF,
but none demonstrated the superiority of new technologies
in the full study populations. Protocol-deﬁned success rates
at 12 months in these studies ranged from 61% to 72.5% (pri-
mary effectiveness deﬁnitions were not identical across
studies). Because these studies were designed to demonstrate
noninferiority to an approved device with the same indica-
tions for use, they have been subject to the same limitations
in terms of patient population, follow-up duration, etc., as
the earlier studies.
An additional study of a phased array multielectrode RF
ablation system performed under regulatory supervision by
the FDA in patients with persistent AF refractory to 1
AAD has also been completed.733 In this study, patients
were randomized to ablation vs treatment with an alternative
AAD or increased dose of a previously ineffective drug and
DC cardioversion. As expected, protocol-deﬁned success
was higher following ablation at 6 months (56% vs 26%).
However, the study did not meet its prespeciﬁed safety end
point, partly due to the occurrence of 4 strokes (2.9% of
the patients randomized to ablation) that mainly occurred
during early experience with the ablation system. As a result,
this system has not been approved in the United States.
For the purpose of regulatory approval, it is expected that
future ablation technologies designed to treat PAF will
continue to be compared with previously approved ablation
systems in randomized studies. We believe that this is appro-
priate, although there should be careful consideration of the
possibility of a downward “creep” in acceptable effectiveness
(if each device is numerically inferior but statistically equiv-
alent to the prior comparator device). In the future, we expect
that devices designed to treat patients with symptomatic PAF
might alternatively be evaluated in nonrandomized trials,
comparing prespeciﬁed performance goals or objective per-
formance criteria (OPC), if uniformly established and
applied. However, given the rapid evolution of the ﬁeld of
AF management, it should be understood that such perfor-mance criteria are potentially subject to change over time.
An OPC refers to a numerical target value derived from his-
torical data from clinical studies and/or registries and can be
used in a dichotomous (pass or fail) manner by the FDA for
the review and comparison of safety or effectiveness end-
points. Currently, no such OPC has been validated with
respect to catheter ablation of persistent AF or PAF. If an
OPC is employed, it is important to clarify the patient popu-
lation to which it applies. It is anticipated that the patient pop-
ulation should be similar to predicate patient populations.
However, in the clinical trials section of this document we
have provided what we believe are acceptable OPC for AF
ablation clinical trials.
Studies seeking regulatory approval for the treatment of
persistent and long-standing persistent AF can follow one of
two potential approaches. As in the past, future studies might
compare novel ablation systems against medical management
because, at this point, no ablation system is expressly approved
for persistent or long-standing persistent AF in the United
States. Alternatively, a novel ablation system could be evalu-
ated in single-arm trials with prespeciﬁed OPCs.AF Ablation as Second-Line Rhythm Control
Therapy
At the time of this writing, at least 16 randomized clinical tri-
als have been completed comparing AF ablation with AADs
in patients with AF refractory to one or more AADs. Each of
these trials is summarized in Table 7. In addition to the trials
for FDA approval listed in Table 7, four of these trials exclu-
sively enrolled patients with paroxysmal (or “early persis-
tent”) AF, three trials enrolled only patients with persistent
AF, and three trials enrolled patients with either AF
pattern.261,462,684,733,1025,1026,1027,1028,1029,1030 Additional
randomized trials in patients with HF and persistent AF
have been completed, comparing ablation with rate control,
amiodarone, or AV junction ablation with biventricular
pacing.235,236,237,390,529 The HF trials will be reviewed in a
later section of this document.
In general, the trials involving PAF focused on PVI
(although adjunctive ablation was allowed or encouraged to
varying degrees), and reported success rates at 12 months
ranged from 59%–89%. In all cases, freedom from
arrhythmia at 12 months was signiﬁcantly higher than with
drug therapy, which had reported success rates of 5%–
23%. Among trials that included patients with persistent
AF or combined paroxysmal and persistent populations, the
ablation techniques more frequently incorporated linear
lesion sets or ablation with CFAEs. Reported success rates
with ablation ranged from 59%–80% at 6 or 12 months,
whereas success rates with drug therapy ranged from 9%–
58%. In all cases, maintenance of sinus rhythm was signiﬁ-
cantly higher with ablation.
It is difﬁcult to directly compare adverse events from AF
ablation to those from AADs. In most of the above trials, low
rates of serious procedural complications were reported.
With the exception of the HF trials, most of the second-line
e356 Heart Rhythm, Vol 14, No 10, October 2017rhythm control trials enrolled relatively healthy and young
patients with AF. Mortality rates in these relatively small tri-
als have therefore been very low, precluding any meaningful
attempts to determine whether ablation has any impact on
mortality.
The many trials comparing AF ablation with AADs for
second-line rhythm control have been evaluated in a number
of meta-analyses and technology assessments.262,1031,1032
Pooling of results across trials indicates that AF ablation is
clearly superior to AAD therapy for the maintenance of
sinus rhythm. The impact of AF ablation on other key
outcomes, including HF, stroke, and QOL, will be
reviewed in subsequent sections of this document.Outcomes and Efﬁcacy of Catheter Ablation of AF as
First-Line Rhythm Control Therapy
There have been several studies performed to investigate the
role of AF ablation as ﬁrst-line therapy, prior to a trial of a
membrane-active antiarrhythmic medication.377,378,379 The
Medical ANtiarrhythmic Treatment or Radiofrequency
Ablation in Paroxysmal Atrial Fibrillation (MANTRA-
PAF)494 trial compared catheter ablation with AAD therapy
for the ﬁrst-line therapy of symptomatic PAF.378 The trial
did not show a reduction in the cumulative AF burden over
2 years; however, catheter ablation was associated with a
lower rate of AF recurrence (15% vs 29%, P 5.004) and a
similar rate of complications (17% vs 15%) compared with
AAD. The unexpected result in the MANTRA-PAF might
be explained by the ablation techniques with discretional
circumferential ablation without conﬁrmation of PVI with a
circular mapping catheter as well as by the choice of reduc-
tion in AF burden on 7-day Holter as a primary endpoint. Re-
ductions in AF burden on a short 7-day Holter can be difﬁcult
to demonstrate in a paroxysmal population. In the Radiofre-
quency Ablation versus Antiarrhythmic drugs as First-line
Treatment of Paroxysmal AF (RAAFT-2) trial, PV antrum
isolation was performed using irrigated-tip ablation catheters
conﬁrmed by recordings from a circular mapping catheter.379
The results of the RAAFT-2 demonstrated that AF or AT
recurred in 55% of the catheter ablation group compared
with 72% of the patients in the AAD group after a 2-year
follow-up (P 5 .016).
Moreover, a meta-analysis showed that ﬁrst-line therapy
with catheter ablation was more effective than AAD for
long-term maintenance of sinus rhythm and was associated
with comparable rates of adverse events in relatively young
patients with PAF and minimal structural heart disease.380
A preliminary analysis based on the results of the ﬁrst
RAAFT trial suggests that catheter ablation as a ﬁrst-line
therapy also has a better cost-effectiveness proﬁle.1033 These
results provide some support for the role of catheter ablation
as ﬁrst-line therapy for PAF. Whether such beneﬁts extend to
elderly patients with PAF, patients with associated structural
heart disease, or non-PAF is still controversial.
One small, prospective, multicenter randomized study
was performed to evaluate whether catheter ablation is supe-rior to AAD in patients with HF and persistent AF.529 The
main goal of the ablation procedure was PV antrum isolation
and LA posterior wall isolation. The results showed that cath-
eter ablation was superior to amiodarone in achieving
freedom from AF at the long-term follow-up (70% vs 34%,
P ,.001). Moreover, ablation improved QOL and exercise
capacity, and reduced hospitalization (31% vs 57%, P
,.001) and mortality (8% vs 18%, P 5 .037). These data
provide some support for the notion of AF ablation as ﬁrst-
line therapy; however, further studies are needed.Published Literature Review: Survey Results
A worldwide survey on the methods, efﬁcacy, and safety
of catheter ablation of AF was ﬁrst published in 2005.806
The outcomes of nearly 9000 AF ablation procedures
were reported. More than one ablation procedure was per-
formed in 27% of patients. The success rate, deﬁned as
freedom from symptomatic AF in the absence of antiar-
rhythmic therapy, was 52%. An additional 24% of patients
were free of symptomatic AF in the presence of a previ-
ously ineffective AAD. The incidence of major complica-
tions was 6%.
In a subsequent survey from the same group, the clinical
outcome and safety of AF ablation performed between the
years 2003 to 2006 in 85 participating centers proved to be
better than in the previous years.920 During a follow-up of
10 6 8 months, 192 procedures per center were reported
with a 70% efﬁcacy rate free of AADs, and an additional
10% efﬁcacy rate in the presence of previously ineffective
AADs. Ablation of PAF was associated with a 35% and
66% larger probability of success compared with ablation
of persistent and long-standing persistent AF, respectively.
Despite a larger prevalence of centers reporting catheter abla-
tion of persistent and long-standing persistent AF, the overall
complication rate was 4.5%. There were 25 procedure-related
deaths (0.15%), 37 strokes (0.23%), 115 TIAs (0.71%), and
213 episodes of tamponade (1.31%).
In a subsequent report analyzing the risk of periprocedural
death by means of an aggregate calculation from the previous
two surveys, 32 fatal events were observed (0.98 per 1000 pa-
tients) during 45,115 procedures in 32,569 patients.908 Car-
diac tamponade was found to be the most frequent cause of
death, with 8 patients (1 more than 30 days) suffering a fatal
outcome as a consequence of this complication. Stroke was
reported as the cause of death in 5 patients (2 more than 30
days), AEF in 5 patients, and massive pneumonia in 2
patients.
More recently, the same authors provided a systematic
analysis of 45 delayed tamponade events (e.g., cardiac tam-
ponade occurring at least 1 hour after procedure termination)
in 21,478 patients undergoing 27,921 procedures (0.2%).1034
The median time to tamponade was 12 days (range: 0.2–45
days) after procedure termination, with only 4 patients expe-
riencing this event prior to discharge. The mode of clinical
presentation varied, with 39 patients exhibiting gradual pro-
gression to cardiac tamponade and 6 patients experiencing
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complication (risk of death 1 per 10,000 patients).
In January 2014, another survey reported on the ﬁrst
prospective series providing preprocedural, procedural, and
1-year follow up data on 72 centers enrolling about 1400 pa-
tients undergoing a median of 1.2 procedures.969 In their reg-
istry, the authors reported a 1-year success rate free from
AAD therapy of only 40% (44% in PAF; 30% in persistent
AF; 37% in long-term persistent AF). Adding AAD therapy
increased the successful control rate to 72%. This result was
achieved with 20% of the patients having undergone at least a
second procedure. Using a multivariate analysis, the authors
found that AF recurrence during the 3-month blanking period
was the only predictor of failure at the 1-year follow-up.
In 2014, the Prospective European Survey on AFAblation
investigators published a prospective consecutive series of
946 consecutive patients enrolled in 35 centers.1035 AF pat-
terns were paroxysmal, persistent, and long-standing persis-
tent in 52%, 36%, and 12% of patients, respectively, with
12% of the centers offering AF ablation as ﬁrst-line therapy.
PVI was performed in all the centers, with empiric linear le-
sions and/or ablation of CFAEs being delivered as adjunctive
approaches in patients with non-PAF. RF was the dominant
energy form used (more than 95% of procedures), with cry-
oenergy and laser offered in 4% and less than 1% of proced-
ures, respectively.
In a recent survey led by the EHRA, the strategy used by
30 European centers for treating persistent AF was re-
ported.540 Almost half of the recruiting centers were perform-
ing more than 400 catheter ablations per year and more than
200 LA ablations. PVI was the main technique in patients un-
dergoing ﬁrst-time ablation for persistent, but not long-
standing persistent, AF in the majority of the centers
(67%), with ablation using fractionated electrograms, either
as an addition to PVI or as a stand-alone procedure, in 13%
and 3% of centers, respectively. A stepwise AF ablation tech-
nique was used in only 3% of centers. In patients with long-
standing persistent AF, stand-alone PVI was adopted in only
one-third of centers. In the remaining two-thirds, ablation
with fractionated electrograms, stepwise ablation until AF
was terminated, and PVI plus linear lesions at the LA roof
or the mitral isthmus were the most frequently reported tech-
niques. When PVI was the only technique used in patients
with persistent or long-standing persistent AF, 20% and
10% of procedures were performed with CB, respectively.
The 1-year success rate after a single procedure at 1 year
was found to be 50%–60% in 40% of the centers, with three
centers reporting a success rate of less than 40% and three
centers reporting a success rate higher than 80%.Outcomes of AF Ablation in Populations Not
Well Represented in Clinical Trials
Outcomes of Catheter Ablation of Persistent and
Long-Standing Persistent AF
Persistent AF is quite heterogeneous regarding the patho-
physiological mechanisms responsible for electrical andstructural remodeling of the atria. In addition, persistent AF
itself is an independent predictor of recurrence, and catheter
ablation has reduced success compared with PAF.268 Success
rates vary according to the heterogeneity of the patient pop-
ulation and ablation strategies that are encompassed under
the umbrella “non-PAF.” It is now increasingly well recog-
nized that the duration of continuous AF is an important pre-
dictor of the efﬁcacy of AF ablation. Patients with continuous
AF of 12 months or less duration are very different from pa-
tients who have been in continuous AF for years.
The quality and quantity of data concerning the outcomes
of AF ablation in patients with non-PAF, including both
persistent and long-standing persistent AF, is limited.529,
733,1015,1030 Table 7 shows the outcomes of four trials of cath-
eter ablation for persistent AF.245,733,1026,1030 Despite the
widespread performance of AF ablation on patients with
persistent AF, no ablation catheters have received FDA or
CE Mark labeling speciﬁcally for the indication of ablation
of persistent AF. One completed clinical trial was
performed with a goal of obtaining FDA labeling for
ablation of persistent AF using a novel, phased RF
multielectrode ablation system.733 In this study, patients
were randomized to ablation or to treatment with an alterna-
tive AAD or an increased dose of a previously ineffective
drug, and DC cardioversion. As expected, protocol-deﬁned
success was higher following ablation at 6 months (56% vs
26%). However, the study did not meet its prespeciﬁed safety
endpoint, partly due to the occurrence of 4 strokes (2.9% of
the patients randomized to ablation) that mainly occurred
during early experience with the ablation system. As a result,
this system has not been approved in the United States. There
have been a number of studies performed comparing ablation
strategies in patients with persistent AF. The largest was the
recently published STAR-AF trial.245 This well-performed
and adequately powered study randomized patients with
persistent AF to ablation with PVI alone, PVI alone plus
linear ablation, or PVI plus ablation of CFAEs. No difference
in efﬁcacy was observed, and there was a trend toward supe-
riority of PVI alone.
It is important to note, however, that several prospective
clinical trials are planned or have begun in an effort to obtain
FDA labeling for the use of point-by-point RF ablation and
cryoablation. Both these trials have chosen to enroll patients
with early persistent AF (and to exclude patients with long-
standing persistent AF) and to employ OPC. In addition to
these trials, there has been one small, prospective, random-
ized clinical trial that compared the outcomes of ablation
with AAD therapy in 146 patients with persistent AF. The ef-
ﬁcacy of AF ablation in this study was superior to AAD ther-
apy.1030
The writing group recommendations for techniques to be
used for ablation of persistent and long-standing persistent
AF are shown in Table 3. PVI remains the cornerstone of
all AF ablation procedures and is recommended. Several
new ablation strategies are being explored for use in patients
with persistent AF. These approaches include mapping and
ablation of rotational activity, ablation of areas of low
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ﬁbrosis, ablation of non-PV triggers, as well as LAA focal
ablation, isolation, and/or ligation. Each of these techniques
is described elsewhere in this document.
In this regard, there is considerable debate as to which of
these techniques, if any, should be employed during an initial
or repeat AF ablation procedure in patients with long-
standing persistent AF. An important study was a report of
the 5-year outcomes of the “stepwise” approach to AF abla-
tion515 The single-procedure efﬁcacy of this approach at 1
year was 35%, falling to 17% at year 5. With repeated pro-
cedures, the arrhythmia-free survival after the last procedure
at the 5-year follow-up was 63%. These and other trials are an
important reminder that new ablation strategies should not be
widely adopted into routine clinical practice until the safety,
efﬁcacy, and true clinical value of these new strategies have
been demonstrated in well-designed and adequately powered
prospective randomized clinical trials. As a result of these
and other studies, use of the stepwise ablation strategy,
empiric linear ablation, and ablation of CFAEs are much
less commonly performed today than in the past, when this
was a popular ablation strategy for patients with persistent
AF.Outcomes of AF Ablation in Elderly Patients
Several studies have been published describing the outcomes
of AF ablation in elderly patients. One study compared the
safety and efﬁcacy of catheter ablation in three groups of pa-
tients:,65 years, 65–74 years, and75 years. Although the
total study population included 1165 patients, the group75
years only included 32 patients. Over a mean follow-up of 27
months, AF control deﬁned as no AF on or off AADs or
“rare” AFwas comparable in the older and younger patients.
The older patients were less likely to undergo repeat ablation
and were more likely to remain on AADs. Complication rates
were similar.1036 In another study of 174 patients.75 years,
55% of whom had PAF, 127 (73%) maintained sinus rhythm
after a single procedure, with an acute major complication
rate of 1%.1037 Another study evaluated catheter ablation
for AF in 103 octogenarians with paroxysmal, persistent, or
long-standing persistent AF compared with patients ,80
years.399,400,401 The proportion of patients with the
different types of AF was similar in both groups. A higher
rate of non-PV triggers (84% vs 69%, P 5 .001) was found
in the octogenarians. After a mean follow-up of 18 6 6
months, 71 (69%) of the octogenarians remained free from
AF off AADs after a single procedure vs 71% in patients
,80 years (P 5 NS). Complication rates did not differ be-
tween the two groups. Other studies of octogenarians have
found similar results.398,1038
In a retrospective cohort study involving Medicare claims
for 15,423 patients who underwent ablation procedures asso-
ciated with a primary diagnosis of AF, it was found that
advanced age was a major risk factor for all adverse out-
comes. However, the overall rate of adverse outcomes was
fairly small. Only 11% of patients underwent a second abla-tion procedure by 1 year after the index procedure, a low rate
that has been observed in other studies.1039 In another anal-
ysis of a large commercial claims database, acute complica-
tions in patients over and under the age of 65 years were
nearly identical.1040 Although comparable rates of periproce-
dural strokes have generally been found, late stroke might be
more common in older patients.1041
In general, studies have shown similar success rates with
catheter ablation for AF in older patients compared with
younger patients, with comparable complication rates. How-
ever, the small number of elderly patients in most studies
compared with the much greater prevalence of AF in the
elderly indicates that ablation is being performed in a highly
selected group of older patients. A consistent ﬁnding is that
older patients are less likely to undergo a second procedure
if the index procedure fails to eliminate the arrhythmia. The
recommendations for AF ablation in elderly patients are
shown in Table 2.Outcomes of AF Ablation in Patients with
Congestive Heart Failure and the Impact of
Ablation on Left Ventricular Function
A number of clinical trials have examined the role of catheter
ablation of AF in patients with HF. The initial study to
address this important topic was published in 2004.232,1042
This study examined the role of catheter ablation in 58
patients with HF with an EF of less than 45% and 58
controls. During a mean follow-up of 12 6 7 months, 78%
of patients with HF and 84% of controls remained in sinus
rhythm. Of particular note is that the EF improved by 21%
6 13%. Improvements also were seen in exercise capacity
and in QOL. Another study is the Pulmonary Vein Antrum
Isolation versus AV Node Ablation with Bi-Ventricular Pac-
ing for Treatment of AF in Patients with Congestive Heart
Failure (PABA-CHF) study that compared the efﬁcacy of
AF ablation with AV node ablation and pacemaker implanta-
tion.235 The primary endpoint of this prospective, multicenter
clinical trial was a composite of EF, distance on a 6-minute
walk, and Minnesota Living with Heart Failure (MLWHF)
questionnaire score after a 6-month follow-up. This study
demonstrated an overall superiority of PVI to AV node abla-
tion and pacing given by a lower score on the MLWHF ques-
tionnaire (60 vs 82), longer walking distance (340 m vs 297
m), and higher EF (35% vs 28%). A third case-controlled se-
ries reported that the efﬁcacy of AF ablation was similar in
patients with and without LV systolic dysfunction and re-
ported an improvement in EF at the 6-month follow-up.388
Since publication of the last consensus document, four addi-
tional prospective randomized clinical trials have been pub-
lished focusing on the outcomes of AF ablation in patients
with HF.236,237,390,529 The ﬁrst three were included in a
recent meta-analysis.392 The meta-analysis reported data
from 4 randomized trials involving a total of 224 patients,
83% of whom had persistent AF. AF ablation was associated
with an increase in LVEF of 8.5% compared with rate con-
trol. AF ablation was also superior in improving QOL as
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tance. Major adverse events were not signiﬁcantly different.
The most recent trial randomized patients with persistent AF
and HF (Ablation vs Amiodarone for Treatment of Atrial
Fibrillation in Patients With Congestive Heart Failure and
an Implanted ICD/CRTD [AATAC] trial) to AF ablation or
treatment with amiodarone. Catheter ablation was more
effective than amiodarone in preventing recurrent AF (70%
after a mean of 1.4 procedures vs 34%) and was associated
with a lower rate of unplanned hospitalization.529 Taken as
a whole, the results of these studies suggest that catheter abla-
tion of AF is safe and effective in selected patients with HF.
As compared with rate control alone, catheter ablation results
in a greater improvement in EF. The recommendations for
AF ablation in patients with HF are shown in Table 2.Outcomes of AF Ablation in Patients with
Hypertrophic Cardiomyopathy
AF is a commonly reported complication of hypertrophic car-
diomyopathy (HCM) with a prevalence and annual incidence
of 22.5% and 3.1%, respectively.1043 The substrate for AF is
complex and determined by atrial ﬁbrosis, atrial dilatation, or
intrinsic atrial myopathy. In patients with HCM, develop-
ment of AF is associated with marked exacerbation of symp-
toms, increased risk of stroke, and excess HCM-related
mortality.1043
Due to the association of AF with HCM-related morbidity
and mortality, there is general agreement that vigorous main-
tenance of sinus rhythm should be attempted.273,274
Randomized data regarding the efﬁcacy of AADs are not
available for patients with HCM; in daily practice,
however, drugs are frequently ineffective in eliminating AF
recurrence. In addition, the efﬁcacy and safety of catheter
ablation in the setting of HCM is poorly characterized, with
studies in small patient cohorts, observational in nature,
and providing contradictory results. A recent systematic
review and meta-analysis of these studies aimed to determine
the efﬁcacy and safety of catheter ablation of AF in patients
with HCM.1044 Single-procedure success (freedom from AF
or AT recurrence) was 38.7% in patients with HCM (vs
49.8% in controls; OR 2.25; 95% CI 1.09–4.64; P 5 .03).
Outcome after 1 procedure amounted to 51.8% (vs 71.2%
in controls; OR 2.62; 95% CI 1.52–4.51, P5 .0006). Repeat
procedures (mean difference 5 0.16; 95% CI 0.0–0.32, P 5
.05) and AADs (OR 4.70; 95% CI 2.31–9.55, P ,.0001)
were more frequently needed in patients with HCM. Sensi-
tivity analyses suggested that the outcome in patients with
HCM with less dilated atria and PAF might be more compa-
rable to the general population. Overall, the risk of
procedure-related adverse events was low. In summary,
even though the likelihood of recurrence is twofold higher,
catheter ablation can be effective in patients with HCM and
AF, particularly in patients with PAF and smaller atria. The
recommendations for AF ablation in patients with HF are
shown in Table 2.Outcomes of AF Ablation in Young Patients
As an age-related condition, AF is uncommon in young
adults. However, younger patients with AF are often highly
symptomatic and might have a desire to avoid long-term
medical therapy, making catheter ablation a potentially
attractive treatment option.
Limited information is available regarding the outcomes
of AF ablation in unusually young patients. At least two
single-center studies and one multicenter study have reported
on the outcomes of AF ablation in unusually young pa-
tients.405,1045 Two of these three studies deﬁned young
ablation patients as those under the age of 45 years; the
other reported on outcomes of AF ablation for lone AF,
deﬁned as age ,65 with no cardiac, pulmonary, or
structural heart disease (mean age 45).
In a 2010 single-center study, 232 patients under age 45
were identiﬁed from an overall ablation cohort.405 The au-
thors reported that younger patients had lower rates of major
complications compared with more typically aged AF abla-
tion patients. The rate of the author-deﬁned primary outcome
of AF controlwas similar across age groups, but a higher pro-
portion of young patients (76%) were AF-free in the absence
of AADs after 1 or more ablation procedures than older pa-
tients (from 53%–68%). A 2016 single-center study reported
on ablation outcomes in 76 patients with lone AF (9% of their
overall ablation population). Freedom from atrial arrhythmia
after one procedure was 74%, whereas freedom from atrial
arrhythmia after the last procedure without AADs was
96%. The largest study on AF ablation in younger patients
was a multicenter German registry in which 593 patients
aged 45 years were compared with 6650 patients aged
.45 years. In this study, the younger patients had lower rates
of complication, shorter hospital stays, and lower rates of AF
recurrence and AAD than older patients. Together, these
studies suggest that AF ablation might be both safer and
more effective in younger patients compared with “average”
or older AF patients, although this result could be due in part
to a lower burden of cardiac and noncardiac comorbid dis-
eases. It has been suggested that AF ablation might more
readily be considered ﬁrst-line rhythm control therapy in
younger rather than older patients; however the evidence
base for making such a recommendation is not strong. The
recommendations for AF ablation in young patients are
shown in Table 2.Outcomes of AF Ablation in Women
Multiple studies have found that women are more symptom-
atic from AF, have a lower QOL, and are less tolerant of
AADs than men.806,1046,1047,1048,1049 However, the rate of
referral of women for catheter ablation of AF is
signiﬁcantly lower than men, and women are referred much
later after failing more AADs.920 There has not been consis-
tent evidence to support female sex as a predictor of recur-
rence after AF ablation, based on multiple univariate and
multivariate analyses.252,1050,1051 A systematic review of
predictors of AF recurrence after catheter ablation reported
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of recurrence.1050
At least four major studies have speciﬁcally examined out-
comes after ablation of AF in women. A large, retrospective
multicenter study involved 3265 consecutive patients with
drug-refractory AF who underwent PVI.289,290,291 Women
constituted a much lower percentage of the patients
referred for ablation, were referred later for ablation, had
failed more AADs, more often had hypertension, and were
older at the time of the procedure. After 24 6 16 months of
follow-up, the women had signiﬁcantly lower success rates
than the men, deﬁned as single-procedure freedom from
recurrent AF off AADs (68.5 vs 77.5%; P ,.001). Another
study also found a lower success rate in women after a single
catheter ablation procedure (35.6% in women vs 57.1% in
men; P5 .003); however, once repeat procedures were taken
into account, there was no signiﬁcant difference in
outcome.1052
Other studies have not shown a difference in outcomes be-
tween men and women.1053,1054 Most recently, a large-scale
prospective analysis of sex-related differences in catheter
ablation of AF that enrolled 1124 patients with PAF was re-
ported from Japan.1054 After a mean follow-up of 31.7 6
24.4 months following the index ablation, there was no sig-
niﬁcant difference in success rates or complication rates be-
tween women and men.
Sex-related recurrence rates have been reported as nonpri-
mary end points in at least 17 other studies, most of which did
not reveal signiﬁcant sex-related differences.1055
Female sex has been reported as a predictor of complica-
tions after AF ablation, and higher complication rates from
AF ablation in women have repeatedly been found.252,289,
290,291,806,808,920,1050,1051,1052,1053,1054,1056,1057,1058,1059 A
multicenter U.S. retrospective study reported total
complications of 3265 (518 in women vs 2747 in men),
with a 5% complication rate in women vs 2.4% in men (P
,.001). This study found more hematomas and
pseudoaneurysms in women.289,290,291 A large multicenter
registry from Italy that enrolled 2323 patients also reported
a signiﬁcantly higher complication rate in women (7% vs
4.4%), and female sex was reported to be an independent
predictor of a higher risk of complications by univariate
analysis (OR 2.643; 95% CI 1.686–4.143; P ,.0001).1059
Overall, studies have not shown a signiﬁcant sex-related
difference in outcomes with AF ablation in women compared
with men, but complication rates are consistently higher in
women.Outcomes of Cryoballoon Ablation
Within the past 10 years, CB-based catheter ablation has
emerged as an alternative technique to RF ablation for the
treatment of patients with symptomatic AF, especially for
those with PAF. This change is not only related to the simpli-
ﬁed handling of the cryoablation catheter when compared
with point-by-point RF ablation, but also to technological de-
velopments and the steadily increasing number of clinical tri-als consistently reporting an overall comparable efﬁcacy to
RF ablation. It is important to note that, as in the whole ﬁeld
of AF ablation, the reported efﬁcacy outcomes must be inter-
preted with caution due to differences in the intensity of
follow-up and endpoint deﬁnitions.
In 2012, the second-generation CB was introduced. A
modiﬁed refrigerant injection system allows for a more uni-
form cooling across the distal balloon hemisphere.489,691,
692,1060,1061,1062,1063,1064,1065
Since the 2012 update of this consensus paper, multiple
randomized and nonrandomized studies including a large-
scale registry have been published that compared CBA
against point-by-point RF ablation with respect to rhythm
outcome in patients with PAF.490,492,493,695,696,1066,1067,1068,
1069,1070,1071,1072 The majority of these studies revealed that
CBA was similarly effective in the prevention of
arrhythmia recurrences, with arrhythmia-free survival
ranging from 54% to 85% in patients undergoing cryoabla-
tion and from 55% to 88% in patients undergoing RF ablation
after 1 to 2 years of follow-up. In particular, there was no dif-
ference in efﬁcacy when the second-generation CB was
compared with advanced-generation RF catheters featuring
CF measurements for improved wall contact.1068,1070
In the FREEZE-AF study, 315 patients with PAF were
randomized to open irrigated radiofrequency ablation or
CBA for PVI.1069 Cryoablation was exclusively performed
with the ﬁrst-generation CB catheter. The primary endpoint
was freedom from atrial arrhythmia recurrence with absence
of persistent complications. At 12 months, the primary
endpoint was met by 70.7% of the patients in the RF ablation
group and by 73.6% of the patients in the cryoablation group
after at least one ablation procedure with similar rates of redo
procedures in both groups (19.5% vs 19.9%). Periprocedural
complications occurred more frequently in the cryoablation
group compared with the RF ablation group (12.2% vs
5.0%), which was largely driven by 9 transient PN injuries
(5.8%) in the cryoablation arm.
The most robust data are provided by the FIRE AND ICE
trial that, to date, is the largest randomized trial comparing
both technologies in patients with symptomatic drug-
refractory PAF.490 In this multicenter trial, 762 patients
were randomly assigned to undergo PVI by open irrigated
RF (approximately one-fourth with CF) or by CBA (approx-
imately three-fourths with CB-2). The primary efﬁcacy
endpoint was deﬁned as ﬁrst documented clinical failure, a
composite of recurrent AF, occurrence of AFL or AT,
AAD use, or repeat ablation. After a mean follow-up of 1.5
years, CBA was noninferior to RF ablation with regard to ef-
ﬁcacy, with the primary endpoint occurring in 34.6% and
35.9% of patients in the cryoablation group and in the RF
ablation group, respectively. There was no statistically signif-
icant difference in the primary safety endpoint: a composite
of death, cerebrovascular events, and serious treatment-
related adverse events (10.2% vs 12.8% for cryoablation vs
RF ablation, respectively). There were 10 PN injuries
(2.7%) in the cryoablation group, with nine of these injuries
resolving by 6 months after ablation. Thus, the incidence of
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ported that the patients who underwent CBA had fewer repeat
AF ablation procedures, direct current cardioversions, all-
cause hospitalizations, and cardiovascular hospitalizations
during follow-up compared with the group randomized to
RF ablation.489 Limitations of this subsequent analysis,
which need to be considered when interpreting the results,
included the inclusion of nonprespeciﬁed endpoints, as
well the fact that this analysis was industry sponsored.
The role of cryoablation in patients with persistent AF is less
well established. To date, data are predominantly derived from
relatively small, noncontrolled trials and mostly reﬂect a single-
center experience.486,1073,1074,1075,1076,1077 Overall,
cryoablation appears to be associated with a favorable long-
term outcome in patients with persistent AF, with arrhythmia-
free survival ranging from 56% to 82%. In one non-
randomized study, arrhythmia-free survival off AADs was
similar when cryoablation was compared with RF ablation at
1-year follow-up after a single procedure (60% vs 50%).1078
Preliminary results from a single-center study demonstrated
the feasibility of extra-PV CBA in patients with long-standing
persistent AF.1077 Future prospective randomized trials are
needed to more precisely deﬁne the role of CBA in patients
with persistent and long-term persistent AF.Outcome of Rotational Activity Ablation for AF
Several studies have used phase mapping techniques to
identify the rotational activity in patients with AF. Further-
more, catheter ablation of AF guided by phase mapping
targeting rotational activity has been found to be effective
at eliminating AF in some reports. However, the preva-
lence of rotational activity and the outcome of rotational
activity ablation have varied widely, and long-term out-
comes of rotational activity ablation are still lacking. An
early investigator used the 64-pole basket catheter to
map rotational activity in patients with paroxysmal or
persistent AF, and found a high prevalence of rotational
activity; application of RF energy on the rotational activity
eliminated AF in more than 90% of the patients.563 A more
recent study reported favorable results when using an abla-
tion strategy that combined PVI and ablation or rotational
activity in patients with non-PAF. However, another inves-
tigator1079 used the same mapping tool and techniques for
AF ablation and identiﬁed rotational activity in less than
20% of AF patients.569 Other investigators could not
reproduce a high percentage of rotational activity in pa-
tients with AF and found disappointing results with rota-
tional activity-based ablation.1080 Another investigator
used the body-surface high-density mapping technique
and identiﬁed reentrant drivers in 80.5% of paroxysmal
and persistent patients with AF, and AF was eliminated
in 75% of the AF with reentry drivers.222 In another study,
high-density activation mapping identiﬁed rotational
activity in 15% of the patients with persistent AF.224
Although the Non-Invasive Mapping of Atrial Fibrillation
(AFACART) study also showed an 80% success rate interminating AF, the long-term success rate for eliminating
AF was signiﬁcantly less. However, the duodecapolar
mapping catheter with phase mapping identiﬁed rotational
activity in 65% of persistent AF and long-term persistent
AF; application of RF energy on these areas of rotational
activity after PVI rendered 65% of the AF free (mean
follow-up 18 months).497 Although the application of
phase mapping facilitates identiﬁcation of rotational activ-
ity, conventional activation mapping might not see rota-
tional activity clearly. Due to the controversy around the
various ablation techniques for persistent and long-term
persistent AF, the prevalence and outcome of rotational ac-
tivity ablations need further investigation.1081Outcomes of Laser Balloon Ablation
Visually guided PVI using the laser balloon is a recently
developed technology. It was ﬁrst introduced in Europe
and was approved in the United States in 2016. Since
2010, there have been a number of publications describing
its use.497,498,499,501,502,503,1082,1083,1084,1085 The number of
patients included in these studies has ranged from 50 to
200.498,1084 The patients in all these studies had PAF,
except for one study that included patients with persistent
AF.1085
The laser balloon is highly effective in achieving PVI. The
rate of acute PVI ranged from 98% to 100%.498,501,502
Remapping studies also demonstrated a highly durable rate
of isolation of the PVs using this technology.503 The freedom
from AF at follow-up ranged from 60% to 88%, which is
comparable to the outcome of PVI using RF energy in similar
populations.503,1085 The patients in all the published studies
were followed for at least 12 months.
The laser beam positioning during PVI is executed under
direct visualization. However, manipulating the catheter in
the LA is guided by X-ray imaging. The ﬂuoroscopy time
for laser balloon PVI has been reported to range between
13 and 36 minutes, with a total procedure time range of 2–
4 hours.498,1082
The FDA-reviewed HeartLight study was a prospective,
multicenter randomized trial comparing laser balloon PVI
with conventional RF ablation.503,1082 The 1-year success
rate of the laser balloon did not differ from ablation with
the ThermoCool System (61.1% vs 61.7%, respectively).
The rates of stroke (1.2%) and tamponade (1.2%) were
similar to RF ablation. Diaphragmatic paralysis secondary
to PN injury occurred in 3.6% of the patients with the laser
balloon, which was more common than with RF ablation.
Persistent PN paralysis at 1 year occurred in 1.8% of patients.
PV stenosis was observed only in patients randomized to RF
ablation (2.9%). There were no deaths or AEFs in the study.
This ablation system is now approved for clinical use in Eu-
rope and the United States.Long-Term Ablation Efﬁcacy
During the past decade, a large number of studies have been
published that have examined the important issue of the
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clinical studies presented data from short-term follow-ups,
often less than 12 months in duration. The ﬁrst of these
studies was published 5 years ago and described the long-
term outcomes of a series of 264 patients who were AF-
free and off AAD therapy at the 12-month point following
an initial ablation procedure.284 During a mean follow-up
of 28 6 12 months, AF recurred in 23 patients (8.7%).
The actuarial recurrence rate of AF at 5 years was 25.5%.
Similar ﬁndings have been reported in each of the subse-
quent trials.266,267,268,1022,1086,1087 The predictors of late
recurrence most commonly identiﬁed include persistent
AF as well as comorbid conditions. Despite the low
single-procedure, long-term success rate reported in virtu-
ally all of these clinical trials, they also reveal that with
the use of repeat AF ablation procedures and/or AAD ther-
apy, much higher rates of freedom from recurrent AF as well
as concomitant reductions in AF burden can be achieved.Impact of Catheter Ablation of AF on QOL
Because symptomatic improvement is a primary objective in
the treatment of patients with AF, formal assessments of
QOL have played an increasingly important role in the eval-
uation of ablation outcomes.47,63,1088 These measures can
provide a more global reﬂection of symptom change,
symptomatic arrhythmia burden, and the difference
between actual and desired health and function than more
focused endpoints of rhythm status at speciﬁc points in
time. Generic tools, such as the SF-36 health survey,1089
which is applicable to a broad range of disease states and
health conditions, and disease-speciﬁc questionnaires1090,
1091 developed to assess symptom burden in patients with
arrhythmias, have been most widely employed.
Patients with AF, as reﬂected by standardized SF-36
scores, have substantially impaired QOL, below population
norms and comparable to patients with coronary artery dis-
ease and congestive HF.47,1088,1092 A number of single-
center, nonrandomized observational studies of AF ablation
have demonstrated signiﬁcant and sustained improvements
in QOL scores following catheter ablation.63,1088 Taken
alone, these ﬁndings need to be interpreted cautiously,
because in the absence of a comparison group or treatment
blinding, placebo effects cannot be excluded. Two studies
demonstrated that over a 12-month period following treat-
ment, changes in QOL scores were strongly related to the
presence or absence of documented AF recurrence within
the previous 30 days.1093,1094
More important are the results of randomized clinical tri-
als that compared catheter ablation with AAD therapy in pa-
tients with PAF, and evaluated QOL as an outcome
measure.261,377,378,379,684 Investigating catheter ablation as
second-line therapy after failed AAD treatment, catheter
ablation was associated with signiﬁcant improvements in
SF-36 scores relative to baseline, with restoration to levels
at or above population norms.261,684 QOL scores were
signiﬁcantly higher for patients treated with catheterablation than for patients treated with drug therapy, in
whom there was little change from baseline scores.
In the three trials investigating catheter ablation as ﬁrst-
line therapy for AF, QOL improved with both AAD treat-
ment and catheter ablation, and signiﬁcantly more with cath-
eter ablation, using the SF-36,377,378,1091 or 4312 EQ-5D379
instruments (EuroQOL ﬁve dimensions questionnaire).
A recent meta-analysis included data from 12 RCTs
comparing catheter ablation (as ﬁrst- or second-line therapy)
and AAD treatment, and including a total of 1707 patients
with symptomatic AF. In this analysis, catheter ablation led
to greater improvements in several areas of the SF-36 ques-
tionnaire and in the symptom frequency score from baseline
to 3 months follow-up. However, for all QOL metrics as well
as for symptom frequency and severity scores, the differences
between catheter ablation and AAD treatment diminished
with increasing duration of follow-up, and no signiﬁcant dif-
ferences remained beyond 9 months of follow-up.1032 In the
randomized trials, an impact of crossover from AAD treat-
ment to catheter ablation cannot be excluded. However, in
an on-treatment analysis of data from a randomized trial
comparing catheter ablation and AAD treatment as ﬁrst-
line therapy, no differences in QOL were observed between
patients treated with catheter ablation, patients treated with
AADs, and patients treated with a combination of both.494
Concerns have been raised that generic QOL instruments
such as SF-36 are not sufﬁciently sensitive or focused to detect
changes in disease-speciﬁc symptoms such as those associated
withAF.63,974 AF-speciﬁcQOLmeasures, including theAFEf-
fect on QOL (AFEQT) questionnaire,1095 the Mayo AF Symp-
tom Inventories,63 and the Arrhythmia-Speciﬁc questionnaire
in Tachycardia and Arrhythmia (ASTA),1096 have been devel-
oped and are in the process of validation. A recent study re-
ported that disease-speciﬁc assessments of QOL are superior
to generic questionnaires.1097 Preliminary ﬁndings indicate
that these tools also demonstrate substantial improvements in
QOL with ablation, and can more accurately reﬂect ablation ef-
ﬁcacy. However, there is currently no general agreement that
any of the AF-speciﬁc QOL instruments are superior to others
or to the general QOL instruments. The use of QOL measures
will be discussed further in the section.Impact of Catheter Ablation of AF on LA Size and
Function
Experimental and clinical research has demonstrated that
in some settings AF results in, or is accompanied by,
electrical, structural, and functional remodeling of the
atrium.14,587,1098,1099 The results of a subset of these studies
suggest that AF can be viewed, in some patients, as a rate-
related atrial cardiomyopathy. As discussed elsewhere in
the document, AF can also follow and be the consequence
of prior atrial damage and ﬁbrosis (atrial myopathy). To the
extent that rate-related cardiomyopathies lead to reversible
chamber dilatation and dysfunction, it was anticipated that
reverse remodeling might also occur in a subset of patients
who underwent AF catheter ablation.
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catheter ablation.437,1100,1101,1102 These studies have
demonstrated a signiﬁcant decrease in the size of the LA
after PVI of PAF, regardless of whether echocardiography,
MRI, or CT was used for LA imaging. The reverse
remodeling of LA was more pronounced when sinus
rhythm had been successfully restored.1103 Although the pre-
cise mechanism of this decrease in size is not clear, it appears
consistent with reverse remodeling due to the decreased
burden of AF and scar formation from the ablation procedure.
The impact of catheter ablation of AF on LA transport
function was investigated in patients with paroxysmal and
persistent AF, with conﬂicting results.1104,1105 A meta-
analysis showed a signiﬁcant decrease in LA volume but
did not ﬁnd signiﬁcant changes in active LA function,
including studies with persistent as well as PAF ablation pro-
cedures.1106 However, because AF eliminates essentially
all contractility of the LA, there is general agreement
that restoration of sinus rhythm in patients with
persistent AF improves atrial function if sinus rhythm is
maintained.391,1107,1108,1109
However, ablation-related scarring with the risk of
causing persistent atrial dysfunction still remains a major
concern after extensive ablation for persistent AF. The
long-term outcome after stepwise approach for persistent
AF demonstrated the impaired contractility and compliance
of LA, which was related to scar burden.1110 Moreover, a
recent study has reported a series of patients who developed
LA diastolic dysfunction and pulmonary hypertension
following AF ablation.1111 The precise cause of “stiff LA
syndrome” or a “noncompliant LA” and methods to prevent
it will clearly be an area for further study going forward.Impact of Catheter Ablation on Stroke Risk
Conceptually, it appears logical that catheter ablation—by
elimination of or reductions in AF burden—lowers the risk
of stroke or TIA; initial reports from single-center, non-
randomized studies did demonstrate a relatively low rate of
stroke or TIA after catheter ablation.231,545 To date
however, there are no RCTs verifying the hypothesis that
ablation lowers the long-term incidence of stroke or TIA.
Please refer to Section 7 for a more detailed discussion of
the recommendations made by the writing group for long-
term anticoagulation post-AF ablation.
Indirect evidence stems from four large, health adminis-
trative databases using propensity-score matching to create
a “control” population and to even out differences between
patient groups.239,1112,1113,1114 In a very large, prospectively
collected registry (the Intermountain Healthcare Database in
Utah), investigators reported a signiﬁcantly lower rate of
stroke in 4212 ablated patients (follow-up 3.1 6 2.4
years), compared with those who did not undergo
ablation.239 Moreover, ablated patients had comparable
stroke rates when compared with age- and sex-matched pa-
tients who did not have a history of AF. Both observations
were independent of baseline stroke risk score. Anotherpropensity score-matched analysis of medically treated
and ablated patients within the U.S. MarketScan Research
Database (n 5 805 in each group with follow-up of up to
3 years), showed that AF ablation was associated with a
reduced risk of stroke or TIA compared with AAD therapy
(HR 0.62; 95% CI 0.44–0.86, P 5 .005).1112 Similarly, data
from the Taiwanese national health insurance claims data-
base reported lower risk of stroke in 846 ablated patients
compared with the control group (HR 0.57; 95% CI 0.35–
0.94; P 5 .026).1113 Recently, a retrospective, propensity
score-matched analysis (using as many as 51 parameters)
of medically treated and ablated patients from Swedish
health registries (n 5 2836 in each group during a
follow-up period of 4.4 years) conﬁrmed that ablation was
associated with a lower incidence of ischemic stroke than
nonablated patients (HR 0.69; 95% CI 0.51–0.93; P 5
.016).1114 This association between ablation and stroke
was pronounced in patients with a CHA2DS2-VASc score
2 points, but was not discernible among patients with
low stroke risk.
Three other observational studies determined possible
predictors for stroke-free survival within the ablated patient
group.241,242,408 Multivariate analysis in 174 ablated
Taiwanese patients showed that ablation outcome was the
strongest independent predictor for survival free of major
adverse cardiovascular events, including stroke (HR 0.225;
95% CI 0.076–0.671; P5 .007).241 A Kaplan-Meier survival
analysis demonstrated that ablation-treated patients without
AF recurrence had a lower incidence of ischemic strokes
and TIAs (P 5 .015) compared with patients with AF recur-
rence or medically treated patients. Of interest, a retrospec-
tive analysis of 3058 ablated low-risk patients from a
single-center registry showed only a modest, non-
signiﬁcant reduction in the risk of cerebrovascular events in
patients who maintained sinus rhythm when compared with
those who had AF recurrence.242
The above studies suggest that catheter ablation can lower
the risk of stroke via maintenance of sinus rhythm. However
it is recognized that the retrospective nature of these studies
makes them prone to bias. The above studies are limited by
a lack of detailed data on rhythm and/or anticoagulation sta-
tus, selection bias (low stroke risk at baseline), relatively
short follow-up, and the extent to which patient groups can
be matched. Despite the fact that propensity score matching
was successful in creating a control population that was
similar to the ablated group, adjustment is only possible for
observable factors. Unknown confounding factors could ac-
count for why patients treated with ablation had lower rates
of stroke or TIA (post hoc ergo propter hoc). Bias of unmea-
sured variables can only be fully neutralized in RCTs.
Finally, it should be noted that some of the above studies
made comparisons to historical cohorts whose risk of stroke
appears to be much higher than the risk reported in recent
studies.
Therefore, the above ﬁndings cannot be viewed as deﬁn-
itive and do not provide sufﬁcient evidence that ablation re-
duces stroke risk. Instead, they reinforce the hypothesis
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which will provide more deﬁnitive evidence. However, the
results will not be available until 2018, and, as with most
long-term studies in ablation, their relevance could be chal-
lenged by the rapidly evolving nature of the ablation ﬁeld.Predictors of Success Following AF Ablation
A large number of studies have been performed to examine
clinical predictors of the efﬁcacy of AF ablation.328,329,365,
1050,1115,1116,1117 Factors that have been identiﬁed as
predictors of a poorer outcome, at least in some studies,
include (1) non-PAF and particularly long-term persistent
AF; (2) sleep apnea and obesity; (3) increased LA size; (4)
increased age; (5) hypertension; and (6) LA ﬁbrosis as de-
tected by cardiac MRI.365
A systematic review of predictors of AF recurrence after
AF ablation analyzed data from 45 studies, 25 of which
included a multivariable analysis of predictors of recur-
rence.1050 Among the 17 studies that examined AF type as
a predictor of recurrence, 11 studies reported no impact of
AF type on recurrence, whereas six studies reported that
the presence of non-PAF was an independent predictor of a
higher rate of recurrence (HR ranging from 1.8 to 22). Seven-
teen studies evaluated EF as a predictor of recurrence. Very
few patients in any of these studies had an EF less than
40%. Among these 17 studies, only ﬁve reported a signiﬁcant
association between lower EF and a higher rate of AF recur-
rence. Twenty studies examined LA diameter as a predictor
of AF recurrence. Very few patients in any study had LAD
.60 mm. Among these 20 studies, four reported a signiﬁcant
association between larger LAD and a higher rate of recur-
rence of AF. Among 21 studies that examined the presence
of structural heart disease as a predictor, only one reported
a signiﬁcant association at 12 months of follow-up. Most
studies examined sex, and no association between recurrence
and sex was found. Only one of 22 studies reported an inde-
pendent association between age and recurrence.Cost-Effectiveness of AF Ablation
The cost-effectiveness of AF ablation has been evaluated in a
number of individual studies and several systematic re-
views.1118,1119,1120,1121,1122,1123,1124,1125 The costs of AF
ablation procedures can vary widely, depending on the
treatment setting and the actual equipment used.409,1126
Estimates of the cost-effectiveness of AF ablation can vary
further based on a number of additional factors, including
the patient population, the severity of symptoms, the analytic
time horizon, and assumptions about the impact of AF abla-
tion on QOL, stroke, and other clinical outcomes. One issue
supporting the potential cost-effectiveness of AF ablation is
that the costs of ablation are at least partly offset over time
by reducing long-term, arrhythmia-related health care
resource utilization for patients not treated with ablation, as
supported by some empirical evidence.90,476,1033,1127
However, most formal cost-effectiveness studies have notfound AF ablation to be cost neutral or cost saving in the short
to intermediate term.
The majority of published cost-effectiveness studies have
compared AF ablation to AADs as second-line therapy in pa-
tients with PAF.1119,1120,1122,1124,1128,1129 In general, these
studies have reported acceptable cost-effectiveness ratios—
in the range of $27,000 to $59,000 (Canadian) per quality-
adjusted life year (QALY) gained over 5-year time hori-
zons.1122,1128 Results would be more favorable if ablation
were found to signiﬁcantly reduce the risk of stroke.1118
U.S. experts have recently indicated that cost-effectiveness
ratios below $50,000 per QALY indicate high value, and be-
tween $50 and $150,000 indicate intermediate value.1130
Less is known about the cost-effectiveness of ablation in
the ﬁrst-line setting or in patients with persistent or long-
term persistent AF. One report based on the First Line Radio-
frequency Ablation Versus Antiarrhythmic Drugs for Atrial
Fibrillation Treatment (RAAFT) pilot study suggested that
costs for patients initially treated with drugs would catch
up to those for patients treated with ablation within 2 years
due to a very high rate of crossover. However, another
more detailed cost-effectiveness study modeled after the
MANTRA-PAF trial population indicated that AF ablation
might only be cost-effective as ﬁrst-line therapy in younger
patients.1125
Assessments of cost-effectiveness at present rely greatly
on extrapolations from clinical trials with limited follow-up
duration and sample sizes, necessitating assumptions about
key clinical beneﬁts. Robust data from larger, longer studies
will be needed to reﬁne cost-effectiveness estimates.Section 10: Complications
Overview
Catheter ablation of AF is one of the most complex interven-
tional electrophysiological procedures. AF ablation by its na-
ture involves catheter manipulation and ablation in the
delicate thin-walled atria, which are in close proximity to
other important organs and structures that can be impacted
through collateral damage. It is therefore not surprising that
AF ablation is associated with a signiﬁcant risk of complica-
tions, some of which might result in life-long disability and/
or death. In this section of the document we will review the
complications associated with catheter ablation procedures
performed to treat AF. The complications are deﬁned and
their mechanisms explored. Emphasis is placed on both those
complications that occur most frequently as well as those
very infrequent complications that have the potential to result
in the greatest disability and/or death. Means of avoiding
complications are described and recommendations are
made regarding management should the complications occur.
It is noteworthy that the publications from which these
data are derived come from high-volume centers where one
would expect the incidence of complications to be lower
than in lower-volume centers. As the practice of AF ablation
grows with an increasing number of low-volume centers per-
forming these procedures, it is likely that the true
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described here. Furthermore, other data such as those derived
from the two worldwide surveys of catheter ablation of AF
were provided voluntarily and, again, are therefore likely to
underestimate the true complication rate.806,920 It is notable
that a recent paper reported on the trends in hospital
complication rates associated with AF ablation between
2000 and 2010 based on the Nationwide Inpatient Sample
involving 93,801 procedures.921 The overall incidence of
complications was 6.29%—increasing from 5.3% in 2000
to 7.5% in 2010. The in-hospital mortality was 0.46%. Not
surprisingly, lower operator and hospital procedure volume
was an important predictor of complications. These data
are a stark reminder that our efforts to eliminate complica-
tions associated with AF ablation are incomplete and there
is more work to do.
As our experience with AF ablation continues to grow,
new complications are recognized and are reviewed here.
These include stiff LA syndrome, cough, pulmonary injury,
gastric hypomotility, and sinus tachycardia. Once again, the
writing group strongly recommends that standardized report-
ing of complications be part of all published reports on AF
ablation. In this document, we have provided deﬁnitions of
the most important complications associated with AF abla-
tion (Table 8). We hope these deﬁnitions and reporting stan-
dards can be incorporated in the design of future clinical trials
of AF ablation. Shown in Table 9 is an overview of the inci-
dence, prevention, diagnosis, and management of selected
complications, and Table 5 presents signs and symptoms
associated with various complications early and late posta-
blation.Cardiac Tamponade
Cardiac tamponade remains the most common potentially
life-threatening complication associated with AF ablation.921
A recent paper reported on the trends in in-hospital complica-
tion rates associated with AF ablation between 2000 and
2010 based on the Nationwide Inpatient Sample involving
93,801 procedures.921 In this analysis, the overall incidence
of a “pericardial complication” was 1.5%. The incidence of
pericardial complications increased from 0.74% in 2000 to
2.24% in 2010.921 The markedly higher incidence of cardiac
tamponade during AF ablation compared with routine car-
diac electrophysiology procedures can be attributed to a num-
ber of important procedural differences, including extensive
intracardiac catheter manipulation and ablation, the common
need for two or more transseptal punctures, and the need for
systemic anticoagulation.806,920,921,1131,1132,1133,1134,1135 The
most common causes of cardiac perforation leading to
cardiac tamponade during AF ablation are (1) misdirected
transseptal punctures either with punctures performed too
posteriorly exiting the RA into the pericardium before
entering the LA or punctures exiting the LA via the roof,
LAA, or the lateral LA wall; (2) direct mechanical trauma,
especially through the LAA; and (3) overheating during RF
energy delivery, with or without the development of asteam pop. Excessive power, temperatures, and CF might
also be contributory.
The need for periprocedural anticoagulation (with the use
of interrupted or uninterrupted OAC strategies) and for intra-
procedural anticoagulation (with the infusion of intravenous
heparin to achieve a stable ACT above 300 seconds
throughout the procedure duration) can exacerbate the
bleeding risk and increase the volume of bleeding following
the occurrence of one or more of the causes above. One initial
large study reported that uninterrupted VKA anticoagulation
therapy did not result in a higher incidence of tamponade
compared with interrupted VKA anticoagulation therapy
with bridging heparin.532,533 This observation was further
corroborated by two meta-analyses.399,400,401,1136 Another
study compared the outcomes of 23 patients who
developed pericardial tamponade with an INR ,2 to 17
patients on warfarin with an INR .2. No difference was
observed in the initial pericardial drainage, or the duration
of drainage; no patients required surgery.1137 A more recent
shift in periprocedural anticoagulation strategies during AF
ablation involves performing AF ablation on uninterrupted
NOAC therapy. The results of the RE-CIRCUIT study,
which was a head-to-head comparison of performing AF
ablation on uninterrupted dabigatran vs uninterrupted
warfarin, were recently published.841 This study randomized
704 patients across 104 sites to these two anticoagulation
strategies. The incidence of major bleeding events during
and up to 8 weeks postablation among the 635 patients
who underwent AF ablation was signiﬁcantly lower with da-
bigatran than with warfarin (5 patients [1.6%] vs 22 patients
[6.9%]; absolute RD -5.3%; RR reduction 77%). It is notable
that there were six patients with cardiac tamponade in the
warfarin arm vs one in the dabigatran arm. All the patients
with cardiac tamponade underwent successful pericardio-
centesis with no need for surgical drainage. No strokes or
other thromboembolic events occurred in the dabigatran
arm compared with one TIA in the warfarin arm. No patients
in the dabigatran arm required the speciﬁc reversal agent idar-
ucizumab. Another smaller prospective trial of 250 patients
that randomized patients to undergoing AF ablation on unin-
terrupted rivaroxaban versus uninterrupted warfarin has been
published.842 The incidence of major bleeding was low
(0.4%), and no patient developed pericardial tamponade. A
recent meta-analysis reported that performance of AF abla-
tion on NOACs was associated with a lower risk of minor
bleeding and no major differences in the risk of stroke or
TIA, cardiac tamponade, or groin hematomas.1138 Another
recent study described the outcomes of 16 patients who
developed a pericardial effusion while taking an uninter-
rupted Xa inhibitor. Eleven occurred in the periprocedural
setting and 5 occurred between 1 and 28 days postprocedure.
All the patients underwent pericardiocentesis. Protamine and
4-factor prothrombin complex concentrate were given to all
periprocedure cases. Two patients required surgery. There
were no deaths in this series.
The incidence of tamponade might be as high as 6%1135
and as low as 0%. The risk factors for tamponade identiﬁed
Table 8 Deﬁnitions of complications associated with AF ablation
Asymptomatic cerebral
embolism
Asymptomatic cerebral embolism is deﬁned as an occlusion of a blood vessel in the brain due to an embolus that
does not result in any acute clinical symptoms. Silent cerebral embolism is generally detected using a
diffusion weighted MRI.
Atrioesophageal ﬁstula An atrioesophagealﬁstula is deﬁned as a connection between the atrium and the lumen of the esophagus. Evidence
supporting this diagnosis includes documentation of esophageal erosion combined with evidence of a ﬁstulous
connection to the atrium, such as air emboli, an embolic event, or direct observation at the time of surgical
repair. A CT scan or MRI scan is the most common method of documentation of an atrioesophageal ﬁstula.
Bleeding Bleeding is deﬁned as a major complication of AF ablation if it requires and/or is treated with transfusion or
results in a 20% or greater fall in hematocrit.
Bleeding following cardiac
surgery
Excessive bleeding following a surgical AF ablation procedure is deﬁned as bleeding requiring reoperation or2
units of PRBC transfusion within any 24 hours of the ﬁrst 7 days following the index procedure.
Cardiac perforation We recommend that cardiac perforation be deﬁned together with cardiac tamponade. See “Cardiac tamponade/
perforation.”
Cardiac tamponade We recommend that cardiac tamponade be deﬁned together with cardiac perforation. See “Cardiac tamponade/
perforation.”
Cardiac tamponade/
perforation
Cardiac tamponade/perforation is deﬁned as the development of a signiﬁcant pericardial effusion during or
within 30 days of undergoing an AF ablation procedure. A signiﬁcant pericardial effusion is one that results in
hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more
pericardial effusion as documented by echocardiography. Cardiac tamponade/perforation should also be
classiﬁed as “early” or “late” depending on whether it is diagnosed during or following initial discharge from
the hospital.
Deep sternal wound
infection/mediastinitis
following cardiac
surgery
Deep sternal wound infection/mediastinitis following cardiac surgery requires one of the following: (1) an
organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed during
surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (.38C), in combination
with either purulent discharge from the mediastinum or an organism isolated from blood culture or culture of
mediastinal drainage.
Esophageal injury Esophageal injury is deﬁned as an erosion, ulceration, or perforation of the esophagus. The method of screening
for esophageal injury should be speciﬁed. Esophageal injury can be a mild complication (erosion or ulceration)
or a major complication (perforation).
Gastric motility/pyloric
spasm disorders
Gastric motility/pyloric spasm disorder should be considered a major complication of AF ablation when it
prolongs or requires hospitalization, requires intervention, or results in late disability, such as weight loss,
early satiety, diarrhea, or GI disturbance.
Major complication A major complication is a complication that results in permanent injury or death, requires intervention for
treatment, or prolongs or requires hospitalization for more than 48 hours. Because early recurrences of AF/
AFL/AT are to be expected following AF ablation, recurrent AF/AFL/AT within 3 months that requires or
prolongs a patient’s hospitalization should not be considered to be a major complication of AF ablation.
Mediastinitis Mediastinitis is deﬁned as inﬂammation of the mediastinum. Diagnosis requires one of the following: (1) an
organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed during
surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (.38C), in combination
with either purulent discharge from the mediastinum or an organism isolated from blood culture or culture of
mediastinal drainage.
Myocardial infarction in
the context of AF
ablation
The universal deﬁnition of myocardial infarction1399 cannot be applied in the context of catheter or surgical AF
ablation procedures because it relies heavily on cardiac biomarkers (troponin and CPK), which are anticipated
to increase in all patients who undergo AF ablation as a result of the ablation of myocardial tissue. Similarly,
chest pain and other cardiac symptoms are difﬁcult to interpret in the context of AF ablation both because of
the required sedation and anesthesia and also because most patients experience chest pain following the
procedure as a result of the associated pericarditis that occurs following catheter ablation. We therefore
propose that a myocardial infarction, in the context of catheter or surgical ablation, be deﬁned as the
presence of any one of the following criteria: (1) detection of ECG changes indicative of new ischemia (new ST-
T wave changes or new LBBB) that persist for more than 1 hour; (2) development of new pathological Q waves
on an ECG; (3) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Pericarditis Pericarditis should be considered a major complication following ablation if it results in an effusion that leads to
hemodynamic compromise or requires pericardiocentesis, prolongs hospitalization by more than 48 hours,
requires hospitalization, or persists for more than 30 days following the ablation procedure.
Phrenic nerve paralysis Phrenic nerve paralysis is deﬁned as absent phrenic nerve function as assessed by a sniff test. A phrenic nerve
paralysis is considered to be permanent when it is documented to be present 12 months or longer following
ablation.
Pulmonary vein stenosis Pulmonary vein stenosis is deﬁned as a reduction of the diameter of a PV or PV branch. PV stenosis can be
categorized as mild,50%, moderate 50%–70%, and severe 70% reduction in the diameter of the PV or PV
branch. A severe PV stenosis should be considered a major complication of AF ablation.
Serious adverse device
effect
A serious adverse device effect is deﬁned as a serious adverse event that is attributed to use of a particular
device.
Stiff left atrial syndrome Stiff left atrial syndrome is a clinical syndrome deﬁned by the presence of signs of right heart failure in the
presence of preserved LV function, pulmonary hypertension (mean PA pressure.25 mm Hg or during exercise
.30 mm Hg), and large V waves10 mm Hg or higher) on PCWP or left atrial pressure tracings in the absence
of signiﬁcant mitral valve disease or PV stenosis.
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Table 8 (Continued )
Stroke or TIA postablation Stroke diagnostic criteria
 Rapid onset of a focal or global neurological deﬁcit with at least one of the following: change in level of
consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia
or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke
 Duration of a focal or global neurological deﬁcit24 hours; OR,24 hours if therapeutic intervention(s) were
performed (e.g., thrombolytic therapy or intracranial angioplasty); OR available neuroimaging documents a
new hemorrhage or infarct; OR the neurological deﬁcit results in death.
 No other readily identiﬁable nonstroke cause for the clinical presentation (e.g., brain tumor, trauma,
infection, hypoglycemia, peripheral lesion, pharmacological inﬂuences).^
 Conﬁrmation of the diagnosis by at least one of the following: neurology or neurosurgical specialist;
neuroimaging procedure (MRI or CT scan or cerebral angiography); lumbar puncture (i.e., spinal ﬂuid analysis
diagnostic of intracranial hemorrhage)
Stroke deﬁnitions
 Transient ischemic attack: new focal neurological deﬁcit with rapid symptom resolution (usually 1 to 2 hours),
always within 24 hours; neuroimaging without tissue injury
 Stroke: (diagnosis as above, preferably with positive neuroimaging study);
Minor—Modiﬁed Rankin score ,2 at 30 and 90 days†
Major—Modiﬁed Rankin score 2 at 30 and 90 days
Unanticipated adverse
device effect
Unanticipated adverse device effect is deﬁned as complication of an ablation procedure that has not been
previously known to be associated with catheter or surgical ablation procedures.
Vagal nerve injury Vagal nerve injury is deﬁned as injury to the vagal nerve that results in esophageal dysmotility or gastroparesis.
Vagal nerve injury is considered to be a major complication if it prolongs hospitalization, requires
hospitalization, or results in ongoing symptoms for more than 30 days following an ablation procedure.
Vascular access
complication
Vascular access complications include development of a hematoma, an AV ﬁstula, or a pseudoaneurysm. A major
vascular complication is deﬁned as one that requires intervention, such as surgical repair or transfusion,
prolongs the hospital stay, or requires hospital admission.
AF 5 atrial ﬁbrillation; CT 5 computed tomography; MRI 5 magnetic resonance imaging; PRBC 5 packed red blood cell; AFL 5 atrial ﬂutter; AT 5 atrial
tachycardia; CPK 5 creatine phosphokinase; ECG 5 electrocardiogram; LBBB 5 left bundle branch block.
^Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal evidence based on neuroimaging studies.
†Modiﬁed Rankin score assessments should be made by qualiﬁed individuals according to a certiﬁcation process. If there is discordance between the 30- and 90-day
modiﬁed Rankin scores, a ﬁnal determination of major versus minor stroke will be adjudicated by the neurology members of the clinical events committee.
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power. A “pop” was heard during eight of these 10 cases of
tamponade. Another large series reported cardiac tamponade
during 15 of 632 ablation procedures (2.4%).1134 Two of
these patients required surgical intervention. In contrast to
the prior study, no “pop” was reported. The two worldwide
surveys of AF ablation reported a 1.2% and a 1.3% incidence
of cardiac tamponade, respectively.806,920 A recent meta-
analysis of ablation procedures reported a 0.9% incidence
of tamponade.1139 Women were 1.83-fold more likely to
develop tamponade compared with men. A reciprocal rela-
tionship between center volume and the incidence of out-
comes of cardiac tamponade was observed. Overall, 16%
of tamponade cases required surgery, with lower rates of sur-
gery in high-volume centers.1139 A meta-analysis of CBA
with data on 1308 procedures reported an overall incidence
of cardiac effusion or tamponade of 1.5%.482 A more recent
prospective RCT of CBA vs RF ablation reported an inci-
dence of tamponade of 1.3% in the RF arm and of 0.3% in
the CB arm.489 Although it was hoped the recent introduction
of force-sensing catheters would reduce the rate of tampo-
nade, this has not been conﬁrmed in clinical trials. The inci-
dence of cardiac tamponade was 2.5% among 161 patients in
the safety cohort of the recently published SMART-AF trial
of the Smart Touch catheter.673 And in the TOCCASTAR
trial, which randomized patients to ablation with a force-sensing catheter (Endosense) or a standard irrigated RF cath-
eter, no difference in the incidence of cardiac tamponade was
observed in the two arms (0.66% vs 0.7%, P 5 NS).655 It is
important to recognize that the presentation of cardiac tampo-
nade might be delayed and can occur any time from an hour
after the procedure to weeks later.1034,1139 The incidence of
delayed tamponade was 0.2% in the worldwide survey
report.1034 Most, but not all, patients presented with warning
symptoms and 13% of patients presented with hypotension
and shock.
Cardiac tamponade presents either as an abrupt dramatic
fall in BP, or more insidiously, as a gradual decrease in BP.
In the latter case, administration of ﬂuid might return the
BP to normal before it subsequently declines. However, it
is vital that operators and staff be vigilant to the development
of cardiac tamponade, as a delay in diagnosis can be fatal.
Sixty percent of the writing group members use an arterial
line for BP monitoring during the AF ablation procedure.
The development of hypotension in any patient should be
assumed to indicate tamponade until proven otherwise by im-
mediate ECG. An early sign of cardiac tamponade is a reduc-
tion in the excursion of the cardiac silhouette on ﬂuoroscopy
with a simultaneous fall in systemic BP. Ninety percent of the
writing group members have an echomachine in their EP lab-
oratory. Sixty percent of the writing groupmembers routinely
image the heart with an echocardiogram prior to the patient
Table 9 Incidence, prevention, diagnosis, and treatment of selected complications of AF ablation
Complication Incidence Selected prevention techniques Diagnostic testing Selected treatment options References
Air embolism ,1% Sheath management Nothing or cardiac
catheterization
Supportive care with ﬂuid, oxygen,
head down tilt, hyperbaric
oxygen
803,1218–1223
Asymptomatic cerebral
emboli (ACE)
2% to 15% Anticoagulation, catheter and
sheath management, TEE
Brain MRI None 723,724,728,731,800,1205–1217
Atrial esophageal ﬁstula 0.02% to 0.11% Reduce power, force, and RF time
on posterior wall, monitor
esophageal temp, use proton
pump inhibitors; avoid energy
delivery over esophagus
CT scan of chest, MRI; avoid
endoscopy with air
insufﬂation
Surgical repair 637,705,806,866,877–920,1162–1178,1398
Cardiac tamponade 0.2% to 5% Cather manipulation, transseptal
technique, reduce power, force,
and RF time
Echocardiography Pericardiocentesis or surgical
drainage
482,806,908,920,921,1034,1131–1135,
1139–1141
Coronary artery stenosis/
occlusion
,0.1% Avoid high-power energy delivery
near coronary arteries
Cardiac catheterization PTCA 923,1233–1240
Death ,0.1% to 0.4% Meticulous performance of
procedure, attentive
postprocedure care
NA NA 921,806,908,920,1039
Gastric hypomotility 0% to 17% Reduce power, force, and RF time
on posterior wall
Endoscopy, barium swallow,
gastric emptying study
Metoclopramide, possibly
intravenous erythromycin
536,1017–1021,1179–1185
Mitral valve entrapment ,0.1% Avoid circular catheter placement
near or across mitral valve;
clockwise torque on catheter
Echocardiography Gentle catheter manipulation,
surgical extraction
1263–1269,1396
Pericarditis 0% to 50% None proven Clinical history, ECG,
sedimentation rate,
echocardiogram
NSAID, colchicine, steroids 985,986,1257–1262
Permanent phrenic nerve
paralysis
0% to 0.4% Monitor diaphragm during phrenic
pacing, CMAP monitoring,
phrenic pacing to identify
location and adjust lesion
location
CXR, sniff test Supportive care 462,482,490,503,532,533,536,706,707,779,
808,903,920,1017,1075,1182–1201
Pulmonary vein stenosis ,1% Avoid energy delivery within PV CT or MRI, V/Q wave scan Angioplasty, stent, surgery 244,434,462,482,498,503,927,928,
1142–1160
Radiation injury ,0.1% Minimize ﬂuoroscopy exposure,
especially in obese and repeat
ablation patients, X-ray
equipment
None Supportive care, rarely skin graft 747,749,763,1186,1241–1256
Stiff left atrial syndrome ,1.5% Limit extent of left atrial ablation Echocardiography, cardiac
catheterization
Diuretics 1110,1111,1270–1275
Stroke and TIA 0% to 2% Pre-, post-, and intraprocedure
anticoagulation, catheter and
sheath management, TEE
Head CT or MRI, cerebral
angiography
Thrombolytic therapy, angioplasty 242,489,503,532,655,673,796,798,799,806,
920,921,1202–1204
Vascular complications 0.2% to 1.5% Vascular access techniques,
ultrasound-guided access,
anticoagulation management
Vascular ultrasound, CT scan Conservative treatment, surgical
repair, transfusion
806–808,834,840–842,920,921,1224–1232
AF5 atrial ﬁbrillation; CT5 computed tomography; MRI5magnetic resonance imaging; TEE5 transesophageal electrocardiogram; RF5 radiofrequency; PTCA5 percutaneous transluminal coronary angioplasty;
NA 5 not applicable; ECG 5 electrocardiogram; NSAID 5 nonsteroidal anti-inﬂammatory drug; CMAP 5 compound motor action potentials; CXR 5 chest X-ray; TIA 5 transient ischemic attack.
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group members routinely obtain an echocardiogram of the
heart prior to discharge. ICE has been reported to allow
earlier detection of pericardial effusion. It is important to
recognize that small, asymptomatic pericardial effusions
are commonly observed following AF ablation procedures.
ICE imaging has the potential to detect pericardial effusion
earlier. A survey of writing group members reveals that
53% of members routinely employ ICE imaging during AF
ablation. Our survey revealed that ICE was being used
routinely by 87% of the writing group members in the United
States and Canada as compared with 13% of the writing
group members from other countries. Monitoring ﬁlling pres-
sures in the LA and RA can be helpful in order to evaluate
progression of the effusion and/or effective drainage of the
pericardial collection. Ninety-three percent of the writing
group members hospitalize their AF ablation patients for at
least one night following their procedure.
The majority of episodes of cardiac tamponade can be
managed successfully by immediate percutaneous drainage
and reversal of anticoagulation with protamine. In patients
anticoagulated with warfarin, fresh frozen plasma is often
administered. And in patients on an Xa inhibitor, 4-factor
prothrombin complex concentrate is often appropriate. For
patients on dabigatran, the reversal agent idarucizumab is
now available worldwide and provides the opportunity to
immediately reverse the anticoagulant effects of dabiga-
tran.844 Factor Xa inhibitors can be reversed with
andexanet alfa (currently not approved for clinical use).845
Percutaneous drainage is best achieved by subxiphoid Sel-
dinger puncture of the pericardial sac and placement of an in-
trapericardial catheter. The pericardial tap can be performed
either with ﬂuoroscopic guidance based on anatomic land-
marks or with echo guidance.1140 After initial aspiration,
the BP promptly returns to normal. Once the pericardial space
has been drained, the patient needs to be monitored for
ongoing bleeding with the drainage catheter. The drainage
catheter is typically left in place for at least 12 hours postabla-
tion. In rare cases, if there has been a tear, percutaneous
drainage might be inadequate, and surgical drainage and
repair could be necessary.1134 One recent meta-analysis re-
ported that 16% of cases of cardiac tamponade required sur-
gical intervention.1139 It is for this reason that AF ablation
procedures should only be performed in hospitals equipped
or prepared to manage these types of emergencies with access
to emergency surgical support when required. Three cases
have been reported of emergent drainage of a pericardial effu-
sion through a sheath, either inadvertently or purposely
placed into the pericardial space using an endocardial
approach, although this would not be considered to be a stan-
dard approach.532,533,1132,1141 Early recognition and rapid
appropriate treatment of cardiac tamponade is mandatory to
prevent irreversible deterioration in perfusion of the brain
and other important organs. In a dedicated worldwide
survey, cardiac tamponade was reported to be the most
frequent cause of periprocedural death, with 25% of all
fatalities occurring in association with this complication.908PV Stenosis
PV stenosis is a well-recognized complication of AF ablation
that results from thermal injury to the PVs, including the me-
dia, intima, adventitia, and PV musculature. Since ﬁrst re-
ported in 1998, numerous studies have sought to determine
the incidence, cause, diagnostic strategy and treatment
approach for PV stenosis.434,927,1142,1143,1144,1145 Although
the precise pathophysiological mechanisms are still
uncertain, a progressive neointimal proliferation and
myocardial ﬁbrosis resulting in endovascular contraction
has been reported after extensive radiofrequency energy
ablation (RFA) to canine PVs.1146 PV stenosis has been
described for both point-by-point RF ablation as well as
CBA.244,462,482,928,1146,1147 To the best of our knowledge,
signiﬁcant PV stenosis has not been reported with the laser
balloon system.498,503 There are controversial data
regarding any impact that RF power output has on the rate
of PV stenosis.244,1147 The incidence of PV stenosis might
be somewhat lower with CB AF ablation than with
RFA.1148,1149 In experienced hands, however, PV stenosis
has become an increasingly uncommon complication with
either ablation technology.489 The highest risk for PV steno-
sis is associated with RFA close to the PV oriﬁces and/or
within the PVs, with a 5.6-fold higher incidence in compari-
son with antral ablation.1147 Ablation within the PVs should
be avoided, but can occur due to shifts in the 3D electroana-
tomic map, respiratory motion, poor catheter stability, and/or
an inexperienced operator.
The published incidence of PV stenosis varies widely,
from 0% to 40%.434,505,778,1142,1144,1150,1151 This variation
results from differences in the ablation technique,
deﬁnitions of PV stenosis, the intensity of screening for
this complication, and the date the study was performed.
When PV ablation for treating AF began in the late 1990s,
investigators were unaware that PV stenosis was a potential
complication. In contrast, operators today understand that
PV stenosis can be prevented by avoiding RF energy
delivery within a PV. This increased awareness and
improvements in imaging modalities have enabled better
identiﬁcation of the true PV ostium and have resulted in a
dramatic reduction in the incidence of PV stenosis.1141,1147
The incidence of symptomatic PV stenosis in experienced
hands approaches zero, although the incidence of
asymptomatic PV stenosis or PV narrowing might be higher.
Symptoms usually occur weeks to months after the abla-
tion procedure.927,1152 Prominent symptoms are dyspnea,
hemoptysis, cough, (recurrent) pulmonary infections or
pneumonia, and chest pain.1142,1143,1152 These have often
led to a misdiagnosis of pneumonia, pulmonary embolism,
or even lung cancer; thus, patients should be told of the
importance of returning to their ablation center if such
signs or symptoms develop. There are data showing a
progression of stenosis during 3 months after RFA despite
a normal imaging examination at 1 month after the index
procedure. Furthermore, severe stenosis can also remain
asymptomatic.927 According to the percentage reduction of
the luminal diameter, the severity of PV stenosis is generally
e370 Heart Rhythm, Vol 14, No 10, October 2017deﬁned as mild (,50%), moderate (50%–70%), or severe
(.70%). In this consensus statement, we recommend that a
signiﬁcant PV stenosis be deﬁned as a .70% reduction in
luminal diameter. PV stenosis can develop in any PV; and
in some patients, multiple PV stenoses occur.927,928,1143,
1152 It is unclear whether such patients are more prone to
develop PV stenosis compared with others.
PV stenosis can be diagnosed by CT imaging, MRI, perfu-
sion scans, TEE, or pulmonary venography. The preferred
imaging modality is MRI or CT because location and severity
of PV lesions can be precisely visualized. Advantages of
MRI include the fact that pulmonary perfusion data can be
obtained simultaneously and that the diagnostic procedure
is free of radiation. Eleven percent of the writing group mem-
bers routinely obtain a CT or MR scan several months post-
ablation to screen for asymptomatic PV stenosis.
Although the incidence of PV stenosis has decreased over
recent years, it remains a signiﬁcant complication because it
is difﬁcult to treat and, rarely, it can lead to death. It is
notable that 51% of the writing group members report having
had a patient at their center develop PV stenosis requiring
intervention. Most of these procedures were performed
more than a decade ago. The indication for intervention is
guided predominantly by the presence or absence of symp-
toms. Asymptomatic or mild symptomatic PV stenosis
should be managed conservatively with watchful waiting,
given symptomatic amelioration has been observed after
PV stenosis or occlusion without treatment and indicates
collateral formation or recruitment.1153 For symptomatic pa-
tients, PV angioplasty should be considered. In patients with
more than one PV stenosis, perfusion imaging may be
applied to identify the “culprit” lesion. The dilation proced-
ure is often complex, especially if the target PV is completely
occluded with failed visualization from direct angiography
via the LA as well as antegradely via pulmonary artery angi-
ography. Electroanatomical 3D mapping with registration of
the anatomy of the LA and the PVs, as well as fusion with the
reconstructed LA from the imaging scan before the index
procedure, enables a precise localization of the occluded
PV.1154 Baseline CT or MRI is more helpful in deﬁning
the PV anatomy.
Many PV stenoses are rigid and difﬁcult to dilate. Even af-
ter acutely successful angioplasty, PV restenosis occurs in up
to 50% of cases.927,1142,1143,1152,1155 Stent sizes of 9 mm or
more, and especially drug-eluting stents, revealed signiﬁ-
cantly better results, although drug-eluting stents of this size
are not available.1142,1143,1144,1156 Whether or not primary
stenting of PV stenosis offers better results than angioplasty
alone has now been systematically studied by several
groups.1144,1155 The risk of restenosis is signiﬁcantly less
with PV stenting, providing a stent of 8–10 mm in diameter
can be used. A further problem is the small sample size of
the published case series. Complications of interventional
treatment of PV stenosis include LA perforation with or
without tamponade, but also PV dissection with massive
bleeding, stent embolization, and stent thrombosis.1142,1143
There are limited data regarding the need for and intensityof anticoagulation and antiplatelet therapy. For cases in
which anticoagulation is otherwise indicated for AF, a
regimen including the addition of clopidogrel is most
commonly used. Without the indication for anticoagulation,
warfarin and clopidogrel should be combined. The duration
of anticoagulation needed remains unclear. In the case of
restenosing PVs, anticoagulation for life might be
necessary. In the setting of stable PV stents over the course
of 1–2 years, clopidogrel and, subsequently, warfarin can
be discontinued. The role of NOACs in PV stenosis has not
been readily studied. Surgical patch repair of primary PV
stenosis in children reveals a 5-year success rate of 67%,
with an in-hospital mortality of 10%.1157 Only one case of
surgical treatment of severe PV stenosis with patch implanta-
tion after catheter ablation has been reported.1158 Thus, it re-
mains unclear whether the results are better than with
conventional interventional treatment. Connecting the patch
to the proximal end of the stenosis is difﬁcult, because this
end is buried in the lung parenchyma. Given this challenge,
and the excessive risk, there is no foundation for recommend-
ing its use in patients with recurrent PV stenosis after AF abla-
tion, and decision making cannot be based on a single case
report. Even for patients with recurrent severe and persistent
problems due to restenosis despite interventional treatment,
recurrent infection and hemoptysis are uncommon, readily
manageable, and the need for lobectomy or pneumonectomy
is very rare. In the largest series of PV stenosis to date, both
patients who underwent subsequent pneumonectomy at
outside institutions died during or after surgery.1155 Although
lung transplantation can be considered in a case of congenital
PV stenosis,1159 this has never been required in AF-ablation
patients. Dealing with patients with ﬁbrosing mediastinitis
and PV or peripheral artery (PA) stenosis is, in contrast,
exceptionally difﬁcult.1160
Successful PV angioplasty or stenting usually results in a
signiﬁcant relief of symptoms.1142,1143,1144,1145,1155,1156
Thus, follow-up strategies and intensity should be based on
symptoms. Patients with restenosis usually report an increase
of complaints existing prior to the intervention. In such cases,
MRI is recommended. There is an additional critical consid-
eration in dealing with PV stenosis. With the decline in
follow-up CT scans after AF ablation, the occurrence of
serious stenosis, hemoptysis, permanent PV occlusion, scar-
ring, lung infarction, and intraparenchymal hemorrhage has
increased. Many such patients are being inappropriately eval-
uated for lung cancer because of the appearance of intrapar-
enchymal hemorrhage. Candidate veins for intervention are
also increasingly problematic. These are more difﬁcult to
open and have a higher restenosis rate, requiring repetitive re-
intervention. Because of this, it is recommended that if a pa-
tient does not undergo a routine follow-up 3-month CT or
MR, at a minimum, those with recurrent pulmonary symp-
toms after AF ablation should be scanned to exclude PV ste-
nosis. Patients should also be routinely screened for
symptoms at the time of follow-up evaluations. The take-
home message is to identify PV stenosis before it becomes
a serious problem.
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and Esophageal Hematoma
Esophageal injury is one of the most important complications
associated with catheter and surgical ablation of AF. In this
section of the document we will focus on three types of
esophageal injury: (1) esophageal hematoma, (2) atrial peri-
cardial ﬁstula, and (3) AEF. We will consider esophagoperi-
cardial ﬁstula and AEF as one topic, and will focus mainly on
this serious and often lethal complication of AF ablation.
However, to be complete, we will also comment on the
recently described complication of an esophageal hematoma.
Esophageal Hematoma
The esophagus can be injured directly as a result of trauma
from a transesophageal probe. Esophageal hematoma is a
recognized complication after a transesophageal echo study,
which can be performed in association with the ablation pro-
cedure.1161 A recent study reported that 0.27% of the patients
who underwent an AF ablation with a preprocedure TEE
experienced this complication. The predominant symptoms
were pain on swallowing, regurgitation, and hoarseness,
with an onset within 12 hours of the procedure. Fever and
neurological symptoms were not present. The diagnosis
was established by a CT scan, which ruled out an AEF and
revealed a hematoma localized to either the upper esophagus
or extending the length of the esophagus. Endoscopy can
further conﬁrm the diagnosis. Conservative management is
advised. Long-term consequences of this complication
include an esophageal stricture, esophageal dysmotility,
and vocal cord paralysis.1161AEF and Atrial Pericardial Fistula
Esophageal ulceration, perforation, or development of a left
AEF or atrial pericardial ﬁstula, have been reported after
both catheter ablation of AF and surgical ablation of AF using
unipolar RF current.806,866,920,1162,1163,1164,1165,1166,1167,1168,1169
It is a possible complication after catheter ablation using any
energy modality that produces transmural atrial lesions.
Although early reports showed AEF resulting from RF
ablation, more recently, AEFs have also been reported after
CBA.877,878,879,1170 An adequately powered study
examining the relative frequency of this complication with
the two primary ablation modalities has not yet been
performed. AEFs have also been reported following
ablation with a focal ultrasound balloon ablation system
that is no longer clinically available.705,1167 Esophageal
erosion has also been reported with a circular
multielectrode irrigated RF ablation system.1171 It is notable
that 51% of the writing group members report having had a
patient at their center develop an AEF following AF ablation.
It should be clear, however, that the occurrence of an esoph-
ageal ulcer is not the same as an AEF. Although AEFs can be
accompanied by ulcers, the presence of an ulcer is not predic-
tive of an AEF. Occurring in 10%–40% of patients undergo-
ing an AF ablation, the prevalence of an AEF is closer to one
in one thousand in those with an ulcer.Although the precise mechanism of esophageal tissue
injury is not understood, potential mechanisms include direct
thermal injury, acid reﬂux, infection from the lumen, and
ischemic injury through thermal occlusion of end arterioles.
It has been hypothesized that vagal damage resulting from
ablation on the posterior LA wall can cause gastroesophageal
reﬂux by damaging the vagal nerves that run along the esoph-
agus, altering the lower esophageal sphincter pressure. This
hypothesis proposes that high esophageal acid production
could contribute indirectly to the formation of
AEFs.1172,1173 This hypothesis is attractive; however, one
study that attempted to validate it by measuring esophageal
acid levels post-AF ablation was negative.1173 The preva-
lence of esophageal reﬂux and an AEF are also very different.
Although the development of an AEF following AF
ablation is a very uncommon complication, its importance
rests in the lethality of this complication. The Updated
Worldwide Survey on the Methods, Efﬁcacy, and Safety
of Catheter Ablation for Human Atrial Fibrillation reported
an AEF in six patients (0.04%).920 This incidence was
similar to a separate survey of members of the Heart
Rhythm Society. In this survey, an AEF was reported in
6 of 20,425 patients (0.03%).1168 All six of these patients
experienced major cerebrovascular events, and ﬁve (83%)
died. In contrast to an AEF, which is very rare, subclinical
injury to the esophagus is extremely common following AF
ablation. A more recent study reported an AEF incidence of
0.11%. In a number of studies, an endoscopy has been per-
formed to screen for esophageal injury 1–3 days following
AF ablation.1174 Esophageal tissue injury has been reported
in up to 50% of patients.637,882,1175 Observed asymptomatic
esophageal ulcers were usually healed on repeat endoscopy
at 2–3 weeks.1176 One study reported endoscopy performed
on 267 patients who underwent RF ablation. The power on
the posterior wall was limited to 25 W. Among these pa-
tients, 6 (2.2%) had either erythema (n 5 2) or a necrotic
ulcer (n 5 4) on endoscopy. Multivariate analysis revealed
that the distance between the LA and the esophagus was the
only independent predictor, although an LA isthmus line
and CS ablation showed a trend.900 After treatment with a
PPI (pantoprazole or esomeprazole) and sucralfate, all
recovered without development of an AEF. One study re-
ported a higher incidence of esophageal injury among pa-
tients undergoing AF ablation with general anesthesia
compared with conscious sedation.637 It has been proposed
that this relationship reﬂects the absence of pain feedback
and reduced esophageal motility resulting from general
anesthesia.
The clinical manifestations of an AEF usually present 2–4
weeks after the ablation procedure. The most common symp-
toms are fever and recurrent neurological events (septic
emboli), but patients can present with septic shock, esopha-
geal bleeding, or death. A recent case series of 53 patients
who developed an AEF following AF ablation reported a
mean interval between the procedure and presentation of
206 12 days, ranging from 2 to 60 days. In this series, fever
was the most common presenting symptom, followed by
e372 Heart Rhythm, Vol 14, No 10, October 2017neurological deﬁcits and hematemesis.1176 The preferred
diagnostic modality is a chest CT scan.1169,1176 It is
important to recognize that a normal chest CT scan does
not rule out the presence of an AEF with 100% sensitivity.
Ongoing vigilance and evaluation are important if the
clinical suspicion is high. Although a barium swallow can
detect a ﬁstula, its sensitivity is low. IV contrast is much
more likely to demonstrate a lesion passing from the
esophagus to the mediastinum, the pericardium, or the LA.
If an AEF is suspected, endoscopy with air insufﬂation
should be avoided, given that insufﬂation of the esophagus
with air can result in a large air embolus, producing stroke
or death. An alternative strategy, which some members of
the writing group employ and which appears to have lower
risk, is to use CO2 instead of air for insufﬂation in this
setting. If CO2 were introduced into the LA, there would
be little adverse consequence. The early recognition of an
AEF can be missed due to the low awareness of this rare
complication. It is important for patients to be educated as
to warning signs and to contact their AF ablation center
should any suggestive symptoms develop.
Considerable efforts have been made to reduce the fre-
quency of this complication. Approaches that have been pro-
posed include avoiding ablation on the posterior wall of the
atrium (or at least over the trajectory of the esophagus),
reducing RF power on the posterior wall (to 25 W or less),
using ICE to image the esophagus, and using an esophageal
temperature sensor.637,900 Many institutions use an
esophageal temperature probe to prevent thermal injury;
however, it is widely acknowledged that use of an
esophageal temperature probe does not eliminate the risk of
esophageal injury.341,417,910 A survey of the writing group
members shows that 87% use lower RF power on the
posterior wall. This survey also reveals that two-thirds
routinely use an esophageal temperature probe. Among those
who use a temperature probe, one-third report using a temper-
ature probe with multiple temperature sensors, whereas two-
thirds use a probe with only one temperature sensor. It is
important to recognize that the temperature probe should be
as close as possible to the ablation catheter at all times during
the procedure. Another variable concerns when to stop power
delivery. Whereas some operators ablate until a predeﬁned
temperature has been met (e.g., 39C or 40C), other opera-
tors use a more conservative approach and terminate power
when the esophageal temperature increases by as little as
0.2. Esophageal temperature monitoring is also commonly
used during CB AF ablation. Energy delivery is generally
stopped when the esophageal temperature is lower than
-20C. An alternative approach to the prevention of this
complication is to move the esophagus away from the site
of ablation using an endoscope or stylet positioned through
a chest tube.894,895,1177
None of the writing group members employ this strategy.
Other widely used strategies include the use of PPIs; although
this approach is unproven, it has become a common
approach. Seventy-two percent of the writing group members
employ a PPI for 1–4 weeks following AF ablation. Use ofPPIs is more common following RF ablation (95%)
compared with CBA (54%). It is important to note, however,
that this practice is based on the observation that esophageal
ulcerations can be observed on endoscopy following abla-
tion. There is no proof that this approach reduces the devel-
opment of an AEF.
Treatment of an AEF is a medical emergency that requires
urgent surgical repair.341,417,906,910,911,1169,1176,1178 Recent
case series have reported an 83% to 100% mortality
without surgical repair compared with a 34% mortality
with surgical repair.341,417,906,910,1176 Although several case
reports have been published describing favorable outcomes
with esophageal stent placement for treatment of an
esophageal perforation or an esophageal pericardial ﬁstula,
the mortality rate for stent placement in a patient with a
true AEF approaches 100%.341,417,905,907,910,911
In summary, AEF is a rare but unpredictable complication
with severe consequences that might only be mitigated by
cautious use of energy on the posterior wall of the LA, early
detection, and intervention. Prompt diagnosis and surgical
treatment are typically required. Support for the use of esoph-
ageal stenting is limited, and progression of the AEF process
can still occur despite this stenting procedure.Gastric Hypomotility and Periesophageal Vagal
Nerve Injury
Injury to the vagal anterior esophageal plexus can occur when
RF energy is applied to the posterior wall of the LA, which
can cause acute pyloric spasm and gastric hypomotility.
Common symptoms include nausea, vomiting, bloating,
and abdominal pain developing within a few hours to a few
weeks after the ablation procedure.1018,1020,1179,1180,1181
Some patients also experience sinus tachycardia.1180 The
incidence of symptomatic gastric problems can be as high
as 17%.1020,1181 One recent study reported that
asymptomatic functional impairment of the upper GI tract
occurred in 74% of patients. After AF ablation, although
the abnormality is often asymptomatic, the time to recovery
is variable, with some patients recovering within 2 weeks,
but others requiring a much more protracted time to
recovery.536
The initial evaluation can include endoscopy or a barium
swallow study to look for residual food after an overnight
fast. CT shows marked gastric dilation. Solid food labeled
with technetium-99 can demonstrate delayed gastric
emptying. The 13C-acetate breath test has been reported to
be a noninvasive alternative to scintigraphy.1182 Real-time
MRI has been used to assess gastric motility and pyloric
spasm.1179 In addition, electrogastrography can reveal gastric
dysrhythmia with bradygastria in patients after ablation.1183
The integrity of the vagal innervation to the gastrointestinal
system can be assessed by the pancreatic polypeptide
response to sham feeding. Patients with this complication
exhibit an abnormal kinetic and peak response. The normal
response is a biphasic increase in pancreatic polypeptide.
Injury to the vagus nerve impairs the ﬁrst phase of the
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level elevation by less than 50% from baseline was consid-
ered as abnormal.
Management of this complication depends on the severity
of symptoms and whether gastric immotility or pylorospasm
predominates. Small, low-fat, and low-ﬁber meals can alle-
viate symptoms. Intravenous erythromycin can be effective
in the acute stage to improve diabetic gastroparesis but has
not been evaluated post-AF ablation.1184 Metoclopramide
can be used to promote gastric motility for 1–3 months, but
long-term treatment is associated with a risk of movement
disorders. Botulinum injections or surgery might be required
to alleviate pyloric spasm.1185 In severe cases, surgery or
gastric pacing might be required.1185
Although there is no established method to prevent
injury to the vagal nerves, the risk can be reduced by using
the same techniques used to avoid an AEF, described earlier
in this document. A recent report identiﬁes higher BMI and
limiting the power to 20–25 W on the posterior LA wall as
protective against periesophageal nerve injury during AF
ablation.1020Phrenic Nerve Palsy
PN palsy is an important complication of AF ablation and re-
sults from direct thermal injury.536,903,1017,1182,1183,1184,1185
The right PN is most commonly affected, given it descends
in close proximity to sites of ablation in the SVC and both
right-sided PVs (Figure 1).536,903,1184,1185,1187 It courses
slightly further from the RIPV so that injury during
treatment of this vein is less common than that occurring
with RSPV ablation. PN palsy is observed with all
technologies for AF ablation, including RF, cryoablation,
ultrasound, and laser ablation.490,536,903,1017,1182,1183,1184,1185,1187
PN palsy can be asymptomatic or can cause dyspnea,
tachypnea, cough, hiccups, and thoracic pain. The
diagnosis is suggested when newly elevated
hemidiaphragm with atelectasis of the ipsilateral lung base
is observed on postprocedure chest radiograph. When
suspected, diaphragm excursion should be evaluated using
ﬂuoroscopy (sniff test) or ultrasound to conﬁrm the
diagnosis. Of the writing group members, 64% report
having had a patient at their center develop permanent PN
palsy, and 36% of the writing group members report
having had a patient at their center develop permanent PN
palsy following AF ablation with RF energy.
The most common scenario in which PN injury occurs is
with CBA, with an incidence of transient PN palsy of 3.5%–
11.2%.462,1075,1188,1189 Permanent PN palsy resulting from
CBA is far less common, with an incidence of 0.3% in the
recently completed FIRE AND ICE trial.490 PN palsy has
also been reported with the laser-balloon ablation system.
In the HeartLight study of the laser balloon, diaphragmatic
paralysis secondary to PN injury occurred in 3.6% of the pa-
tients with the laser balloon and was more common than with
RF ablation. Persistent PN paralysis at 1 year occurred in
1.8% of the patients.503 The hot balloon ablation catheter em-ploys a compliant balloon ﬁlled with saline that is inﬂated to
occlude the PV.706 Because of the mechanism of balloon
heating, the possibility of hot spots forming in deeper tissue
planes or in collateral structures such as the esophagus is un-
likely.707 The main reported complications with this technol-
ogy were PN palsy (3.4%) and PV stenosis (1.7%).708 A
recent, prospective, multicenter clinical trial compared the
outcomes of hot balloon ablation vs AAD therapy for
PAF.706 The incidence of PN injury was 3.7%.
Several mechanisms have been proposed to explain the
increased incidence of balloon-based (CB, laser balloon,
hot balloon) AF ablation and PN injury. First, wedging or ex-
erting force to direct the balloon into the RSPV for complete
PV occlusion can distort the anatomy and decrease the dis-
tance between the RSPV endocardium and the right
PN.1190 Second, a small balloon size relative to PV diameter
can increase the likelihood of distal ablation in the vein.779
Third, the broader, circumferential thermal gradient and use
of additional freeze cycles can increase risk of dose-
dependent nerve palsy.1075 Studies have shown a higher
risk of PN injury associated with the smaller 23-mm balloon
compared with the larger 28-mm balloon with more proximal
energy application.462,482 The smaller balloon is potentially
advanced further within the PV, causing distortion of the
anatomy, creating a higher susceptibility to PN thermal
injury. PN palsy can also occur during WACA using RF
energy. This likely results from thermal injury to the PN as
it courses anterior to the right PVs.
The second most common scenario of PN palsy is during
electrical isolation of the SVC using point-by-point RF abla-
tion; the reported incidence is 2.1%–10%.1191,1192 Ablation
within a persistent left SVC can result in left PN paralysis,
but appears rarely, and has been associated with the use of
CB.1193 Injury to the left PN during isolation of a persistent
left SVC was not observed in several case series using RF en-
ergy.232,1042,1194,1195 Very rarely, ablation at the roof of the
LAA can result in left PN damage1184; however, it was not
observed in a large study in which LAA isolation was per-
formed using RF ablation.532,533 The incidence of PN palsy
is 0.17%–0.48% with PV antrum isolation using RF
ablation, even though the PN is found within the typical
WACA and carina lines of the right-sided PVs in 30% of pa-
tients.808,920,1184,1196 This highlights the importance of
factors other than anatomic proximity alone contributing to
the higher incidence of injury with CB.
A number of strategies have been employed to prevent PN
palsy. These include limiting ablation to antral regions with
various balloon maneuvers; preablation high-output pacing
to establish whether the PN can be captured from the pro-
posed ablation site before ablation; PN mapping with
anatomic tagging of its course using an EAM system to guide
the modiﬁcation of the ablation lesion set; and monitoring of
diaphragmatic excursion with abdominal palpation, ﬂuoros-
copy, or intracardiac ultrasound while pacing the PN from
the SVC or subclavian vein during ablation.1196 Monitoring
the effects of pacing the right PN is now considered a stan-
dard part of CBA and should be considered during SVC
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96% report employing this technique when performing CB
AF ablation. Finally, diaphragmatic electromyography for
direct monitoring of diaphragmatic compound motor action
potentials (CMAP) during ablation is a technique for early
detection of PN palsy that has been reported to reduce inci-
dence of palsy.1197,1198 CMAPs are recorded using body
surface electrodes, esophageal electrodes, or a diagnostic
catheter positioned in the hepatic vein. A decrease in the
amplitude of the myopotential by 30% is more sensitive
than abdominal palpation for predicting the subsequent
reduction in diaphragmatic excursion and nerve palsy.1199
Energy delivery should be interrupted immediately at the ﬁrst
sign of PN injury. One-third of the writing group members
report employing this technique when performing CB AF
ablation. One-third of the writing group members also report
pacing anterior to the right PVs to tag the PN when perform-
ing AF ablation using RF energy.
PN palsy can be asymptomatic or can cause dyspnea, ta-
chypnea, cough, hiccups, and thoracic pain.903,1017,1184,1187
The diagnosis is suggested when newly elevated
hemidiaphragm with atelectasis of the ipsilateral lung base is
observed on postprocedure chest radiograph. When
suspected, diaphragm excursion should be evaluated using
ﬂuoroscopy (sniff test) or ultrasound to conﬁrm the diagnosis.
There are various stages of PN palsy, ranging from detect-
able decrease in CMAP before a reduction in diaphragmatic
excursion is perceived to persistent paralysis. With CBA,
most PN injuries are transient and resolve within mi-
nutes.903,1184 In patients with persistent nerve palsy, most
recover nerve function within weeks and almost all by 12
months, although 18–24 months might be required in some
patients.1200 In a large meta-analysis of 22 studies enrolling
1308 patients undergoing CBA, 4.7% had persistent PN pa-
ralysis after the ablation procedure, but only 0.37% had paral-
ysis lasting longer than 1 year.482 The pathophysiology of the
palsy differs by type of ablation energy. With RF ablation,
there is a dose-dependent response, and permanent palsy is
characterized acutely by edema, coagulation, and homogeni-
zation of cytoplasmic contents and smearing of nuclear chro-
matin.536 With CB, the palsy is also dose-dependent;
however, histopathology studies have shown Wallerian
degeneration of large myelinated axons, and that axonal
regeneration accounts for late recovery of nerve function.1201
There is no active treatment known to facilitate PN healing;
however, in symptomatic patients with permanent nerve
palsy, diaphragmatic plication can improve dyspnea and
functional status.
Stroke, TIA, and Silent Microemboli
Stroke and TIA
Embolism of air or thrombus is one of the most signiﬁcant
complications of AF ablation, and both are potential causes
of cerebral, coronary, and peripheral vascular compromise.
The incidence of thromboembolism associated
with AF ablation is reported to be between 0% and7%.242,489,503,532,533,655,673,796,798,799,806,920,921,1202,1203,1204
More than two-thirds of the clinical trials reviewed for
preparation of this document reported one or more cerebro-
vascular events. Thromboembolic events typically occur
within 24 hours of the ablation procedure, with the high-
risk period extending for the ﬁrst 2 weeks following abla-
tion.798,1204 In one series that surveyed 26 embolic stroke
events that occurred in a series of 3060 patients, long-term
neurological outcomes were as follows: severe impairment
(3 patients, with 2 possibly related deaths); moderate impair-
ment (10 patients); mild impairment (9 patients); and un-
known (4 patients).1202
A number of potential explanations for the development of
thromboembolic complications have been proposed. These
include the development of thrombi on or within stationary
sheaths or ablation catheters positioned within the LA, char
formation at the tip of the ablation catheter and at the site of
ablation, disruption of a thrombus located in the atrium prior
to the ablation procedure, and electrical cardioversion during
procedures.875 Incidence of these events can be reduced by a
combination of detailed preprocedural imaging, a strict antico-
agulation protocol, meticulous attention to sheath manage-
ment, and careful control of RF energy to minimize the risk
of char formation. Of the writing group members, 68% report
maintaining a constant heparinized ﬂush through all long
sheaths with access to the LA, and most heparinize to an
ACT .300 seconds before transseptal catheterization.
Diagnosis of a symptomatic thromboembolic event is usu-
ally straightforward when ischemia or infarction results from
arterial occlusion interrupting perfusion of dependent tissue.
The potential manifestations depend on where the occlusion
occurs, whether it be intracranial, coronary arterial, abdom-
inal, or in other peripheral arterial beds. We have previously
discussed the prevention of thromboembolism by intraproce-
dural and postprocedural anticoagulation in Section 7: Tech-
nical Aspects of Ablation to Maximize Safety and
Anticoagulation. Treatment of a thromboembolic event will
vary according to the location of the embolus. Peripheral arte-
rial embolization might be amenable to surgical thrombec-
tomy, whereas cerebral embolization has traditionally been
managed conservatively and the consequences accepted.
There is growing interest, however, in aggressive early man-
agement of such events, using either thrombolytic drugs or
percutaneous interventional techniques. Some delay in diag-
nosis of a thromboembolic event that occurs during an abla-
tion procedure while a patient is under general anesthesia
cannot be avoided.
Asymptomatic Cerebral Emboli
ACE is deﬁned as an occlusion of a blood vessel in the brain
due to an embolus that does not result in any acute clinical
symptoms and is therefore “silent.”800,1205 Emboli can
result from a thrombus, air, gas, tissue, or fat. During an
AF ablation procedure, potential sources of these
microemboli include thrombi, which can develop on
intracardiac catheters; sheath materials; air introduction
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dislodgement of thrombi in the heart; or as a result of
thrombi or gas that forms during the ablation process.
Diffusion-weighted MRI (DW-MRI), with or without ﬂuid-
attenuated inversion recovery (FLAIR) imaging, is very sen-
sitive for identifying acute ischemic injury and can detect a
cerebral lesion created by an embolus as early as 30 minutes
postablation.
The ﬁrst report of ACE lesions following AF ablation was
published in 2006.1206 In this report, 2 of 20 patients devel-
oped new asymptomatic cerebral lesions on MRI, following
AF ablation. Subsequent to this report, multiple studies
have reported that DW-MRI can detect new acute lesions
created by emboli, following up to 50% of AF ablation
procedures.723,724,800,1205,1207,1208,1209
The incidence of this complication initially appeared to
vary according to the system used for ablation, and was re-
ported to be highest with the use of nonirrigated circumferen-
tial multielectrode ablation catheters with duty cycled phased
RF energy.1209,1210 Based on these ﬁndings, modiﬁcations
were made in anticoagulation, sheath management, and
energy delivery protocols. Following introduction of these
modiﬁcations, two subsequent studies reported a 2% or
lower incidence of ACE lesions with use of this same
circular phased RF ablation catheter.728,731,1211 One study
examined the important question concerning whether these
lesions persist on repeat DW-MRI and T2 FLAIR scanning.
In this study, 14 patients who had 50 new silent cerebral
emboli detected post-AF ablation had a repeat MRI a median
of 3 months later. It was notable that 47 of the 50 lesions
(94%) resolved in the interim. The three lesions in three pa-
tients that produced a residual defect at repeat scanning
were initially .10 mm in size, and one of these patients
had neurological symptoms. When considering the signiﬁ-
cance of the ACE lesions that have been observed following
AF ablation, it is important to note that cerebral embolism has
also been observed after most types of cardiac invasive pro-
cedures, including coronary angiography, carotid artery
stenting, and cardiac valve replacement.1212,1213
Importantly, as of now, a direct link between silent cerebral
embolism and a decline in neurocognitive function has not
been proven.800,1205,1211,1212 However, one study has
reported mild postoperative neurocognitive dysfunction in
13% of patients undergoing ablation for PAF and in 20%
undergoing ablation for persistent AF. The precise
mechanism of this neurocognitive dysfunction and its
possible link to ACE lesions needs to be explored further.1214
A decade after the ﬁrst description of ACE lesions
following AF ablation, a tremendous amount of new knowl-
edge has been generated concerning this important complica-
tion of AF ablation.800,1205,1211,1215,1216 These efforts have
resulted in a striking decrease in the incidence of this
complication. During this period of time, studies have
identiﬁed a number of techniques to lower the risk of ACE
lesions, including (1) aggressive anticoagulation prior to,
during, and following ablation; (2) careful sheath
management; (3) modiﬁcations in the delivery of phased RFenergy; and (4) choice of ablation energy source and lesion
sets. The long-term prognostic implications of ACE following
AF ablation remain unclear. Because multiple studies have re-
ported that the majority of acute lesions regress without evi-
dence of chronic glial scar when reassessed several weeks to
months later, the occurrence of long-term sequelae appears un-
likely.1205 Nevertheless, there is a possibility of long-term
sequelae, given the association between silent cerebral infarcts
and an increased long-term risk of dementia.1217While further
work remains, the amount of progress is striking and will
beneﬁt our patients in the long term.Air Embolism
The most common cause of air embolism is introduction of
air via the transseptal sheath. Although this can be introduced
through the infusion line, it can also occur with suction when
catheters are removed. Air embolism has been reported
with coronary angiography, percutaneous interventions
requiring access to the LA, and during ablation
procedures.803,1218,1219,1220,1221 Air embolism to the
cerebral vasculature can be associated with altered mental
status, seizure, and focal neurological signs. Central
nervous system dysfunction is attributable to both
mechanical obstruction of the arterioles and thrombotic-
inﬂammatory responses of air-injured epithelium.1219,1220
Although immediate diagnosis and treatment is based on
clinical suspicion, prompt MRI or CT scans obtained
before the intravascular air is absorbed might show
multiple serpiginous hypodensities representing air in
the cerebral vasculature, with or without acute
infarction.803,1221 Most importantly, AEF should be ruled
out if air embolism is documented after the ablation. A
common presentation of air embolism during AF ablation
is acute inferior ischemia and/or heart block. This reﬂects
the preferential downstream migration of air emboli into
the right coronary artery (RCA). The preferential
manifestation of air emboli into the RCA territory might
reﬂect the superior position of the RCA ostium in the
supine patient. Supportive care usually results in complete
resolution of symptoms and signs within minutes.
However, pacing and cardiopulmonary resuscitation might
be needed if the hypotension and AV block persist. A
recent study reported the clinical characteristics and
outcomes of 5 out of a series of 2976 patients who
underwent AF ablation who experienced a massive air
embolism during the procedure. Hemodynamic collapse
and hypoxemia occurred in all the patients and persisted for
10–35 minutes. Despite this, all the patients had complete
recovery.1221 it is imperative, however, that all infusion lines
be monitored closely for bubbles. Whenever catheters are
removed, they should be withdrawn slowly to minimize suc-
tion effects, and the ﬂuid column within the sheath should be
aspirated simultaneously. Particular care is advised when in-
serting and removing balloon catheters through large
sheaths.1222 Treatment should be initiated immediately in
the laboratory if cerebral air embolism is suspected. The
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by the administration of ﬂuids and supplemental oxygen,
which increases the rate of nitrogen absorption from air bub-
bles. For large air emboli, it might be beneﬁcial to brieﬂy sus-
pend the patient in a head-down position.1218,1219 Treatment
with hyperbaric oxygen can reverse the condition and
minimize endothelial thromboinﬂammatory injury if it is
started within a few hours.1220 Heparin appears to limit injury
in animal models of cerebral arterial air embolism.1223Vascular Complications
Vascular complications, including groin hematoma, retroper-
itoneal bleed, femoral artery pseudoaneurysm, or arteriove-
nous ﬁstula, are the most common complications of AF
ablation. The incidence of the more signiﬁcant of these
complications (femoral pseudoaneurysm, arteriovenous ﬁs-
tula, and retroperitoneal bleeding) varies from 0.2% to
1.5%.806,808,920,921,1224,1225,1226 The ﬁrst and updated
worldwide surveys of AF ablation in 2005 and 2010,
respectively, reported that the incidence of vascular
complications was 0.95% (84 of 8745 patients) and 1.5%
(240 of 16309 patients), respectively.806,920 A report from
the United States analyzing an estimated 93,801 AF
ablations between 2000 and 2010 showed the overall
incidence of vascular complications requiring blood
transfusion or surgical repair was 1.53%, which remained
statistically unchanged from year 2000 to 2010.921 More
recent reports from Czechia, Belgium, Japan, and the United
States reported the incidence of these complications as 1.1%
(13 of 1192 procedures in 959 patients), 1.2% (15 of 1233
procedures in 947 patients), 0.2% (7 of 3373 patients), and
1.5% (18 of 1190 patients), respectively.808,1224,1225,1226
The incidence of vascular complications that result from
AF ablation is lower than those reported for ventricular
tachycardia ablation (range, 3.6%–6.9%), in which femoral
arterial access is used in many cases.1227,1228 Most groin
hematomas can be managed conservatively or with
ultrasound-guided compression. However, complications
such as femoral pseudoaneurysm, arteriovenous ﬁstula, and
retroperitoneal bleeding might require blood transfusion and/
or surgical or percutaneous repair, which leads to increased
morbidity and prolonged hospital stay.1229 Rarely, a large
dense hematoma can lead to femoral neurological sequelae.
The incidence of these complications can be related to the
number and size of the venous sheaths used, insertion of an
arterial pressure line, and perhaps to the intense anticoagula-
tion management before, during, and after the procedure.
Recent studies have suggested uninterrupted warfarin as an
optimal anticoagulation regimen because it reduces stroke
and nonmajor bleeding complications compared with inter-
rupted warfarin with heparin bridging.834 Further, uninter-
rupted or brieﬂy interrupted use of a direct oral
anticoagulant was shown to be as safe and effective as
uninterrupted warfarin.840,842,1230 The results of the
RE-CIRCUIT study were recently published, which was a
head-to-head comparison of performing AF ablation on pa-tients receiving uninterrupted dabigatran vs uninterrupted
warfarin.841 This study randomized 704 patients across 104
sites to these two anticoagulation strategies. The incidence
of major bleeding events during and up to 8 weeks postabla-
tion among the 635 patients who underwent AF ablation was
signiﬁcantly lower with dabigatran than with warfarin (5 pa-
tients [1.6%] vs 22 patients [6.9%]); absolute RD -5.3%, RR
reduction 77%). There has been one other smaller head-to-
head comparison published of uninterrupted rivaroxaban vs
uninterrupted warfarin (Venture-AF,N5 248).842 This study
reported one major bleeding event, one ischemic stroke, and
one vascular death, each of which occurred in the warfarin
arm of the study.
The approach used for femoral venous access can impact
on the risk of vascular complications. When an inferior
approach to femoral vein access is used, small medial
branches of the femoral artery, which can run across and su-
perﬁcial to the femoral vein, might be penetrated before entry
to the femoral vein, possibly leading to a femoral pseudoa-
neurysm and arteriovenous ﬁstula. When a superior approach
is used, there is an increased risk of retroperitoneal bleeding.
To prevent these vascular complications, real-time ultra-
sound-guided venipuncture is useful and can be recommen-
ded because it reduces both major and minor vascular
complications in patients undergoing AF ablation and/or
electrophysiological procedures.1231,1232 Among the
writing group members, two-thirds routinely use ultrasound
imaging to guide vascular access.Acute Coronary Artery Occlusion and Stenosis
Injury to the coronary arteries during AF ablation is rare. In a
consecutive series of 5709 patients undergoing ablation of
AF, coronary arterial injury was observed to occur in eight
patients (0.14%).1233
The circumﬂex artery is in close proximity to the lateral LA
and can potentially be injured during ablation at sites adjacent
to its course within the CS, the lateral mitral isthmus, or the
base of the LAA. Occlusion of the circumﬂex accounted for
three of the eight cases in the above series, all presenting
with ventricular ﬁbrillation 20 and 60 minutes after mitral
isthmus ablation and 6 hours after ablation at the LAA base,
respectively.1233 Others have also described features of acute
myocardial infarctionwith ST segment changes occurring dur-
ing ablation at the mitral isthmus.923 These patients have var-
iably undergone unsuccessful intracoronary vasodilators or
thrombectomy and have had to progress to coronary stenting.
A single case presenting 48 hours after mitral isthmus ablation
with total circumﬂex occlusion and ventricular arrhythmia
storm is described as having ongoing ventricular arrhythmia
requiring ablation and deﬁbrillator implantation, highlighting
the potential for ongoing consequences as a result of coronary
artery injury.1234
The sinus node artery originates from the proximal
circumﬂex artery in one-third of cases and then courses along
the anterior LA and then the septal SVC, and could therefore
be susceptible to injury during ablation. In the above series,
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dysfunction.1233 In most of these cases, the culprit site was
adjacent to the sinus node artery (per CT) at the anterior
LA or septal RA. All these cases presented with sinus arrest
during or within 1 hour of ablation and with no evidence of
any other electrocardiographic changes associated with coro-
nary occlusion. Two of these patients eventually required
permanent pacemaker insertion with signiﬁcant atrial pacing
during follow-up. Others have described a more transient si-
nus node dysfunction due to occlusion of the sinus node ar-
tery.1235
The cavotricuspid isthmus can be ablated in conjunction
with AF ablation. This region is in close proximity to the
RCA, and injury to this vessel has been described.1236,1237
These have occurred both acutely and later during the case,
and with both septal and lateral approaches to the ablation.
In addition to the direct injury and occlusion at the sites of
ablation, a single case of thromboembolic occlusion of the left
anterior descending artery the day after ablation has been
described.1238 This case was known to have factor V Leiden
mutation, was therapeutically anticoagulated with an INR of
2, and the activated clotting time had been maintained be-
tween 280 and 390 seconds. Angiography demonstrated
thrombus in the left anterior descending artery, requiring inter-
vention. This case highlights the need for meticulous anticoa-
gulation, sheath management, and physician awareness of the
potential for thromboembolism to present as coronary occlu-
sion. Although presentation with acute coronary artery occlu-
sion is low, the possibility of thermal injury without occlusion
and the possibility of subsequent remodeling leading to steno-
sis of a coronary artery should be considered. The most
vulnerable location for this would appear to be the circumﬂex
vessel during ablation of the mitral isthmus. In a series of 54
patients who had undergone mitral isthmus ablation, coronary
angiography was performed before and after ablation.1239
Fifteen patients (28%) had angiographic changes following
ablation, eight with midcircumﬂex narrowing, one with
circumﬂex and obtuse marginal narrowing, one with obtuse
marginal narrowing only, and ﬁve with distal circumﬂex nar-
rowing or occlusion. A further ﬁve had signiﬁcant narrowing
that resolved with intracoronary vasodilators. Patients with
such coronary arterial changes had a signiﬁcantly longer abla-
tion time within the CS. Therefore, limiting excessive abla-
tion, particularly in areas adjacent to the coronary
vasculature, should be a consideration in planning the ablation
strategy. In the intraoperative setting, late coronary stenosis
has been described at sites of previous ablation.1240
There can be several determining factors in the develop-
ment of coronary artery injury during AF ablation. These
include the degree of protective epicardial adiposity, coro-
nary blood ﬂow, and the intensity and duration of ablation;
however, the most predictable is that of the location of abla-
tion adjacent to the course of the coronary artery. Careful
monitoring and avoiding high-power energy delivery in the
vicinity of these vessels are potentially important in mini-
mizing the risk of arterial injury.Radiation Exposure During Catheter Ablation of AF
An important, less easily recognized, and rarely considered
potential complication of AF ablation is the delayed effect
of the radiation received by the patients, including acute
and subacute skin injury, malignancy, and genetic abnor-
malities.1,1241,1242,1243,1244,1245,1246,1247 Fluoroscopy is
required for most components of the procedure, including
catheter placement, positioning a multielectrode catheter
into the CS, double transseptal catheterization, PV
angiography, and LA ablation. A survey of the writing
group members reveals that two-thirds use single-plane
ﬂuoroscopy, whereas one-third employ biplane. One study
reported a mean ﬂuoroscopy time .60 minutes, with corre-
sponding higher effective radiation doses in obese pa-
tients.1244,1246 By using a vest containing 50–60
dosimeters to measure peak skin doses (PSDs), another
study reported a mean PSD of 1.0 6 0.5 Gy in the right
anterior oblique and 1.5 6 0.4 Gy in the left anterior
oblique projection, during a mean ﬂuoroscopy time of
67.8 6 21 minutes.1245 They estimated an overall lifetime
risk of excess fatal malignancies normalized to 60 minutes
of ﬂuoroscopy of 0.07% for women and of 0.1% for
men.1245 The relatively low radiation exposure to the pa-
tients in this study despite the prolonged ﬂuoroscopy dura-
tions was attributable to the state-of-the-art very low pulsed
ﬂuoroscopy frame rate, the avoidance of magniﬁcation, and
the optimal adjustments of ﬂuoroscopy exposure rates. The
resulting lifetime risk of malignancy was thus within the
range previously reported for ablation of supraventricular
tachycardias. However, this study demonstrated that cath-
eter ablation of AF required signiﬁcantly greater ﬂuoros-
copy duration and radiation exposure than simpler
catheter ablation procedures. Thus, and especially because
AF ablation procedures often need to be repeated, electro-
physiologists should make every attempt to minimize radi-
ation exposure.
Increasing availability and familiarity of electrophysiolo-
gists with 3D mapping systems, as well as the availability of
CF monitoring, have signiﬁcantly reduced ﬂuoroscopy time
and the need for ﬂuoroscopy in recent years.747,1186,1248,1249
This can only be achieved, however, by an awareness of the
importance of reducing ﬂuoroscopy time, and therefore
radiation exposure, by the operator.1250 It has been shown
that use of optimized conventional ﬂuoroscopy and optimized
use of 3D mapping can result in a marked reduction in radia-
tion exposure.1251 It is also important to recognize that ﬂuoros-
copy time is only weakly linked to true radiation exposure,
because it does not reﬂect the ﬂuoroscopy equipment being
used, nor patient-speciﬁc factors such as obesity. The use of
remote navigation for PVI appears to be effective, with fewer
periprocedural complications and signiﬁcant reductions in ﬂuo-
roscopy exposure for both patient and operator.749,1252,1253
Another interesting option to minimize radiation exposure
to the operator and to alleviate the orthopedic implications
of conventional lead aprons is the use of a radioprotection
cabin or a suspended lead apron.1254
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without using ﬂuoroscopy or with extremely limited ﬂuoros-
copy. To safely navigate catheters in the heart with no ﬂuo-
roscopy, intracardiac ultrasound is mandatory, as well as
imaging integration with preacquired CT or MRI.763,1255,1256
Pericarditis
More than 50% of the patients who undergo catheter ablation
of AF note some pleuritic chest pain in the ﬁrst several days
following their procedure. It is also common to observe a
“trace” pericardial effusion following AF ablation. These
largely self-limited manifestations of AF ablation-induced
pericarditis are so common and of so little consequence
that they are considered as part of the standard clinical course
for patients who undergo AF ablation rather than as a compli-
cation of the procedure. A small subset of these patients will
go on to develop more severe and clinically signiﬁcant man-
ifestations of pericarditis. In two recent multicenter registries,
pericarditis has been reported to occur in 0.1% and 0.6% of
patients, respectively.1059,1257 When transmural lesions are
generated during catheter ablation of AF, some epicardial
inﬂammation, and therefore some pericarditis, is inevitable.
However, more extensive pericarditis can complicate AF
ablation procedures both acutely and at some delay. These
presentations include Dressler syndrome, pericarditis
leading to delayed cardiac tamponade, and constrictive
pericarditis.1258,1259,1260 These severe manifestations and
consequences of pericarditis presented between 18 days
and 3 months after their ablation procedures. The standard
international practice for a short hospital stay after AF
ablation procedures can contribute to an underappreciation
of early postablation pericarditis.
There is currently no evidence to support the use of
nonsteroidal anti-inﬂammatory drugs (NSAIDs) or steroids
to prevent AF recurrences. A single bolus injection of low-
dose hydrocortisone (100 mg) reduced the incidence of peri-
carditis from 2.5% to 1.1% in one recent series from Japan,
but no difference in early or late recurrences was found after
AF ablation.1261 Another Japanese study also failed to
demonstrate a reduction in immediate, early, or midterm
AF recurrence with either a low-dose (hydrocortisone 100
mg) or moderate-dose (methylprednisolone 125 mg) single
steroid bolus.
Colchicine is currently the cornerstone of pericarditis
treatment that occurs outside of the AF ablation setting,
although speciﬁc data after AF ablation are lacking. In
one trial, however, in which patients were randomized to
a 3-month course of colchicine (0.5 mg twice daily) or pla-
cebo, early recurrence was signiﬁcantly reduced (33.5% of
placebo patients vs 16% for colchicine), and this was
strongly associated with a reduction in inﬂammatory medi-
ators such as IL-6 and C-reactive protein. After a 15-month
follow-up, a 37% reduction in the RR of AF recurrence was
observed (number needed to treat 5 6).985 In a subsequent
randomized study of 233 patients with PAF, these investi-
gators reported that the long-term recurrence rate was31% among the patients treated with colchicine vs 49%
among the placebo patients. Colchicine also resulted in an
improvement in QOL.986Mitral Valve Trauma and Curvilinear Catheter
Entrapment
Entrapmentof a circularmultielectrodemappingcatheter by the
mitral valve apparatus is an uncommon but established compli-
cation of AF ablation.1262,1263,1264,1265,1266,1267,1268,1396
It results from inadvertent positioning of a circular electrode
catheter close to the mitral valve or into the left ventricle,
often during attempts to position the catheter into the LIPV or
when using such catheters to create electroanatomical maps
of the LA. This complication should be suspected when
attempts to reposition the catheter into another PV are met
with resistance. When suspected, it is important to conﬁrm
the diagnosis with echocardiography. Although successful
freeing of the catheter has been reported with gentle
clockwise catheter manipulation and advancing the sheath
into the ventricle in two patients, there have also been a
number of cases reported in which the mitral valve apparatus
and/or papillary muscles are torn during attempts to free the
catheter.1263,1264,1268,1269,1396 There have also been several
cases reported in which the distal tip of the circular catheter
broke off during attempts at catheter removal and had to be
subsequently removed either with a snare or with an open
surgical procedure.1263,1265,1266 We recommend that if gentle
attempts to free the catheter fail, elective surgical removal of
the catheter should be performed.
It is important for all electrophysiologists who perform
AF ablation to be aware of this potentially serious
complication. Every effort should be made to be certain
that the circular catheter is kept safely away from the
mitral valve and that only clockwise torque be applied
to the catheter, with particular care taken when approach-
ing the LIPV. The incidence of this rare complication is
unknown, but might have decreased in recent years due
to improved awareness.
Limited data are available regarding outcomes of AF abla-
tion in patients with prosthetic valves. One small, matched
cohort study suggested that long-term outcomes might be
similar, but ablation procedures were longer and were associ-
ated with a numerically higher rate of complications in pa-
tients with prior mitral or aortic valve replacement
(AVR).908 The development of new perivalvular leak
following AF ablation in a patient with a mitral prosthesis
has been reported, suggesting that care should be taken
when ablating near the annulus in such patients.921Mortality Risk with AF Ablation
Although AF ablation is generally considered to be safe,
devastating complications can occur rarely, some being fatal.
In a recent survey, death was reported in 32 of 32,569 (or 1 in
1017) patients undergoing AF ablation procedures world-
wide.1039 The most frequent cause of death was cardiac
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occurred later than 30 days after the procedure. Stroke was
responsible in 16% of the cases, of which 6% occurred later
than 30 days. AEF also accounted for 16% of the deaths, with
extensive pneumonia responsible for 6%. Less common
causes of death observed in the periprocedural phase
included myocardial infarction, irreversible torsades de
pointes, septicemia, sudden respiratory arrest, extrapericar-
dial PV perforation, occlusion of both lateral PVs, hemo-
thorax, and anaphylaxis, which were each responsible for
3% of early deaths.
Twenty-two percent of all deaths occurred more than 30
days after the procedure. Among the identiﬁed causes of
late death were asphyxia from tracheal compression second-
ary to subclavian hematoma, intracranial bleeding, acute res-
piratory distress syndrome, and esophageal perforation by the
intraoperative TEE probe, with each cause contributing to 3%
of all late deaths.
It should be noted that these reported mortality risks of AF
ablation came mostly from experienced operators and cen-
ters. In the community setting, the mortality risk of AF abla-
tion can be much higher. Indeed, one study of 93,801 patients
undergoing AF ablation in the United States between 2000
and 2010 showed that one in 238 AF ablation patients were
never discharged alive following their procedure. These mor-
tality risks were due primarily to inexperienced operators
who performed fewer than 25 procedures annually, and to
low-volume hospitals that performed fewer than 50 proced-
ures annually.921
When a 30-day all-cause mortality deﬁnition is used for
AF ablation, AF ablation mortality rises to 1 in 125 patients
within the Medicare population (mean age of 72).921 Aware-
ness about the risk of death and the possible causes might
help physicians set more appropriate and efﬁcient standards
for procedural safety, and need to be considered in the pa-
tient’s decision-making process.Stiff Left Atrial Syndrome
First described after mitral valve surgery in 1988, stiff LA
syndrome was recognized as a rare complication of LA cath-
eter ablation in 2011.1110,1111,1270,1271,1272,1273 One early
report described a series of three patients with unexplained
exertional dyspnea, LA hypertension, and large V waves
on LA pressure or pulmonary capillary wedge pressure
(PCWP) tracings after multiple surgical LA ablation
procedures.1271 A subsequent study prospectively collected
1380 consecutive patients undergoing ablation, obtaining
echocardiograms before and after ablation to assess for pul-
monary hypertension.1272 Excluding patients with PV steno-
sis or signiﬁcant mitral valve disease, there were 19 patients
(1.4%) with new or worsening pulmonary hypertension, LA
diastolic abnormalities, and clinical ﬁndings of dyspnea, HF,
pulmonary hypertension (mean PA pressure 25 mm Hg or
during exercise 30 mm Hg), and large V waves (10 mm
Hg and higher than mean LA pressure tracings) on PCWP or
LA pressure tracings. Other authors reported worsened pul-monary hypertension (echocardiographic right ventricular
systolic pressure (RVSP) .35 mm Hg with increases of
.10 mm Hg) in 41 of 499 patients (8.2%) by 3 months after
ablation.1110 These studies were ﬂawed, however, by the low
cutoff for diagnosing PA hypertension, particularly after an
ablation with excess volume delivery. Stiff LA syndrome
was also reported in 9 patients after surgical maze proced-
ures, presenting with unexplained dyspnea, severe pulmo-
nary and LA hypertension, giant LA V waves, absent LA
or LV Awaves, blunted X descents, and elevated left ventric-
ular end-diastolic pressure attributed to abnormal LA compli-
ance and contractility.1274
Studies have identiﬁed small LA size (45 mm), high
mean LA pressure, severe LA scarring (.60%), diabetes
mellitus (DM), and OSA as independent predictors of pulmo-
nary hypertension or stiff LA syndrome postablation.1272 The
potential importance of scar burden and the extent of RF abla-
tion to LA stiffness or function has also been noted by other
investigators. In another study of 26 patients with mean
follow-up of 80 months, LA scar by MRI was related to
the number of procedures, total RF duration, LAA EF, and
expansion index.1275 LAAEF correlated with exercise capac-
ity at follow-up, and LA scar extent had a negative correla-
tion with exercise capacity. Another study reported that LA
stiffness index, derived from invasive pressure measurements
and cardiac MRI volumes during sinus rhythm (DP/DV) was
higher in patients with persistent rather than PAF, older age,
and prior LA ablation.1276 A subsequent study reported that
in 70 patients with 12-month follow-up, LV diastolic
dysfunction worsened in 27% and correlated with total abla-
tion time, concluding that more aggressive ablation might
aggravate diastolic dysfunction.1145
The stiff LA syndrome fortunately appears to be largely
responsive to diuretic therapy. One study reported that all
19 of their patients had symptomatic improvement after
diuretic therapy, noting that diuretics appeared more effective
for this syndrome than for other forms of pulmonary hyper-
tension.1272 In contrast, another study reported a case of stiff
LA syndrome after two AF catheter ablation procedures that
failed with furosemide and spironolactone, but which re-
sponded to sildenaﬁl.927
In summary, stiff LA syndrome or worsened pulmonary
hypertension appears to occur in 1.4%–8% of patients after
AF RF catheter ablation. The diagnosis of stiff LA syndrome
after AF or LA ablation should be sought for patients who pre-
sent with unexplained dyspnea with signs of right HF. Diag-
nosis can be made by signs of right HF in the presence of
preserved left ventricular function, pulmonary hypertension
(mean PA pressure 25 mm Hg or during exercise 30 mm
Hg), and large V waves (20 mm Hg and higher than mean
LA pressure tracings) on PCWP or LA pressure tracings in
the absence of signiﬁcant mitral valve disease or PV stenosis.
We also recommend that to reduce the risk of stiff LA syn-
drome, judicious use of extensive LA ablation be considered
in patients with small LA size, high LA pressures, preexisting
severe LA scarring, DM, or OSA. Patients with stiff LA syn-
drome usually respond well to diuretics.
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Cough is a speciﬁc respiratory symptom that can occur after
catheter ablation of AF. It might be a sign of underlying PV
stenosis, PN injury, direct bronchial injury, stiff LA syn-
drome, gastroesophageal reﬂux, pulmonary embolism, peri-
carditis, or other iatrogenic respiratory complications such
as ventilator-associated pneumonia or postprocedure aspira-
tion pneumonia. Although there is a paucity of data on the
incidence and mechanisms of postprocedure cough, the un-
derlying mechanisms can vary according to the ablation tech-
nology.
After RF ablation, cough might point to the presence of
RF-induced PV stenosis. Whereas mild PV stenosis is
frequently asymptomatic, patients with more extensive and
severe PV narrowing can present with cough, dyspnea, chest
pain, or hemoptysis.1152,1200 Similarly, another study
reported that in 18 patients with severe PV stenosis, 7
(39%) reported cough.462 Cough might also be a sign of
RF-induced PN injury. Although a rare complication
(0.48%), RF-induced PN injury is frequently (9 of 22 pa-
tients) associated with immediate features of dyspnea, cough,
hiccup, and/or sudden diaphragmatic elevation.1277
Cough following CBA is more frequent. In fact, as many
as 1 in 6 patients can develop a dry cough following CBA,
which is usually self-limiting in 91%.1278 Whereas the
most evident mechanism for postprocedure cough is that of
CBA-induced PN injury (up to 11%), some reports suggest
that the cough is caused by direct upper airway irritation dur-
ing CBA (bronchial or pulmonary injury).1278 In an experi-
mental model, Aryana et al showed that CBA can elicit
direct and acute bronchial inﬂammation, bleeding, and
mucosal injury.1277 A recent study reported ice formation
within the left main-stem bronchus using real-time bronchos-
copy during CBA.583,584 Given the increasing number of
case reports detailing respiratory complaints after CBA, a
systematic examination of the short- and long-term conse-
quences of CBA on normal bronchial tissue during PVI is
warranted.Increase in Heart Rate and/or Sinus Tachycardia
A subset of patients will experience a signiﬁcant increase in
their resting sinus heart rate following AF ablation.110
Although this typically results in a 10–20 beats per minute
(bpm) increase in heart rate (well below the 100 bpm
threshold to classify the increase as sinus tachycardia), the re-
sulting increase in heart rate can exceed 100 bpm in a very
small subset of patients. This phenomenon is related to shifts
in autonomic tone following ablation and is predictive of
ablation success. This shift in autonomic tone results from
ablation of GP that are commonly located near the PV antra,
as previously discussed.110,121 Stimulation of GP has been
shown to elicit AF by producing repetitive bursts of rapid
focal PV ﬁring, and ablation of GP can play a role in AF
treatment.257,577,1279 Following ablation of GPs, signs of
parasympathetic withdrawal such as increased heart rate
and attenuated heart rate variability can be observed, andthese signs have been associated with improved procedural
outcomes.118,126,577,1280,1281 Although the increase in heart
rate and reduction in heart rate variability after ablation
typically follow a transient time course, with resolution
within 3 months, some studies have shown that the long-
term persistence of these autonomic changes is associated
with improved clinical outcomes.126 These clinical data are
consistent with experimental ﬁndings demonstrating a reduc-
tion in stellate ganglion nerve activity and subsequent AF
with continuous low-level vagal nerve stimulation.1200
Thus, the observation of increased heart rate following abla-
tion can be a normal ﬁnding with potential positive prog-
nostic implications regarding outcomes and is not
necessarily a procedural complication per se.Section 11: Training Requirements
Overview
The strategies, speciﬁc methods, and technology pertaining
to AF ablation are evolving. Accordingly, the guidelines
for training to perform this procedure must be ﬂexible in
recognition of various approaches and technologies that
will change with advances in the ﬁeld. Training for AF abla-
tion should encompass six fundamental principles: (1) appro-
priate selection of patients; (2) knowledge of the anatomy of
the atria and adjacent structures; (3) conceptual knowledge of
strategies to ablate AF; (4) technical competence; (5) recog-
nition, prevention, and management of complications; and
(6) appropriate follow-up and long-term management.
The training required in each of these areas differs from
other ablation procedures because, in comparison, ablation
of AF is technically more difﬁcult, is associated with greater
risks, and requires more careful follow-up.Appropriate Selection of Patients
Trainees should recognize clinical attributes that can increase
the difﬁculty of a transseptal puncture, increase the risk of the
procedure, and affect short- and long-term outcomes. These
factors are discussed in Sections 8 and 9 of this document.
The trainee should also develop the judgment to decide
whether conscious sedation or general anesthesia would be
most appropriate for the case under consideration. It is also
important to assess the severity of symptoms related to AF
and the potential beneﬁt of an ablation procedure. Trainees
should be experienced in counseling patients about the poten-
tial risks and beneﬁts of, as well as the alternatives to, an abla-
tion procedure and should be able to apply this knowledge for
recommendations speciﬁc to the needs of individual patients.
They should also take into consideration the prior use of
AADs and pharmacological alternatives to AF ablation.
It is also important for electrophysiologists involved with
catheter ablation to be knowledgeable about surgical ablation
techniques for AF. In particular, electrophysiologists who
perform AF ablation procedures must be aware of the indica-
tions, techniques, and outcomes of surgical approaches for
AF ablation. This applies both to the new minimally invasive
surgical approaches, AF surgery combined with other cardiac
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Section 12).Anatomy of the Atria and Adjacent Structures
Detailed knowledge about the anatomy of the LA and its
adjacent structures is crucial for performing the technical as-
pects of transseptal puncture and cannulation, LA mapping,
and isolation of the PVs or modiﬁcation of the substrate
that sustains AF. The trainee must recognize the anatomic
relationship of the atria, SVC, and PVs to the pulmonary ar-
teries, aorta, mitral annulus, PNs, sympathetic and parasym-
pathetic innervation, esophagus, and other mediastinal
structures (Figure 1). These anatomic relationships affect
the ability to perform the procedure successfully and to avoid
complications.Conceptual Knowledge of Strategies to Ablate AF
Trainees should understand the pathophysiology of AF and
its implications for strategies to ablate AF. This includes
the role of the PVs, the SVC, the musculature of the LA,
and the potential impact of autonomic stimulation. They
should understand the rationale for isolation of the PVs and
elimination of the foci that trigger AF, as well as the basis
for broad circumferential ablation of tissue or elimination
of fractionated potentials or other technologies that appear
to alter the substrate that sustains AF.Technical Competence
The technical skills needed for ablation of AF are substantial.
These include anticoagulation management, transseptal nee-
dle puncture and cannulation of the LA, precise manipulation
of the catheter for mapping and ablation, identiﬁcation of the
pulmonary ostia, adjustment of the energy used for ablation,
and the appropriate use of ﬂuoroscopy, radiographic contrast
for imaging, 3D mapping systems and/or ICE. Simulation
technologies are evolving that could help trainees gain
experience with fundamental techniques in the early phase
of learning procedural skills or the recognition and
management of acute complications such as cardiac
tamponade.1250,1282,1283 There are substantial differences
among laboratories in the use of radiographic contrast
imaging, EAM or echocardiography, and the number and
types of catheters used to identify electrical endpoints and
to perform ablation. The degree of expertise gained in the
use of a speciﬁc technology will depend on where training
is completed, as well as the duration of training.
Nonetheless, trainees should be expected to understand the
potential advantages and limitations of these systems and
should have the ability to interpret basic images and
electrical recordings obtained from these various
methodologies. They should be well versed in the
principles of radiation safety for patients and the medical
personnel who perform ablation procedures.
Training programs should emphasize the interpretation of
intracardiac electrograms for recognition of PV potentialsand determination of when electrical isolation of a PV has
been achieved, the role of CS and LAA pacing in the differ-
entiation of far ﬁeld electrograms from PV potentials, identi-
ﬁcation of fractionated low-amplitude LA potentials, and
techniques required to map and ablate right and/or LA tachy-
cardias or AFL. Concepts related to entrainment are espe-
cially important. Trainees need to be skilled in identifying
the presence, mechanism, origin, and ablation of other supra-
ventricular tachycardias that could act as triggering mecha-
nisms for AF, such as AV nodal reentrant tachycardia and
AV reentrant tachycardia. Training and competence in RF
catheter ablation are essential because this ablation technol-
ogy is needed for ablation of typical and atypical AFL.
Many electrophysiology laboratories also use RF energy as
the preferred energy source for ablation of AF. Many other
electrophysiologists prefer CBA for their AF ablation pro-
cedures. Other ablation technologies that are currently avail-
able in some parts of the world include laser balloon ablation
and ablation using circular multielectrode RF ablation cathe-
ters. Trainees should be familiar with the advantages and lim-
itations of each energy source and associated delivery
system.
Procedural Experience
The 2015 American College of Cardiology/American Heart
Association/Heart Rhythm Society Advanced Training State-
ment on Clinical Cardiac Electrophysiology proposed a min-
imum of 5 ﬁve focal ATs, 30 macroreentrant ATs (including
20 isthmus- and 10 nonisthmus-dependent/complex macro-
reentry) and 50 AF ablation procedures for those who un-
dergo fellowships in clinical cardiac electrophysiology.1284
The writing group members are supportive of the require-
ment that trainees perform at least 50 AF ablation procedures
and at least 30 macroreentrant ATs (including 20 isthmus-
and 10 nonisthmus-dependent/complex macroreentry) dur-
ing fellowship training. Furthermore, the writing group rec-
ommends that those performing the procedure perform at
least several AF ablation procedures per month to maintain
competence.
These numbers underestimate the experience required
for a high degree of proﬁciency.991,992,1082,1285,1286 Exact
numerical values are difﬁcult to specify because
technical skills develop at different rates. Nonetheless,
comparisons of high- and low-volume centers suggest
that outcomes are better at centers that have performed
more than 100 procedures.806 Other data report improved
outcomes for operators with an annual procedure volume
of at least 25 cases and for centers with an annual proced-
ure volume of at least 50 cases.921 Moreover, the selection
of patients and interpretation of AFL and other ATs that
are often observed in patients with AF require training
that is unique to electrophysiology fellowships. Trainees
who intend to perform AF ablation independently should
receive additional training after the standard fellowship
is completed if they performed fewer than 50 AF ablation
procedures during training.
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Complications
As previously discussed, ablation of AF is associatedwith sub-
stantial risks that must be recognized. Training programs must
emphasize techniques that reduce these risks. This includes
careful manipulation of catheters, appropriate use of anticoa-
gulation, modiﬁcation of energy delivered on the posterior
wall of the LA, and the risk of applying energy within the
PVs or LAA. Fellows should be trained to suspect cardiac tam-
ponade or internal bleeding as a common cause of hypoten-
sion. Training should also include management of these
complications. The skills to perform an emergent echocardio-
gram when cardiac tamponade is suspected are important. It is
preferable for fellows to undergo training in pericardiocente-
sis. If trainees do not gain proﬁciency in pericardiocentesis,
they must be able to recognize and diagnose cardiac tampo-
nade and have immediate access to a physician who can
perform an emergency pericardiocentesis. They should under-
stand the risks of conscious sedation, which include hypoven-
tilation, aspiration, and respiratory arrest. They should also
recognize the delayed time course associatedwith the develop-
ment of AEFs or PV stenosis, as well as the appropriate steps
needed to diagnose and manage these complications.
Appropriate Follow-up and Long-TermManagement
Management of patients after hospital discharge can be com-
plex and requires commitment from the physician (cardiolo-
gist or internist) who will be following the patient on an
ongoing basis. Individuals undergoing training in AF ablation
should participate in a longitudinal clinic in which these pa-
tients are followed. Experience must be gained in diagnosis
and management of postprocedure complications, including
esophageal injury, PV stenosis, and late tamponade, pseudoa-
neurysm, or arteriovenous ﬁstula. Because the prevalence of
some of these complications is very low, it is possible that
the trainee will not have ﬁrst-hand experience with patients.
Therefore, supplementation of clinical experience with didac-
tic presentations on diagnosis and management of postablation
complications is required. Prophylaxis against and manage-
ment of postprocedure atrial arrhythmias, including timing
of repeat ablation and use of concomitant AADs, must be
taught to trainees. Finally, the training experiencemust address
the risk-beneﬁt decision-making regarding the use of interme-
diate and long-term anticoagulation therapy. Given the
complexity of these issues, it would be ill-advised for cardiol-
ogists who are not trained in electrophysiology to consider per-
forming ablation procedures for AF. Due to these issues and
prerequisites for obtaining and maintaining competency, this
statement should also extend to the performance of cryoabla-
tion or other balloon ablation.Section 12: Surgical and Hybrid AF Ablation
Historical Considerations and Development of the
Cox-Maze Procedure
There is a rich history of surgery for AF. Initial procedures
were aimed at controlling the ventricular response rate. Laterprocedures were directed at converting AF to a normal sinus
rhythm. Following experimental investigation, the Maze pro-
cedure was introduced for the surgical treatment of AF in
1987 by James Cox. This procedure was designed to interrupt
macroreentrant circuits, thereby reducing the ability of the
atrium to ﬁbrillate. Fortuitously, the surgery also isolated
all of the PVs and the posterior LA. In contrast to previous
procedures, such as the corridor procedure and LA transec-
tion procedures, the Cox-Maze procedure successfully
restored both AV synchrony and sinus rhythm and decreased
the incidence of late stroke.1287 This effect was attributed to
both AF control and amputation of the LAA. The surgery
involved creating multiple strategically placed incisions
across both the RA and LA. The surgical incisions were
placed so that the sinus node could “direct” the propagation
of the sinus impulse throughout both atria. It also allowed
most of the atrial myocardium to be activated, resulting
in preservation of atrial transport function in
most patients.1288 The ﬁnal iteration of this procedure, the
Cox-Maze III, became the standard for the surgical treatment
of AF.
Long-term outcomes of 198 patients who underwent the
Cox-Maze III procedure for treatment of paroxysmal (n 5
113) or persistent or long-standing persistent AF (n 5 85)
have been reported.1289 The mean follow-up was 5.4 6
2.9 years. Among the 112 patients who underwent surgery
only for AF treatment, 96% were in sinus rhythm with or
without AAD therapy and 80% were in sinus rhythm and
free of AAD therapy at the last follow-up. Among the 86
patients who underwent AF surgery in conjunction with
other cardiac surgery, 97% were in sinus rhythm with or
without AAD therapy and 73% were in sinus rhythm
free of AAD therapy. The incidence of major complica-
tions among the 112 patients who only underwent AF sur-
gery was 11%. Among these were two perioperative deaths
and two perioperative strokes or TIAs. Nine patients (8%)
required pacemaker placement. The incidence of major
complications among the 86 patients who underwent AF
surgery at the time of other cardiac surgical procedures
was 14%. Among these were one perioperative death
and one perioperative stroke. Twenty patients (23%)
required pacemaker placement.
In considering the results of these early reports of cardiac
surgery for treatment of AF, it is now recognized that these
patients did not undergo rigorous follow-up by present stan-
dards. Rhythms were documented by means of a mailed
questionnaire, telephone interview, and/or an ECG for docu-
mentation. It is clear that the pioneering work of Cox and his
team paved the way for the current, less invasive Cox-Maze
IV surgery and other surgical approaches for AF ablation, as
well as the ﬁeld of endocardial catheter ablation of AF.
The term lone AF holds different meanings in EP jargon
compared with surgical jargon. Electrophysiologists refer to
lone AF when there is no other structural heart disease pre-
sent. Surgeons often refer to a lone AF procedure as one in
which the only surgical procedure performed is the ablation
as opposed to a concomitant procedure. To eliminate
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to describe populations of AF patients, and furthermore, we
recommend the term stand-alone ablation when no other
concomitant procedure is performed at the same operative
encounter. As noted earlier in the document, the writing
group recommends that the term lone AF not be used in
any context related to AF or AF ablation.Surgical Ablation Technology
Despite its efﬁcacy, the Cox-Maze procedure did not gain
widespread application due to its complexity, technical difﬁ-
culty, and morbidity. The development and subsequent avail-
ability of technology to perform atrial ablation allowed
surgeons to replace some of the traditional cut-and-sew le-
sions with ablation lines using this technology. The simpli-
ﬁed Cox-Maze procedure lessened procedural morbidity,
thus leading to wider adoption and extending its beneﬁts to
more patients. Although a variety of energy sources for abla-
tion were initially developed, only cryothermy and RF en-
ergy delivery have emerged as practical and efﬁcacious.
The only surgical ablation system approved and speciﬁcally
labeled for surgical AF ablation is the Atricure Ablation Sys-
tem, which includes a number of ablation tools, including a
bipolar RF clamp.1290
Cryothermy can be thought of as nondirectional
(although shielding mechanisms can be employed),
whereas RF is a directional source. The RF technologies
can be organized into two major groups: unipolar and bipo-
lar. Bipolar RF can be directional bipolar or constrained bi-
polar. The directional bipolar devices have two side-by-side
poles that are applied to the tissue surface, with the energy
passing through the tissue between them. As the tissue be-
tween the poles desiccates and the impedance rises, the en-
ergy passes deeper into healthy tissue, with the goal of
tissue transmurality.
The constrained bipolar devices consist of a clamp with
two jaws, which are applied on opposite sides of the atrial tis-
sue. The energy passes through the tissue between the two
jaws. When conductance falls, transmurality is inferred.
The unipolar devices do not provide the surgeon with a trans-
murality indicator. Since most of these ablation systems were
released clinically without dose-response studies, their use
has led to occasional collateral cardiac and extracardiac dam-
age.1162,1291,1292 Moreover, both unipolar and directional
bipolar energy sources have had difﬁculty creating
transmural lesions when used from the epicardial surface
on the beating heart.1293,1294,1295,1296,1297,1298 This
difﬁculty occurs because the circulating intracavitary blood
pool produces convective cooling, which makes transmural
lesions difﬁcult to achieve.1299 In an attempt to obviate this
problem, one device provides suction to pull two walls of
atrial tissue into apposition in a shallow trough, thus
excluding the circulating heat sink of intracavitary blood
while the energy is applied. All of these energy sources
have a ﬁxed depth of penetration, which makes their use in
pathologically thickened atria problematic.Bipolar RF ablation has overcome some of these short-
comings. Because energy is delivered between two closely
approximated electrodes embedded in the jaw of a clamp
device, the energy is focused and results in discrete
lesions. The energy is conﬁned to between the jaws of
the clamp, reducing the possibility of collateral cardiac
or extracardiac damage. By measuring the tissue conduc-
tance between the two electrodes, algorithms have been
developed that help predict lesion transmurality in the
experimental laboratory. The weakness of these devices
is that they can only ablate tissue that can be clamped
within the jaws of the device. This problem has limited
the potential lesion sets, particularly in the beating heart.
Moreover, in the clinical situation, multiple ablations
have often been required to achieve entrance and exit
block. These devices have been incapable of fully ablating
the RA and LA isthmus and have required adjunctive cry-
othermy, or unipolar or directional bipolar RF ablation to
perform a complete Cox-Maze III lesion set.
Nevertheless, the development of these new ablation
technologies has beneﬁted the surgical treatment of AF
by making a technically difﬁcult and time-consuming sur-
gery easier for all cardiac surgeons to perform. At present,
more than 50% of the patients undergoing open-heart
surgery who have AF are offered concomitant AF sur-
gery.1300 Replicating the full Cox-Maze lesion set with
linear lines of ablation has been shown to be both
feasible and clinically effective. A number of groups
have reported excellent results with ablation-assisted
Cox-Maze procedures.1301,1302,1303,1304,1305,1306
The largest of these experiences included 282 patients
who underwent the Cox-Maze IV procedure over a 7-year
period with either paroxysmal (n 5 118), persistent (n 5
28), or long-standing persistent AF (n 5 135).1301 A total
of 124 patients (44%) underwent surgery only for AF treat-
ment, and 158 patients (56%) had other cardiac surgery per-
formed, which included mitral valve surgery in
approximately 50% of patients. Among the entire patient
cohort, 89% of the patients were in sinus rhythm with or
without AAD therapy, and 78% were in sinus rhythm and
free of AAD therapy at 12 months of follow-up. In contrast
to early studies on surgical AF ablation, more intensive moni-
toring was performed with Holter monitors every 3 months in
70% of the patients. The incidence of major complications
was 11%, including an operative mortality of 2% and a
1.7% incidence of stroke. Pacemakers were implanted in
9% postoperatively. A propensity analysis, matching patients
who underwent an ablation-assisted Cox-Maze with those
having had a traditional cut-and-sew Cox-Maze III, showed
no differences in freedom from AF at 3, 6, and 12 months
of follow-up.1307 Further recent work has shown signiﬁcantly
improved results when the entire posterior LA is excluded by
the so-called box lesion.1306,1308
A long-term study followed 576 patients from 2002 to
2014 with long-term monitoring.1306 At 5 years, freedom
from ATAs was 73% (102 of 139) and freedom from
ATAs off AADs was 61% (80 of 135). There was no
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more persistent forms. There was also no difference between
outcomes for those patients who had stand-alone procedures
and those who had concomitant procedures. Because out-
comes were signiﬁcantly better at 12 months of follow-up
(92% freedom from ATAs overall and 88% freedom from
ATAs off AADs), this paper highlights the importance of
long-term follow-up. Currently, the limitations of the energy
delivery devices and the attempt to deploy them through min-
imal access incisions or ports place constraints on the loca-
tion and number of ablation lesions that can be performed.
The impact on results of these alternative lesion patterns
and the less invasive surgical approaches requires further
observational prospective analysis and randomized trials.
There has only been one completed trial of concomitant
surgical AF ablation that has resulted in speciﬁc FDA label-
ing for clinical treatment of AF.1290 This was the Atricure
Synergy Ablation System trial intended for the ablation of
persistent and long-standing persistent AF in patients who
are undergoing open concomitant coronary artery bypass
grafting (CABG) and/or valve replacement or repair. The
principal device used in this trial was an Atricure Synergy
Ablation clamp. This system had originally been approved
by the FDA for soft tissue ablation without speciﬁcally label-
ing for AF ablation. This prospective nonrandomized clinical
trial, using a Bayesian adaptive design with prespeciﬁed
early stopping rules, enrolled 55 patients between February
2008 and June 2009. Along with concomitant cardiac sur-
gery, investigators performed the Cox-Maze IV lesion set.
The median patient age was 72 years, the median EF was
50%, and the median LA size was 6 cm. 56% of patients un-
derwent valve surgery alone or in conjunction with CABG.
The incidence of major adverse events was 9%, including
death in 2 patients (3.6%), major bleeding in 2 patients
(3.6%), and stroke in one patient (1.8%). In addition to these
major complications, 25% of the patients required implanta-
tion of a permanent pacemaker for AV node dysfunction
(8.3%) or sinus node dysfunction (17%). The effectiveness
of the procedure was assessed in 50 evaluable patients,
excluding four patients who died and one withdrawal. At 6
months of follow-up, 74% of the patients were AF-free
and off AAD therapy, and 84% of the patients were free of
AF on or off AAD therapy. The freedom from AF at 12
months of follow-up was also 75%. The results of this study
were reviewed at an FDA panel meeting, leading to approval
for clinical use in 2011. This surgical ablation system is
currently the only system speciﬁcally labeled for treatment
of AF.
We recommend that the termMaze procedure is appropri-
ately used only to refer to the biatrial lesion set of the Cox-
Maze surgery. It requires ablation of the RA isthmus and
the LA isthmus. Less extensive lesion sets should not be
referred to as a Maze procedure, but rather as a surgical AF
ablation procedure. In general, surgical ablation procedures
for AF can be grouped into three different groups: (1) a full
biatrial Cox-Maze procedure, (2) PVI alone, and (3) PVI
combined with LA lesion sets.Surgical Technology for Appendage Ligation or
Removal and Outcomes of These Procedures
The LAA is a site of thrombus formation in patients with AF.
Retrospective evaluation has suggested that the LAA is
responsible for up to 90% of the strokes in patients with
AF and nonrheumatic heart disease.1309 Accordingly, it has
been the target of elimination in the original Cox-Maze, as
well as in the majority of its modiﬁcations. Early evaluation
of the cut-and-sew Cox-Maze suggested a reduction of stroke
late after surgery.1287 Other small, retrospective series subse-
quently suggested a lower-than-expected incidence of late
neurological event (stroke or TIA) after a Maze, possibly in-
dependent of CHA2DS2-VASc score.
1287,1310,1311 The
reduction in stroke has been attributed to a combination of
sinus restoration and LAA elimination. The role of the
LAA has been clouded by small numbers of patients and
the continuation of anticoagulation in a minority of
postoperative patients, as well as a retrospective series
suggesting a persistent stroke risk in postoperative patients
who are in sinus rhythm, with large atria, and poor atrial
contraction leading to effective LA asystole.1312
The strongest evidence that LAA elimination decreases
stroke comes from the WATCHMAN Left Atrial Appendage
System for Embolic Protection in Patients With Atrial Fibril-
lation (PROTECT AF) andWATCHMANLAAClosure De-
vice in Patients With Atrial Fibrillation Versus Long Term
Warfarin Therapy (PREVAIL) trials that randomized patients
to either anticoagulation or implantation of a WATCHMAN
device in the LAA. The 4-year results of the PROTECT AF
trial suggested that elimination of the LAA was superior to
anticoagulation for the composite endpoint of cardiovascular
death, all stroke, and systemic embolization.1313,1314
An important concern for surgical excision has been the
complication of bleeding. This complication is especially
important in older patients and those with enlarged atria in
whom the tissue may be more friable. This has led to several
different techniques for LAA elimination at the time of sur-
gery. The most common have been internal ligation (e.g.,
sewing the LAA oriﬁce closed from the inside) and stapled
excision. There is a paucity of data that examines effective-
ness of any surgical technique. However, with stapled exci-
sion, reported rates of tears requiring repair have been
approximately 10%.1315,1316
Another issue is the potential for arrhythmia generation
from the LAA. One study demonstrated LAA ﬁring in 29%
of patients and the only site of recurrence in 8.7% of patients
who had undergone catheter ablation of paroxysmal or
persistent AF; additional LAA isolation could increase the
freedom from AF.532,533 Thus, the isolation or surgical
excision of the LAA could inﬂuence procedure efﬁcacy
and reduce the risk of thromboembolic events.
However, a randomized study including 176 patients with
persistent AF who were undergoing surgical ablation via
thoracoscopic approach reported that additional LAA ampu-
tation did not reduce the rate of any atrial arrhythmias
compared with the standard surgical ablation set. The
follow-up period of this study was 18 months and the results
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rhythm or thromboembolic events prevention.1317
An emerging concern is the effectiveness of these alterna-
tive techniques. Most evidence is anecdotal and revolves
around case reports because the LAA is not routinely evalu-
ated late after surgery unless there is a clinical indication. In a
series of 137 such patients, the LAA was incompletely
ligated (either leaving a stump greater than 1 cm or a gap
with ﬂow) in 27% of patients after surgical excision. In inter-
nally ligated patients, the failure rate was 77%. There were no
successes when the LAA was stapled without amputation of
the distal remnant.1318 One limitation of this small series is
that it only looked at the 5% of patients who received inter-
vention who had an indication for late TEE, which included
only 12 in the stapled group. A more recent small, random-
ized trial of internal ligation, surgical excision, and stapled
excision reported that, at TEE evaluation in follow-up of 5
months, all three of these techniques left either a stump or
a gap at least 50 percent of the time.1319
Epicardial LAA ligation with a LARIAT device has been
developed through the combined transseptal and subxiphoid
approach.1320 The results from the multicenter registry
demonstrated a high acute closure rate, but procedural suc-
cess was limited by bleeding.1321 More recent results showed
that LARIAT device implantation was associated with a
lower rate of leaks at 1 year of follow-up and a 1.1% rate
of TIA or stroke.1322
Newer techniques include an external clip (Atriclip) that
was approved by the FDA in 2011 for the occlusion of the
LAA under direct visualization in patients undergoing other
open cardiac surgical procedures, as indicated in the
approved Indication statement of the AtriClip device. This
study reported 98% success in 60 of 71 patients available
for follow-up.1323 A longer-term study followed 36 patients
with annual CT scans.1324 At 3.5 years of follow-up, all the
clips were stable with no thrombi, no LAA perfused, no
neck.1 cm, and no neurological events. The use of an endo-
loop has been described, as well as a silicone fastener, which
is not currently available (Tiger paw). The true efﬁcacy of
any single technique is unknown and will require more inves-
tigation before any recommendations can be made.
There are data that suggest that despite the limitations of
all these techniques, a reduction in strokes might occur.
One series of 773 patients undergoing surgery for AF
compared surgical excision with alternative techniques.
The annual rates of late neurological events was approxi-
mately 1% using alternative techniques, and only one event
was fatal.1325 This suggested at least a reduction of clot
burden even in incompletely successful techniques. Our un-
derstanding of surgical elimination continues to rapidly
evolve, and current studies are inadequate to make a distinc-
tion between LAA excision or exclusion techniques. It is
reasonable and probably helpful to eliminate the LAA with
any technique at the time of AF surgery, but late evaluation
should be performed prior to cessation of anticoagulation.
We have elected not to make recommendations regarding
appendage occlusion, resection, or ligation in this document,because this is beyond the scope of this document and avail-
able data.
Concomitant Surgical Ablation
Historical Considerations
Surgical ablation is most commonly applied as a concomitant
procedure during valve or CABG surgeries. Prior consensus
recommendations referred to cardiac surgery as a whole,
grouping data from multiple studies to derive IIa LOE C rec-
ommendations.2 However, that document went on to say, “It
is advisable that all patients with documented AF referred for
other cardiac surgeries undergo a left or biatrial procedure for
AF at an experienced center, unless it. will add signiﬁcant
risk..”2
More recent AHA/ACC/HRS Guidelines continued this
procedural grouping but included more recent randomized
comparisons to determine that surgical ablation at the time
of another surgery is a IIa LOE B recommendation. The fre-
quencies of surgical ablation performance and durable rhythm
success have steadily increased. Furthermore, as noted above,
the FDA has now approved an ablation system for treatment
of persistent AF in patients undergoing concomitant cardiac
surgical procedures.1290 Recently, more information has
become available on AF mechanisms and the potential inﬂu-
ence of speciﬁc structural heart abnormalities on outcome.
Therefore, this surgical section provides updated recommen-
dations for three operation categories for which more data are
now available: primary open atrial operations, primary closed
atrial operations, and stand-alone operations for AF.Concomitant Surgical Ablation
Open concomitant cardiac surgical operations, in which a left
atriotomy is being performed for the primary procedure,
commonly include patients receiving mitral valve repair or
replacement (MVRR), with or without concomitant tricuspid
valve repair or replacement, or closure of an ASD. Closed
concomitant surgical ablation operations, in which a left at-
riotomy is not otherwise performed, commonly include pa-
tients undergoing prosthetic AVR, CABG, or AVR1CABG.
The prevalence of preoperative AF and frequency of
concomitant cardiac surgical operations varies between these
procedure classes. AF is found in one-third of patients pre-
senting for mitral valve surgery, but in only 6% of patients
undergoing isolated CABG, and in 14% of patients at the
time of AVR. Mitral valve repair for primary regurgitation
has largely supplanted mitral valve replacement and does
not require lifelong anticoagulation. Thus, successful surgi-
cal ablation concomitant to mitral repair can mitigate the
need for long-term anticoagulation or medicinal therapy for
AF. The performance rate of concomitant cardiac surgery
in patients with AF at the time of mitral operations has risen
from 52% to 62%. In an analysis of operations performed in
the early 2000s, the likelihood of surgical ablation performed
for AF at the time of AVRwas 31%, and only 26% at the time
of CABG. Although differential application of surgical AF
ablation exists among operative procedures, more recent
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especially in the mitral subgroup.Surgical Ablation at the Time of Concomitant Open Atrial
Operations
At the time of a primary atriotomy, AF surgery can be per-
formed during concomitant MVRR with or without tricuspid
surgery, with or without closure of ASD, and with or without
other concomitant procedures such as CABG.1326 The results
of the only prospective study performed to achieve FDA la-
beling for AF ablation reported a 9%major complication rate,
a 25% rate of pacemaker implantation, and a 75% freedom
from AF at 12 months of follow-up among 54 consecutive
patients with persistent AF undergoing other types of
cardiac surgery who were enrolled in this clinical trial.1290
Several other RCTs and meta-analyses are available to
evaluate AF surgery at the time of concomitant mitral
procedures.1327,1328,1329,1330,1331,1332,1333,1334 Large LA, AF
duration, advanced age, and failure to isolate the entire
posterior LA are common predictors of reduced long-term ef-
ﬁcacy. High baseline comorbid risk is a common reason cited
for not performing surgical ablation, though many institu-
tional studies note that this is not a contraindication to surgi-
cal ablation. The safety of concomitant surgical ablation has
been established in the literature and in updated valve risk
models from the STS database.
A multivariable regression and propensity matched
cohort, composed of 52% mitral procedures from the STS
database, demonstrated no impact on 30-day mortality with
surgical AF ablation.1300 However, patients undergoing sur-
gical AF ablation had a 26% higher chance of requiring a per-
manent pacemaker (OR 1.26). In a recent randomized trial of
mitral valve operations, there was no increase in major com-
plications associated with the addition of surgical ablation
other than a doubling of pacemaker risk.1331,1333
Conversely, recent large meta-analyses conﬁrmed the safety
of concomitant surgical ablation, but did not ﬁnd a signiﬁcant
increase in pacemaker use. The incidence and outcome rele-
vance of pacemaker implantation remains a point of contro-
versy. In analyses of more recent STS data, risk-adjusted
mortality was either not impacted or actually decreased
with surgical AF ablation in the mitral and multiple valve
populations.1335 A longitudinal study (up to 120 months)
demonstrated that restoration of sinus rhythm by a Cox-
Maze procedure combined with heart surgery markedly
increased long-term survival.1336
Despite previously published variability of efﬁcacy of sur-
gical ablation in heterogeneous populations, the longitudinal
beneﬁts of concomitant surgical AF ablation at the time of
MVRR are now becoming clearer. Several recent RCTs
andmeta-analyses indicate that concomitant surgical ablation
at the time of MVRR reduces the longitudinal incidence of
postoperative AF greater than 50% for at least 1 year, with
results ranging from 60%–90%.1327,1328,1329,1330,1331,1333,
1334,1337,1338 In addition to LA size and preoperative AF
duration, there is a procedural learning curve that canimpact efﬁcacy, and thus surgeons should seek appropriate
training prior to performing surgical ablation.
Therefore, based on the literature and the experience of the
writing group members, surgical ablation for AF is recom-
mended at the time of concomitant open atrial procedures,
such as mitral valve surgery in patients with symptomatic
AF (Class I, LOE B-NR) (Table 2, Figure 8).Surgical Ablation at the Time of Concomitant Closed Atrial
Operation
Concomitant surgical ablation of AF at the time of primary
nonatriotomy operations includes patients undergoing iso-
lated AVR, isolated CABG, or AVR1CABG. The presence
of AF at the time of these operations, especially if left un-
treated, is associated with increased risk of early and late
mortality and morbidity. When no intracardiac pathology ex-
ists in the setting of AF, further surgical decision-making is
required. Although full open Cox-Maze IV has been shown
to be safe and effective in these cases, surgeons are reluctant
to add a left atriotomy to address AF. If less aggressive ap-
proaches, such as epicardial PVI or the Dallas lesion set are
to be applied, care should be taken to note the mechanism
and type of AF being treated.1339,1340,1341 Recent
randomized and matched cohort studies of surgical ablation
and concomitant AVR, AVR1CABG, and isolated CABG
all consistently show no differences in 30-day or in-
hospital morbidity or mortality.1342,1343,1344
We have known that at the time of isolated CABG opera-
tions, the open atrial Cox-Maze procedure is effective up-
wards of 90% at 5 years of follow-up.1345 The application
of bipolar RF clamps to perform PVI has shown variable
50%-89% 1-year success superior to AAD alone in patients
with paroxysmal and persistent AF.1346,1347,1348,1349,1350 A
recent meta-analysis of 16 RCTs of surgical ablation and
concomitant operations evaluated predominantly mitral oper-
ations, but included both AVR and CABG operations.1333
There were no signiﬁcant differences in mortality, stroke,
or pacemaker requirement between surgical ablation
compared with no ablation; however, the surgical ablation
groups demonstrated superior 1-year freedom from AF in
AVR and AVR1CABG.
Therefore, based on the literature and the experience of the
writing groupmembers, surgical ablation for AF is recommen-
ded at the time of concomitant closed atrial procedures such as
isolated AVR, isolated CABG, and AVR1CABG in patients
with symptomatic AF refractory or intolerant to at least one
Class I or III antiarrhythmic medication (Class I, LOE B-NR)
(Table 2, Figure 8). For symptomatic patients with AF who
have not previously been treated with antiarrhythmic therapy,
concomitant closed AF surgery is recommended with a Class
IIa indication, LOE B-NR (Table 2, Figure 8).
At the time of a planned cardiac operation for symptom-
atic structural pathology, it should be noted that interpreting
symptoms of concomitant AF as distinct might or might not
be feasible because these could be masked by symptoms
prompting the primary cardiac operation (i.e., valvular or
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tomatic surgical pathology, the presence or absence of AF
symptoms should not be the only factor involved in surgical
decision making on the concomitant performance of surgical
ablation. It should be noted that the surgeon members of the
writing committee, as well as other surgeon reviewers, felt
that the evidence might warrant a Class I indication for this
patient subgroup; however, among the larger group,
consensus was attained for a level IIA recommendation.Stand-Alone Surgical Ablation of AF
Stand-Alone Operations for AF and Their Outcomes
The primary indication for stand-alone surgery that was
described in the 2012 Consensus Document was the presence
of symptomatic AF, refractory or intolerant to at least one
Class I or Class III AAD.2 In current practice, most patients
also have experienced at least one unsuccessful catheter abla-
tion before referral, unless the patient has a strong preference
for a cure with a single procedure.
There has been over two decades of experience with oper-
ations performed solely for treatment of AF (stand-alone op-
erations). The wide use of these procedures has been limited
by a reluctance to refer patients to surgery for AF, procedural
complexity, and limited data regarding outcomes. Moreover,
the types of procedures and the technologies used to perform
them have multiplied and are variable between operators.
This has led to relatively modest-sized single-site case series,
or at best multicenter series without comparison groups. In
addition, the rigor and methodology of follow-up have
changed dramatically over time and have further limited
comparisons of outcomes. Lastly, the development of hybrid
procedures, especially when staged, make comparisons even
more difﬁcult. This section will focus only on single-stage
surgeries as sole AF therapies. A discussion of hybrid pro-
cedures will follow. Perhaps the best way to distinguish the
types of surgeries is by those that require cardiopulmonary
bypass and cardiac arrest and those that do not. In order to
effectively create a lesion down to the mitral annulus, an
open heart is required.
The earliest—and one of the largest—reported study of
stand-alone operations for AF has been the 112 patients
who underwent the cut-and-sew Cox-Maze III procedure
by James Cox.1351 This procedure is performed through a
sternotomy on cardiopulmonary bypass on an arrested heart
and physically cuts and re-sews the atria to create a collection
of lines of block. Cryothermia is used to destroy the tissue
down to the mitral annulus. Among the 112 patients, 96%
were in sinus rhythm with or without AAD therapy, and
80% were in sinus rhythm and free of AAD therapy at last
follow-up. There was one late stroke in this group, and
88% of the patients were off chronic anticoagulation at last
follow-up. The only risk factor for late recurrence was the
preoperative duration of AF.1351 There have been several
other published series with similar results that combine
both stand-alone and concomitant patients with smaller
numbers of patients. This procedure requires a sophisticatedlevel of training and skill. As such, it is performed rarely, and
only by experienced surgeons. Ideal patients for stand-alone
AF ablation have failed other therapies, want deﬁnitive cures,
or have clots in the LAA, making other approaches not using
cardiopulmonary bypass risk prohibitive.
With the introduction of new ablation technology,
including bipolar RF energy and new cryoablation systems,
there has been renewed interest in less invasive procedures
for stand-alone AF ablation. These new tools can be used
in the open chest or through small incisions between the
ribs. When used in the open chest with a full biatrial Cox-
Maze lesion set performed, the procedure has been termed
the Cox-Maze IV procedure. Techniques for a Cox-Maze
IV procedure through a small, right inframammary incision
have also been perfected. As noted in the earlier section on
new surgical ablation technology, the outcomes achieved
with the Cox-Maze IV procedure are similar to those
achieved with the earlier Cox-Maze procedure. Importantly,
the cross-clamp times are shorter with the Cox-Maze IV pro-
cedure.1301 The advantage of these approaches includes the
ability to reliably create the endocardial lesions of the
Maze, down to the mitral annulus. Late evaluation of this pro-
cedure in 146 stand-alone patients has shown a 72% freedom
from AF at 5 years of follow-up and a 59% freedom from AF
off antiarrhythmic medications.1306 Cryothermia alone has
been used and described in a series of 77 patients, with a 6-
month result of 88% freedom from AF, antiarrhythmic med-
ications, and anticoagulants, but late follow-up is lack-
ing.1306,1352
Other approaches have limited the lesions to only those
that can be created from the epicardium without the need to
open the heart, and use both cardiopulmonary bypass and car-
diac arrest. This approach has limited the extent of lesions
from the Maze that can be created, because the mitral line
is buried by an epicardial fat pad that makes destruction of tis-
sue in this area unreliable. The minimally invasive surgical
approach using video-assisted PV ablation and exclusion of
the LAA was ﬁrst described in 2005.1353 A bipolar RF clamp
was used for PVI on the beating heart in 27 patients, among
whom 18 had PAF. Among the 23 patients followed for more
than 3 months, 21 (91%) were free of AF and 65% were off
all AADs. There were four major complications, but no
deaths, and no pacemakers were implanted. An additional
ablation strategy that has been reported is minimally invasive
PVI and partial autonomic denervation.1354 In a study of 74
patients undergoing this approach, 84% of the patients with
PAF were free of AF and 57% of patients with persistent or
long-standing persistent AF were free of AF at 6 months.
There was one death, one hemothorax, one case of transient
renal insufﬁciency, and one patient with a transient brachial
plexopathy. A second, larger report from this group in 114
patients reported that 72%, 46.9%, and 32% of patients
with paroxysmal, persistent, and long-standing persistent
AF, respectively, were free of AF and off antiarrhythmic
medications at 195 days of follow-up.1355 Another multi-
center series of 100 patients with a similar approach and
mean follow-up of 13.6 months reported a sinus restoration
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results of these and other trials cited earlier in this section
have made it clear that a more extensive lesion set than
PVI alone is required for successful surgical treatment of
persistent and long-standing persistent AF. Most surgeons
who still perform this type of procedure have moved toward
a hybrid approach in either a single or staged operation. How-
ever, a PVI alone remains a reasonable approach for patients
with PAF.
The Dallas Lesion Set was developed to create a complete
approach, which can be performed on a beating heart without
cardiopulmonary bypass.1339,1340,1341 The set replicates the
LA lesions of the Cox-Maze III, but changes the connection
of the PVI to the aortic annulus in continuity with the mitral.
Early results have been published on 30 patients.1339,1340
The group included 10 patients with persistent AF and 20
patients with long-standing persistent AF. Electrocardio-
graphic long-term monitoring and the use of AAD data were
collected 6 months postprocedure, and follow-up was 100%.
Procedure-related complications did not occur during follow-
up, nor were there any deaths. At 6 months of follow-up,
90% of the patients with persistent AF and 75% of the patients
with long-standing persistent AF were in sinus rhythm. AAD
therapy was continued in 22% of the patients with persistent
AF and 53% of the patients with long-standing persistent
AF. In a series of 100 paroxysmal patients randomized to
include the Dallas Lesion Set or not, the additional lesion, as
expected in a paroxysmal population, did not impact success
at 16 months of follow-up.520 Much like the results of catheter
ablation, this suggests that the type of AF will inﬂuence the
success of the procedure. Persistent AF is likely to require a
more extensive lesion set. An important area of interest is
the decision to offer a patient surgery or catheter ablation.
The AF Catheter Ablation Versus Surgical Ablation
Treatment (FAST) trial sought to compare catheter ablation
with minimally invasive surgery.601 A total of 124 patients
who had drug-refractory AF with dilated atria or failed cath-
eter ablation were randomized to either catheter ablation or
minimally invasive surgery using bipolar clamps, with or
without additional connecting lesions. At 1 year of follow-
up, freedom from AF was 37% in the catheter ablation group
and 66% in the surgical group. Although this was somewhat
offset by the increased adverse events in the surgical group
(34% vs 16%), the only death was in the catheter ablation
group.601 A different analysis of 7 studies, including two
RCTs, suggested superior freedom from AF in the surgical
group, with similar complication rates, except for an increase
in pacemaker implantation in surgical patients.1357 However,
the technologies and groups were fairly heterogeneous.
Other approaches, such as epicardial box lesions with
suction-assisted unidirectional uni- and bipolar RF and a
complete box lesion with bipolar clamps, have been
described in numbers insufﬁcient to draw any conclusion.
As the new techniques have been introduced, there has
been appropriate concern regarding the safety of minimally
invasive stand-alone surgery. Although safety is dependent
on procedure and site, it has been examined in a systematicreview that compiled results from 23 observational studies
with 752 patients who underwent minimally invasive
stand-alone procedures.1349 Operative mortality was 0.4%.
Complication rates attributed to surgery were only 3.2%. Re-
ports from the STS National Database showed an operative
mortality rate of 0.74%. The complication rate was consider-
ably higher at 16.43%, although major morbidities such as
stroke (0.72%), renal failure (2.45%), and bleeding (0.99%)
were low. Pacemakers were implanted in 1.03% of patients.
The outcomes of stand-alone AF ablation from the STS
database were recently reported.1358 Between 2005 and
2010, a total of 91,801 surgical AF ablations were performed,
of which 4893 (5.3%) were stand-alone. During this period of
time, the number of stand-alone AF surgeries increased from
552 cases in 2005 to 1041 cases in 2010. The mean age of the
stand-alone group was 60 years, and 71% were men. Some
80% of the stand-alone procedures were off pump. The over-
all operative mortality was 0.74% (1.7% on pump vs 0.5% off
pump), the rate of pacemaker implantation was 1%, and the
overall complication rate was 16% (28% on pump vs 13%
off pump).1358
The Atrial Fibrillation Ablation and Autonomic Modula-
tion via Thoracoscopic Surgery (AFACT) study compared
the outcomes of thoracoscopic surgical AF ablation in 240 pa-
tients with advanced AF at a single European center.123 A total
of 59% of the patients had persistent AF and 68% had an
enlarged LA. One-fourth of these patients had previously
failed catheter AF ablation. Patients were randomized to un-
dergo surgical AF ablation alone or combined with epicardial
ablation of the four major GP. At 12 months follow-up, no re-
currences of AF were observed in 71% and 68% in the GP and
control groups, respectively; the incidence of major complica-
tions was greater in the group that underwent GP ablation
(19% vs 8%, respectively). Major bleeding occurred in nine
patients in the GP group, one of whom required sternotomy.
Sinus node dysfunction occurred in 12 patients in the GP
group and in 4 controls. The authors concluded that GP abla-
tion during thoracoscopic surgery for advanced AF is associ-
ated with higher risk and no appreciable improvement in AF
control. This center also recently examined the 5-year out-
comes of thoracoscopic surgery for AF in 66 patients. A total
of 50% of patients experienced no AF recurrences and discon-
tinued AAD therapy at the 5-year follow-up, and 88% of the
patients were in sinus rhythm. In this cohort, persistent AF
and previous failure of catheter ablation were independently
associated with AF recurrence.1359
Superior efﬁcacy of a single approach has also been difﬁ-
cult to establish. A systematic review of 48 studies including
3832 patients suggested that the efﬁcacy of bipolar RF was
equivalent to the cut-and-sew Maze III technique for stand-
alone surgical ablation, as long as both were applied meticu-
lously.1360 Another meta-analysis of 16 published random-
ized trials indicated that the cut-and-sew Maze III produced
slightly better recovery of SR and stroke prevention, but
with increased perioperative risk.1361 Deﬁnitive recommen-
dations for a surgical approach with or without cardiopulmo-
nary bypass await more data.
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e389Using a surgical approach with or without cardiopulmo-
nary bypass that creates all, some, or a modiﬁcation of the
maze is reasonable, especially in patients in whom catheter
ablation has failed or who are at high risk for an unsuccessful
catheter-based result. However, a stand-alone operation
should have the ability to create the complete full Maze lesion
set, whether it is in a single operation or staged. This
approach is especially important for those patients who
have persistent AF.
Therefore, based on the literature and the experience of the
writing group members, stand-alone surgical ablation of
paroxysmal AAD-refractory AF can be considered for pa-
tients who have failed one or more attempts at catheter abla-
tion, and after review of the relative safely and efﬁcacy of
catheter ablation vs a stand-alone surgical approach for those
who are intolerant or refractory to AAD therapy and prefer a
surgical approach (Class IIb, LOE B-NR). For patients with
persistent and long-standing persistent AF, stand-alone surgi-
cal ablation is reasonable for patients who have failed one or
more attempts at catheter ablation, and after review of the
relative safely and efﬁcacy of catheter ablation vs a stand-
alone surgical approach for those who are intolerant or refrac-
tory to AAD therapy and prefer a surgical approach (Class
IIa, LOE B-NR, Figure 8). Stand-alone surgical AF ablation
is not recommended for patients who have not failed a trial of
at least one antiarrhythmic medication.Catheter Ablation After AF Surgery
The idea of a “touch-up” ablation for AF recurrence is not
new to catheter ablation. It is, however, relatively new to
the treatment algorithms of failure after cardiac surgery for
AF, which has historically been considered the end of the
road for sinus restoration. Now, catheter ablation can be a
critical adjuvant for patients who undergo surgical AF abla-
tion yet still suffer from residual AF. The potpourri of surgi-
cal AF treatment—ranging from PVI through complete LA to
complete biatrial lesions and combinations in between—
makes standardized conclusions difﬁcult in this area. This
endpoint is further obscured by the myriad of technologies
used to create the lines of block, as well as the underlying
type of ﬁbrillation treated and the limited number of patients
in published series. However, there are several publications
that offer some guidance, which will be reviewed below.
What has become clear over time is that, as with redo-
catheter AF ablation procedures, ﬁnding a reconnection of
the PVs is also to be expected in a patient undergoing a
catheter-based AF ablation procedure following a surgical
AF ablation procedure.
Because the cut-and-sew Maze was the earliest described
procedure, initial reports focused on patients who underwent
that speciﬁc procedure. One of the earliest studies reported on
23 patients who presented a mean 14 months after a cut-and-
sew Maze. In this report, 8 patients had only undergone a
Maze, and 15 had undergone a concomitant procedure.1361
The most common site of failure was around the PVs, which
occurred in eight (35%) patients. Five patients had focaltachycardia (3 in the CS and 1 each in the posterior lateral
RA and LA septum). Four patients had RA incisional ﬂutter
and six had left AFL, which mapped around the mitral valve
annulus in four patients and around the PVs in two. One year
after ablation, 19 of the 23 patients were both arrhythmia-free
and off AADs.
The vulnerability of PVI was supported by another study
that followed 20 patients with arrhythmias after surgical
ablation.1362 This group, however, was much more hetero-
geneous: alternative energy sources were used to create
the initial lines of block, including microwave, RF, cryo-
thermy, and laser; most patients had only LA lesion sets
at the time of initial surgery, and nearly half the patients
had more than one mechanism of tachycardia. This report
also highlighted the involvement of the mitral isthmus,
including the CS and the LAA. The vulnerability of the
mitral isthmus, especially at the CS, was also highlighted
in a series of 22 patients failing after the Cox-Maze
III.1363 Of note, this outcome represented a 15% failure
rate among a total of 143 patients in whom lesions were
created using a combination of cut-and-sew and cryo-
thermy. Frequently, out of concern for injury to the circum-
ﬂex, cryothermy is used at the mitral annulus and is often
used to connect the PVs in a small area so that reapproxima-
tion of the tissue is easier.
In a series of patients with ﬁve different surgical types,
various rates of failure were identiﬁed.1364 High-intensity
focused ultrasound was associated with a 37.5% need for
touch-up catheter ablation, which was much more frequent
than the other groups. This group had failures primarily
around the PVs, suggesting an incomplete lesion creation at
initial operation. The other groups—consisting of cut-and-
sewMaze, biatrial Maze using primarily RF, LA maze alone,
and PVI alone—had no signiﬁcant difference in success,
ranging from 90% for the cut-and-sew to 69% for PVI alone.
When the RA was not addressed at the time of initial opera-
tion, it was the site of failure in 75% of those who had recur-
rent AF. In the other groups, the mitral isthmus was again
identiﬁed as an area for failure. Successful ablation was
achieved in approximately 70% of patients.
These ﬁndings have relevance as new paradigms for
treatment evolve. Using hybrid strategies with technology
that replaces cut-and-sew and new lesion sets might require
a more individualized approach to each patient. New tech-
nology can introduce an area of vulnerability around the
PVs. In one series of 154 patients undergoing minimally
invasive PVI, eight failures were studied. Half had gaps
in the lesions created with new enabling technology.1365
The remainder had ﬂutters around the mitral isthmus. In a
series that compared a cut-and-sew Maze to a hybrid
approach, only 8% of the patients needed ablation after a
cut-and-sew Maze.1366 However, after PVI using bipolar
RF, 7 of 25 (29%) patients needed a second-stage catheter
ablation. All seven had at least one failure around the PVs,
for a total of 15 veins. Reconnection was most common in
the RI region. Interestingly, there were no RA failures in
this group.
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gical failures after AF treatment. It is likely that catheter abla-
tion can help selected patients restore sinus rhythm after
failures. These treatments should be performed at experi-
enced centers by experienced individuals who will tailor
the procedure to the individual patient based on initial lesion
set, the ablation technology and strategy used during initial
AF surgery, and the results of extensive mapping and provoc-
ative testing at the time of the redo ablation procedure. As the
experience with new hybrid approaches evolve, more deﬁn-
itive conclusions should arise.Hybrid Epicardial and Endocardial AF Ablation
Procedures
Background
Forward-thinking practitioners view catheter AF ablation and
minimal access surgical ablation as complementary rather
than competitive techniques, having found that patients
who fail a surgical ablation usually fail as paroxysmal with
a relatively low burden of AF. Whereas they might not
have been candidates for catheter AF ablation preoperatively,
they are now ideal candidates for a “touch-up” catheter AF
ablation. The electrophysiologist will frequently ﬁnd a single
small break in a line, which is easily completed with a cath-
eter; thus, the procedure is converted to a success. This real-
ization of the complementary nature of these disciplines has
led some to believe that perhaps combining these approaches
could lead to better outcomes than either approach alone.
There are other reasons why surgical (epicardial) and cath-
eter (endocardial) ablation can be viewed as complementary.
Surgical devices can fail to penetrate the endocardium; cath-
eter devices can fail to penetrate to the epicardium. Surgeons
are skilled at making lines; the tools are designed for it, the
smooth epicardial surface is ideal for it, and visual imaging
can reveal breaks in a line. Electrophysiologists excel at
“spot welding.” The catheter tip is punctuated by design, so
it can slip off of endocardial ridges or trabeculations, result-
ing in breaks, and nonvisual imaging does not show continu-
ity of burns. Surgeons might have difﬁculty mapping for
completeness; they are constrained by pericardial reﬂections,
they might lack formal training, and their tools are ﬁrst- or
second-generation. Electrophysiologists excel at mapping
for success; they have full access to the entire endocardial
surface, they are formally trained in the techniques, and
they have mature enabling technology. In addition, each spe-
cialty has its own unique contributions. Surgeons can fully
divide the ligament of Marshall, eliminate the atrial
appendage, perform targeted ablation of GP, and isolate the
SVC with little risk of injury to the PN. Electrophysiologists
can easily make a cavotricuspid isthmus line, map for
ﬂutters, ablate within the CS, and map and ablate focal
triggers.1367,1368 Recognition of the complementary nature
of these techniques has led some centers to explore
“hybrid” procedures (combined surgical and catheter
ablation), with early promising results.606The advent of minimal access surgical ablation laid the
groundwork for hybrid ablation. Seeking to advance the suc-
cess of the Cox-Maze III yet lessen the morbidity, surgeons
began exploring minimal-access approaches. Three things
led to the expansion of minimal-access techniques: First
was the focus on the PVs as the seminal goal of ablation; sec-
ond, advances in enabling technology allowed lesion creation
using RF energy and cryothermy; and third was the published
data revealing modest success for catheter ablation of the
persistent forms of AF.2,931
Thus, with the focus on the PV triggers, surgeons began
performing an increasing number of minimal-access PVI pro-
cedures.197,1369,1370,1371 However, investigators showed that
this treatment was inadequate for patients with persistent and
long-standing persistent AF.1355 This led to the belief that the
persistent forms of AF needed both substrate modiﬁcation
and trigger isolation, and this provided the impetus to
develop the Dallas lesion set, which replicated all the LA le-
sions of the Cox-Maze III, yet allowed them to be placed on
the surface of the full-beating LA. Although it was a major
step forward, with a success rate of 79%, this approach failed
to reach the success rates of the Cox-Maze III.1339,1340 To
enhance the robustness of lesion formation, the
complementary processes of performing a catheter-based
endocardial ablation in combination with surgical epicardial
ablation were contemplated, and this led to hybrid ap-
proaches.1372,1373,1374
Though these hybrid techniques are under active investi-
gation, the published literature is limited to a few early feasi-
bility studies. Early investigators used a unilateral right
thoracoscopic approach to isolate the PVs with a single encir-
cling box lesion. The energy source for the surgical ablation
was monopolar RF (Cobra Adhere, Estech, San Ramon, CA).
Nineteen consecutive patients underwent a right unilateral
minimally invasive hybrid procedure. Ten patients (52.6%)
had long-standing persistent AF, whereas four (21.1%) had
persistent and ﬁve (26.3%) PAF.1375 In 17 patients, one or
more PVs (mostly the LSPV) were not isolated, and an endo-
cardial touch-up was needed. It was possible to complete all
the procedures as planned, without any conversion to cardio-
pulmonary bypass. No patient died during the follow-up. At 1
year, 7 of 19 (36.8%) patients were in sinus rhythm with no
episode of AF and off AADs. Among the patients with long-
standing persistent AF, 20% (2 of 10) were in sinus rhythm
and off AAD, 50% (2 of 4) in persistent and 60% (3 of 5)
in PAF. Disappointing 1-year results were attributed to an
inadequate energy source. Thus, the surgical portion of the
procedure was converted to use a bipolar RF clamp (AtriCure
Inc., West Chester, OH), which had been shown to be more
effective.1376 This approach provided improved results, and
in most cases, gaps in surgical lesions could be completed
by endocardial catheter ablation during the same proced-
ure.608 A sequential hybrid approach was subsequently
developed.606 There are advantages and disadvantages to
simultaneous and staged hybrid procedures.
An important concern of single-stage hybrid is that
edema and stunning induced by surgical ablation might
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later, when edema has subsided. This presence of an incom-
plete block at delayed catheter mapping was reported by an
investigator who performed bilateral PVI box lesion and an
additional rooﬂine and LAA exclusion with clips in 30 pa-
tients with persistent AF. At staged catheter hybrid 3
months later, they found gaps in 77%–87% of the PVI le-
sions, nearly 70% of the rooﬂines, and 40% of the ﬂoor
lines, requiring endocardial touch-up ablation. Neverthe-
less, they were able to obtain a 1-year freedom from AF
and AAD by 7-day Holter of 90% (27 of 30). Other sur-
geons compared 25 staged hybrid procedures using bipolar
RF with 38 classic cut-and-sew Maze III procedures.1366 At
1 year of follow-up, freedom from AF and antiarrhythmic
medication was 52% for the staged hybrid and 87.5% for
the Maze III (P 5 .004). Other approaches included a uni-
lateral thoracoscopic approach using the monopolar RF suc-
tion Estech Cobra Adhere XL device (AtriCure Inc., West
Chester, OH) without atrial appendage occlusion, applied
to 19 patients.1375 At immediate hybrid catheter ablation,
every lesion required touch-up and 1-year freedom from
AF and AAD was 36%.
An innovative approach has been the passage of a scope
from the subxiphoid, transperitoneal and transdiaphragmatic
region to approach the posterior LA (the convergent proced-
ure). The surgeon uses the nContact monopolar RF coagula-
tion system to produce a comprehensive biatrial lesion
pattern on the outside of a beating heart while eliminating
chest incisions. Then, the electrophysiologist uses an ablation
catheter endocardially to ﬁnish the lesion pattern and ensure
that all reentrant circuits are interrupted.
Reported success rates have varied, from 16.7% to 100%;
however, there has been an elevated adverse event rate in
most published series, with an associated mortality of up to
12.5%, mostly related to AEF and sudden death.607,609,613,
1368,1377,1378,1379,1380,1381,1382,1383 This procedure has been
largely redesigned to prevent these adverse results, and two
papers have reported no mortality and no AEF.613,1381
A recent meta-analysis compared the Cox-Maze to hybrid
procedures. The overall freedom from AF and freedom from
AF off AAD at 1-year of follow-up was 87% vs 71%, respec-
tively, but the complication rates were higher with hybrid
procedures.1384 Based on current literature, the hybrid
approach with the most effective outcomes and safety proﬁle
appears to be the bilateral PVI procedures with LAAmanage-
ment. Available published data on the monopolar convergent
procedure do not indicate an adequate safety and efﬁcacy
proﬁle.
Currently, there is investigation into both simultaneous
and staged hybrid procedures, with no clinical trials showing
one strategy superior to the other. The Dual Epicardial Endo-
cardial Persistent Atrial Fibrillation trial is a prospective ran-
domized staged hybrid study using bipolar RF. The
CONVERGE trial is a set of prospective randomized simul-
taneous hybrid trials using monopolar RF. These trials also
use different operative approaches. There are a number of
other ongoing multicenter trials that are likely to deﬁne theroles and lesion sets for treatment of patients with persistent
AF using these strategies.
The hybrid approach could hold signiﬁcant promise for
those patients with persistent or long-standing persistent,
drug-resistant AF to offer improved results over minimal
access surgical ablation or catheter ablation alone. Based
on the literature and the experience of the writing group
members, we believe that it might be reasonable to apply
the indications for stand-alone surgical ablation described
above to patients being considered for hybrid surgical abla-
tion (Class IIb, LOE C-EO, Table 2).The Future
The most successful programs in the future might be those that
employ an interdisciplinary, collaborative team approach to
the treatment of AF, resulting in higher success rates for pa-
tients. Many of these patients are well read and mobile and
will seek out such centers, thus increasing both catheter and
surgical volumes. Practitioners in the future will likely ﬁnd
value to working as part of a multidisciplinary team. The pre-
cedent is set for this type of collaboration. The STS, the ACC,
the FDA, and the Centers for Medicare and Medicaid Services
have joined together to collaboratively introduce transcatheter
AVR as a mandatory multidisciplinary team approach with
mandatory long-term follow-up. More work is needed in the
area of collaborative ablation of AF.
Section 13: Clinical Trial Design
Overview
Although there have been many advances made in the ﬁeld of
catheter and surgical ablation of AF, there is still much to be
learned about the mechanisms of initiation and maintenance
of AF and how to apply this knowledge to the still-evolving
techniques of AF ablation. Although single-center, observa-
tional reports have dominated the early days of this ﬁeld, we
are quickly moving into an era in which hypotheses are put
through the rigor of testing in well-designed, randomized,
multicenter clinical trials. It is as a result of these trials that
conventional thinking about the best techniques, success
rates, complication rates, and long-term outcomes beyond
AF recurrence—such as thromboembolism and mortality—
is being put to the test. The ablation literature has also seen
a proliferation of meta-analyses and other aggregate ana-
lyses, which reinforce the need for consistency in the
approach to reporting the results of clinical trials. This section
will review the minimum requirements for reporting on AF
ablation trials. It will also acknowledge the potential limita-
tions of using speciﬁc primary outcomes and emphasize the
need for broad and consistent reporting of secondary out-
comes to assist the end-user in determining not only the sci-
entiﬁc, but also the clinical relevance of the results.
Types of Clinical Trials, Strengths, and Weaknesses
Mortality Trials
Large, randomized, controlled multicenter trials are consid-
ered the “gold standard” for many therapies in cardiovascular
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standing of the outcomes of speciﬁc aspects of ablative inter-
vention. Although AF is associated with increased mortality
and morbidity from stroke, HF, and recurrent hospitalization,
most of the AF ablation literature is focused on AF recurrence
and symptomatic improvement. It remains unclear whether
ablation can affect AF burden sufﬁciently to have a positive
outcome with respect to mortality and stroke endpoints. Tri-
als powered to demonstrate a beneﬁt for ablation with regard
to these “hard” endpoints require large numbers of patients
with extensive follow-up and its accompanying expense;
however, the need for such trials cannot be understated.
The CABANA trial was powered to examine stroke and mor-
tality outcomes of AF ablation compared with pharmacolog-
ical rate and rhythm control strategies. CABANA, which
recently completed enrollment, requires a minimum of 5
years of follow-up; thus, results will not be available until
2018. In the meantime, EAST is a study that is currently
enrolling and is designed to compare standard care vs a strat-
egy of early rhythm control with ablation and/or AADs with
endpoints including a composite outcome of cardiovascular
death, stroke, and hospitalization due to worsening of HF
or acute coronary syndrome. Although it is unclear whether
these trials will demonstrate a mortality beneﬁt of AF abla-
tion, both are designed to examine a host of prespeciﬁed sec-
ondary endpoints. Secondary endpoints such as HF
hospitalizations are especially important for patients with un-
controlled rates and HF with preserved EF or tachycardia-
induced cardiomyopathy. Finally, because both trials will
include larger numbers of patient ablations with more novel
technologies such as cryoablation and CFS than have been
available in any other study to date, signiﬁcant advances in
the understanding of ablation procedure with these systems
should be possible. Nevertheless, it remains imperative to
continue with designs of large mortality trials that reﬂect
shifting global ablation techniques, technologies, and patient
selection. There are currently 45 trials that meet the search
criteria of “ablation mortality AF” on ClinicalTrials.gov;
however, fewer than 10 have mortality as part of the primary
endpoint.Stroke and Thromboembolism Trials
Reductions in stroke and thromboembolism remain the most
important goals of AF treatment. It is unclear, however, if
elimination of or reductions in AF will necessarily reduce
the associated risk of stroke, and whether such outcomes
exceed those possible with NOAC agents. Although an
increased risk of stroke appears to be associated with brief ep-
isodes of AF detected by implanted cardiac devices, multiple
large randomized trials have demonstrated that there might be
no temporal relationship between AF episodes and AF
thromboembolic events. This possibility has cast signiﬁcant
doubt regarding the direct causal role that AF plays in stroke.
On the other hand, some cohort studies of AF ablation have
reported a lower risk of stroke postablation compared with
matched, nonablated AF populations. The impact of AF abla-tion on stroke and thromboembolism is an important topic of
future study and will likely require a combination of very
large studies with long durations of follow-up akin to
CABANA and EAST. The OCEAN study is currently getting
started, and will examine the optimal strategy for ongoing an-
tithrombotic therapy 1 year after successful ablation in a
moderate-risk proﬁle population with a primary endpoint of
overt and covert stroke. It is important to stress that until
the results of these trials are known, the current recommenda-
tions are to continue anticoagulation indeﬁnitely in patients
with CHA2DS2-VASc 2, regardless of the success of the
ablation procedure.
Periprocedural stroke reduction is an important topic that is
actively being studied, with various strategies of anticoagula-
tion, particularly continuous administration of VKA and non-
VKA oral anticoagulants through the ablation procedure.834,
841,842 In addition, concomitant LAA occlusion is being
tested. In percutaneous procedures, there are few if any
studies powered for stroke alone; most primarily evaluate
AF recurrence.
Finally, multiple studies have demonstrated small ACE on
MR brain imaging after ablation.724,728,1207 The clinical
signiﬁcance of such ACE lesions is not known, and many
will resolve to the point of being undetectable after weeks
or months. The impact on cognitive function, if any, is not
clear. At this point, there are no mandates for performing
periprocedural brain imaging for novel technologies to
evaluate the incidence of silent cerebral embolism, in large
part because of its unknown clinical signiﬁcance and the
cost and burden of MRI on patients. However, further
evaluation of the signiﬁcance of such ﬁndings remains an
important area of study.
Screening substudies could be reasonable for high-risk de-
vices and should be combined with clinical neurological and
cognitive assessments. These silent cerebral emboli are to be
distinguished from covert embolic strokes secondary to long-
term AF, which have been linked with long-term cognitive
decline, and are much larger than the silent emboli seen peri-
procedurally.1385,1386,1387,1388
Multicenter Outcome Studies
There has been a proliferation of multicenter, randomized
studies primarily geared toward the outcome of AF recur-
rence in the last several years. Many of these studies have
had the appropriate size and power to make some important
statements on the appropriate techniques for AF ablation.
Because of the endpoint of AF recurrence, these studies
can be performed with smaller sample sizes and shorter
follow-up periods compared with mortality- or stroke-
driven trials. A number of randomized trials have demon-
strated the superiority of AF ablation over AADs in drug-
refractory patients. First-line catheter ablation has shown
mixed results over ﬁrst-line drug therapy in the MANTRA-
PAF and RAAFT-2 studies.378,379 STAR AF 2, Adenosine
Following Pulmonary Vein Isolation to Target Dormant
Conduction Elimination (ADVICE), FIRE AND ICE, and
TOCCASTAR are just a few examples of multicenter
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per study and added important contributions to the daily
practice of AF ablation.245,265,378,379,489,655 STAR AF 2,
for example, challenged the long-held belief that additional
ablation beyond PVI is important for ablation of persistent
AF and has launched a new search for alternative targets to
CFAE and empiric lines. It remains possible that incomplete
ablation in these arenas is more problematic than the ablation
format itself. As reported recently, the FIRE AND ICE trial
has shown an equivalence of evolving cryoablation technol-
ogies to traditional RF. The ADVICE trial showed that sys-
tematic use of adenosine to search for dormant conduction
can improve durability of PVI and associated 1-year
outcome, although studies reported earlier in this document
raise questions about the overall utility of adenosine or
isoproterenol. There are many more studies planned to
examine various aspects of AF ablation, primarily around
the comparison of techniques in certain patient populations
to improve ablation outcomes. As expected, a criticism of
all such trials is that the technology and techniques are
outdated prior to trial completion. STAR AF 2 did not use
CFS and FIRE AND ICE used a mixture of ﬁrst- and
second-generation CB technologies. Therefore, ongoing tri-
als comparing the most up-to-date technologies will always
be required. Larger-scale surgical ablation trials are lacking,
and the consensus group believes that the development of
well designed, highly agile, large-scale multicenter surgical
trials with similar monitoring regimens need to be encour-
aged and performed. As with catheter-based studies and reg-
istries, the use of patient-reported outcome measures as part
of the study endpoints is highly recommended.
Industry-Sponsored Device Approval Studies
There have been a number of prospective randomized studies
performed to evaluate the safety and efﬁcacy of investiga-
tional devices used for AF ablation. These studies, such as
THERMOCOOL IDE and STOP AF, have all provided
important, high-quality data demonstrating the superiority
of catheter ablation over drug therapy in drug refractory pa-
tients.462,684 Now that the utility of ablation over drug
therapy in such patients has been accepted, many of the
current studies are focused on comparing new technologies
against approved devices in a noninferiority design.
Although these studies are important from a safety and
efﬁcacy perspective and are often mandated by health
approval bodies such as the FDA, the incremental yield in
knowledge could be limited. Prespeciﬁed subgroup
analyses, or the use of novel endpoints. could therefore be
important to determine whether incremental value is added
by the newer technology. TOCCASTAR, for example,
demonstrated statistical noninferiority of CF-driven RF
ablation to traditional RF. However, only in a post-hoc anal-
ysis did the trial show that optimal CF was associated with
better outcomes, ﬁndings which should be viewed with
caution due to the limitations of post hoc analyses. Testing
of the durability of lesion sets such as PVI either after delayed
waiting, drug (adenosine) challenge, or repeat electrophysi-ology study after 3 months might also help assess compara-
tive efﬁcacy more accurately. Industry must also look to
see whether safety and efﬁcacy parameters demonstrated in
PAF also apply to nonparoxysmal populations. Several
industry-sponsored studies are either being planned or are
in progress to assess outcomes in this challenging population.
Registry Studies
AF ablation registries offer a unique opportunity to collect
data from large numbers of patients to examine outcomes.
In particular, registries might help assess how ablation is be-
ing performed in the “real world” compared with controlled
clinical trials that are often performed on a highly selected pa-
tient population in very experienced centers. The deﬁnition
of real world remains problematic, however, because recent
studies have shown reasonable congruence between the out-
comes of RCTs and registries. Registries are well suited to
determining early complication rates of ablation, particularly
for less common ones such as PV stenosis, esophageal injury,
or mortality. Appropriateness of patient selection and out-
comes in patient subgroups that are underrepresented in
studies, such as women or patients with underlying structural
heart disease, can also be assessed in sizable registries. The
collection of this kind of information, by itself, makes regis-
tries worthwhile if they can be performed with sufﬁcient rep-
resentation of a majority of centers. Still, well-controlled
efforts such as the STS database have shown an even-
handed approach to collecting this kind of material. World-
wide surveys of AF ablation have been published, and
ongoing efforts are being made to harmonize various centers
or national databases to pool ablation information. Many
countries are now setting up provincial or national registries
to examine the use and outcomes of AF ablation. In the
United States, for example, the older Safety of Atrial Fibril-
lation Ablation Registry Initiative registry project was dis-
continued, but another started by the National
Cardiovascular Data Registry (NCDR) has been launched na-
tionally, with voluntary participation. The HRS is also
collaborating with the AHA to develop an additional AF
ablation registry. Surgical data are currently being collected
in the STS database; however, although data on safety and
outcome are available, lesion-speciﬁc information for surgi-
cal ablation remains preliminary. Collection of longitudinal
data, particularly longer-term outcomes, can be limited by a
lack of patient follow-up at the same center and a lack of
consistent monitoring protocols. The need for informed con-
sent to collect follow-up data also remains an obstacle to ob-
taining outcome data. The burden of data entry can also lead
to inadequate reporting, and the cost of auditing data can be
very expensive and tedious. The purpose of establishing a
registry and the realistic goals of data collection must be
stated outright upon establishment, because the opportunity
and ﬁnancial costs could be alternatively spent on well-
designed clinical trials. Comparison of performance among
sites, for example, must be based on the stated purposes
and strengths of the registry. If the main purpose is to report
acute complications, then long-term outcomes cannot be
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characteristics, referral patterns to the institution, and
community-based versus advanced academic practices.
Finally, once the stated goals of the registry are accom-
plished, there should be speciﬁc timeframes for termination
of the registry to avoid indeﬁnite data collection with no spe-
ciﬁc stated purpose.Clinical Endpoint Considerations
Early data in the ﬁeld of AF ablation were limited by the
multitude of different endpoints used in the trials, including
multiple deﬁnitions of success, complications, and minimum
monitoring postablation. Prior consensus statements sought
to create consistency in the reporting of clinical trials by
adopting standardized deﬁnitions for AF type, blanking pe-
riods, deﬁnitions of success, recommendations for minimal
monitoring postablation, major complications, and device-
related complications.1,2 Again, this document outlines the
deﬁnitions of various types of AF (Table 1), deﬁnitions of ef-
ﬁcacy (Table 10), QOL measures (Table 11), non-AF recur-
rence endpoints (Table 12), and deﬁnitions of complications
(Table 8).
Clinical endpoints for AF ablation trials may either consist
of clinical events like mortality, stroke, re-initiation of AAD
treatment, need for cardioversion, reablation and rehospitali-
zation, or of patient-reported outcomes such as symptom
severity or QOL. AF recurrence or change in AF behavior
is a very important endpoint to report in trials targeting AF
elimination. The following section will focus on recommen-
dations and deﬁnitions for AF-related measurements used in
clinical ablation trials.
Blanking Period
It has long been recognized that in the weeks immediately
following AF ablation, early recurrences of atrial arrhythmia
can occur that subsequently subside over time.253,254,255,436
Whether this is due to an early “inﬂammatory” response in
the atrium or pericardium remains hypothetical. Based on
these observations, prior consensus statements, and the
present consensus document, the writing group
recommends the use of a 3-month blanking period immedi-
ately postablation, during which arrhythmia recurrences are
not counted toward the primary recurrence endpoint
(Table 10). The use of a blanking period is not without lim-
itations. Although half of all early recurrences might subside,
early recurrence remains a very signiﬁcant predictor of late
recurrence of AF.141,142,143,255 Furthermore, some studies
have shown that recurrences occurring early in the
blanking period (within 1–2 months) are less predictive of
late recurrence, whereas those occurring in the third
month have a very high predictive value for later
recurrence.933,977,1389 Blanking periods can also be applied
inconsistently, typically after the initial ablation, but not
typically after repeat procedures, particularly when there is
only a limited duration of follow-up. Despite these limita-tions, the writing group consensus continues to recommend
the use of a 3-month blanking period for atrial arrhythmia re-
currences post-initial ablation for AF. If alternate durations of
blanking are employed, they should be prespeciﬁed in the
trial methodology. Clinical trials should also consider routine
discontinuation of AADs after the blanking period to deter-
mine off-drug success rates of ablation. Large clinical trials
such as CABANA have also employed extensive ongoing
monitoring, which could shed light on more robust blanking
period deﬁnitions. The currently recommended deﬁnitions of
the blanking periods, monitoring standards, complications,
and other AF ablation clinical trial deﬁnitions are provided
in Tables 8 and 10.AF Recurrence Endpoints
The selection of a primary endpoint depends on the objec-
tives of the trial. As mentioned earlier in this section, trials
with mortality, stroke, or hospitalization outcomes are of
particular interest in advancing the ﬁeld of AF ablation. How-
ever, now and in the foreseeable future, recurrence of AF will
remain of primary interest for most clinical trials. A summary
of AF-related endpoints is listed in Table 13, along with the
advantages and disadvantages of each endpoint.
The consensus statement reafﬁrms the use of freedom
from any atrial arrhythmia (e.g., AF, AT, or AFL) greater
than 30 seconds off antiarrhythmic therapy as the gold stan-
dard for reporting the efﬁcacy of AF ablation (Table 10). The
writing group also believes that all trials should report single-
procedure, off AAD therapy efﬁcacy for ablation with a min-
imum of 12 months follow-up. Slight variations in this
endpoint have been used in several clinical trials, but ideally,
all categories of recurrence should be reported transparently,
such as freedom from AF separately from other atrial
arrhythmia, one- and multiple-procedure success rates, and
success on and off antiarrhythmic therapy. By reporting all
of these variations, the reader can determine the most relevant
outcome for themselves and can also easily compare results
between clinical trials. A recent study that reported outcomes
using a wide variety of endpoints can serve as an excellent
example of this approach to reporting outcomes.245 The in-
clusion of all atrial arrhythmias compared with AF in isola-
tion recognizes the fact that ablation can result in iatrogenic
macro- and microreentrant tachycardias caused by incom-
plete scar formation from the procedure itself. Furthermore,
patients might present with mixed pictures of both AFL
and ﬁbrillation, and elimination of one but not the other
will not improve patient outcomes.
The consensus statement recognizes that the 30-second
cutoff for arrhythmia recurrence is stringent and might not
accurately reﬂect more clinically relevant endpoints, such
as reduction in total AF burden, symptom abatement, and
improvement in QOL. A strict cutoff might also underesti-
mate the true beneﬁt of ablation, especially when presented
in the format of a Kaplan-Meier analysis. Isolated, brief
recurrences can result in a patient being considered a
Table 10 Deﬁnitions for use when reporting outcomes of AF ablation and in designing clinical trials of catheter or surgical ablation of AF
Acute procedural success
(pulmonary vein isolation)
Acute procedural success is deﬁned as electrical isolation of all pulmonary veins. A minimal
assessment of electrical isolation of the PVs should consist of an assessment of entrance block. If
other methods are used to assess PVI, including exit block and/or the use of provocative agents
such as adenosine or isoproterenol, they should be prespeciﬁed. Furthermore, it is recommended
that the wait time used to screen for early recurrence of PV conduction once initial electrical
isolation is documented be speciﬁed in all prospective clinical trials.
Acute procedural success (not
related by pulmonary vein
isolation)
Typically, this would apply to substrate ablation performed in addition to PVI for persistent AF.
Although some have proposed AF termination as a surrogate for acute procedural success, its
relationship to long-term success is controversial. Complete elimination of the additional substrate
(localized rotational activation, scar region, non-PV trigger, or other target) and/or demonstration
of bidirectional conduction block across a linear ablation lesion would typically be considered the
appropriate endpoint.
One-year success* One-year success is deﬁned as freedom from AF/AFL/AT after removal from antiarrhythmic drug
therapy as assessed from the end of the 3month blanking period to 12 months following the
ablation procedure. Because cavotricuspid isthmus-dependent atrial ﬂutter is easily treated with
cavotricuspid isthmus ablation and is not an iatrogenic arrhythmia following a left atrial ablation
procedure for AF, it is reasonable for clinical trials to choose to prespecify that occurrence of
isthmus-dependent atrial ﬂutter, if conﬁrmed by entrainment maneuvers during electrophysiology
testing, should not be considered an ablation failure or primary effectiveness endpoint.
Alternative one-year success Although the one-year success deﬁnition provided above remains the recommended end point that
should be reported in all AF ablation trials, and the endpoint for which the objective performance
criteria listed below were developed, the Task Force recognizes that alternative deﬁnitions for
success can be used if the main goal of therapy in the study is to relieve AF-related symptoms and to
improve patient QOL. In particular, it is appropriate for clinical trials to deﬁne success as freedom
from only symptomatic AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed from
the end of the 3-month blanking period to 12 months following the ablation procedure if the main
goal of therapy in the study is to relieve AF-related symptoms and to improve patient QOL. However,
because symptoms of AF can resolve over time, and because studies have shown that asymptomatic
AF represents a greater proportion of all AF postablation than prior to ablation, clinical trials need
to continue to report freedom from both symptomatic and asymptomatic AF even if this alternative
one year success deﬁnition is used as the primary trial endpoint.
Clinical/partial success* It is reasonable for clinical trials to deﬁne and incorporate one or more secondary deﬁnitions of
success that can be referred to as “clinical success” or “partial success.” If these alternative
deﬁnitions of success are included, they should be deﬁned prospectively. In prior Consensus
Documents the Task Force has proposed that clinical/partial success be deﬁned as a “75% or greater
reduction in the number of AF episodes, the duration of AF episodes, or the % time a patient is in AF
as assessed with a device capable of measuring AF burden in the presence or absence of previously
ineffective antiarrhythmic drug therapy.” Because there is no ﬁrm scientiﬁc basis for selecting the
cutoff of 75% rather than a different cutoff, this prior recommendation is provided only as an
example of what future clinical trials may choose to use as a deﬁnition of clinical/partial success.
Long-term success* Long-term success is deﬁned as freedom from AF/AFL/AT recurrences following the 3-month blanking
period through a minimum of 36-month follow-up from the date of the ablation procedure in the
absence of Class I and III antiarrhythmic drug therapy.
Recurrent AF/AFL/AT Recurrent AF/AFL/AT is deﬁned as AF/AFL/AT of at least 30 seconds’ duration that is documented by an
ECG or device recording system and occurs following catheter ablation. Recurrent AF/AFL/AT may
occur within or following the post ablation blanking period. Recurrent AF/AFL/AT that occurs within
the postablation blanking period is not considered a failure of AF ablation.
Early recurrence of AF/AFL/AT Early recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation within three months of
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a “recurrence.”
These are not counted toward the success rate if a blanking period is speciﬁed.
Recurrence of AF/AFL/AT Recurrence of AF/AFL/AT postablation is deﬁned as a recurrence of atrial ﬁbrillation more than 3
months following AF ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed
as a “recurrence.”
Late recurrence of AF/AFL/AT Late recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation 12 months or more after AF
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a “recurrence.”
Blanking period A blanking period of three months should be employed after ablation when reporting efﬁcacy
outcomes. Thus, early recurrences of AF/AFL/AT within the ﬁrst 3 months should not be classiﬁed as
treatment failure. If a blanking period of less than 3 months is chosen, it should be prespeciﬁed and
included in the Methods section.
Stroke screening A risk-based approach to determine the level of postablation stroke screening in clinical trials is
recommended by the Task Force. For ablation devices with a lower risk of stroke and for which a
stroke signal has not been reported, a minimum standardized neurological assessment of stroke
should be conducted by a physician at baseline and at hospital discharge or 24 hours after the
procedure, whichever is later. If this neurological assessment demonstrates new abnormal ﬁndings,
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the patient should have a formal neurological consult and examination with appropriate imaging
(i.e., DW-MRI), used to conﬁrm any suspected diagnosis of stroke. For devices in which a higher risk
of stroke is suspected or revealed in prior trials, a formal neurological examination by a neurologist
at discharge or 24 hours after the procedure, whichever is later, is recommended. Appropriate
imaging should be obtained if this evaluation reveals a new neurological ﬁnding. In some studies in
which delayed stroke is a concern, repeat neurological screening at 30 days postablation might be
appropriate.
Detectable AF/AFL/AT Detectable AF is deﬁned as AF/AFL/AT of at least 30 seconds’ duration when assessed with ECG
monitoring. If other monitoring systems are used, including implantable pacemakers, implantable
deﬁbrillators, and subcutaneous ECG monitoring devices, the deﬁnition of detectable AF needs to
be prespeciﬁed in the clinical trial based on the sensitivity and speciﬁcity of AF detection with the
particular device. We recommend that episodes of atrial ﬂutter and atrial tachycardia be included
within the broader deﬁnition of a detectable AF/AFL/AT episode.
AF/AFL/AT burden It is reasonable for clinical trials to incorporate AF/AFL/AT burden as a secondary endpoint in a clinical
trial of AF ablation. In stating this it is recognized that there are no conclusive data that have
validated a rate of AF burden reduction as a predictor of patient beneﬁt (i.e. reduction in mortality
and major morbidities such as stroke, CHF, QOL, or hospitalization). If AF burden is included, it is
important to predeﬁne and standardize the monitoring technique that will be used to measure AF
burden. Available monitoring techniques have been discussed in this document. Should AF burden
be selected as an endpoint in a clinical trial, the chosen monitoring technique should be employed
at least a month prior to ablation to establish a baseline burden of AF.
Entrance block Entrance block is deﬁned as the absence, or if present, the dissociation, of electrical activity within
the PV antrum. Entrance block is most commonly evaluated using a circular multielectrode mapping
catheter positioned at the PV antrum. Entrance block can also be assessed using detailed point-by-
point mapping of the PV antrum guided by an electroanatomical mapping system. The particular
method used to assess entrance block should be speciﬁed in all clinical trials. Entrance block of the
left PVs should be assessed during distal coronary sinus or left atrial appendage pacing in order to
distinguish far-ﬁeld atrial potentials from PV potentials. It is recommended that reassessment of
entrance block be performed a minimum of 20 minutes after initial establishment of PV isolation.
Procedural endpoints for AF
ablation strategies not
targeting the PVs
Procedural endpoints for AF ablation strategies not targeting the PVs: The acute procedural endpoints
for ablation strategies not targeting the PVs vary depending on the speciﬁc ablation strategy and
tool. It is important that they be prespeciﬁed in all clinical trials. For example, if a linear ablation
strategy is used, documentation of bidirectional block across the ablation line must be shown. For
ablation of CFAEs, rotational activity, or non-PV triggers, the acute endpoint should at a minimum
be elimination of CFAEs, rotational activity, or non-PV triggers. Demonstration of AF slowing or
termination is an appropriate procedural endpoint, but it is not required as a procedural endpoint
for AF ablation strategies not targeting the PVs.
Esophageal temperature
monitoring
Esophageal temperature monitoring should be performed in all clinical trials of AF ablation. At a
minimum, a single thermocouple should be used. The location of the probe should be adjusted
during the procedure to reﬂect the location of energy delivery. Although this document does not
provide formal recommendations regarding the speciﬁc temperature or temperature change at
which energy delivery should be terminated, the Task Force does recommend that all trials
prespecify temperature guidelines for termination of energy delivery.
Enrolled subject An enrolled subject is deﬁned as a subject who has signed written informed consent to participate in
the trial in question.
Exit block Exit block is deﬁned as the inability to capture the atrium during pacing at multiple sites within the PV
antrum. Local capture of musculature within the pulmonary veins and/or antrum must be
documented to be present to make this assessment. Exit block is demonstrated by a dissociated
spontaneous pulmonary vein rhythm.
Nonablative strategies The optimal nonablative therapy for patients with persistent and long-standing persistent AF who are
randomized to the control arm of an AF ablation trial is a trial of a new Class I or III antiarrhythmic
agent or a higher dose of a previously failed antiarrhythmic agent. For patients with persistent or
long-standing persistent AF, performance of a direct-current cardioversion while taking the new or
dose adjusted antiarrhythmic agent should be performed, if restoration of sinus rhythm is not
achieved following initiation and/or dose adjustment of antiarrhythmic drug therapy. Failure of
pharmacological cardioversion alone is not adequate to declare this pharmacological strategy
unsuccessful.
Noninducibility of atrial
ﬁbrillation
Noninducibility of atrial ﬁbrillation is deﬁned as the inability to induce atrial ﬁbrillation with a
standardized prespeciﬁed pharmacological or electrical stimulation protocol. The stimulation
protocol should be prespeciﬁed in the speciﬁc clinical trial. Common stimulation approaches
include a high-dose isoproterenol infusion protocol or repeated atrial burst pacing at progressively
more rapid rates.
Patient populations for inclusion
in clinical trials
It is considered optimal for clinical trials to enroll patients with only one type of AF: paroxysmal,
persistent, or long-standing persistent. If more than one type of AF patient is enrolled, the results
of the trial should also be reported separately for each of the AF types. It is recognized that “early
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persistent” AF responds to AF ablation to a similar degree as patients with paroxysmal AF and that
the response of patients with “late persistent AF” is more similar to that in those with long-standing
persistent AF.
Therapy consolidation period Following a 3-month blanking period, it is reasonable for clinical trials to incorporate an additional 1-
to 3-month therapy consolidation period. During this time, adjustment of antiarrhythmic
medications and/or cardioversion can be performed. Should a consolidation period be incorporated
into a clinical trial design, the minimum follow-up duration should be 9 months following the
therapy consolidation period. Performance of a repeat ablation procedure during the blanking or
therapy consolidation period would “reset” the endpoint of the study and trigger a new 3-month
blanking period. Incorporation of a therapy consolidation period can be especially appropriate for
clinical trials evaluating the efﬁcacy of AF ablation for persistent or long-standing persistent AF.
The challenge of this approach is that it prolongs the overall study duration. Because of this concern
regarding overall study duration, we suggest that the therapy consolidation period be no more than
3 months in duration following the 3-month blanking period.
Recommendations regarding
repeat ablation procedures
It is recommended that all clinical trials report the single procedure efﬁcacy of catheter ablation.
Success is deﬁned as freedom from symptomatic or asymptomatic AF/AFL/AT of 30 seconds or
longer at 12 months postablation. Recurrences of AF/AFL/AT during the ﬁrst 3-month blanking
period post-AF ablation are not considered a failure. Performance of a repeat ablation procedure at
any point after the initial ablation procedure should be considered a failure of a single procedure
strategy. It is acceptable for a clinical trial to choose to prespecify and use a multiprocedure success
rate as the primary endpoint of a clinical trial. When a multiprocedure success is selected as the
primary endpoint, efﬁcacy should be deﬁned as freedom from AF/ﬂutter or tachycardia at 12
months after the ﬁnal ablation procedure. In the case of multiple procedures, repeat ablation
procedures can be performed at any time following the initial ablation procedure. All ablation
procedures are subject to a 3-month post blanking window, and all ablation trials should report
efﬁcacy at 12 months after the ﬁnal ablation procedure.
Cardioversion deﬁnitions
Failed electrical cardioversion Failed electrical cardioversion is deﬁned as the inability to restore sinus rhythm for 30 seconds or
longer following electrical cardioversion.
Successful electrical
cardioversion
Successful electrical cardioversion is deﬁned as the ability to restore sinus rhythm for at least 30
seconds following cardioversion.
Immediate AF recurrence
postcardioversion
Immediate AF recurrence postcardioversion is deﬁned as a recurrence of AF within 24 hours following
cardioversion. The most common time for an immediate recurrence is within 30–60 minutes
postcardioversion.
Early AF recurrence
postcardioversion
Early AF recurrence postcardioversion is deﬁned as a recurrence of AF within 30 days of a successful
cardioversion.
Late AF recurrence
postcardioversion
Late AF recurrence postcardioversion is deﬁned as recurrence of AF more than 30 days following a
successful cardioversion.
Surgical ablation deﬁnitions
Hybrid AF surgical ablation
procedure
Hybrid AF surgical ablation procedure is deﬁned as a joint AF ablation procedure performed by
electrophysiologists and cardiac surgeons either as part of a single “joint” procedure or performed
as two preplanned separate ablation procedures separated by no more than 6 months.
Surgical Maze ablation
procedure
Surgical Maze ablation procedure is deﬁned as a surgical ablation procedure for AF that includes, at a
minimum, the following components: (1) line from SVC to IVC; (2) line from IVC to the tricuspid
valve; (3) isolation of the PVs; (4) isolation of the posterior left atrium; (5) line from MV to the PVs;
(6) management of the LA appendage.
Stand-alone surgical AF
ablation
A surgical AF ablation procedure during which other cardiac surgical procedures are not performed
such as CABG, valve replacement, or valve repair.
Nomenclature for types of
surgical AF ablation
procedures
We recommend that the term “Maze” procedure is appropriately used only to refer to the biatrial lesion
set of the Cox-Maze operation. It requires ablation of the RA and LA isthmuses. Less extensive lesion
sets should not be referred to as a “Maze” procedure, but rather as a surgical AF ablation procedure.
In general, surgical ablation procedures for AF can be grouped into three different groups: (1) a full
biatrial Cox-Maze procedure; (2) PVI alone; and (3) PVI combined with left atrial lesion sets.
Hybrid epicardial and
endocardial AF ablation
This term refers to a combined AF ablation procedure involving an off-pump minimally invasive
surgical AF ablation as well as a catheter-based AF ablation procedure designed to complement the
surgical lesion set. Hybrid ablation procedures may be performed in a single-procedure setting in a
hybrid operating room or a cardiac catheterization laboratory environment, or it can be staged.
When staged, it is most typical to have the patient undergo the minimally invasive surgical ablation
procedure ﬁrst following by a catheter ablation procedure 1 to 3 months later. This latter approach
is referred to as a “staged Hybrid AF ablation procedure.”
(Continued )
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Minimum AF documentation, endpoints, TEE performance, and success rates in clinical trials
Minimum documentation for
paroxysmal AF
The minimum AF documentation requirement for paroxysmal AF is (1) physician’s note indicating
recurrent self-terminating AF and (2) one electrocardiographically documented AF episode within 6
months prior to the ablation procedure.
Minimum documentation for
persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating
continuous AF .7 days but no more than 1 year and (2) a 24-hour Holter within 90 days of the
ablation procedure showing continuous AF.
Minimum documentation for
early persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating
continuous AF.7 days but no more than 3 months and (2) a 24-hour Holter showing continuous AF
within 90 days of the ablation procedure.
Minimum documentation for
long-standing persistent AF
The minimum AF documentation requirement for long-standing persistent AF is as follows: physician’s
note indicating at least 1 year of continuous AF plus a 24-hour Holter within 90 days of the ablation
procedure showing continuous AF. The performance of a successful cardioversion (sinus rhythm
.30 seconds) within 12 months of an ablation procedure with documented early recurrence of AF
within 30 days should not alter the classiﬁcation of AF as long-standing persistent.
Symptomatic AF/AFL/AT AF/AFL/AT that results in symptoms that are experienced by the patient. These symptoms can include
but are not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath. For
patients in continuous AF, reassessment of symptoms after restoration of sinus rhythm is
recommended to establish the relationship between symptoms and AF.
Documentation of AF-related
symptoms
Documentation by a physician evaluating the patient that the patient experiences symptoms that
could be attributable to AF. This does not require a time-stamped ECG, Holter, or event monitor at
the precise time of symptoms. For patients with persistent AF who initially report no symptoms, it is
reasonable to reassess symptom status after restoration of sinus rhythm with cardioversion.
Minimum effectiveness
endpoint for patients with
symptomatic and
asymptomatic AF
The minimum effectiveness endpoint is freedom from symptomatic and asymptomatic episodes of AF/
AFL/AT recurrences at 12 months following ablation, free from antiarrhythmic drug therapy, and
including a prespeciﬁed blanking period.
Minimum chronic acceptable
success rate: paroxysmal AF
at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for paroxysmal AF at 12-month
follow-up is 50%.
Minimum chronic acceptable
success rate: persistent AF at
12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for persistent AF at 12-month
follow-up is 40%.
Minimum chronic acceptable
success rate: long-standing
persistent AF at 12-month
follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for long-standing persistent AF at
12-month follow-up is 30%.
Minimum follow-up screening
for paroxysmal AF recurrence
For paroxysmal AF, the minimum follow-up screening should include (1) 12-lead ECG at each follow-up
visit; (2) 24-hour Holter at the end of the follow-up period (e.g., 12 months); and (3) event
recording with an event monitor regularly and when symptoms occur from the end of the 3-month
blanking period to the end of follow-up (e.g., 12 months).
Minimum follow-up screening
for persistent or long-
standing AF recurrence
For persistent and long-standing persistent AF, the minimum follow-up screening should include (1)
12-lead ECG at each follow-up visit; (2) 24-hour Holter every 6 months; and (3) symptom-driven
event monitoring.
Requirements for
transesophageal
echocardiogram
It is recommended that the minimum requirement for performance of a TEE in a clinical trial should be
those requirements set forth in ACC/AHA/HRS 2014 Guidelines for AF Management pertaining to
anticoagulation at the time of cardioversion. Prior to undergoing an AF ablation procedure a TEE
should be performed in all patients with AF of .48 hours’ duration or of unknown duration if
adequate systemic anticoagulation has not been maintained for at least 3 weeks prior to AF
ablation. If a TEE is performed for this indication, it should be performed within 24 hours of the
ablation procedure.
AF 5 atrial ﬁbrillation; DW-MRI 5 diffusion-weighted magnetic resonance imaging; CHF 5 congestive heart failure; QOL 5 quality of life; ECG 5 electro-
cardiogram; CABG 5 coronary artery bypass grafting; PV 5 pulmonary vein; SVC 5 superior vena cava; IVC 5 inferior vena cava; CFAE 5 complex fractionated
atrial electrogram; PVI5 pulmonary vein isolation; AFL5 atrial ﬂutter; AT5 atrial tachycardia; ACC5 American College of Cardiology; AHA5 American Heart
Association; HRS 5 Heart Rhythm Society.
*When reporting outcomes of AF ablation, the development of atrial tachycardia or atrial ﬂutter should be included in the broad deﬁnition of recurrence following
AF ablation. All studies should report freedom from AF, atrial tachycardia, and atrial ﬂutter. These endpoints can also be reported separately. All studies should
also clearly specify the type and frequency of ECG monitoring as well as the degree of compliance with the prespeciﬁed monitoring protocol.
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burden has been substantial. Patients with preablation high-
burden PAF might continue to experience AF episodes, but
with a reduced frequency and duration and a signiﬁcant
improvement in QOL. More liberal cutoff points have beensuggested based on implantable monitoring technology
detection limits (.2 minutes) or based on hypothesized
thresholds for stroke risk (.6 minutes or.5–6 hours). How-
ever, selection of any other cutoff would be as arbitrary as the
initial selection of 30 seconds, which has now been in place
Table 11 Quality-of-life scales, deﬁnitions, and strengths
Scale Deﬁnition/Details Strengths/Weaknesses
Short Form (36) Health
Survey (SF36)38
(General)
Consists of 8 equally weighted, scaled scores in the
following sections: vitality, physical functioning,
bodily pain, general health perceptions, physical
role functioning, emotional role functioning, social
role functioning, mental health. Each section
receives a scale score from 0 to 100.
Physical component summary (PCS) and mental
component summary (MCS) is an average of all the
physically and mentally relevant questions,
respectively.
The Short Form (12) Health Survey (SF12) is a shorter
version of the SF-36, which uses just 12 questions
and still provides scores that can be compared with
SF-36 norms, especially for summary physical and
mental functioning.
Gives more precision in measuring QOL than EQ-5D but
can be harder to transform into cost utility analysis.
Advantages: extensively validated in a number of
disease and health states. Might have more
resolution than EQ-50 for AF QOL.
Disadvantages: not speciﬁc for AF, so might not
have resolution to detect AF-speciﬁc changes in
QOL.
EuroQol Five Dimensions
Questionnaire (EQ-5D)39
(General)
Two components: Health state description is measured
in ﬁve dimensions: mobility, self-care, usual
activities, pain/discomfort, anxiety/depression.
Answers may be provided on a three-level (3L) or
ﬁve-level (5L) scale. In the Evaluation section,
respondents evaluate their overall health status
using a visual analogue scale (EQ-VAS). Results can
easily be converted to quality-adjusted life years for
cost utility analysis.
Advantages: extensively validated in a number of
disease and health states. Can easily be
converted into quality-adjusted life years for
cost-effectiveness analysis.
Disadvantages: might not be speciﬁc enough to
detect AF-speciﬁc changes in QOL. Might be less
speciﬁc than SF-36.
AF effect on Quality of Life
Survey (AFEQT)40
(AF speciﬁc)
20 questions: 4 targeting AF-related symptoms, 8
evaluating daily function, and 6 assessing AF
treatment concerns. Each item scored on a 7-point
Likert scale.
Advantages: brief, simple, very responsive to AF
interventions. Good internal validity and well
validated against a number of other global and
AF-speciﬁc QOL scales. Used in CABANA.
Disadvantages: validation in only two published
studies (approximately 219 patients).
Quality of Life
Questionnaire for
Patients with AF
(AF-QoL)41
(AF speciﬁc)
18-item self-administered questionnaire with three
domains: psychological, physical, and sexual
activity. Each item scores on a 5-point Likert scale.
Advantages: brief, simple, responsive to AF
interventions; good internal validity; used in
SARA trial.
Disadvantages: external validity compared only to
SF-36; formal validation in 1 study
(approximately 400 patients).
Arrhythmia-Related
Symptom Checklist (SCL)
42 (AF speciﬁc)
16 items covering AF symptom frequency and
symptom severity.
Advantages: most extensively validated in a
number of arrhythmia cohorts and clinical trials.
Disadvantages: time-consuming and uncertain
generalizability.
Mayo AF Speciﬁc Symptom
Inventory (MAFSI)43
(AF speciﬁc)
10 items covering AF symptom frequency and severity.
Combination of 5- point and 3-point Likert scale
responses.
Used in CABANA trial.
Advantages: validated in an AF ablation population
and responsive to ablation outcome; used in
CABANA trial.
Disadvantages: external validity compared only to
SF-36; 1 validation study (approximately 300
patients).
University of Toronto Atrial
Fibrillation Severity Scale
(AFSS) (AF speciﬁc)44
10 items covering frequency, duration, and severity.
7-point Likert scale responses.
Advantages: validated and reproducible; used in
CTAF trial.
Disadvantages: time-consuming and uncertain
generalizability.
Arrhythmia Speciﬁc
Questionnaire in
Tachycardia and
Arrhythmia (ASTA)45
(AF speciﬁc)
Records number of AF episodes and average episode
duration during last 3 months. 8 symptoms and 2
disabling symptoms are recorded with scores from
1–4 for each.
Advantages: validated in various arrhythmia
groups; external validity compared with SCL,
EQ5D, and SF-36; used in MANTRA-PAF; brief;
simple.
Disadvantages: one validation study
(approximately 300 patients).
European Heart Rhythm
Association (EHRA)46
(AF speciﬁc)
Like NYHA scale. I 5 no symptoms, II 5 mild
symptoms not affecting daily activity, III 5 severe
symptoms affecting daily activity, and IV 5
disabling symptoms terminating daily activities.
Advantage: very simple, like NYHA.
Disadvantages: not used in studies and not well
validated; not very speciﬁc; unknown
generalizability.
(Continued )
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Table 11 (Continued )
Scale Deﬁnition/Details Strengths/Weaknesses
Canadian Cardiovascular
Society Severity of Atrial
Fibrillation Scale (CCS-
SAF)47 (AF speciﬁc)
Like NYHA scale. O5 asymptomatic, I5 AF symptoms
have minimal effect on patient’s QOL, II 5 AF
symptoms have minor effect on patient QOL, III 5
symptoms have moderate effect on patient QOL,
IV5 AF symptoms have severe effect on patient
QOL.
Advantages: very simple, like NYHA; validated
against SF-36 and University of Toronto AFSS.
Disadvantages: poor correlation with subjective
AF burden; not very speciﬁc.
AF5 atrial ﬁbrillation; QOL5 quality of life; CABANA5 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation; SARA5 Study of Ablation
Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation; CTAF 5 Canadian Trial of Atrial Fibrillation; MANTRA-PAF 5 Medical ANtiarrhythmic Treatment or
Radiofrequency Ablation in Paroxysmal Atrial Fibrillation; NYHA 5 New York Heart Association; AFSS 5 atrial ﬁbrillation severity scale.
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fore allow for comparison of future studies against those per-
formed in the past. It also remains unclear whether the
selection of a somewhat more generous threshold would
actually signiﬁcantly alter reported success rates in a time
to event analysis.
Arrhythmia recurrence is often reported as time to ﬁrst AF
episode of a particular type, such as any episode of an ATA
lasting more than 30 seconds, veriﬁed by surface ECG (loop
recorder) or an intracardiac electrogram. This parameter
might best reﬂect differences in lesion quality around PVs
for electrical isolation. Ineffective ablation and early gap for-
mation could result in an earlier time to ﬁrst recurrent AF.
Even the time to the second or third AF recurrence might
further allow insights into such ablation effects and could
therefore be used as a secondary outcome measurement.
Cutoffs of more than 30 seconds can be reported in addi-
tion to the 30-second primary endpoint to show how proce-
dural success might change. In fact, the consensus group
encourages such reporting routinely in all clinical trials to
better assess the most clinically relevant outcomes for future
clinical trials. In particular, higher cutoffs can be used for pa-
tients with persistent or long-standing persistent AF because
of the very high burden of preablation AF and the lower like-
lihood that ablation will result in a full “cure” of the
arrhythmia. It is strongly suggested that other cutoffs be pre-
speciﬁed and reported in secondary outcomes of trials so the
true effects of catheter ablation on various types of AF can be
put into proper context outside of the 30-second cutoff.
A cutoff that can be used in addition to 30 seconds would
be the time to ﬁrst clinical or stroke-relevant AF duration
(e.g., more than 1 hour or 5.5 hours). As already described,
the SOS trial revealed AF activity of more than 1 hour per
day as a cutoff for an increased risk of stroke, whereas other
investigation revealed various AF burden levels, such as a
marker of an increased risk for thromboembolism. This
parameter might be used preferentially in studies in which
the potential of ablation to reduce outcomes such as thrombo-
embolism might be the primary interest. “Time to ﬁrst persis-
tent AF” could be considered for trials of persistent AF
ablation in which time to the ﬁrst episode of more than 7
days might be a relevant parameter while investigating sub-
strate modifying ablation therapies such as atrial lines or
localized rotational activity elimination.AF Burden Endpoints
Rather than report time to an AF recurrence of a speciﬁc dura-
tion, many feel that AF burden is a more optimal endpoint for
assessing ablation efﬁcacy. AF burden can be estimated
based on serial long-term monitoring results and patient
symptom reporting, but only continuous monitoring through
a cardiac implantable electronic device (loop, pacemaker,
ICD) can truly deﬁne the burden. Furthermore, placement
of such an implantable recording device should ideally be
performed preablation so that pre- and postablation outcomes
can be compared. Use of such devices, however, can be quite
costly and impose undue difﬁculty in performing clinical tri-
als. AF burden can be used in various ways in AF ablation
trials. Freedom from relevant AF—classically deﬁned as an
absence of any ATA of more than 30 seconds—might be
deﬁned, for example, as a low daily AF burden less than
1%–2%. This approach would recognize the fact that occa-
sional and short-lasting atrial arrhythmias over a few minutes
might be an acceptable outcome. It should be noted, however,
that there is a substantial difference between long-term, daily
monitoring of AF burden versus a detection period of 3
months, as in the Asymptomatic Atrial Fibrillation and
Stroke Evaluation in Pacemaker Patients and the Atrial
Fibrillation Reduction Atrial Pacing Trial, in which short-
lasting AF was likely a marker for future long-lasting AF
outside the monitoring period.1390 Reduction in AF burden
more than 75% could be considered as clinical success just
as much as reduction in both the number and duration of
AF episodes. However, the number and duration of episodes
are signiﬁcantly more sensitive to under- or oversensing with
subcutaneous devices but also implanted pacemakers or deﬁ-
brillators for various technical reasons. In contrast, the num-
ber of episodes necessitating urgent or emergency care visits
might not only be clinically relevant, but might also help
demonstrate the cost-effectiveness of the procedure. Further-
more, because there is no ﬁrm scientiﬁc basis for selecting the
cutoff of 75%, this prior recommendation is provided only as
an example of what future clinical trials might choose to use
as a deﬁnition of clinical or partial success.
In recognition that AF ablation may not be curative,
particularly for patients with persistent or long-standing
persistent AF, the concepts of AF progression and regression,
while unproven, could be of interest. Many patients might
initially present with very infrequent episodes of PAF that
Table 12 Non-AF recurrence–related endpoints for reporting in AF ablation trials
Stroke and bleeding endpoints Deﬁnitions/Details
Stroke (2014 ACC/AHA Key Data
Elements)
An acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal
vascular injury as a result of hemorrhage or infarction. Symptoms or signs must persist 24
hours, or if documented by CT, MRI or autopsy, the duration of symptoms/signs may be less than
24 hours. Stroke may be classiﬁed as ischemic (including hemorrhagic transformation of
ischemic stroke), hemorrhagic, or undetermined. Stroke disability measurement is typically
performed using the modiﬁed Rankin Scale (mRS).
Transient ischemic attack
(2014 ACC/AHA Key Data Elements)
Transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal
ischemia without acute infarction and with signs and symptoms lasting less than 24 hours.
Major bleeding (ISTH deﬁnition) Fatal bleeding AND/OR symptomatic bleeding in a critical area or organ, such as intracranial,
intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with
compartment syndrome AND/OR bleeding causing a fall in hemoglobin level of
2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of blood.
Clinically relevant nonmajor bleed
(ISTH deﬁnition)
An acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but
prompts a clinical response such that it leads to one of the following: hospital admission for
bleeding; physician-guided medical or surgical treatment for bleeding; change in
antithrombotic therapy (including interruption or discontinuation).
Minor bleeding (ISTH deﬁnition) All nonmajor bleeds. Minor bleeds are further divided into clinically relevant and not.
Incidence and discontinuation of oral
anticoagulation
The number of patients receiving oral anticoagulation and the type of oral anticoagulation should
be documented at the end of follow-up. If patients have their oral anticoagulation discontinued,
the number of patients discontinuing, the timing of discontinuation, and the reasons for
discontinuation of oral anticoagulation, as well as the clinical characteristics and stroke risk
proﬁle of the patients should be reported.
AF 5 atrial ﬁbrillation; CT 5 computed tomography; MRI 5 magnetic resonance imaging.
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tion in this setting might help delay progression to higher
burden paroxysmal or persistent AF, which could be associ-
ated with decreased functioning but also increased risks of
stroke, HF, or death. On the other hand, patients with persis-
tent AF who can be converted into infrequent, paroxysmal
forms of AF (so-called AF regression) might experience
not only QOL beneﬁts but also a potential reduction in
morbidity and mortality. In order for these endpoints to be
widely implemented, thresholds of AF must be established
under which patient QOL and risk of adverse outcomes are
reliably improved, which has yet to be done. For example,
one substudy of the STAR AF 1 trial showed that patients
with very high-burden paroxysmal or persistent AF could
continue to experience up to 2 or more hours of AF per month
postablation and still report an improvement in QOL.1391 The
patient-reported symptoms did not deteriorate until they
experienced more than 27 hours of AF per month. This
outcome remains an important focus for ongoing clinical
investigation.
When an implanted device is not used, many trials have
attempted to estimate changes in AF burden by using various
methods. If careful recording of patient symptoms and clini-
cally apparent recurrences is performed, including duration
and frequency of episodes over a speciﬁc period of time,
then these could be used to estimate AF burden pre- and post-
ablation.1391 Total AF detected on intermittent continuous
monitoring (like intermittent 7 day Holters) could be used,
although the accuracy is somewhat limited depending on
the duration and frequency of monitoring.378 Intermittent,
but frequent, transtelephonic or other portable monitors can
provide brief strips of rhythm status. Time in sinus rhythmcould be estimated by the number of weeks (for example),
with sinus transmissions divided by the total number of
weeks of the monitoring period, akin to a time in therapeutic
range for OAC with VKA.245 A combination of symptom re-
porting and ECG status at various time points can also be
used to calculate estimated time in sinus rhythm, as was em-
ployed in a substudy of the Atrial Fibrillation and Congestive
Heart Failure study.1392Endpoint Differences for Paroxysmal vs Nonparoxysmal AF
Ablation Studies
Important consideration should be given to differences in
AF recurrence endpoint reporting in trials of paroxysmal
versus persistent AF. For patients with PAF, the burden
might not be well suited for determining the outcome of
ablation. Because the preablation burden can be relatively
low in the months preceding ablation, with a large range
in the burden, it might be hard to realize a statistically sig-
niﬁcant change postablation or between treatment arms.
This was demonstrated in theMANTRA-PAF trial, in which
total AF burden (measured on 7-day Holters) did not differ
between drug and ablation therapy, but the total number of
patients free from any AF recurrence was signiﬁcantly
higher in the ablation arm.378 For these patients, a time to
recurrence or proportion free from arrhythmia endpoint
might be a better option. Other statistical concerns that
need to be considered for AF burden as an outcome measure
for ablation in PAF patients include regression to the mean
and the clustered, nonrandom pattern of PAF episodes. For
persistent AF, reduction in burden can be much more rele-
vant because the preablation burden will be high (close to
Table 13 Advantages and disadvantages of AF-related endpoints in AF ablation trials
Endpoint Advantages Disadvantages Relevance and Comments
Freedom from AF/AFL/AT recurrence
“gold standard” is 30 seconds - Has been in use for many years
- Can be used to compare results of new
trials with historical trials
- Sets a high bar for AF elimination
- Can systematically underestimate the
efﬁcacy of AF ablation, particularly for
persistent AF, if 30-second cutoff is used
- Particularly well suited for paroxysmal AF
outcomes
- Reporting of cutoffs other than 30
seconds encouraged as secondary
endpoints to better contextualize results
- May be reported as proportion of patients
free from arrhythmia or time to recurrence
Freedom from stroke-relevant AF/
AFL/AT-duration cutoff of 1 hour
- Useful for trials in which interest is more
for prognostic change conferred by
ablation rather than elimination of all
arrhythmias
- No consistent deﬁnition of what a
stroke-relevant duration of AF is: ranges
from 6 minutes to 24 hours in literature
- More than 1 hour could be a useful cutoff
based on results of 505 trial
- May be reported as proportion of patients
free from arrhythmia or time to recurrence
Freedom from AF/AFL/AT requiring
intervention (emergency visits,
cardioversion, urgent care visit,
reablation, etc.)
- Can provide an endpoint more relevant
to systemic costs of AF recurrence
- Clinically relevant
- Will overestimate efﬁcacy of ablation by
ignoring shorter episodes not requiring
intervention that still might be important
to quality of life or stroke
- Determination of what is an
“intervention” must be prespeciﬁed in
protocol and biases mitigated to avoid
over- or underintervention in the trial
Freedom from persistent AF/AFL/AT-
duration cutoff of 7 days
- Useful for trials assessing additional
substrate modiﬁcation in persistent AF
- Can systematically overestimate the
efﬁcacy of AF ablation, particularly for
persistent AF
- Can require continuous monitoring to
deﬁnitively assess if episode is .7 days
Freedom from AF/AFL/AT on
previously ineffective
antiarrhythmic therapy
- If patient maintains sinus rhythm on
previously ineffective drug therapy, this
may be considered a clinically relevant,
successful outcome
- Will increase the success rate compared
with off-drug success
- May not be relevant to patients hoping to
discontinue drug therapy
- Postablation drug and dosage of drug
should be identical to preablation drug
and dosage
Signiﬁcant reduction in AF burden:
.75% reduction from pre- to
postablation and/or total
postablation burden ,12%
- Can be useful in persistent AF studies,
but might not be suited for early,
paroxysmal AF studies
- Ideally requires continuous monitoring
using an implantable device
- No scientiﬁc basic exists showing that a
75% reduction in AF burden impacts hard
endpoints, including heart failure, stroke,
and mortality
- AF burden can be estimated by
intermittent monitoring and reporting of
patient symptoms and recurrences like a
“time in therapeutic range” report for oral
anticoagulation; see text
- Could also see 75% reduction in number
and duration of AF episodes
- Because there is no ﬁrm scientiﬁc basis
for selecting the cutoff of 75%, this prior
recommendation is provided only as an
example of what future clinical trials may
choose to use as a deﬁnition of clinical/
partial success
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Prevention in AF progression: time to
ﬁrst episode of persistent AF (.7
days)
- Does not assume that total elimination
of AF is required
- Well suited for paroxysmal or “early” AF
studies in which goal is to prevent
progression to persistent AF
- Prevention in progression might be
irrelevant for stroke or thromboembolic
outcomes
- Long follow-up time might be required
unless population is “enriched”
- Can ideally require continuous
implantable monitoring
- Might be useful for speciﬁc populations
such as heart failure or hypertrophic
cardiomyopathy, in which progression to
persistent AF can lead to increased
hospitalization
Regression of AF: reduction in burden
to a given threshold or conversion
of persistent to paroxysmal AF
- Does not assume that total elimination
of AF is required
- Well suited for persistent “late” AF
studies in which goal is to regress to
paroxysmal AF, which might be easier to
control with drug therapy
- Regression endpoint will overestimate
efﬁcacy of AF ablation
- Might ideally require continuous
implantable monitoring
- Patients will require ongoing drug therapy
- Could be particularly useful for long-
standing persistent AF populations with
structural heart disease, heart failure, etc.
Acute AF termination during ablation
procedure
- Could provide indication of successful
modiﬁcation of substrate responsible
for maintaining AF, most relevant to
persistent or long-standing persistent
AF
- Limited studies have linked acute AF
termination to long-term success
- Relevance of acute AF termination has not
consistently been shown to correlate to
long-term success
- Endpoint might not be relevant to
paroxysmal AF patients in whom AF might
terminate spontaneously
- Some studies employ administration of
intravenous or oral antiarrhythmics
during ablation that could cause
spontaneous termination
- Studies consider termination as reversion
to sinus rhythm, whereas others consider
reversion to any regular tachycardia as
termination
- Intraprocedural administration of
preprocedural oral antiarrhythmics or
intraprocedural intravenous
antiarrhythmics are discouraged
- If antiarrhythmics are used, their use and
dosage before and during the ablation
should be clearly documented
- Termination to sinus rhythm and
termination to another regular
tachycardia (AT or AFL) should be
separately reported
AF 5 atrial ﬁbrillation; AFL 5 atrial ﬂutter; AT 5 atrial tachycardia.
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reduction postablation easier to deﬁne. On the other hand,
the use of freedom from 30-second endpoints could under-
estimate the true clinical effect of ablation in the persistent
population. The consensus group still maintains that the
30-second endpoint should be reported, but secondary end-
points such as changes in AF burden and/or AF progression
or regression should also be described. Both CABANA and
EAST, with more extensive monitoring, should both shed
additional light on these issues.
The writing group members encourage reporting of other
secondary endpoints that might better represent clinically
relevant outcomes of the ablation procedure. Improvements
in patient QOL are very important to assessing the clinical
success of AF ablation, but as with any intervention, the
magnitude of the improvements might be confounded by ex-
pectancy bias (“placebo effect”). A detailed discussion of
QOLmeasurements and potential beneﬁts and limitations ap-
pears later in this section.
Symptomatic vs Asymptomatic Recurrence
Even in patients with highly symptomatic AF, as many as
half of all episodes can occur without associated symp-
toms.56 The ratio of asymptomatic to symptomatic episodes
increases up to 4-fold postablation, perhaps due to shorter
durations, slower rates, or autonomic modulation after the
procedure.58 In highly symptomatic AF patients, asymp-
tomatic episodes often coexist with the symptomatic; thus,
patient reporting of symptoms can still serve as a rough sur-
rogate for procedural success. For clinical trial purposes,
however, reporting of only symptomatic AF recurrences
could overestimate procedural success by 20% or more by
missing asymptomatic recurrences. The importance of
asymptomatic AF detection depends in part on the purpose
of the clinical trial. If patient QOL and symptom abatement
is the primary goal of therapy in the study, then underdetec-
tion of asymptomatic AF could be of little relevance. How-
ever, if the study goal is to reduce the associated risks of AF
(stroke, HF) and to change potential therapy, including
OAC, then the detection of asymptomatic AF is much
more critical. Typically, the detection of asymptomatic AF
recurrence is accomplished by longer-term, frequent, or
implantable monitoring approaches.
AF Monitoring Postablation
Arrhythmia monitoring can be performed with the use of
noncontinuous or continuous ECG monitoring tools. The
choice of eithermethod depends on individual need and conse-
quence of arrhythmia detection. Basically, more intensive
monitoring is associated with a greater likelihood of detecting
both symptomatic and asymptomatic AF.56,58,937
Identiﬁcation of patients with AF and assessment of AF
burden with intermittent monitoring have been shown to
depend on a patient’s actual AF burden, and improve with an
increasing frequency or duration of intermittent monitoring.
Conversely, the more complex and longer the method of
monitoring that is used, the lower the patient compliance.Available noncontinuous detection tools include sched-
uled or symptom-initiated standard ECGs, Holter (24 hours
to 7 days), transtelephonic recordings, patient- and
automatically activated devices, and external loop recorders
(Table 6). Scheduled 7-day Holter ECG recordings or daily
plus symptom-activated event recordings are estimated to
document approximately 70% of AF recurrences, with an
estimated negative predictive value for absence of AF be-
tween 25% and 40%.947,1393
Continuous ECGmonitoring is permanent monitoring for a
long time period (1, 2, or more years). Continuous ECGmoni-
toring can be facilitated with the use of implantable devices.
Implantable pacemakers or deﬁbrillatorswith atrial leads allow
the burden of AF to be assessed by tracking the number and
duration of mode switch episodes, particularly when an
arrhythmia duration of 5 minutes is used as the cutoff
value.1394 More recently, a long-term subcutaneous implant-
able loop monitor has become available to facilitate contin-
uous AF monitoring based on R-R interval analysis over a
period of 2 years.58,952 These types of continuous ECG
monitoring devices can be used to evaluate the results of AF
ablation. Although implantable subcutaneous monitors hold
promise for determination of AF burden long term,
important limitations include less than 100% speciﬁcity due
to myopotentials, atrial and ventricular premature beats, as
well as limited memory resulting in electrograms not being
retrievable to verify the correct rhythm diagnosis. Another
major limitation for the performance of clinical trials is cost.
If the consensus mandated ILR monitoring for all clinical
trials, the cost of performing such trials would likely become
prohibitive. There are also a number of patients who might
refuse long-term devices.
Again, the purpose of the trial should be married to the
type of monitoring performed. If the ultimate goal is to
improve patients’ QOL, then excessive monitoring for
asymptomatic AF might not be worth the effort. However,
if the goal is to reduce AF burden, or change prognosis,
particularly from a stroke point of view, then continuous
monitoring should be required.
In the past, the consensus statement has provided mini-
mum clinical requirements for postablation monitoring for
clinical trials. Initially, these were quite stringent, and in
the last consensus statement, the requirements were made
more ﬂexible. The current consensus recommends the
following minimum monitoring requirements: For PAF,
follow-up screening should include a minimum of three visits
(e.g., at 3, 6, and 12 months), with a 12-lead ECG at each
visit, a 24-hour Holter at the end of the follow-up period
(e.g., 12 months), and more limited event recording from
the end of the 3-month blanking period to the end of
follow-up (e.g., 12 months), both at regular periods and
with patient activated recordings obtained at the time of
symptoms (or equivalent). Follow-up beyond 1 year is
encouraged and might occur every 6 months with Holter
and ECG (or equivalent). For persistent and long-standing
persistent AF, follow-up screening should include a mini-
mum of three visits (e.g., at 3, 6, and 12 months), with a
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and event recording from the end of the 3-month blanking
period to the end of follow-up (e.g., 12 months), as well as
at the time of symptoms (or equivalent). Follow-up beyond
1 year is encouraged and might occur every 6 months with
Holter and ECG (or equivalent) (Table 10). In making these
recommendations, it is important to recognize that the writing
group views these as minimal monitoring recommendations.
More intensive follow-up with more frequent Holters and/or
extended ECG monitoring is encouraged. Similarly, follow-
up beyond 1 year is encouraged and might occur every 6
months with Holter and ECG (or equivalent). It is acknowl-
edged that this recommendation falls short of continuous
monitoring and will largely detect symptomatic recurrences
with only a limited ability to detect asymptomatic recur-
rences. However, this minimum standard will at least provide
some consistency in trial reporting, and trials are encouraged
to exceed this standard where possible. Details are speciﬁed
in Table 10.QOL Measurement
QOL should remain an important endpoint for AF abla-
tion studies, but not necessarily the primary endpoint.
QOL is limited by treatment expectancy bias. Although
sham procedures have not been performed to assess the
true magnitude of this bias, it is unlikely that such studies
will be performed because they would be extremely chal-
lenging.
QOL can be measured both using well-established scales
like the SF-36 and EQ5D, but also using more speciﬁc scales
like the Atrial Fibrillation Effect on QualiTy-of-Life
(AFEQT), University of Toronto Atrial Fibrillation Severity
Scale, Mayo AF-Speciﬁc Symptom Inventory, or Symptom
Severity Score. The advantages of the generalized scales is
their wide usage in medicine, the ability to compare improve-
ments in QOL with other medical interventions, and in
the case of the EQ5D, converts QOL changes to cost-
effectiveness measures through the use of QALYs; however,
these scales can lack sensitivity to changes with reductions in
AF burden. AF-speciﬁc scales, on the other hand, might
improve sensitivity and discriminate more effectively be-
tween patients with successful and failed ablation. At present,
the true value of AF-speciﬁc scales requires validation
through randomized studies using standard of care therapy
as a control arm, given the comorbidity associated with AF
can impact the same symptoms that affect the EHRA score
and the Canadian Cardiovascular Society Severity in Atrial
Fibrillation scale. Finally, we still need to know how these
changes compare with other medical interventions and if
the changes would result in substantial reductions in health
care cost or patient morbidity.
The consensus group recommends that all clinical trials
incorporate some measure of patient-reported outcomes and
preferably measure them using both a general and an AF-
speciﬁc measurement scale. A summary of QOL scales is
provided in Table 11.Other Endpoint Reporting
There are important subgroups of patients and clinical out-
comes that need to be studied, but are unlikely to be ad-
dressed by any one study alone. To facilitate pooled data
analysis, the consensus recommends routine reporting of
additional subgroup analyses, particularly around modiﬁable
lifestyle risk factors. BMI and OSA should be reported in the
baseline characteristics and subgroup analysis, comparing
high vs average BMI and those with and without sleep apnea,
which should be ideally reported in recognition that modiﬁ-
able risk factors are an important contributor to AF progres-
sion and ablation outcome.
The need for a better understanding of the most appro-
priate postablation anticoagulation strategy is particularly
recognized by the consensus group. Due to the rarity of
stroke, TIA, and peripheral thromboembolism, it is unlikely
that sufﬁciently powered studies will ever be conducted to
conclusively resolve this relevant aspect of clinical practice.
In the absence of a clear strategy, it is possible that postabla-
tion patients are exposed to an excess stroke risk if untreated,
or to an excess bleeding risk if treated with no real need. As a
reasonable surrogate to an evidence-based demonstration, the
consensus group recognizes the value of careful reporting of
secondary outcomes in which individual data are made avail-
able for (1) baseline risk factors; (2) postablation anticoagu-
lation strategy (e.g., if continued, and if so, which drug, or
discontinued); and (3) postablation thromboembolic and/or
bleeding events. An effort of this type would not only
enhance the quality of the single studies, but it would also
allow for pooled analyses in the future. Examples of speciﬁc
secondary outcomes that could be reported are summarized
in Tables 10 and 12.Unanswered Questions in AF Ablation
There is still much to be learned about the mechanisms of AF,
techniques of AF ablation, and long-term outcomes. The
following are unanswered questions for future investigation:
1. AF ablation and modiﬁcation of stroke risk and need for
ongoing OAC: The CHA2DS2-VASc score was devel-
oped for patients with clinical AF. If a patient has
received a successful ablation such that he/she no longer
has clinical AF (subclinical, or no AF), then what is the
need for ongoing OAC? Are there any patients in whom
successful ablation could lead to discontinuation of
OAC?
2. Substrate modiﬁcation in catheter-based management of
AF—particularly for persistent AF: What is the proper
lesion set required beyond PVI? Do lines and CFAE
have any remaining role? Are these approaches ill-
advised or simply discouraged?
What is the role of targeting localized rotational activa-
tions? How do we ablate a localized rotational activation?
How can scar be characterized and targeted for ablation?
Do we need to replicate the MAZE procedure? Does the
RA need to be targeted as well as the LA?
e406 Heart Rhythm, Vol 14, No 10, October 20173. Autonomic inﬂuence in AF: Is clinical AF really an auto-
nomic mediated arrhythmia? Is elimination of GP
required? Is there a role for autonomic modulation, for
example, spinal cord or vagal stimulation?
4. Contribution and modulation of risk factors on outcomes
of AF ablation: Obesity reduction has been shown to
reduce AF burden and recurrence in patients undergoing
ablation. What is the role of bariatric surgery?
Does the modulation of other risk factors inﬂuence
outcome such as hypertension, sleep apnea, and diabetes?
5. Outcomes in ablation of high-risk populations: Do high-
risk populations beneﬁt from AF ablation?
Congestive HF has been assessed in smaller trials, but
larger trials are required. Outcome data are needed in pa-
tients with very enlarged LAs, HCM, patients with renal
failure on dialysis, and the very elderly.
6. Surgical vs catheter-based vs hybrid ablation: There
should be more comparative work between percutaneous
and minimally invasive surgical approaches. Both report
similar outcomes, but there is a dearth of comparative
data. Is there any patient beneﬁt to hybrid procedures?
7. How do we characterize patients who are optimal candi-
dates for ablation? Preablation LGE-MRI might identify
patients with heavy burdens of scar who are unlikely to
respond to ablation. These techniques must become
reproducible and reliable and must be assessed in multi-
center trials. Other markers need to be investigated,
including genetic markers, biochemical markers, and
clinical markers based on aggregated risk scores.
8. The incremental role of new technologies: As newer and
often more expensive technologies are produced for AF
ablation, their deﬁnitive incremental value must be deter-
mined in order to justify change in practice or case cost.
These technologies include global (basket) mapping
techniques, newer ablation indices for assessing lesion
durability, advanced imaging for viewing lesions in the
myocardium, etc. New energy sources, including laser,
low-intensity ultrasound, photonic particle therapy,
external beam ablation, and MRI-guided ablation, must
be assessed in comparative fashion.
9. Outcomes of AF ablation: We need to better understand
the clinical relevance of ablation outcomes. What is the
signiﬁcance of time to recurrence of 30 seconds of
arrhythmia? How do we best quantify AF burden?
How do these outcomes relate to QOL and stroke risk?
10. What is the role of surgical LA reduction? Does LAA oc-
clusion or obliteration improve outcome of persistent AF
ablation with an accompanying reduction in stroke?
Does ablation work through atrial size reduction? What
is the incidence of “stiff atrial” syndrome and does this
mitigate the clinical impact of ablation?
11. Working in teams: What is the role of the entire heart
team in AF ablation? Does a team approach achieve bet-
ter outcomes than a “silo” approach?
12. Improving the safety of catheter ablation: As ablation ex-
tends to more operators and less experienced operators,the statistical occurrence of complications will increase.
We need newer techniques to minimize complications
and institute standards for operators to improve the
reproducibility of ablation results and safety proﬁles at
a variety of centers worldwide.
13. How does catheter ablation affect mortality, stroke, and
hospitalization in broad and selected patient populations
receiving catheter ablation for AF?
14. Management of patients who fail initial attempts at cath-
eter ablation: Should there be speciﬁc criteria for repeat
ablations (e.g., atrial size, BMI)? Should patients be
referred for surgery for repeat ablation?
In order to address these and other important questions
in the ﬁeld of catheter and surgical AF ablation, we urge in-
vestigators to create and participate in multisite collabora-
tions and electrophysiology research networks with
involvement of senior and junior investigators on the steer-
ing committees to push forward the next phase of AF
research. We also urge funding bodies to support these
important initiatives.Section 14: Conclusion
Catheter ablation of AF is a very commonly performed
procedure in hospitals throughout the world. Surgical abla-
tion of AF, although less widely available than catheter-
based AF ablation, is also an important therapeutic option
for patients with AF at many major medical centers. This
document provides an up-to-date review of the indications,
techniques, and outcomes of catheter and surgical ablation
of AF. Areas for which a consensus can be reached con-
cerning AF ablation are identiﬁed, and a series of
consensus deﬁnitions have been developed for use in
future clinical trials of AF ablation. Also included within
this document are recommendations concerning indica-
tions for AF ablation, technical performance of this pro-
cedure, and training. It is our hope to improve patient
care by providing a foundation for those involved with
care of patients with AF as well as those who perform
AF ablation. It is recognized that this ﬁeld continues to
evolve rapidly and that this document will need to be up-
dated. Successful AF ablation programs optimally should
consist of a cooperative team of cardiologists, electrophys-
iologists, and surgeons to ensure appropriate indications,
procedure selection, and follow-up.Acknowledgments
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